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Abstract 
Trypanosome alternative oxidase (TAO) is the sole terminal oxidase responsible for the 
aerobic respiration of the parasite T. b. brucei. Specific strains of this parasite cause the 
neglected tropical disease Human African trypanosomiasis (HAT), and thus TAO is an 
interesting target for the potential treatment of this disease.  
Inhibition of TAO with the natural product inhibitors colletochlorin B or ascofuranone has 
been shown to clear infections of T. b. brucei in mice at high concentrations. However, these 
natural product inhibitors contain undesirable chemical functionality and have poor 
physicochemical properties, preventing adequate drug exposure to effectively treat HAT.  
Robust protocols for the expression and purification of recombinant TAO were developed, 
which enabled the development of biochemical assays to identify inhibitors of TAO function. 
Single point inhibition screening of the Medicines Malaria Venture ‘kinetoplastid collection’ 
of 400 compounds identified a range of micro-molar inhibitors of TAO.  
A program of chemical optimisation was carried out around the natural product inhibitor 
colletochlorin B, with the aim to improve the physicochemical properties and retain 
inhibitory potency against TAO. The structure activity relationships generated over the 
course of this exploration identified a dependency on high lipophilicity to retain potent TAO 
inhibition. The TAO inhibitors synthesised were also assessed for parasite growth inhibition 
and mammalian cell cytotoxicity to correlate inhibition data with cellular efficacy, in 
collaboration with Novartis. The physicochemical properties of these novel compounds 
showed improvement over the natural product colletochlorin B and prompted further 
assessment of leading compounds in advanced parasite kill kinetic and parasite clearance 
assays at Novartis. The data generated in these assays for compounds synthesised in this 
thesis determined that TAO inhibition results in a trypanostatic response, and not a preferred 
trypanocidal response in T. b. brucei. 
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Chapter 1 - Introduction 
1.1 The diseases 
Human African trypanosomiasis (HAT), also known as African sleeping sickness, and African 
animal trypanosomiasis (AAT), are caused by the protozoan trypanosome parasite 
Trypanosoma brucei (Figure 1).1 The earliest documented description of the disease dates 
back to Egypt in the 2nd millennium B.C. Further records of the disease in Africa have been 
identified from the middle ages.2 It was first proposed by David Livingstone that ‘Nagana’ 
(now known as AAT) was transmitted by Tsetse flies in 1852; however, it wasn’t until the late 
19th century that the infection of Trypanosoma brucei was shown to cause AAT. Sir David 
Bruce showed that AAT was transmitted by the Tsetse fly vector in the early 20th century.2,3 
Further inspection of HAT patient samples by both Dutton and Castellani in 1902 showed the 
presence of trypanosomes, which were attributed to the cause of the disease.4 
 
 
Figure 1 - Trypanosoma spp. parasites in blood smear from a patient with African trypanosomiasis.5 
 
1.1.1 Human African trypanosomiasis 
HAT is prevalent in sub Saharan Africa and in the most recent figures available from 2012 
there were 20,000 estimated cases with an at risk population of 60 million.1 In 2000 it was 
estimated that 1.34 million disability adjusted life years (DALY’s) are lost to HAT annually.6  
 
Two strains of the parasite, Trypanosoma brucei gambiense and T. b. rhodesiense, are 
responsible for HAT. T. b. gambiense is estimated to be responsible for 95% of cases endemic 
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in Western and Central Africa. The remaining cases of HAT are attributed to the T. b. 
rhodesiense strain which is prevalent in Eastern and Southern Africa.1 The two strains have 
differences in epidemiology, symptoms and progression of the disease.  
 
The disease has two stages: the first is haemo-lymphatic, which then progresses into the 
second meningo-encephalitic stage where more severe symptoms present themselves.7 
After initial contraction of HAT a chancre (a primary sore or ulcer) may appear at the sight of 
infection. Stage one disease symptoms include intermittent fever, headaches, itching and 
musculoskeletal pain. Enlargement of the cervical lymph nodes are also common, referred 
to as Winterbottom’s sign. The second stage of the disease arises once the trypanosomes 
traverse into the central nervous system (CNS), which causes neurological symptoms. 
Sleeping dysfunction arises from the disruption of the circadian rhythm.8 Sensory disorders 
and tremor are also often observed. The disease progresses to coma and death resulting 
from organ haemorrhage if left untreated.7 
 
Diagnosis of the disease is not straightforward, relying on serological and parasitological 
screening. Samples from aspirated lymph nodes or blood are used to diagnose stage one of 
the disease. Diagnosis of stage 2 of the disease requires cerebrospinal fluid (CSF) samples 
taken from lumbar puncture.1 Samples are analysed using the card agglutination test for 
trypanosomiasis (CATT) originally developed by Magnus et al. in 1978.9 The CATT diagnosis 
is used to detect T. b. gambiense specific antibodies from the blood, serum or CSF fluid of 
patients. Positive identification of specific antibodies is then confirmed by parasitological 
screening. An updated thermostable version of the CATT detection antibodies has recently 
been developed.10 The test is also only available for T. b. gambiense; T. b. rhodesiense 
diagnosis continues to rely on parasitological screening. The non-profit Foundation for 
Innovative New Diagnostics (FIND) is working with The World Health Organisation (WHO) to 
more accurately determine levels of HAT. Early diagnosis improves treatment for HAT and 
can identify areas at high risk for preventative measures.  Reported cases of HAT in the 
Democratic Republic of Congo are now below 4,000, the lowest levels observed for 75 
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years.11 Global annual cases are estimated to be 20,000. Currently, screening for HAT is not 
carried out in Nigeria12 or Ghana and the environment is too unstable to carry out effective 
screening in the Central African Republic (CAR).13 Improved diagnostic devices are now 
available for T. b. gambiense HAT,14 facilitating future screening campaigns for the disease.  
 
T. b. rhodesiense causes an acute disease progressing to stage two within a few weeks of 
transmission. Infection from T. b. gambiense progresses more slowly, developing to the 
second stage nine months to two years post infection.1 This has been attributed to the 
greater number of trypanosomes being present in T. b. rhodesiense infection over T. b. 
gambiense.7 Without treatment HAT is considered fatal;15 existing therapies require 
complicated, prolonged administration of compounds that have poor pharmacokinetic and 
CNS penetration properties, or are drugs that are highly toxic resulting in unacceptable side 
effects.16 
 
1.1.2 African animal Trypanosomiasis 
Trypanosomal diseases are also observed in other vertebrates and referred to as Nagana or 
AAT. Cattle and other livestock are the most frequently infected animals due to the feeding 
patterns of Tsetse flies. AAT in domestic animals is observed as a wasting disease; animals 
appear extremely thin, have anaemia and are in general poor condition. AAT is often fatal 
without intervention for domestic animals. Trypanosoma infections have also been observed 
in a range of wild animals. However, wild animals are less affected by the trypanosome and 
have developed some evolutionary trypanotolerance.17 
 
A larger range of Trypanosoma species are responsible for AAT; the most common are T. b. 
spp., T. vivax and T. congolense. AAT parasites are not only detected in Africa; T. vivax is also 
found across South and Central America along with areas of the Caribbean that do not have 
Tsetse flies, where it is thought to be transmitted mechanically by other biting insects.2,18 T. 
evansi has been identified in areas of Vietnam following an investigation into a human case, 
where infected cattle were identified as the source of the parasite.19 
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In Africa it is estimated that the economic burden of AAT in cattle loss alone is 1 to 1.2 billion 
US dollars per year.20 The extra cost of reduced productivity of livestock, and in treating 
infected animals along with preventative measures in affected regions of farming is also a 
detriment of the disease.20 The infected animal populace also provides a reservoir of T. b. 
rhodesiense, from which HAT can be contracted in a zoonotic manner.1  
 
Diagnosis of AAT is also through parasitological investigation from blood smears taken from 
animals that show symptoms of anaemia and emaciation. Confirmation of trypanosome 
infection and species is often carried out by antibody analysis or xenodiagnoses.21,22 Current 
attempts to control AAT consist of Tsetse fly traps and spray on livestock insecticides.1,7,23 
Tsetse habitat removal has also been employed as a means of controlling infection rates with 
some success, along with a range of veterinary treatments and prophylactics.24 
 
1.1.3 Trypanosoma brucei spp. 
Protozoa are a varied group of eukaryotic unicellular organisms that have been sub divided 
into 8 phyla.25 Trypanosoma are of the Kinetoplastea class of Euglenozoa as they contain a 
kinetoplast, a circular structure of mitochondrial DNA,26 located at the base of the flagellum, 
a whip like organelle used for propulsion.27 One of the first recorded observations of 
flagellated protozoan blood parasites was by Gruby in 1843, whilst microscopically studying 
the blood from a frog.28 170 years of further research and study have given a detailed 
perspective of the trypanosome life cycle and biology.  
 
Trypanosoma b. spp. (all Trypanosoma brucei species) have a complex life cycle (Figure 2), 
where adaptations in metabolism and immune evasion are vital for the survival and 
transmission of the parasite. Metacyclic trypomastigotes are initially injected into the 
mammalian host from a Tsetse blood meal. Once in the mammalian blood stream, they 
transform into long slender bloodstream trypomastigotes that rely on glycolysis for 
respiration. No evidence of a functional tricarboxylic acid cycle or respiratory chain has been 
observed.29 Trypanosomes multiply asexually by binary fission to increase parasite load in 
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the host, and can move throughout blood and tissue. Some trypanosomes differentiate into 
short stumpy trypomastigotes which can then be ingested by another Tsetse fly taking a 
blood meal from an infected mammal. Once in the Tsetse mid gut the trypanosome sheds its 
variant surface glycoprotein (VSG) coat, replacing its coat with glycosyl phosphatidylinositol 
(GPI)-anchored procyclins differentiating into procyclic trypomastigotes. This change is 
thought to be a response to the increased levels of proteases and higher pH of the Tsetse 
gut.30 Once the procyclic trypomastigote is established the trypanosome can migrate to the 
anterior of the midgut. The respiratory pathways of procyclic trypanosomes also change; the 
mitochondrion re-establishes tricarboxylic acid cycle enzymes and electron transport chain 
complexes.29 The procyclic forms elongate into mesocyclic trypomastigotes where upon they 
transfer to the Tsetse salivary glands and develop into epimastigotes, attaching to the 
epithelium of the salivary gland wall with their flagella. Over time these epimastigotes 
transform into short infective metacyclic trypomastigotes regenerating their VSG coat ready 
for reinfection of a mammalian host and completing their life cycle (Figure 2). 
 
Trypanosomes have adapted to thrive in both Tsetse and mammalian hosts. Without 
intervention the parasites can multiply to high levels and are one of only a few parasites that 
are able to cross into the CNS. It has been shown that trypanosomes can exploit host derived 
inflammatory mediators such as cytokines, chemokines and adhesion molecules to move 
across membranes.31,32 Trypanosomes also generate cysteine proteases that interact with 
protease-activator receptor 2 (PAR2) a G-coupled protein coupled receptor (GPCR) on 
endothelial cells that can increase blood brain barrier (BBB) permeability.31,33 Once a host 
has been infected, trypanosomes are able to avoid host immune response by antigenic 
variation of their VSG coat.34,35 The VSG coating not only enables the variation of antigen 
expression on the surface of the trypanosome but also sterically blocks recognition of other 
surface proteins. The extent to which trypanosomes are able to alter their surface protein 
expression makes vaccine development extremely difficult,36 highlighting the need for 
identification of safe treatments for HAT and AAT. 
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Figure 2 - Trypanosoma life cycle – image from Centre for Disease Control and Prevention – copyright free Public 
Health Image Library (image 3418), da Silva and Moser 200337 
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1.2 Current Treatments 
1.2.1 Human African trypanosomiasis 
There are currently four treatments for HAT, their use is specific to the strain of infective 
parasite and the stage of disease diagnosis. Many of the drugs used to treat the disease have 
undesirable side effects or complex requirements for administration summarised in Table 1. 
Suramin 
 
Figure 3 – Suramin – 1 
 
Suramin (1 - Figure 3) has been the standard of care for Stage 1 HAT caused by T. b. 
rhodesiense since 1920. Suramin was developed by Bayer in the early 1900s, following the 
discovery of the trypanocidal activity of the azo dye trypan red.38 It is administered as five 
intravenous injections of 20 mg/kg every 5 - 7 days.39 Mild kidney toxicity and fever are often 
seen as adverse reactions.16 It has a very high topological polar surface area (PSA) of 430 Å2 
that is likely responsible for its inability to pass through biological membranes. In general 
compounds with PSA above 140 Å2 have been shown to be poorly passively permeable 
through biological membranes.40 This could be the reason that Suramin has low oral 
bioavailability and requires intravenous administration. It could also give reason for why the 
treatment isn’t effective against stage two of the disease, where the parasite has penetrated 
the CNS.41,42 It has been shown that Suramin binds to serum proteins and is taken up by 
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trypanosomes via receptor mediated endocytosis.43 Suramin is a multi-action kinase and 
dehydrogenase inhibitor, inhibiting all glycolytic enzymes in trypanosomes more potently 
than the mammalian counterparts leading to its efficacy and observed local toxicity upon 
dosing.44 Resistance to suramin has not been frequently observed, supporting the idea that 
it inhibits trypanosomes via multiple mechanisms of action (MOA).45 
Melarsoprol 
 
Figure 4 – Melarsoprol - 2 
 
The meningo-encephalitic stage of HAT caused by T. b. rhodesiense, can presently only be 
effectively treated with Melarsoprol (2 - Figure - 4). It is administered intravenously at 
3.6 mg/kg in a series of 4 injections separated by at least one week.39 Organo-arsenides have 
inherently high levels of toxicity. 5 – 10% of patients treated with the Melarsoprol suffer 
brain injury as a side effect, and in these patients the side effects cause are fatal for 
approximately 1 – 5%.46 Melarsoprol inhibits phosphofructokinase, leading to the depletion 
of fructose-2,6-bisphosphate that halts the activity of pyruvate kinase, glycolysis and overall 
energy production within the trypanosome.47 Uptake of Melarsoprol has been shown to be 
via the P2 amino purine transporter. Melarsoprol resistance can occur in trypanosome 
strains that lack this transporter.48,49 Increasing incidences of resistance have been observed 
and in the early 2000’s failure rates for Melarsoprol treatment had reached 20 – 30%.50 
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Pentamidine 
 
Figure 5 – Pentamidine - 3 
Stage 1 HAT caused by T. b. gambiense is currently treated with a drug developed in the early 
1940s, Pentamidine (3 - Figure 5). It has been shown that Pentamidine has an affinity for 
kinetoplast DNA.51 The mechanism of trypanocidal activity of this molecule is as yet unknown. 
It is hypothesised that pentamidine could have an inhibitory effect on mRNA trans-splicing, 
although further experimental evidence is needed to prove this MOA.45 The uptake of 
pentamidine has also been shown to rely on P2 amino purine and two other similar 
transporters. Resistance against the drug has been observed and attributed to trypanosomes 
having reduced drug uptake.49,52 Pentamidine is administered via a deep muscular injection 
at 4 mg/kg in 7 - 10 daily injections, as it is not orally bioavailable. However, intravenous 
administration results in hypotensive side effects.16,39 The drug has limited effect against the 
second stage of the disease linked to its poor BBB permeability.45 Work into generating a 
pro-drug of di-amidine compounds has been undertaken by Midgley et al. to improve drug 
permeability and tissue distribution, particularly CNS penetration.53 Although improvements 
in permeability and CNS penetration were achieved, compound related toxicity was observed 
in in vivo experiments and further studies into alternative dosing regimens resulted in a lack 
of efficacy in primate models.54,55 
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Eflornithine 
 
Figure 6 – Eflornithine – 4 
 
Stage 2 HAT caused by T. b. gambiense, is now standardly treated with a Nifurtimox (5), 
Eflornithine (4) combination therapy (NECT) replacing the use of Melarsoprol (2). Eflornithine 
(4 - Figure 6) is a suicide inhibitor of orthinine decarboxylase, an enzyme that catalyses the 
first stage of polyamine biosynthesis.56 Polyamines are important for cell growth, 
proliferation, chromatin structure and stability and are involved in gene expression, along 
with ion channel regulation.57 In particular, the polyamine spermidine plays an important 
role in trypanosomes, conjugating two molecules of glutathione into trypanothione which 
regulates redox homeostasis in the parasite.58 Resistance to Eflornithine has been observed 
and attributed to decreases in the expression of specific amino acid transporters that are 
responsible for trypanosomal uptake of drug.59 Eflornithine is administered via slow 
intravenous infusion of 200 mg/kg every 12 h for 7 days with oral administration of 
nifurtimox.39 Side effects most frequently observed are bone marrow toxicity and related 
anaemia.60 
Nifurtimox 
 
Figure 7 – Nifurtimox – 5 and structure of active trypanocide 6 
 
Nifurtimox (5 - Figure 7) has been used for the past 40 years to treat another trypanosomatid 
infection, Chagas disease, and has only recently been approved for stage 2, T. b. gambiense 
HAT infections in a combination therapy with Eflornithine (4).61 Nifurtimox is administered 
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orally 5 mg/kg every 8 h for 10 days. It was originally thought to induce oxidative stress in 
the parasite; however, recent data reported by Hall et al. has shown that Nifurtimox is acting 
as a pro-drug. Nifurtimox is reduced by a trypanosomal nitro-reductase (NTR) resulting in an 
open-chain nitrile product (6) that is cytotoxic and able to inhibit trypanosomal growth.62 The 
combination therapy has proven highly successful, with a cure rate of 95% in studies of 
patients with meningo-encephaltic HAT caused by T. b. gambiense.61 The combination 
therapy provides an improved adverse event profile over Eflornithine alone, and reduces 
treatment time from 2 weeks to 1.63 Unfortunately, due to the rapid regeneration of 
orthinine decarboxylase in T. b. rhodesiense, Eflornithine has limited utility against this strain 
and thus the combination therapy is only recommended for T. b. gambiense infections.64
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Table 1 - Summary of HAT treatments 
Treatment Date 
introduced 
Parasite Species Stage of 
disease 
Dosing Pros Cons 
Suramin 
(1) 
1922 T. b. rhodesiense 1 5 x 20 mg/kg 
every 5 - 7 d 
No resistant strains 
observed 
Stage 1 only 
Kidney toxicity 
Pentamidine 
(3) 
1940’s T. b. gambiense 1 4 mg/kg, 7 – 10 
daily injections 
Effective at treating 
stage 1 T. b. 
gambiense 
Stage 1 only 
Resistant strains observed 
Melarsoprol 
(2) 
1949 T. b. rhodesiense 2 4 x 3.6 mg/kg 
every 7 d 
Effective against stage 
2 of both T. b. 
gambiense and T. b. 
rhodesiense 
High toxicity (0.5% clinical 
fatalities) 
Resistant strains observed 
Failures in the clinic 
NECT 
(5 + 4) 
2009 T. b. gambiense 2 (E) 200 mg/kg 12 
h infusion for 7 d 
(N) 5 mg/kg 
every 8 h 10 d 
Effective against stage 
2 
Prolonged administration 
for 1 week. Requires cold 
storage and transport. 
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New Approaches 
The issues with current HAT treatment options summarised in table 1 have resulted in the 
involvement of the Drugs for Neglected Diseases initiative (DNDi), a non-profit public private 
partnership organisation. The DNDi collaborates with a variety of academic and industrial 
partners to aid the identification and progression of new HAT treatments. They have released 
an ideal product profile for new compounds (Table - 2), to ensure that potential treatments 
have the desired features to improve upon the options presently available in the clinic.65 
There are currently two treatments under investigation, in phase I and phase II/III clinical 
trials, for T. b. gambiense HAT with the DNDi.66 
 Table 2 - DNDi product profile criteria65 
Ideal Acceptable: improvement to current 
Effective against stage 1 & 2 Effective against stage 1 & 2 (used stage 
2 only) 
Broad Spectrum (T. b. gambiense and T. b. 
rhodesiense) 
Efficacy against T. b. gambiense only 
Clinical efficacy > 95% at 18 months follow up 
 
Effective in melarsoprol refractory patients 
 
< 0.1% drug related mortality < 1% drug related mortality 
Safe during pregnancy and for 
lactating women 
 
Adult and paediatric formulations 
 
No monitoring for Adverse Events Weekly simple lab testing (field testing) 
< 7 d oral dosing, once daily (Directly 
Observed Treatment) 
10 d oral dosing (up to three times a 
day) 
< 7 d i.m. once daily 10 d i.m. once daily 
Stability in Zone 4 (tropical – heat and 
humidity) for > 3 years 
Stability in Zone 4 for > 12 months 
Trypanocidal 
 
Multitarget Unique target (but not uptake via P2-
transporter only) 
< 30 € per patient drug course < 100 € per patient drug course 
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Fexinidazole 
 
Figure 8 – Fexinidazole – 7 
 
Fexinidazole (7 - Figure 8) was developed in the 1970s as a broad spectrum antimicrobial 
agent, in the 1980s was shown to have in vivo efficacy against stage 2, T. b. brucei infections 
in mice.67 Further evaluation demonstrated that the compound was acting as a pro-drug, 
being oxidised by a range of CYP450 enzymes to both the sulfone and sulfoxide active 
metabolites.68 Although its mode of action is unknown, there are other nitro-hetero-
aromatic chemotherapeutics that function as pro-drugs, being reduced by target nitro-
reductases to generate cytotoxic agents.69 Some evidence supporting this has been reported.  
A down regulation in the nitro-reductive enzymatic pathway of T. b. brucei, has been shown 
to increase parasite resistance to both Fexinidazole and Nifurtimox.70 An extensive 
pharmacokinetic study has shown that Fexinidazole is suitable for oral administration. The 
parent compound is well absorbed and the active metabolites show long half-lives in vivo, 
producing cures in infected rodents after treatment with 100 mg/kg dosed daily for four 
days.71 The compound was recently assessed in a phase II/III non-inferiority to NECT clinical 
trial, dosing orally for 10 days. The results from the trial showed that a similar efficacy to 
NECT could be achieved with Fexinidazole, with no observed differences in treatment-
emergent adverse events between the two arms of the study.72 Fexinidazole is currently 
undergoing a phase IIIb study investigating home administration of the treatment compared 
to hospitalisation and dosing (ClinicalTrials.gov Identifier: NCT03025789).73 
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SCYX-7158 Oxaborole 
 
Figure 9 - SCYX-7158 Oxaborole - 8 
 
The other compound currently being assessed in the clinic is the oxaborole SCYX-7158 (7 – 
Figure - 9). The oxaborole chemotype was first identified from a phenotypic screen against 
T. b. brucei. Further work to optimise the pharmacokinetic properties of these compounds 
identified SCYX-7158 as having improved blood brain barrier permeability. This compound 
was progressed to in vivo pharmacokinetic models, where good oral bioavailability and long 
duration were observed.74–76 In vivo mouse models indicated that a daily oral dose of 
25 mg/kg for seven days could clear a stage 2 infection of T. b. brucei in mice.75 The 
compound’s MOA is unknown, but initial work has shown that removal of the boron atom 
resulted in complete loss of activity.75 The compound was successfully assessed in healthy 
volunteers in a phase I clinical trial; clinicaltrials.gov NCT01533961.77 A follow-up efficacy 
phase II/III study is currently underway; ClinicalTrials.gov Identifier: NCT03087955.78 
 
NMT inhibitors 
 
Figure 10 - NMT Pyrazole sulphonamide – 9 
 
Further to this, academic and industrial groups have looked into new effective treatments 
for HAT either via inhibiting parasite specific targets or through phenotypic 
screening.44,79,88,89,80–87 N-myristoyltransferase (NMT) has been shown to be vital for 
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trypanosome survival by RNA interference (RNAi) gene knockdown experiments.90 The 
screening of a diverse set of 62,000 compounds by the Dundee Drug Discovery Unit identified 
a class of pyrazole sulfonamide compounds that were inhibitors of this enzyme. They were 
shown to inhibit trypanosome growth, resulting in clearance of a haemo-lymphatic infection 
in mice.83 Further work to optimise BBB penetration resulted in compounds with reduced 
polar surface area (PSA) and increased lipophilicity (9 – Figure 10). Although CNS penetration 
was achieved with these compounds, off target activity attributed to poor tolerability in in 
vivo studies and further work on this target has been halted.81 
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1.2.2 African animal trypanosomiasis 
Homidium 
 
Figure 11 – Homidium – 10 
 
The phenanthridine homidium bromide or chloride (10 - Figure 11) can be used to clear T. 
vivax, T. b. spp and T. congolense infections in cattle and horses.91 Homidium has some action 
as a prophylactic, preventing trypanosomal infections for 17 to 19 weeks.92 The 
phenanthridine chemical class was first identified as a trypanocide in 1938 by Browning et 
al.93 Further development of the class by Watkins and Woolfe identified that the quaternary 
ethyl phenanthridine Homidium was much less toxic than the quaternary methyl 
phenanthridine Dimidium.94 It has been suggested that the phenanthridine class of 
trypanocides act by intercalating DNA base pairs.95 Unfortunately, decades of administration 
of Homidium as a prophylactic has given rise to parasite resistance to the phenanthridine 
class of trypanocides.96,97 Due to the lack of sufficient research funding into these 
agrochemicals, minimal exploration of the resistance mechanisms in AAT has been 
performed. Resistant cases of AAT are alternatively treated with Isometamidium or 
Diminazene. Homidium is now only used as a prophylactic due to observed resistance, and 
not a treatment option for AAT.98 
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Diminazene 
 
Figure 12 – Diminazene – 11 
 
Diminazene (11 - Figure 12) is a diamidine trypanocide, similar in structure to HAT treatment 
pentamidine.99 The compound was introduced to treat infections of T. congolense, T. b. spp., 
T. vivax and babesiasis in 1955.100 It is not recommended for use as a prophylactic, as 
evidence has shown that its protective effect is short lived, lasting for a maximum of 7 days 
as it is excreted rapidly.99 Diminazene acts on binding to kinetoplastid DNA (kDNA) by direct 
interaction with sites rich in thymine-adenine base pairs.101 This blocks the generation of RNA 
primers and inhibits kDNA replication. The inhibition of mitochondrial type II topoisomerase 
has also been shown with Diminazene, which also prevents the replication of DNA.51 
Resistance to Diminazene is seen to a lesser extent than to Homidium (10) and 
Isometamidium (12). The resistance mechanism is unknown but postulated to be similar to 
that of Pentamidine, as it is reliant on P2 amino transport for uptake by the trypanosome.102 
Isometamidium 
 
Figure 13 – Isometamidium – 12 
 
Isometamidium (ISM) (12 - Figure 13), also a phenanthridine, is currently used as both a 
prophylactic and treatment for cattle infections of T. congolense, T. vivax and T. b. spp. The 
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compound was designed in 1961, combining the moieties from the earlier discovered 
trypanocides, Homidium and Diminazene. ISM has been shown to localise in kinetoplastid 
DNA to a greater extent than homidium.103 The compound can act prophylactically for up to 
5 months against single or multiple T. congolense challenges.104 However, resistance to ISM 
by T. congolense has also been observed. Studies carried out by Delespaux et al. identified a 
mutated trypanosomal protein structurally similar to ABC-multidrug transporters as a 
potential mechanism for resistance, that resulted in reduced parasite concentrations.105 
 
Quninapyramine 
 
Figure 14 – Quinapyramine – 13 
 
Quinapyramine, otherwise known as antrycide (13 Figure 14), was discovered in 1950 by 
Curd and Davey as a curative and prophylactic treatment for T. congolense and T. Evansi.106 
It is widely used for infections in horses, camels, pigs and dogs due to its cross reactivity 
against a wide range of trypanosome species: T. vivax; T. congolense; T. evansi; T. b. spp.; T. 
equiperdum; and T. simiae. It has been shown that Quinapyramine inhibits trypanosome cell 
division but not nuclear division and is not itself a trypanocide.107,108 The trypanostatic 
response that it produces presumably enables the host immune system to clear the parasite 
infection.109,110 Resistance to Quinapyramine has been observed in some species of 
trypanosome, but the mechanisms behind this resistance are not well understood.111 
 
46 
New Approaches 
 
Figure 15 - AN7973 Oxaborole – 14 
 
Following on from the apparent success of the oxaborole compound SCYX-7158 as a 
potential treatment option for HAT, the pharmaceutical company Anacor have initiated 
investigations into identifying an oxaborole compound suitable for treating AAT. One 
compound (AN7973 – 14 - Figure 15) was identified to successfully clear T. congolense 
infections in vivo. Efficacy against the T. vivax strain was however not observed at a similar 
dosage. Further follow up compounds are currently being explored to increase potency 
against other strains, specifically T. vivax, and efforts to improve metabolic stability are 
ongoing.112 
 
1.3 Trypanosome alternative oxidase 
1.3.1 The Enzyme 
Despite the recent successes of new approaches towards the treatment of HAT and AAT, 
alternative therapies are needed that are less toxic to the host and that provide efficacy in 
emerging drug-resistant parasite strains. Targeting a trypanocidal mechanism that is absent 
in the host is an attractive strategy to avoid on target host selectivity issues. Trypanosome 
alternative oxidase (TAO) has been investigated by a variety of academic groups as a 
potential target for treating HAT.84–87 The oxidase is the sole aerobic respiratory terminal 
oxidase located in the mitochondria of the long slender bloodstream form of T. b. spp.113,114  
TAO oxidises two equivalents of ubiquinol to ubiquinone, in tandem carrying out the four-
electron reduction of oxygen to water. Ubiquinone is reduced by mitochondrial glycerol 
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phosphate dehydrogenase (GPDH) as part of the glycerol phosphate oxidase system to 
generate flavin adenine dinucleotide (FAD). FAD is further utilised by GPDH to recycle 
glycerol-3-phosphate (G3P) back into dihydroxyacetone phosphate (DHAP).  DHAP can return 
to the glycolytic pathway via triose phosphate isomerase to enable the net generation of 2 
molecules of ATP from each molecule of glucose. ATP is essential for cellular respiration, 
survival and growth of the trypanosome (Red - Figure 16).113,115,116 A compensatory 
anaerobic mechanism of glycolysis is available to T. b. brucei (Blue – Figure 16). Under 
anaerobic conditions, or when TAO is inhibited, G3P accumulates from the breakdown of 
fructose-1,6-biphosphate. Under these increased concentrations of G3P, glycerol kinase (GK) 
can function in reverse to allow the generation of 1 molecule of ATP, facilitating survival of 
the parasite. It has been shown that once glycerol, the by-product from the reverse action 
of GK, accumulates trypanosome viability is compromised and parasites are unable to 
survive.116 Both the aerobic and anaerobic pathways exploit DHAP and cytosolic glycerol 
phosphate dehydrogenase to generate NAD+, which is also essential for parasite energy 
production and function (Figure 16).
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Figure 16 - Glycolysis in T. b. brucei
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TAO was first observed by Chaudhuri et al. whilst immunoblotting mitochondrial proteins 
isolated from T. b. brucei, with monoclonal and polyclonal antibodies that had been raised 
against voodoo lily and skunk cabbage plant alternative oxidases.117 Two protein bands were 
identified, one a dimer that could only be denatured under rigorous conditions. Further 
immunofluorescent studies with the monoclonal antibody showed the protein to be localised 
in the mitochondria of the blood stage long slender trypomastigote and absent in the insect 
stage procyclic trypomastigote. The mitochondrial fraction of the trypanosomes was 
solubilised with lauryl maltoside or NP-40 detergents and fractionated by size exclusion gel 
filtration chromatography to isolate the ~33 kDa protein where TAO enzymatic activity 
resided.117 In a follow up article from the same group cDNA cloning was carried out and the 
mitochondrial protein was characterised as TAO.118 
Ever since the identification of TAO, and the establishment of its role in trypanosome 
respiration,113,119 the generation of purified recombinant trypanosome alternative oxidase 
(rTAO) was a focus of many groups.120–124 The identification of the gene responsible for the 
expression of TAO provided the means to clone and transfect DNA into E. coli for the 
recombinant expression of functionally active TAO.118,122 Different groups have used various 
E. coli expression strains to aid production of active protein. Initially, haem deficient E. coli 
that lack cytochrome respiratory pathways were employed to show that alternative oxidase 
expression could rescue the growth of bacteria and that this could be fully inhibited with the 
plant alternative oxidase inhibitor salicylhydroxamic acid (Figure 20).118 Some groups 
continued to use haem deficient E. coli for recombinant expression of rTAO to remove the 
interference of other ubiquinol oxidases, primarily cytochrome bo and bd, useful for 
assessing the enzymatic activity of crude membrane fractions.120,122,125 Other groups have 
preferred to express rTAO in standard BL21 E. coli strains. Primarily, these were used to 
reduce the effect of disruption of the succinate dehydrogenase complex, a key haem enzyme 
that regulates the energy metabolism of E. coli, that had resulted in poor growth of the E. 
coli cultures and prevented their large scale preparation.126  
Further screening and optimisation of detergents for the efficient solubilisation of E. coli 
inner membrane fractions and rTAO protein has enabled the isolation of larger amounts of 
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higher purity protein.120 This has facilitated biochemical studies of the enzyme and the 
generation of robust functional assays. It has also enabled structure elucidation through 
protein crystallisation to a 2.9 Å resolution, and hence structure based design of new 
inhibitors.127–130 
 
Figure 17 - Trypanosome alternative oxidase - Apo structure adapted from crystal structure PDB 3VV9, Shiba et 
al.129, coloured by helix using Maestro – Schrodinger drug discovery suite 
 
The structure of TAO has 6 α-helices 4 of which are arranged in a 4-α-helix bundle that 
accommodates the di-iron catalytic centre of the enzyme (Figure 17 - orange spheres).131 
The di-iron nature of TAO was first elucidated by inductively coupled plasma mass 
spectrometry (ICP-MS) experiments that confirmed the initial suggestion of a di-iron centre 
from the similar electron paramagnetic resonance spectroscopy (EPR) signals that were 
observed between analysis of TAO and other di-iron carboxylate proteins. 120,132 Site directed 
mutagenesis of the residues around the di-iron active site have shown large detriments to 
the enzymatic activity. Specifically, A216L/N, E213A, E215A, L122A/N, R118A/Q, T219V and 
Y220F mutations lead to complete loss of enzymatic activity (Figure 18).129 
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Figure 18 - Key residues of TAO established by site directed mutagenesis - Apo structure adapted from crystal 
structure PDB 3VV9, Shiba et al.129, mutated residues displayed and labelled, iron atoms coloured orange using 
Maestro – Schrodinger drug discovery suite.  
 
The binding pocket of TAO has been characterised with inhibitor-protein crystal structures 
to 2.5 Å resolutions.129 The natural product inhibitor colletochlorin B (CCB) (Figure – 23) is 
shown to bind close (within 3 - 4 Å) to the di-iron centre of TAO and occupy a lipophilic 
chamber formed inbetween 4 of the α-helices (Figure – 19). 
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Figure 19 - TAO binding pocket adapted from crystal structure PDB 3W54 Shiba et al.129, protein-ligand surface 
displayed grey, CCB in pink, di-iron centre orange spheres. Generated in Maestro – Schrodinger drug discovery 
suite.  
 
The alternative oxidase is a desirable drug target as it is not present in mammalian host cells 
and is specific to the long slender blood stream form of T. b. spp.86 Genetically engineered 
trypanosomes that overexpress TAO show increased resistance to Suramin and reactive 
oxygen species.133,134 A recent study on the AQP2 amino purine drug resistant strains of T. b. 
gambiense and a laboratory generated T. b. brucei AQP1-2-3 mutant have shown a 
heightened sensitivity to TAO inhibition. This has been linked to the parasites reduced 
capacity to effectively efflux glycerol, resulting in faster accumulation, inhibition of anaerobic 
respiration and parasite growth inhibition.135  
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1.3.2 Trypanosome alternative oxidase inhibitors 
Salicylhydroxamic acid 
 
 
Figure 20 - Salicylhydroxamic acid (SHAM) – 15 
 
The first identified inhibitor of TAO was salicylhydroxamic acid (15 – SHAM - Figure 20). It 
was discovered that the target of SHAM’s respiratory inhibition was a non-cytochrome 
alternative oxidase, insensitive to cyanide and antimycin A. 136–138 Similar alternative oxidases 
have been observed in a variety of plants, fungi and the parasitic protozoa T. b. brucei.116 Due 
to TAO’s role in respiratory function within the long slender blood stream form of 
trypanosomes, several groups have investigated inhibiting the proliferation of the parasite 
with SHAM analogues.84,85,87 It has been shown that inhibition of TAO with SHAM and the 
inhibition of the anaerobic glycolysis pathway by mass action with glycerol could clear an 
infection of T. b. brucei in rats.138 The importance of the combination of a TAO inhibitor being 
co-administered with a high concentration of glycerol has been the subject of some debate. 
It is generally thought that glycerol is acting by shutting down the anaerobic glycolytic 
pathway, by stopping the function of glycerol kinase via mass action.138–140 Excipient effects 
on solubility, absorption and distribution of alternative oxidase inhibitors with and without 
glycerol has not been reported in the literature. SHAM is reported to have high micromolar 
affinity for inhibiting TAO.87 
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Ascofuranone 
 
Figure 21 - Ascofuranone (AF) – 16 
 
Ascofuranone (16 - Figure 21), a natural product isolated from the fungus Ascochyta viciae 
was first identified as an antibiotic in the 1970’s.141,142 It was identified from the same fungus 
from which a similar natural product, ascochlorin was isolated.143  
The first synthesis of ascofuranone was reported by Mori and Fujioka, along with its 
hypolipidemic and anti-tumour properties (Figure - 22).144 Treatment of the THP-protected 
intermediate (17) that had previously been utilised by Mori et al. with a preformed lithium 
enolate in an aldol type reaction provided the diol intermediate (18). This could be cyclised 
under acidic conditions to provide the furanone ring (19). Swapping the THP protecting group 
on the terminal alcohol with acetate and protection of the ketone as a cyclic ketal (20) 
allowed, conversion of the terminal alcohol to a geranyl bromide (21) via a tosylated 
intermediate and nucleophilic substitution with LiBr. This intermediate could be reacted with 
the anion of 1,3-dimethoxy-5-methylcyclohexa-1,4-diene to provide (22). Treatment of this 
intermediate with N-chlorosuccinimide (NCS) provided the di-α-chlorinated 
cyclohexanedione intermediate (23). Aromatisation, utilising 1,8-diazabicyclo[5.4.0]undec-7-
ene (DBU) to eliminate HCl and introduction of the diethyl acetal, aldehyde equivalent 
provided ascofuranone upon hydrolysis (16). 
The isolation of enantiomerically pure ascofuranone enantiomers was subsequently 
reported by the same group. The isolation was carried out via the chromatographic 
separation of a diastereomeric mixture of a derivatised intermediate, which provided the 
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individual enantiomers of ascofuranone after cleavage of the chiral auxiliary and completion 
of the synthesis.145  
Further investigation into AF’s anti-tumour properties highlighted the inhibition of 
respiration in macrophages.146 ascofuranone was subsequently identified as a potent 
inhibitor of glucose dependent respiration, specifically inhibiting the glycerol-3-phosphate 
oxidase system in trypanosomes. ascofuranone was identified to inhibit TAO at sub-
nanomolar and low single digit nanomolar concentrations.86,115,147 
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Figure 22 - Ascofuranone synthesis reported by Mori and Fujioka144
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Colletochlorin B (CCB) 
 
Figure 23 - Colletochlorin B (CCB) – 26 
 
Colletochlorin B (26 – Figure 23) was similarly identified in the 1970s, isolated from the 
fungus Colettotrichum nicotianae.148 The first synthesis was again described by Mori et al.149 
The original biological activity was reported to be as a potent cytotoxin of the human 
leukaemia cell line HL-60.150 It was later found to be a potent inhibitor of TAO in similar 
studies to ascofuranone and its analogues.128 Colletochlorin B’s synthesis is somewhat more 
tractable than that of ascofuranone, partly due to its reduced complexity and absence of a 
chiral centre. It shows very similar low nanomolar inhibition of TAO and thus is a preferred 
starting point for analogue synthesis and structure activity relationship (SAR) exploration.128  
Saimoto et al. reported an initial SAR exploration following their groups published crystal 
structure of a colletochlorin B : TAO complex (PDB 3W54 – Figure 19).128,129 They showed 
that the benzaldehyde could be replaced with nitrile or nitro electron withdrawing groups 
without much detriment to activity. Replacement with ketone and ester electron 
withdrawing groups showed 10 - 100-fold decreases in inhibitory potency against TAO, and 
greater than 100-fold decreases observed when replacing the aldehyde with chloro 
(turquoise - Figure 24 - A). They also showed that methylation of one of the phenols was 
tolerated with a small detriment to potency; however, the compound was rendered 
effectively inactive if the phenol ortho to the chloro atom was removed completely (blue - 
Figure 24 - A). Single removal of the chloro atom resulted in a compound with similar potency 
to CCB (orange - Figure 24 - A); however, once this was combined with removal of the methyl 
substituent a 10 to 100-fold decrease in inhibitory activity was observed (red/orange - Figure 
24). The phenol ortho to the aldehyde in the crystal structure (3w54), is expected to form 
hydrogen bond interactions with an arginine residue close to the active di-iron site (ARG118 
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– depicted in Figure 19). The addition of a terminal hydroxy on the geranyl chain resulted in 
a small decrease in potency against TAO and terminal carboxylic acid showed larger 
detriments in potency. Potencies similar to CCB and ascofuranone could be achieved when 
the acid was capped as a large lipophilic ester. (green - Figure 24 - A). When considering 
these extended compounds with regards to the crystal structure reported by the same group 
(3w54), it is likely that these terminal chain modifications are accessing the periphery of the 
enzyme and occupying solvent exposed regions of the protein. 
 
 
Figure 24 - A SAR summary from Saimoto et al.128, B Koning and Dardonville exploration of targeting TAO 
inhibitors to mitochondria. 
 
Recent reports by the groups of Koning and Dardonville on structurally similar TAO inhibitors 
have shown improvement in efficacy against T. b. brucei and T. congolense parasites (Figure 
24 – B). This has been achieved by targeting the compounds to the parasite mitochondria 
through cross linking inhibitors to cationic lipids, which have an affinity to the parasite 
mitochondria.151–153 However, the phenol ether linked analogues (Figure 24 - B – right), have 
shown increased cytotoxicity in mammalian cells and are yet to show an improvement in 
selectivity over the non-targeting inhibitors.151 The ester linked analogues (Figure 24 - B - left) 
have shown some susceptibility to cleavage in serum and higher than expected efficacy in 
parasites indicating alternative mechanisms of action than TAO inhibition alone.152 
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The initial SAR data around the colletochlorin B analogues and the availability of a protein-
inhibitor crystal structure provided an attractive starting point for the further investigation 
and optimisation of this chemotype. The overall aim of this project was to identify drug-like 
inhibitors of TAO, for use as tool compounds to validate TAO inhibition as a suitable target 
for the treatment of African trypanosomiasis. Therefore, colletochlorin B was used as a 
scaffold to investigate the lipophilic tail and aromatic substitution patterns to improve 
compound physicochemical properties. This thesis describes the SAR exploration undertaken 
around this natural product. The first step for this investigation required a source of active 
TAO, to enable the development of robust screening assays, described in the following 
chapters. 
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Chapter 2 
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Chapter 2 – TAO Protein Expression and Isolation 
2.1 Recombinant Protein Expression and Purification Introduction 
Recombinant protein expression has significantly advanced the biochemical sciences. This 
area has been reviewed extensively; for example advancements in bacterial expression 
systems such as Escherichia coli (E. coli) has most recently been reviewed by Rosano and 
Ceccarelli.154 Bacterial expression systems have many strengths: E. coli are able to achieve 
fast growth kinetics and reach high cell densities relatively quickly; the media required for 
culture is easy to prepare from cheap readily available materials; and transformation of 
exogenous DNA is facile.  
Typically, a specific gene of interest is inserted into E. coli cells for expression by mixing a 
plasmid containing the gene, with a competent strain of E. coli and subjecting the mixture to 
a mild heat shock. The short heat shock creates a temporary pressure imbalance between 
the inside and outside of the cell, causing the formation of pores in the cell membrane and 
enables the passage of the supercoiled plasmid DNA into the cell. Following this, the bacteria 
is recovered in super optimal broth with catabolite repression medium to maximise the 
transformation efficiency.155 Antibiotic resistance markers are often also included in the 
plasmid, and allow selection for cells containing the gene of interest.156 Once the gene has 
been transformed into the bacterial strain, large scale cultures of the E. coli can be carried 
out to overexpress the protein of interest. 
Bacterial expression systems often utilise T7 RNA polymerase promoters to activate protein 
expression. T7 RNA polymerase is activated by the lactose operon (lac operon). The lac 
operon is repressed under standard culture conditions by a lac repressor. Isopropyl β-D-1-
thiogalactopyranoside (IPTG) is used as a metabolically stable analogue of allolactose, the lac 
repressor’s endogenous ligand, and remains present at a constant concentration. Once IPTG 
disrupts the binding of the lac repressor to the lac operon, protein synthesis from the T7 
polymerase is initiated, resulting in the recombinant expression of the inserted gene.157 
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Expression of recombinant proteins as fusions with purification handles is common in 
biochemical protein preparations, and has enabled the isolation of tagged proteins to a high 
purity.154 Purification often utilises affinity chromatography where the tag has a high affinity 
to an immobilised resin, allowing the capture of the tagged protein, and removal of other 
protein impurities. The tagged protein can subsequently be eluted from the resin with a resin 
competitive reagent. Tagged recombinant proteins often contain an enzyme cleavable linker, 
which allows the subsequent removal of the purification tag following protein isolation. This 
is important as the tag may interfere with later enzyme function assessment.158 
Following the discovery of the TAO encoding gene by Chaudhuri et al., numerous protocols 
have been established detailing the recombinant expression of TAO in a variety of E. coli 
expression systems.117 Initially, expression systems similar to that used to express plant and 
fungus alternative oxidases were employed.121,122,159 These E. coli were haem deficient, and 
provided the advantage that they could not express respiratory cytochromes, that would 
interfere with the functional assessment of TAO, upon crude purification and isolation. 
However, haem deficient strains are impacted by low growth yields. Fukai et al also 
developed TAO expression systems in standard BL21 E. coli strains to improve yields and 
overcome this problem. These conditions have also been used to generate TAO by other 
groups,87,126 and Fukai’s protocol provided a basis for the recombinant expression of TAO 
described in this thesis. 
 
2.2 TAO Expression and Purification Methods 
2.2.1 TAO cDNA Transformation into Rosetta2® E. Coli 
A pET15b TAO plasmid (Figure 25), supplied by Anthony Moore at the University of Sussex, 
was transformed into Rosetta2® BL21 E. coli cells (Novagen). Cells were thawed on ice and 
treated with 1 µL of plasmid, and incubated on ice for 5 min. The cells were then heat 
shocked at 42 °C for 30 s in a water bath then placed back on ice for 2 min. Super optimal 
broth with catabolite repression medium (250 µL) was added and incubated at 37 °C with 
shaking for 1 h. The cell medium (50 µL) was then spread over lysogeny broth (LB) agar media 
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plates containing 50 µg/mL ampicillin and 35 µg/mL chloramphenicol. Plates were incubated 
at 37 °C overnight. A starter culture was made by picking a single colony into LB media 
(200 mL) containing 50 µg/mL ampicillin and 35 µg/mL chloramphenicol and incubated over 
night at 37 °C. Starter cultures of transformed E. coli were used for inoculating large scale 
cultures (1 L) and for the generation of glycerol stocks by mixing 1:1 with 50% glycerol in 
water. Glycerol stocks were stored at -80 °C for future use.  
 
 
Figure 25 - pET15b-TAO expression plasmid 
 
2.2.2 TAO Plasmid Amplification and Isolation 
To amplify and isolate plasmid DNA, a Qiagen maxi-prep was performed. The plasmid was 
transformed into E. coli (Rosetta2® BL21 DE3 cells). A single colony was picked into LB media 
(100 mL) containing antibiotics as before and grown at 37 °C overnight. The culture was 
centrifuged (4000 rcf, Beckman Coulter Allegra X30R centrifuge, SX4400 rotor) at 4 °C for 
20 min. The maxi-prep was performed using a Qiagen kit according to manufacturer’s 
instructions. The DNA was air dried before being re-suspended in TE buffer pH 8.0 (30 µL). 
The concentration of DNA was measured (NanoDrop Lite double stranded DNA setting) to 
be 1049 ng/µL. The plasmid was sequence confirmed (Eurofins Genomics, Figure 26) before 
storage. 
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2.2.3 TAO Expression Tests 
A pre-culture was prepared by inoculating LB medium (200 mL), containing ampicillin 
(50 µg/mL) and chloramphenicol (35 µg/mL), with the glycerol stock (200 µL) of TAO 
transformed Rosetta2® E. coli cells.  The culture was incubated at 37 °C overnight to provide 
sufficient starter culture to inoculate 8 x 1 L test cultures described overleaf (Table 3), 2 x 1 
L for each condition. Each test culture (1 L) was inoculated with starter culture (1 mL) and 
incubated at 37 °C, 150 rpm until an OD600 of 0.2 was achieved. Each culture was continued 
at 18 °C, 150 rpm until OD600 of 0.6 was achieved. Cultures were cooled at 4 °C for 15 min 
and one sample for each condition was induced, by the addition of IPTG to give a final 
concentration of 500 µM. The other culture was not induced for comparison. Each culture 
was grown at 18 °C. Samples were taken at time points 2 h, 4 h and overnight for comparison 
of expression outcomes (Figure 27). 
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Table 3 - Expression test conditions 
Test Culture Conditions Expression media contents 
LB Media LB media (20 g/L) 
Chloramphenicol (35 µg/mL) 
Ampicillin (50 µg/mL) 
Supplemented LB (Haem 
deficient E. coli conditions)122 
LB media (20 g/L) 
Chloramphenicol (35 µg/mL) 
Ampicillin (50 µg/mL) 
K2HPO4 (10.4 g/L) 
KH2PO4 (3 g/L) 
trisodium-citrate·2H2O (0.75 g/L) 
(NH4)2SO4 (2.5 g/L) 
MgSO4·7H2O (0.05 g/L) 
FeSO4·7H2O (0.025 g/L) 
FeCl3 (0.025 g/L) 
glucose (0.2% w/v) 
Betaine, sorbitol medium LB media (20 g/L) 
Chloramphenicol (35 µg/mL) 
Ampicillin (50 µg/mL) 
Sorbitol (120 g/L) 
Betaine (2.5 µM) 
Turbo broth Turbo broth (16 g/L) 
glycerol (4 mL/L) 
Chloramphenicol (35 µg/mL) 
Ampicillin (50 µg/mL) 
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2.2.4 E. coli Inner Membrane Fraction Isolation and Solubilisation 
A pre-culture was prepared as in the expression tests and used to inoculate 4 × 1 L of betaine 
sorbitol media containing the appropriate antibiotics as described in section 2.2.3. The 
culture was incubated at 37 °C, 150 rpm until an OD600 of 0.2 was achieved, then the 
temperature was reduced to 18 °C until OD600 of 0.6 was achieved. The culture was cooled 
to 4 °C for 15 min, then induced by the addition of IPTG (0.5 mL of 1 M stock, to give a final 
concentration of 500 µM). The cultures were grown at 18 °C overnight. 
The cells were harvested by centrifugation (Beckman Coulter Avanti J26S, JLA9.1000 rotor, 
at 8000 rpm for 1 h at 4 °C) and lysed for purification of TAO immediately. The pellet was 
resuspended in lysis buffer (50 mL, 50 mM Tris HCl, 20% (w/v) sucrose pH 7.4, 1 × protease 
inhibitor cocktail tablet and 2 µL of Benzonase / DNAse® Sigma). Cells were lysed by 
sonication (Sonics Vibracell, 13 mm probe, 35% intensity, 180 s, 5 seconds pulse), then cell 
debris and unbroken cells were removed by centrifugation (Beckman Coulter Avanti J26S, JA 
25.50 rotor, 8000 g, 10 min, 4 °C) to provide the supernatant as the crude fraction for inner 
membrane isolation. 
The crude supernatant was overlaid onto 45% sucrose solution (3 × 20 mL, 50 mM Tris-HCl, 
45% (w/v) sucrose, pH 7.4) and ultra-centrifuged (Beckman Coulter L-80, SW28, 141000 rcf 
max, 1 h, 4 °C) to isolate the E. coli inner membranes as the buoyant supernatant fraction. 
The supernatant from this was diluted 1:1 (50 mM Tris HCl, pH 7.4) to give a 15-20% sucrose 
solution reducing the density of the media and enabling the sedimentation of the inner 
membranes as a pellet by further ultracentrifugation (Beckman Coulter L-80, SW28, 141000 
rcf max, 1 h, 4 °C). 
The inner membrane pellet was solubilised by a re-suspension buffer (37 mL, 50 mM Tris-
HCl, 1.4% OG (w/v), 20% glycerol (v/v), 200 mM MgSO4, pH 7.4) followed by ultra-
centrifugation (Beckman Coulter L-80, SW28, 141000 rcf max, 1 h, 4 °C) to remove un-
solubilised proteins and debris to provide the solubilised inner membrane fraction. 
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2.2.5 TAO Purification 
Purification of the solubilised inner membrane fraction was carried out by immobilised metal 
ion affinity chromatography (IMAC), using the cobalt affinity resin TALON® (6 mL of 
suspended resin). The resin was equilibrated with buffer (50 mL, 20 mM Tris HCl, 1.4% OG, 
20% glycerol, 100 mM MgSO4 pH 7.4) before being incubated with the solubilised 
supernatant for 30 min on a roller shaker at 4 °C. The flow through was collected and the 
resin was washed with buffer 1 (2 × 50 mL 20 mM Tris-HCl, 20 mM imidazole, 0.042% (w/v) 
n-dodecyl-β-D-maltopyranoside (DDM), 20% (v/v) glycerol, 50 mM MgSO4, pH 7.4) and buffer 
2 (1 × 50 mL 20 mM Tris-HCl, 160 mM imidazole, 0.042% (w/v) 
n-dodecyl-β-D-maltopyranoside (DDM), 20% v/v glycerol, 50 mM MgSO4, pH 7.4). rTAO was 
eluted with elution buffer (10 × 10 mL 20 mM Tris-HCl, 200 mM imidazole, 0.042% w/v n-
dodecyl-β-D-maltopyranoside (DDM), 20% v/v glycerol, 50 mM MgSO4, 60 mM NaCl, pH 7.4). 
Fractions were concentrated through a 10 kDa molecular weight cut off Amicon Ultra-15 
filter unit yielding IMAC-purified rTAO protein to a concentration of approximately 8 mg/mL. 
This sample was further purified by size exclusion chromatography (Hiload Superdex 75 pg 
26/600 XK column, GE healthcare) with the (AKTA FPLC, GE Healthcare). The gel filtration 
column was pre-equilibrated with 1 x CV phosphate buffered saline and 2 x CV elution buffer 
(20 mM Tris HCl, 250 mM NaCl, 20% (v/v) glycerol, 0.042% (w/v) DDM). Protein sample was 
loaded in a 10 mL load loop and eluted with 1 x CV of elution buffer (20 mM Tris HCl, 250 
mM NaCl, 20% (v/v) glycerol, 0.042% (w/v) DDM) at 0.75 mL/min. 
2.2.6 TAO Western Blot 
TALON purified TAO protein was run on SDS-PAGE, loading 100 ng per well. The gel was 
transferred onto a 0.45 micron PVDF membrane using a Bio-Rad plate electrode transfer kit 
(30 min at 100 V, 4 °C). The membrane was blocked with 5% milk in tris-HCl buffered saline 
(TBST) for 2 h at 4 °C, then incubated with a primary rabbit polyclonal anti-body raised against 
plant AOX-1/2 supplied by Agrisera (AS04054) at 1:5000 dilution in 5% milk TBST for 16 h at 
4 °C. The membrane was washed three times with 5% milk TBST (30 min incubations), then 
incubated with goat anti rabbit IgG-HRP secondary antibody, supplied by Santa Cruz 
(sc-2004) in a 1:5000 dilution in 5% milk TBST for 1 h at 4 °C. The membrane was again 
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washed three times with 5% milk TBST (30 min incubations) before treatment with ECL 
detection reagent (3 mL). The membrane was developed onto X-RAY film with 3 min 
exposure time. 
2.2.7 TAO Trypsin Digest Mass-Spectrometry 
Affinity-chromatography (TALON) purified TAO protein (100 ng per lane) was run on 
SDS-PAGE. The gel was stained with Coomassie blue, and then the bands correlating to 
38 kDa and 74 kDa were excised from the gel with a scalpel and cut into small pieces. The gel 
pieces were processed for an in-gel trypsin digestion, according to manufacturer’s 
instructions (Thermo Scientific). The gel pieces were initially de-stained with a solution of 
ammonium carbonate in water and acetonitrile (1:1), to remove the Coomassie stain and 
residual SDS. The de-stained gel pieces were then reduced with a 50 mM TCEP solution to 
allow the alkylation of free cysteine residues with a 500 mM iodoacetamide solution. 
Acetonitrile was removed from the gel by air-drying to facilitate the absorption of the trypsin 
digestion buffer. Mass spectrometry grade trypsin (10 ng/µL) buffer (25 µL, Thermo 
Scientific) was incubated with the gel pieces overnight at 30 °C. Addition of 1% TFA solution 
(10 µL) inhibited trypsin activity before the samples were analysed by mass spectrometry. A 
sample (8 µL) from each band was injected onto a peptide Acclaim™ PepMap™ 100 C18 
column. Different constituent peptides were separated via reverse phase chromatography, 
and eluent from the nano-HPLC was directed into the LTQ-OrbitrapXL mass spectrometry. 
Unique protein mass-spectrometry profiles were obtained. 
2.3 Results and discussion 
For this project, a standard BL21 E. coli recombinant expression strain was used, to obtain 
high growth yields.126 A Qiagen maxi-prep isolated plasmid DNA from the culture and 
genomic sequencing confirmed that TAO encoding gene (Figure 25) had been successfully 
transformed into the BL21 Rosetta2® E. coli (Figure 26). 
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Figure 26 - Sequencing results from Eurofins Genomics, of DNA obtained from Qiagen maxi-prep section 2.2.2 
 
With the plasmid containing the TAO gene successfully transformed into E. coli, expression 
tests were carried out to ascertain which conditions provided adequate production of TAO. 
Four conditions were tested; standard LB expression media, turbo broth, supplemented LB 
media (used in the haem deficient E. coli expression systems) and betaine sorbitol expression 
media (Figure 27). 
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Figure 27 - Expression test SDS-PAGE results Expressed rTAO has an expected mw of 38.5 kDa (box), Novex 
Nupage 4-12% Bis-Tris gel, staining with quick Coomassie stain, run for 40 min at 200 V and 1.25 A. Lysate and 
supernatant following overnight expression. 
 
The highest yielding conditions determined qualitatively by SDS-PAGE were from the betaine, 
sorbitol medium. The supplemented LB conditions reported by Kido et al.120 along with 
standard LB media and standard Turbo broth all showed less intense bands for TAO 
expression (Figure 27). High concentrations of sorbitol and betaine have been shown to aid 
the stability of recombinant proteins, when supplemented in expression media.160,161 Under 
these conditions the cellular concentration of osmolytes and chaperones are increased, 
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promoting recombinant protein stability by reducing the likelihood of protein precipitation 
and the formation of insoluble inclusion bodies.  
Plant alternative oxidases reside on the inner leaf of the mitochondrial membrane,162 and 
this is similarly observed in trypanosomes.113 E. coli do not have mitochondria, and in 
previous recombinant expressions of TAO in bacteria the enzyme has been observed in the 
cytoplasmic membrane fraction.126 Isolation of the inner membrane fraction of the E. coli 
cells has previously been reported as a key step in the purification of TAO.120 
 
 
Figure 28 - Inner membrane isolation SDS-PAGE Expressed rTAO has an expected mw of 38.5 kDa (box), Novex 
Nupage 4-12% Bis-Tris gel, staining with quick Coomassie stain, run for 40 min at 200 V and 1.25 A 
 
A variety of groups have commented on the necessity to isolate the inner membrane fraction 
of E. coli to adequately solubilise and purify large amounts of rTAO.120,122 Isopycnic 
centrifugation provides a suitable method for achieving this; however, some protein is lost 
at every stage of the separation as seen in the SDS-PAGE of the isolated fractions. The 1st 
ultracentrifuge supernatant fraction (lane 8 - Figure 28) contains buoyant inner membranes, 
where TAO resides. Some rTAO was potentially lost, that was not separated in the first lysate 
low speed centrifugation and was retained in the remaining debris (lane 7 – figure 28).  These 
isolated membranes are then successfully pelleted by dilution of the media and further ultra-
centrifugation to give the inner membrane pellet (lane 9 - Figure 28), less dense cytosolic 
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proteins should remain in the supernatant of this ultra-centrifugation step (lane 10 – figure 
28). 
Solubilisation of TAO from the inner membrane is vital for isolation of rTAO. Nihei et al. 
carried out a detergent screen to identify suitable detergents for the solubilisation of TAO, 
and found that the only detergent that solubilised active TAO was digitonin, a non-ionic 
surfactant.122 Further screening to find the optimal detergent for TAO solubilisation was 
carried out by Kido et al. and identified octylglucopyranoside (OG) as a preferred 
detergent.120 This successfully solubilised rTAO from the inner membrane fraction (lane 12 – 
Figure 28). Some protein was not successfully solubilised from this step, as the pellet 
contained a visible band for TAO (lane 11 – 28). Further attempts in extracting this pellet with 
more washings of OG detergent provided only small amounts of TAO, and thus more than 
one extraction was not performed routinely.  
 
Figure 29 - TAO IMAC purification - SDS-PAGE Expressed rTAO has an expected mw of 38.5 kDa (box), Novex 
Nupage 4-12% Bis-Tris gel, staining with quick Coomassie stain, run for 40 min at 200 V and 1.25 A 
 
rTAO was expressed with a thrombin linked poly-histidine tag to facilitate purification by 
IMAC. Analysis of the flow through, wash and elution fractions of the IMAC purification by 
SDS-PAGE showed that some rTAO was lost in the initial flow through over the resin with 
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other protein impurities (lane 3 - Figure 29). Kido et al. had observed that upon IMAC 
purification rTAO was retained on the resin when using OG detergents and that the use of n-
dodecyl-β-D-maltopyranoside (DDM) resulted in the successful elution of rTAO.120 These 
conditions were implemented successfully to elute rTAO from the TALON resin.  
 
Figure 30 - FPLC purification and SDS-PAGE analysis of rTAO, dimer and monomer fractions box 
 
Size exclusion chromatography was performed on this sample to further purify the isolated 
rTAO. Proteins are separated through interaction with a stationary phase, dependant on the 
extent that proteins penetrate into the pores of the stationary phase. Smaller protein 
molecules penetrate to a greater extent and are retained on the stationary phase for longer, 
thus effectively separating proteins by their relative size. Both monomer and dimer bands 
co-eluted from the gel filtration column. Analysis of the elution fractions showed rTAO had 
been successfully isolated, in good purity for downstream applications (lanes 4-6 – Figure 
30). Concentration of the combined fractions provided approximately 9 mg of rTAO from the 
8 L culture, that corresponds to a 3-fold increase in protein yield from the reported 
expression using haem deficient mutant E. coli expression systems.120 
Western blot analysis was carried out to confirm the protein isolated was rTAO. Western-
blot or immunoblotting was originally reported by Towbin et al.163 The technique relies on 
the transfer of proteins separated using SDS-PAGE onto a membrane, followed by antibody 
recognition of an epitope of a specific part of a protein, then detection with a secondary 
antibody and chemiluminescent reagent. 
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Figure 31 - SDS-PAGE and Western-blot analysis of rTAO 
 
Analysis of the western blot (lane 3 – figure 30) and SDS-PAGE gel (lane 2 – figure 31) of the 
purified rTAO, showed recognition for the 37-38 kDa band isolated. The primary antibody 
used was raised against a plant alternative oxidase that shares > 75% sequence homology to 
TAO. The other high concentration protein band at ~ 74 kDa observed in the SDS-PAGE was 
not detected in the western blot. We had previously thought this band to be a homo-dimer 
of TAO, that has similarly been reported in the literature by a variety of groups.116,117,124 If 
the epitope recognition site for the antibody is between the dimer interface antibody binding 
would be inhibited and result in no detection in the immunoblot. To confirm that the second 
band was attributed to a dimer of TAO, a trypsin digest of bands excised from the SDS-PAGE 
gel was performed and analysed by protein mass-spectrometry.  
 
Advances in mass-spectrometry resolution, accuracy and detection limits have improved 
proteomic mass-spectrometry, and have been recently reviewed by Cardoza et al.164 It is 
possible to identify proteins by searching unique individual protein mass spectrometry 
fragmentation profiles against large databases of calculated and experimentally determined 
data sets. 
 
The mass spectrum data generated was searched against the Mascot mass-spectrometry 
database supplied by Matrix Scientific. Both the ~ 37 kDa and the ~ 74 kDa excised bands, 
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following trypsin digest, identified TAO as the predominant protein in both samples with 60% 
and 61% sequence coverage of peptide fragments, respectively. Found fragments are 
highlighted in red for the 37 kDa (Figure 32) and 74 kDa (Figure 33) excised bands. The mass 
spectrometry analysis highlighted that rTAO protein was isolated in good purity for further 
assay development. 
 
Figure 32 - 37 kDa excised band from mass spectrometry analysis 
 
 
Figure 33 - 74 kDa excised band from mass spectrometry analysis 
 
Chapter 2 - Protein Expression and Isolation Conclusions 
In conclusion, rTAO has been successfully expressed in E. coli BL21 cells, and isolated from 
the inner membrane fraction. The protein was further purified using IMAC, and analysis by 
Western blot and mass spectrometry confirmed protein identity. Other quinol-oxidase 
proteins (that may have been present from recombinant expression in E. coli) were not 
observed in the protein analyses performed, suggesting that the rTAO produced was 
sufficiently pure for use in assay development and characterising TAO activity. rTAO 
production in sufficient quantity and quality was a vital step for this project, to enable the 
set up and development of robust assays. Chapter three describes the optimisation of a bio-
chemical assay for the determination of the inhibitory activity of synthesised compounds, 
and to perform kinetic studies on rTAO.   
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Chapter 3 – Biochemical Assay Development 
3.1 Activity Assessment of TAO 
TAO functions by catalysing the 4-electron reduction of oxygen to water, utilising the 
substrate ubiquinol by oxidising it to ubiquinone (Figure 34).165 This process can be 
monitored photochemically by UV absorbance. The wavelength at which ubiquinol has the 
strongest absorbance (lambda max) is at 272 nm whereas ubiquinone’s is at 275 nm. This 
small difference makes it hard to achieve a good assay signal window, and because of this, 
the oxidation of ubiquinol is regularly measured at 278 nm, where the absorbance spectra 
are at their largest divergence.87,122,126,166,167 The principal Beer-Lambert law dictates that 
absorbance is linear with concentration if pathlength and molar absorptivity are kept 
constant, therefore absorbance measurements can be used to monitor ubiquinol turnover. 
 
Figure 34 - Ubiquinol / Ubiquinone structure 
 
TAO is a membrane associated protein; in trypanosomes it is located in the inner membrane 
of the mitochondria.113 In order to carry out a biochemical assessment of the enzymatic 
activity using absorbance it is necessary to have a homogeneous solubilised sample of 
enzyme, substrate and inhibitor. In nature, ubiquinol / ubiquinone contains 9 isoprene units 
(Q9) in trypanosomes (Figure 34 – n = 9). Unfortunately, the aqueous solubility of Q9 is too 
low to use in a biochemical assay format with aqueous buffer. Many groups have 
circumvented this problem by utilising shorter chain ubiquinol / ubiquinone analogues’, most 
commonly 1-ubiquinol (Q1) (Figure 34 – n = 1).120 It has been observed that when assessing 
the biochemical activity of TAO and other plant alternative oxidases (AOX) inadequate 
substrate concentrations were achieved to reliably measure kinetic parameters without 
detergents.120,122,168 The use of decyl octaethylene glycol ether (C10E8) specifically has 
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enabled standard Michaelis-Menten kinetic parameters and accurate measurements of 
apparent KM and Vmax to be recorded.120 Using these reported studies as a basis, the 
assessment of the enzymatic function of rTAO described in chapter 2 was undertaken. 
3.2 Methods 
3.2.1 rTAO Activity Assessment - Absorbance Measurements 
The assessment of TAO activity was carried out in single wells of a Greiner 96-well, UV-star 
flat bottom plate suitable for absorbance measurements at 278 nm. Initially, 150 µL of assay 
buffer was added to the wells. 1 µL DMSO was then added to each well as a baseline control 
or a solution of CCB in DMSO to give a final in well concentration of 1000 nM as a positive 
control. This was followed by the addition of rTAO (10 µL) diluted with enzyme dilution buffer 
to give an accurate in-well concentration of enzyme (detailed in the tables below), or with 
buffer alone for a no enzyme control. 1-Ubiquinol (150 µL) was then added, made up from a 
dilution in assay buffer from a 100 mM DMSO stock solution to give an accurate final in-well 
concentration of substrate (detailed in the tables below) and a total assay well volume of 
311 µL. Each condition (enzyme, no enzyme and enzyme and inhibitor (CCB)) was plated in 
triplicate unless otherwise described and the experiment repeated three times to report 
mean and standard error. Absorbance measurements at 278 nm were taken every 90 s 
following a 5 s shake on the BMG Pherastar plate reader.  
Table 4 - Biochemical assay buffers 
Assay Buffer Enzyme dilution buffer 
Tris HCl 50 mM Tris HCl 50 mM 
C10E8 0.05% (w/v) NaCl 60 mM 
pH 7.4 MgSO4 50 mM 
 Glycerol 20% (v/v) 
 DDM 0.042% (w/v) 
 pH 7.4 
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3.2.2 TAO Inhibition 10-point Inhibition Assay 
Enzyme function was measured as described above in 3.2.1. CCB at a 1 µM top concentration 
was used as a positive control inhibitor and a further 3 test compounds (Table 5, A, B, C) at 
32 µM top concentrations were diluted as depicted in the plate map (Table 5). Negative 
control wells had DMSO only, to ensure the final assay plate content was uniform. 
Table 5 - TAO 10-point IC50 plate map, compound concentration indicated in nM 
N
o 
E
nz
ym
e 
CCB 
1000 333.3 111.1 37.0 12.3 4.1 1.4 0.5 0.2 0.1 
En
zy
m
e CCB 
1000 333.3 111.1 37.0 12.3 4.1 1.4 0.5 0.2 0.1 
A 
32000 10666.7 3555.6 1185.2 395.1 131.7 43.9 14.6 4.9 1.6 
A 
32000 10666.7 3555.6 1185.2 395.1 131.7 43.9 14.6 4.9 1.6 
En
zy
m
e 
B 
32000 10666.7 3555.6 1185.2 395.1 131.7 43.9 14.6 4.9 1.6 
N
o 
E
nz
ym
e B 
32000 10666.7 3555.6 1185.2 395.1 131.7 43.9 14.6 4.9 1.6 
C 
32000 10666.7 3555.6 1185.2 395.1 131.7 43.9 14.6 4.9 1.6 
C 
32000 10666.7 3555.6 1185.2 395.1 131.7 43.9 14.6 4.9 1.6 
 
1 µL from each well of this compound plate was then transferred into a Greiner 96-well, 
UV-star flat bottom plate containing assay buffer with enzyme (160 µL) to give a final 3 nM 
enzyme concentration, or blank assay buffer for no enzyme control (Table 5 – red) addition 
via an automated liquid handling robot (Fluid Xpp-721). This was incubated at 22 °C for 
10 min to allow equilibration. The reaction was then initiated by addition of assay buffer 
containing 1-ubiquinol (150 µL) to give a final concentration of 15 µM. Absorbance at 278 nm 
was measured immediately after 1-ubiquinol addition, and then every 90 s following a 5 s 
shake, for a total of 15 min on the BMG Pherastar plate reader.  
3.2.3 TAO Inhibition Single Point Inhibition Assay 
A 96-well DMSO compound plate was manually prepared, to enable compound addition via 
an automated liquid handling robot (Fluid Xpp-721). CCB (1 µM) was used as a positive 
control inhibitor and a further 80 compounds were tested at 10 µM, depicted in the plate 
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map (Table 6). Control wells had DMSO only, to ensure final assay plate content was uniform. 
TAO activity assessment was carried out by measuring absorbance at 278 nm as described 
above in section 3.2.2. 
Table 6 - TAO Single Point Inhibition Plate Map 
N
o 
En
zy
m
e A1 A2 A3 A4 A5 A6 A7 A8 A9 A10 
En
zy
m
e 
B1 B2 B3 B4 B5 B6 B7 B8 B9 B10 
C1 C2 C3 C4 C5 C6 C7 C8 C9 C10 
C
C
B
 D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 
C
C
B
 
E1 E2 E3 E4 E5 E6 E7 E8 E9 E10 
En
zy
m
e F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 
N
o 
E
nz
ym
e 
G1 G2 G3 G4 G5 G6 G7 G8 G9 G10 
H1 H2 H3 H4 H5 H6 H7 H8 H9 H10 
 
3.2.4 TAO 5-Point Inhibition Assay  
A 96-well DMSO compound dilution plate was set up to enable compound addition via an 
automated liquid handling robot (Fluid Xpp-721). A 5 point 1:5 serial dilution was performed 
for each compound, manually changing tips between each dilution step. CCB at a 250 nM 
top concentration was used as a positive control inhibitor, and a further 7 compounds were 
tested at 10 µM top concentration (Table 7). Control wells had neat DMSO, to ensure final 
assay plate content was uniform. TAO activity assessment was carried out by measuring 
absorbance at 278 nm as described above in section 3.2.2 and 3.2.3 
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Table 7 - TAO 5-point IC50 plate map, compound concentration indicated in nM 
N
o 
E
nz
ym
e 
CCB 
250 50 10 2 0.4 
D 
10000 2000 400 80 16 
En
zy
m
e CCB 
250 50 10 2 0.4 
D 
10000 2000 400 80 16 
A 
10000 2000 400 80 16 
E 
10000 2000 400 80 16 
A 
10000 2000 400 80 16 
E 
10000 2000 400 80 16 
En
zy
m
e 
B 
10000 2000 400 80 16 
F 
10000 2000 400 80 16 
N
o 
E
nz
ym
e B 
10000 2000 400 80 16 
F 
10000 2000 400 80 16 
C 
10000 2000 400 80 16 
G 
10000 2000 400 80 16 
C 
10000 2000 400 80 16 
G 
10000 2000 400 80 16 
 
3.3 Results and discussion 
Initial assessment of rTAO activity showed that the rTAO isolated could efficiently catalyse 
the oxidation of 1-ubiquinol to 1-ubiquinone, and this process could be inhibited by CCB. 
These results indicated a good turnover of substrate; however, substrate depletion or 
product inhibition was observed in the uninhibited reaction after approximately 20 mins 
(Figure 35 – green), as the line began to curve downwards, and turnover become non-linear. 
For that reason, the concentration of enzyme used in further kinetic characterisation 
experiments was decreased to 3 nM, to allow steady state measurements at initial velocity 
to be taken. 
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Figure 35 - rTAO activity assessment - rTAO (10 nM), 1-ubiquinol (150 µM), CCB (1000 nM), UV absorbance 
profile at 278 nm over 30 min. Mean of data and ± SEM reported. 
 
Michaelis-Menten kinetic experiments are a valuable tool for characterising enzymes and 
for setting up robust screening assays. The Michaelis-Menten model of enzyme kinetics is 
based on Equation 1 and was described by Michaelis and Menten in the early 1900s. 
Equation 1 describes the relationship between reaction rate and substrate concentration 
(Equation 1). 
Equation 1 - Michaelis-Menten Equation 
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E corresponds to the enzyme, S to the substrate, ES to the enzyme substrate complex and P 
to the product. Kf is the forward rate of ES formation and Kr the reverse rate, as this process 
is viewed as reversible (the reverse rate has a negligible contribution). Kcat is the rate limiting 
process that corresponds to the breakdown of the ES complex and product formation, in the 
process releasing the free enzyme. By measuring the formation of product over time or 
velocity (V), over a range of substrate concentrations, it is possible to calculate the maximal 
velocity (Vmax) of the enzyme and the KM for the substrate that is being consumed. The 
maximal rate achieved by the enzyme (Vmax) assumes that there is a saturated supply of 
substrate so that it does not affect the rate of reaction. ΚM is the Michaelis-Menten constant 
and is the substrate concentration required for ½ Vmax.169 
Historically, graphical plots of the linearisation of this data by performing 1/[S] and 1/V 
manipulations allowed the calculation of both Vmax and KM. Extrapolation of this data to the 
Y intercept gives 1/Vmax and either the gradient (KM/Vmax) or extrapolation to the X-axis 
(-1/KM) would allow KM to be determined. This method was pioneered by Hans Lineweaver 
and Dean Burk, and allowed early enzyme kinetic parameters to be generated without the 
use of computers, hence these graphs are often known as Lineweaver-Burk plots.170 
However, this method suffers from some disadvantages: the double reciprocal plot 
generates a distortion of the error of measured velocities when the reciprocal is taken; errors 
in velocity measurement are more often observed at low velocities and can therefore 
significantly affect the gradient and estimation of Vmax and KM; and the distribution of 
graphical data is often skewed as low 1/[S] values are not easily obtained, as these are limited 
by substrate solubility at high concentrations.171 
As a result, Lineweaver-Burk plots have since become disfavoured for generating enzyme 
kinetic data, and improvements in computing have allowed instead the facile generation of 
non-linear regression analysis to determine Vmax and KM values. These values allow the 
comparison of enzyme preparations and are of importance when developing screening 
assays. It is vital to measure enzyme reaction rates at their initial velocity, determined to be 
before substrate is 10% consumed in the reaction and the generation of product is in a linear 
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phase. This allows the assumption that the rate of reaction is not affected by substrate 
depletion or product inhibition.  
To ensure that measurements were taken in the initial 10% of the reaction progression a 
1-ubiquinone concentration vs absorbance at 278 nm correlation was carried out. Future 
absorbance reads were correlated to this data to ensure measurements were within the 
linear phase of reaction progression. The reaction rate initial velocities were measured over 
a variety of substrate concentrations (1000, 750, 500, 250, 100, 75, 50, 25, 10, 5, 2.5, 1 µM, 
Figure 36) with 3 nM TAO enzyme. 
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Figure 36 - Michaelis-Menten data, A – Non-linear regression plot of initial velocities obtained with 3 nM rTAO 
(filled circles). Auto-oxidation of 1-ubiquinol observed without TAO (unfilled triangles). B – Background velocity 
corrected Michaelis-Menten kinetics, generated from subtracting unfilled triangles from filled circles – (A). Mean 
and ± SEM reported of n = 3 data.  
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When looking at the initial data, measurements at high substrate (> 500 µM) concentrations 
showed a large variability. This had similarly been reported in the literature, and attributed 
to the low solubility of substrate 1-ubiquinol at these concentrations.120 Upon closer 
inspection of these assay wells there was indeed precipitation visible at both 750 µM and 
1000 µM. These points were therefore excluded in the following Michaelis-Menten kinetic 
calculations.  
Measurements at 1 µM and 2.5 µM also proved problematic, as velocities here could not be 
accurately measured at initial velocity due to the turnover being greater than 10% of total 
substrate concentration after two time points. Sensitivity of the reader was also an issue, as 
the lower detection limits for the signal were reached at these low concentrations. This data 
was too close to background absorbance, and as a result these concentrations were also 
excluded from the Michaelis-Menten kinetic calculations. 
Further investigation of the data following a non-linear regression fit using Graph-pad Prism 
v7.03, highlighted a poor curve fit to the data (Figure 36 – A, circles), although similar KM 
values were obtained to what had been previously reported in the literature.87,120,122,126 Upon 
closer inspection of the data generated from the substrate turnover without enzyme (Figure 
36 – A, triangles), interference was observed from the auto-oxidation of substrate at higher 
(> 250 µM) concentrations. Detergent effects on the auto-oxidation of ubiquinol substrates 
had previously been reported by Hoefnagel et al.172 Subtraction of the observed substrate 
turnover without enzyme (Figure 36 – A, triangles) from the turnover observed with enzyme 
(Figure 36 – A, circles) improved the data fitting for graphical Michaelis-Menten calculations 
(Figure 36 – B). Calculations for the Michaelis-Menten constant KM at 16 µM were however, 
lower than previous literature reports, resembling data more closely observed with 
2-ubiquinol.87,115,120,127,167 This could be due to the auto-oxidation of substrate not being 
accounted for in previous studies. The choice of detergent can greatly affect the availability 
of both the enzyme and substrate of the alternative oxidase system and hence impact the 
resulting kinetics observed. The kinetic parameters are taken as apparent measurements 
under the conditions used, as different detergents have been shown to impact the effective 
concentration of substrate available to the enzyme.172 To confirm that the activity and kinetic 
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parameters measured from these studies was from rTAO and not an undetected quinol 
oxidase impurity, an azide inhibition assay was performed. 
TAO is insensitive to respiratory poisons such as cyanide and azide.113 These respiratory 
poisons commonly chelate to the metal centres in essential haem cofactor proteins like 
cytochrome quinol oxidases and fully inhibit their function.173 
 
 
Figure 37 - Azide inhibition of rTAO (3 nM), turnover of 1-ubiquinol (15 µM), CCB (1000 nM) as a positive 
control. Data normalised to in-plate no-enzyme and no-azide controls, mean and ± SEM reported (n = 3). 
 
Analysis of the data generated from the azide inhibition experiment showed that 1-ubiquinol 
turnover was not inhibited by any concentration of sodium azide up to 2 mM (Figure 37 – 
pink). This confirmed that the 1-ubiquinol oxidation activity that was observed is from the 
function of rTAO and not an undetermined quinol oxidase impurity. On the other hand, 1-
ubiquinol oxidation could be completely inhibited with the addition of 1 µM CCB (Figure 37 
– purple).  
With calculated Michaelis-Menten kinetic measurements in-hand, a substrate concentration 
close to the KM was required for maximising detection of substrate competitive inhibitors.174 
Performing inhibition assays at higher than KM substrate concentrations can cause 
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competitive inhibitors to be inaccurately detected as false negatives, as a high concentration 
of substrate can effectively out compete a competitive inhibitor. A concentration of 15 µM 
1-ubiquinol was used for assay development, as this was close to the measured KM. To ensure 
that velocity measurements from future assays were taken in the linear range of reaction 
progression an enzyme concentration experiment was conducted to give reaction 
progression profiles to find the optimal concentration of enzyme. 
 
Figure 38 - Enzyme concentration – 1-ubiquinol (15 µM) oxidation measured by UV absorbance at 278 nm, with 
increasing concentrations of rTAO. 
 
Analysis of the progression curves over 20 min showed that 3 nM of rTAO gave a good 
compromise between 1-ubiquinol turnover and achieving linear conversion over the course 
of the assay (Figure 38 – blue). Concentrations below 1 nM enzyme would require a longer 
assay time to achieve a significant signal window, whereas concentrations above 4 nM would 
require short plate read times to ensure kinetic measurements were within a linear initial 
velocity time frame. Going forward, a final concentration of 3 nM enzyme and 15 µM 
1-ubiquinol were used for rTAO inhibitory assay development experiments. 
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As test compounds will be dissolved and diluted from DMSO it was important to test the 
assay’s tolerance to this solvent, to ensure that any observed effects were due to the test 
compound and not a component solvent.  
 
Figure 39 - DMSO tolerance 
 
Analysis of the rTAO activity in the presence of increasing amounts of DMSO showed a good 
tolerance, with no observed effect on enzymatic performance (Figure 39). Final DMSO 
concentration in the assay going forward will be kept to the minimum possible concentration 
of 0.42%. This is determined from the combined content of 1 µL of DMSO from compound 
addition and the DMSO carried through from the dilution of the 1-ubiquinol substrate that is 
made up in DMSO at 100 µM. 
Determination of IC50 (the concentration that causes 50% inhibition of maximal enzyme 
activity) values is the preferred method to compare different molecules and assess their 
ability to inhibit an enzyme. Standardly, a 10-point 1:3 serial dilution of compound is carried 
out and the relative activity of enzyme is measured at each inhibitor concentration. A 
4-parameter non-linear plot of this data provides an IC50, Hill-slope, and maximum and 
minimum inhibition values. The maximum and minimum values can be normalised to the 
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positive and negative controls within the assay, and IC50 data compared between different 
compounds. The Hill-slope or coefficient gives an indication of the stoichiometry and 
co-operativity of binding. Ideally the Hill-coefficient should be close to 1, which is indicative 
of 1 molecule of inhibitor binding to 1 molecule of enzyme. Enzymes however, often exist in 
oligomeric forms. In these cases, the binding of one ligand may have a positive or negative 
impact on the binding of a second ligand to another structural oligomeric enzyme. This can 
cause the Hill coefficient to deviate either positively or negatively from 1 respectively. 
Compounds that show unusually high Hill slopes are often indicative of protein denaturants, 
tight binding inhibitors or covalent enzyme inhibitors, highlighting the necessity for further 
characterisation when these results arise. Hill slope values less than 1 are indicative of the 
presence of two non-equivalent ligand binding sites in the same enzyme, in which both need 
to be occupied to fully inhibit enzyme activity. Alternatively, Hill coefficients lower than 1 
also arise from the presence of non-equivalent proteins, for example dimers and monomers 
may have differential affinities for ligands generating a shallow Hill slope (< 1). 
To maximise the generation of these data, a 96-well DMSO compound dilution plate was set 
up (Table 5) to enable compound dilution via an automated liquid handling robot (Fluid Xpp-
721). Initially a 10-point 1:3 serial dilution was prepared for each compound by the liquid 
handling robot. Analysis of the initial data set showed an unusually shallow linear IC50 curve 
for the CCB control, suggesting that the serial dilution had not been correctly carried out. 
Performing automated serial dilutions of highly lipophilic compounds can prove challenging, 
due to the compound affinity for plastics. This in turn creates a carryover of higher 
concentrated material into the next well and disrupts the serial dilution. Modification of the 
method by performing compound serial dilution manually and changing the tips of the multi-
channel pipette after each dilution step resolved this issue. Manual preparation of 
compound stocks afforded reproducible IC50 curves for the literature natural product CCB 
with similar values (2.8 ± 2 nM) to what had previously been reported (Figure 40).128 The Hill 
coefficient for CCB was calculated to be 0.6, indicating the presence of two non-equivalent 
ligand binding sites. This could be from differential affinities of dimeric and monomeric forms 
of the enzyme or from the binding of CCB to the two hydrophobic cavities that ubiquinol has 
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been reported to interact with.129 Using this assay format, historical compounds that showed 
structural similarity to CCB synthesised by members of the research group of Professor Simon 
Ward at the University of Sussex were assessed for TAO inhibition. These data will be 
discussed in chapter 4 of this thesis. 
 
Figure 40 - IC50 curve CCB, generated from 3 nM TAO and 15 µM 1-ubiquinol, normalising to no enzyme and no 
inhibitor in plate controls. Data reported is mean ± SEM (n = 3) 
 
To support screening activities of numerous compounds, it was desirable to have a higher 
throughput assay. Single point inhibition assays are routinely used to screen large compound 
collections. The disadvantage of these assays is that each compound is only assessed once 
per plate, so discrepancies in individual wells that are sometimes observed may result in 
some false positive or false negative results. Hits that are identified from these screening 
activities require further assessment to confirm inhibitory activities. Medicines malaria 
venture (MMV), provided a set of 400 compounds that had been identified from the 
phenotypic screening of a range of kinetoplastid parasites. These compounds were tested 
against rTAO at a single concentration of 10 µM, with the aim of identifying a structurally 
distinct class of TAO inhibitor described in section 3.2.3. 
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Figure 41 - Single-point inhibition summary (MMV collection). Binned inhibition data of number of compounds, 
green is enzyme control (DMSO only, no inhibition of TAO), blue is no enzyme control (complete inhibition), 
yellow is CCB in plate positive control. Data is fitted to in-plate controls 0% inhibition is mean of enzyme only 
control, 100% inhibition is mean of no enzyme control. 
 
Analysis of the single point inhibition data generated with the MMV collection identified new 
hits for further validation. Assessment of assay robustness was carried out by calculating Z 
scores for the assay plates. Z prime values are calculated from the mean and standard 
deviation of the high and low controls and are indicative of assay window and variance.175 
Optimal Z prime values above 0.5 indicate a robust assay, and the calculated Z prime scores 
of the single point inhibition assay ranged from 0.52 to 0.66. Compounds that showed 
greater than 50% inhibition at 10 µM were deemed a significant response that warranted 
further testing to confirm inhibition. 70 compounds inhibited rTAO by ≥ 50% at 10 µM (green 
circles, Figure 42, mean value from two assay runs). These compounds were further assessed 
by performing a 5-point IC50 determination described in section 3.2.4. The distribution of the 
data showed a higher than expected number of active compounds, this could be due to these 
compounds already being identified as inhibitors of parasite growth. 
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Figure 42 - MMV TAO Mean Single Point Inhibition data, compounds in green showed > 50% inhibition and were 
confirmed in in 5-point IC50 screening assays 
 
It was clear from this analysis that the single point data generated suffered from a reasonable 
amount of interference, with some measured inhibitions of > 100 and < 0%. Absorbance 
assays are prone to interference due to insoluble particulates or absorbance of analyte 
compounds. It is important to verify any identified hits from single point assays in more 
robust multiple point inhibition screens.176 
Analysis of the 5-point IC50 curves showed that 20 compounds had reproducible IC50s below 
10 µM (Table 8). From these 20 compounds, 10 were available to re-purchase as solids from 
MMV. These compounds were re-ordered to perform full 10-point IC50 determinations, 
which were carried out as described in section 3.2.2. These data are discussed in chapter 4. 
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Table 8 - MMV Hits Summary 5-point IC50 confirmation 
Structure # 
TAO% 
Inhibition 
(at 10 µM)b 
5-point 
TAO 
(pIC50 )b 
 
27* 175 ± 56 5.7 ± 0.3 
 
28* 135 ± 100 5.5 ± 0.1 
 
29 121 ± 17 5.2 ± 0.2 
 
30 111 ± 29 5.2 ± 0.1 
 
31 100 ± 20 5.1 ± 0.1 
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32 96 ± 42 5.3 ± 0.1 
 
33* 93 ± 4 5.8 ± 0.1 
 
34 90 ± 15 5.1 ± 0.1 
 
35 89 ± 99 5.4 ± 0.2 
 
36* 88 ± 12 5.4 ± 0.1 
 
37 83 ± 14 5.1 ± 0.1 
 
38* 83 ± 18 5.6 ± 0.2 
96 
 
39* 81 ± 22 5.5 ± 0.1 
 
40* 75 ± 38 5.5 ± 0.1 
 
41* 71 ± 49 5.7 ± 0.1 
 
42 67 ± 3 5.3 ± 0.1 
 
43* 60 ± 9 5.7 ± 0.1 
 
44 59 ± 3 6.0 ± 0.1 
 
45* 54 ± 24 5.4 ± 0.1 
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46 53 ± 37 5.0 ± 0.1 
 
a% Inhibition of rTAO activity at 10 µM compound concentration, with s.d. (n = 2). b 5-point pIC50 calculated from 
negative log of IC50 value from 5-point 4-parameter non-linear regression fit of inhibition data, with s.d. (n = 2). * 
Indicates compound availability for confirmation in 10-point IC50 experiments from solid sample. 
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Chapter 3 - Biochemical Assay Development Conclusions 
In conclusion, the isolated rTAO that was described in chapter 2 showed functional activity, 
catalysing the oxidation of 1-ubiquinol to 1-ubiquinone. Robust assays were developed to 
determine the enzymatic activity of rTAO, allowing the kinetic characterisation of rTAO. It 
was of interest that the Michaelis Menten enzyme kinetics observed with rTAO expressed in 
Rosetta® BL21 E. coli vary from previous reports of other expressions of TAO from alternative 
strains of E. coli. This discrepancy could be due to other laboratories not observing and 
correcting for the auto-oxidation of 1-ubiquinol. This could also be linked to the use of C10E8 
as a detergent in the assay, as detergents have similarly been shown to have an effect on the 
auto-oxidation of ubiquinol substrates.172 Alternatively, the expression described here may 
contain higher concentrations of co-factors that may improve the kinetics observed in these 
experiments. For example, pyruvate has previously been shown to affect the activity of 
TAO.168  
It was important to show that the enzyme was insensitive to azide, to give confidence that 
the 1-ubiquinol turnover observed was not from an undetected quinol oxidase impurity, and 
due to rTAO. A range of screening assays were developed, that allowed the single point 
inhibition screening of the MMV ‘kinetoplastid box’ collection of 400 compounds. This 
identified a range of compounds that inhibited TAO at micro-molar concentrations. One 
important outcome from the development of the 10-point inhibition assay highlighted the 
need to change pipette tips between each dilution step during the preparation of the 
compound dilution series. This ensured that accurate dilutions were performed and made 
sure that there was no erroneous transfer of compound. This supplemented the single point 
screening assay allowing inhibitor confirmation in robust 5 and 10-point IC50 determination 
assays. TAO was shown to be sensitive to colletochlorin B at similar concentrations to what 
had previously been reported in the literature,128 allowing the inclusion of a positive control 
in assay plates when assessing future compounds. The next steps for this project were to 
design and synthesise drug-like inhibitors of TAO, that are described in chapters 4, 5 and 6. 
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Chapter 4 – TAO inhibitor – lead compound identification 
A suitable starting point for lead optimisation, amenable for high throughput synthetic 
exploration, was required to progress this project. A variety of hit molecules had been 
identified as potential lead compounds. Both the MMV single point screen and initial SAR 
described in the literature around the natural products ascofuranone and CCB provided 
interesting compounds for potential exploration. Some structurally similar analogues of CCB 
had also been synthesised in house prior to the initiation of this work. The activity of these 
compounds was tested in the 10-point TAO IC50 assay described in chapter 3, which provided 
some direction for further analogue design. 
An ideal lead compound would be a synthetically amenable molecule allowing for further 
analogue design and synthesis. The lead should show potency against the target enzyme, 
that correlates to activity in cellular assays. It is important that cellular efficacy tracks to 
enzyme inhibition and the compound is specific for parasite inhibition and not acting as a 
general cytotoxin. Before embarking on analogue synthesis and further exploration of 
chemical hits, it is vital to confirm and validate the biological activity of hit molecules from 
pure characterised material, as often erroneous data can be generated from poor quality 
samples that exist in screening libraries.177  
4.1 MMV Screening follow up 
Screening of the MMV ‘pathogen box’ identified 20 compounds with reproducible binding 
curves and pIC50 > 5.0, when assessed by a 5-point IC50 determination. As part of follow up 
investigations, 10 compounds could be reordered from MMV as solids. Compounds 27, 28, 
33, 36, 38, 39, 40, 41, 43 and 45 (Table 9) were available and were re-ordered to perform 
validation assays. For each compound, 10-point TAO IC50 determination and in collaboration 
with Novartis, T. b. brucei growth inhibition (EC50) determination and cytotoxicity evaluation 
in mammalian HepG2 cells (CC50), were performed, these data are summarised in Table 9. 
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Table 9 - MMV hit follow up 
Structure # TAO (pIC50)a 
T. b. 
brucei 
(pEC50)b  
HepG2 
(pCC50)c 
 
27 < 4.5 4.5 ± 0.1 4.8 ± 0.1 
 
28 5.5 ± 0.1  4.6 ± 0.1 5.4 ± 0.1 
 
33 5.8 ± 0.1 5.3 ± 0.1 4.8 ± 0.1 
 
36 < 4.5 4.7 ± 0.1 4.9 ± 0.1 
 
38 5.6 ± 0.1 5.1 ± 0.1 5.5 ± 0.1 
 
39 5.5 ± 0.3 7.4 ± 0.1 4.9 ± 0.1 
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40 4.9 ± 0.1 4.8 ± 0.1 5.1 ± 0.1 
 
41 5.6 ± 0.2 5.2 ± 0.1 5.3 ± 0.1 
 
 43 5.7 ± 0.1 5.7 ± 0.1 5.4 ± 0.1 
 
45 5.0 ± 0.1 5.8 ± 0.1 5.6 ± 0.1 
 
a Negative log concentration and standard deviation of compounds required for 50% inhibition of trypanosome 
alternative oxidase. b Negative log concentration and standard deviation of compounds required for 50% growth 
inhibition of T. b. brucei Lister427. c Negative log concentration and standard deviation of compounds required for 
50% growth inhibition of HepG2 cell line. 
 
Examination of these data generated against the 10 MMV hit compounds showed that two 
compounds did not reconfirm activity against TAO in a 10-point IC50 assessment (27, 36).  
Compound 39 showed excellent inhibition of parasite growth; however, this was at a higher 
potency than TAO inhibition, indicating that this compound is inhibiting parasite growth by 
an alternative mechanism. The remaining compounds showed similar inhibitory activities 
against TAO and the parasite, with a slight decrease in potency observed from the 
biochemical enzymatic assay to the parasite assay. This is thought to be due to compound 
permeability into the parasite, leading to the effective internal parasite concentration being 
lower. Unfortunately, when the growth inhibition of the parasite is compared to the growth 
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inhibition of mammalian HepG2 cells there seems to be negligible selectivity for parasite 
inhibition with these identified compounds. This could be due to compound inhibition of 
similar quinol oxidases, necessary respiratory function in the mammalian cell. Compounds 
33 and 43 showed a small window of selectivity for parasite inhibition although this was 
deemed too narrow to warrant further exploration. On the other hand, CCB showed 2 to 3 
orders of magnitude selectivity for parasite growth inhibition over mammalian cells, and so 
the compounds identified from the MMV screen were not taken forward, and CCB was 
explored as an alternative starting point for inhibitor design. 
4.2 CCB Profile 
CCB showed high potency for inhibiting TAO (TAO pIC50 8.5), which corresponded to similar 
high potency for T. b. brucei parasite growth inhibition (T. b. b. pEC50 8.4) (Figure 43). CCB 
also showed good selectivity for parasite growth inhibition over mammalian cells with a 
> 1000-fold selectivity window (HepG2 pCC50 5.1).178 
 
Figure 43 -- CCB TAO IC50 and T. b. brucei EC50 
 
In consideration of the high enzymatic inhibitory activity, high efficacy in the parasite growth 
inhibition assay, favourable selectivity over mammalian cells, a published crystal structure of 
CCB with TAO (PDB: 3W54), and the basic SAR previously described; further optimisation of 
the CCB chemotype was undertaken with an aim to identify a synthetically amenable lead 
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compound that could be developed into a more drug-like tool compound to enable the 
validation of TAO as a potential treatment for African trypanosomiasis. 
A number of CCB analogues had previously been synthesised in the Sussex Drug Discovery 
Centre (SDDC) at the University of Sussex; however, biological data on these compounds 
were limited. These compounds were screened in the 10-point TAO inhibition assay to give 
an initial insight into the SAR around CCB, these data are summarised in Table 10 and 
published in the European Journal of Medicinal Chemistry.178 
 
Table 10 – SAR summary of CCB analogues previously synthesised at the SDDC. 
Structure # TAO (pIC50)a 
T. b. 
brucei 
(pEC50)b 
HepG2 
(pCC50)c 
 
26 
CCB 8.5 ± 0.3 8.4 ± 0.1 5.1 ± 0.1 
 
47 8.4 ± 0.2  6.4 ± 0.1 4.9 ± 0.1 
 
48 7.3 ± 0.1 5.6 ± 0.1 - 
 
49 6.5 ± 0.2 7.4 ± 0.7 4.8 ± 0.1 
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50 7.0 ± 0.2  6.6 ± 0.1 < 4.8 
 
51 7.6 ± 0.3 5.2 ± 0.1 4.4 ± 0.1 
 
52 6.1 ± 0.3 5.7 ± 0.1 5.0 ± 0.1 
 
53 5.5 ± 0.2 5.8 ± 0.1 4.4 ± 0.1 
 
54 5.4 ± 0.2 - - 
 
55 5.4 ± 0.2 - - 
 
56 5.4 ± 0.1 - - 
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57 6.9 ± 0.2 4.9 ± 0.1 4.9 ± 0.1  
 
58 6.6 ± 0.2 5.5 ± 0.2 4.7 ± 0.1 
 
59 6.0 ± 0.1 4.9 ± 0.2 5.0 ± 0.1 
 
60 8.1 ± 0.1 7.0 ± 0.2 5.3 ± 0.1 
 
61 7.2 ± 0.1 6.2 ± 0.1 5.1 ± 0.1 
 
a Negative log concentration and standard deviation of compounds required for 50% inhibition of trypanosome 
alternative oxidase. b Negative log concentration and standard deviation of compounds required for 50% growth 
inhibition of T. b. brucei Lister427. c Negative log concentration and standard deviation of compounds required for 
50% growth inhibition of HepG2 cell line. 
 
Substituting the benzaldehyde of CCB (26) for the nitrile (47) showed minimal detriment to 
TAO inhibitory activity. A benzonitrile moiety is preferred over a benzaldehyde group in a 
drug molecule, as hard electrophiles such as aldehydes are metabolic weak spots for 
oxidation.179 Aldehydes can also readily form adducts with glutathione (GSH), or cysteine, 
creating toxic liabilities, via GSH depletion or nonspecific interaction with proteins.180 The 
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removal of the aromatic methyl group provided 10-100-fold drop in potency against TAO (50 
& 51). A key requirement for potent inhibitory activity of TAO was the chloro group; removal 
of this in compound 53 led to a 100 to 1000-fold decrease in potency. Results concerning the 
availability of the hydrogen bond donor phenols were mixed. Compound 57 surprisingly still 
inhibited TAO with reasonable potency. Potency was also retained with compounds 58 and 
59 where the geranyl tail point of attachment was explored, albeit with around 100-fold 
detriment in potency.  
In addition to the data that was published in the European Journal of Medicinal Chemistry,178 
two other bicyclic inhibitors of TAO had been synthesised in Simon Ward’s group. The 1,2-
benzisoxazole intermediate (60) was converted via a Kemp elimination to the nitrile analogue 
47.181 Compound 60 showed good inhibitory activity of TAO and warranted further synthetic 
exploration. The coumarin analogue (61) had also been synthesised and showed respectable 
potency against TAO. 
The initial project strategy was to identify a synthetically tractable lead compound that would 
facilitate late stage diversification and generation of SAR. The nitrile analogue was preferred 
to the benzaldehyde as TAO inhibition of both analogues were shown to be similar and the 
nitrile had a reduced metabolic and toxic liability. The other advantage that the nitrile 
provided was an improved chemical stability, allowing a wider range of reaction conditions 
to be employed at later stage synthetic steps. The 1,2-benzisoxazole was also of interest, as 
it provided a means to remove of one of the HBDs, improving the likelihood of achieving CNS 
penetrantration.182 
4.3 Resorcinol analogue synthesis and TAO activity assessment 
The established synthetic routes to analogues of CCB are not trivial and often require 
multiple synthetic steps, with a variety of protection and deprotection strategies. Previous 
work from the Ward group has highlighted the difficulties in the generation of advanced 
intermediates for late stage diversification of this chemotype.183 A synthetic route to an 
advanced intermediate was developed to investigate late stage diversification of the 
‘lipophilic tail’ region of the CCB chemotype (Figure – 44). It was anticipated that 
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intermediate 66 could provide access to tail modifications through electrophilic aromatic 
substitution. Previous efforts from our group had focused on diversification through 
halogenation and subsequent transition metal mediated cross couplings, Lewis acid 
mediated rearrangement or directed lithiation chemistries. Unfortunately these methods 
had not been fruitful in providing analogues of CCB.183 
 
Figure 44 - Resorcinol advanced intermediate synthesis 
 
The readily available resorcinol starting material (62) could be formylated under Vilsmeier-
Haack conditions in high yield (79%).184 Generation of the Vilsmeier intermediate (67 – Figure 
45) by the dehydration and chlorination of DMF, provided the species that underwent 
electrophilic aromatic substitution with the electron rich resorcinol. Subsequent hydrolysis 
of the dimethyl iminium species afforded the benzaldehyde (63). 
 
Figure 45 - Vilsmeier-Haack intermediate formation 
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To aid isolation of the compound on large scale the reaction was performed in acetonitrile. 
Quenching the reaction with water provided small amounts of solid product and then 
removal of acetonitrile by concentration under vacuum afforded the desired product as a 
yellow solid in satisfactory purity for continuation of synthesis. In contrast, conducting the 
reaction in neat DMF provided crude material that had to be purified by flash 
chromatography, limiting isolation on a large scale. The characteristic aldehyde proton signal 
at 10.04 ppm and the shift of the ortho-phenol to 12.05 ppm (due to the intramolecular 
hydrogen bond formation between the aldehyde) were indicative of formation of the 
benzaldehyde (63). Oxime formation was carried out by the addition of an aqueous solution 
of hydroxylamine in acetonitrile under reflux to provide (64). This could be dehydrated 
through chlorination with thionyl chloride then cyclisation with the adjacent phenol. In situ 
Kemp elimination with aqueous sodium hydroxide provided nitrile intermediate (65), with a 
characteristic band at 2225 cm-1 for the CN triple bond stretch in the infra-red (IR) spectrum. 
Treatment of this with an electrophilic chlorination reagent (68), generated from sulfuryl 
chloride and diethyl ether (Figure 46) as described by Masilamani et al.185, provided the 
desired chloro nitrile resorcinol intermediate (66) for further synthesis.  
 
Figure 46 - Electrophilic chlorinating agent generation as reported by Masilamani et al.185 
 
Chlorination of the benzaldehyde intermediate (63) under identical chlorination conditions 
provided the comparative chloro benzaldehyde (69) for further synthetic exploration (Figure 
47). 
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Figure 47 - chlorination of benzaldehyde 
 
It was envisaged that Mannich-phenol chemistry could be employed to furnish the aromatic 
system with a tail containing a benzylic amine as a final step diversification. The inclusion of 
a hetero atom in the lipophilic chain was desirable, as the introduction of polarity improves 
cLogP and cLogD, thus significantly improving the CNS MPO score (discussed later) for these 
molecules. The target benzylamine molecule was modelled in the binding cavity of TAO in 
complex with CCB (PDB: 3W54).129 Replacing CCB present in the 3W54 crystal structure with 
the benzyl amine analogue (71) and performing an energy minimisation with the OPLS3 
(Optimized Potentials for Liquid Simulations 3) forcefield showed good structural similarity 
to CCB (Figure 48), using Schrödinger drug discovery suite - Maestro. OPLS is a forcefield that 
is used to calculate the molecular dynamics of biomolecules. Recent refinements to the latest 
forcefield OPLS3 have included the description of aryl nitrogen lone pairs, halogen bonding 
via off atom charge sites and refined dihedral parameters of peptide bonds. This has allowed 
more accurate simulations, calculations and model generation, which compare to 
experimentally observed binding modes.186 
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Figure 48 - Modelled benzylamine analogue (green) compared to CCB (pink), overlayed energy minimised 
structures, using OPLS3 forcefield in Maestro – Schrodinger drug discovery suite. Strucutral data from published 
crystal structure PDB: 3W54, Shiba et al.129 
 
Formation of the iminium species (70) following the dehydration of paraformaldehyde with 
N-hexylmethylamine in ethanol and subsequent electrophilic aromatic substitution with the 
benzaldehyde resorcinol intermediate (69), provided the desired benzylamine derivative (71) 
(Figure 49). Similarly, analogues of the benzonitrile intermediate (66) were synthesised by a 
Master’s student (Thomas Cunningham) under my supervision with the same reaction 
conditions to provide compounds 72 & 73 (Table 11). 
 
Figure 49 - Mannich Phenol Chemistry 
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Table 11 - TAO inhibition of resorcinol benzylamine analogues 
Structure # TAO (pIC50)a 
cLogPb 
cLogD7.4
c 
CNS 
MPO 
d 
 
71 < 4.5 5.0 3.3 4.4 
 
72 < 4.5  3.0 1.4 5.3 
 
73 < 4.5 3.0 1.3 5.1 
 
a Negative log concentration and standard deviation of compounds required for 50% inhibition of trypanosome 
alternative oxidase. b, c, d Calculated using ChemAxon MarvinSketch 17.25.0. 
 
Assessment of the TAO inhibitory activity of these compounds was disappointing, with no 
inhibition of TAO observed, despite the improvement of calculated physicochemical 
properties (Table 11). These data suggest that inclusion of a basic centre in this part of the 
molecule is disfavoured. Due to the extensive synthetic effort of accessing these resorcinol 
aromatic systems, these targets were deprioritised in favour of investigating the bicyclic 
compounds that had been identified, in particular the 1,2-benzisoxazole (60). 
4.4 Synthesis and activity assessment of bicyclic analogues 
Compound 60 showed promising inhibitory activity against TAO (Table 10). The synthesis of 
a halogenated advanced intermediate was devised to facilitate the exploration of the tail 
region of these molecules through transition metal cross coupling. 
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Figure 50 - Benzisoxazole / benzoxazole synthesis 
 
Electrophilic bromination of 69 with tetrabutylammonium tribromide at 0 °C provided 
compound 74 in reasonable yield. Oxime formation was carried out under similar conditions 
as used for non-halogenated analogue 64. Cyclisation of this intermediate was initially 
carried out in the presence of trifluoroacetic anhydride in dichloromethane reported by 
Kalkhambkar et al.187 However, the poor solubility of 75 in dichloromethane prevented any 
reaction in neat solvent. Modification of the solvent system to 10:1 dichloromethane 
acetonitrile provided small amounts of product at room temperature following prolonged 
reaction times. Heating the reaction in the microwave to 100 °C expediated the reaction, and 
after 1 hour the reaction had proceeded to completion (Figure 50). Initial analysis by LCMS 
showed the correct molecular ion of the 1,2-benzisoxazole (76). However, upon analysis of 
the 2D NMRs of the purified material, nuclear Overhauser effect experiments failed to show 
expected correlations between the methyl C-H and the aromatic C-H and hetero-nuclear 
multi-bond correlation spectroscopy experiments also failed to show correlation between 
the aromatic C-H and the aromatic carbon bearing the methyl group (Figure 51). 
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Figure 51 - NOE, HMBC correlation 
 
Previously the non-chlorinated 1,2-benzisoxazole synthesis was carried out via dehydration 
of the oxime with thionyl chloride in pyridine. This promoted intra-molecular cyclisation with 
the adjacent phenol, that upon Kemp elimination with NaOH provided compound 65. These 
initial cyclisation conditions were attempted with analogue 76. This reaction provided a 
product that had a different retention time by LCMS to the microwave conditions but 
contained the desired product molecular weight. Analysis of the purified material from this 
reaction showed NOE correlation between the methyl C-H and the aromatic C-H at 9.40 ppm 
and 2.53 ppm (Figure 52) confirming that the correct product had been isolated. 
 
Figure 52 - NOE correlation for 1,2-isoxazole 
 
It was suspected that conducting the reaction at elevated temperatures promoted a 
Beckman rearrangement of the oxime that had previously been reported by Thomas et al 
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(Figure 53).188 This would give rise to the 1,3-benzoxazole (77) upon cyclisation, which 
matched the NMR data obtained for this compound. To provide further evidence that the 
correct assignment of the benzisoxazoles was made, the products were subjected to Kemp 
elimination conditions. The products were dissolved in acetonitrile and treated with 3 M 
aqueous sodium hydroxide. In agreement to the NMR studies, the 1,2-isoxazole product 
underwent Kemp elimination181 to give the nitrile phenol product, whereas the product 
isolated from the initial trifluoroacetic acid anhydride, dichloromethane, 100 °C reaction was 
stable to these conditions. 
 
Figure 53 – Plausible mechanism of Beckmann rearrangement to 1,3-benzoxazole 
 
With the 1,2-benzisoxazole (76) now in hand, a variety of palladium mediated cross-couplings 
were attempted to furnish substituents of the lipophilic tail. Unfortunately, despite screening 
a matrix of 3 bases (K2CO3, K3PO4 and triethylamine) and 3 catalysts [Pd(PPh3)2Cl2, Pd(dppf)Cl2 
and Pd(dptpf)Cl2], Suzuki-Miyaura cross coupling with 3,4-difluorophenyl boronic acid was 
unsuccessful.189,190 Under these basic reaction conditions at elevated temperatures, Kemp 
elimination was predominant, and the starting material degraded to the nitrile phenol. 
Similarly, attempts at Mizoroki-Heck cross coupling with 1-octene were also 
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unsuccessful,191,192 again providing the ring opened starting material. At this point an 
alternative strategy was sought for two reasons. Firstly, any future base mediated reactions 
would likely provide Kemp eliminated products, creating purification and elucidation 
problems, that would limit the synthetic versatility of this intermediate. Secondly, the long-
term chemical stability of these compounds is uncertain, especially regarding the demanding 
stability requirements that had been set out for new treatments for HAT by DNDi (Table 2). 
These chemical stability issues could also prove problematic in more advanced in vivo 
pharmacokinetic and pharmacodynamic studies. 
4.5 Mono phenol analogue synthesis and biological assessment 
The TAO inhibitory activity of the 1,2-benzisoxazole (60) and compounds 57, 58 and 61 
provided an interesting observation: removal of the hydrogen bond donating phenol ortho 
to the aldehyde or nitrile appeared to be tolerated, as these compounds retained potent 
inhibition of TAO. The hydrogen bond donor had previously been suggested as important for 
the interaction with the enzyme, forming hydrogen bonds with arginine (R118) and 
threonine (T219) residues.128,129 However, analogues challenging this hypothesis had not 
previously been synthesised or reported. The data generated here was of particular interest 
and looked to challenge this assumption. Removal of the other phenol para to the aldehyde 
however was not tolerated well resulting in a 40-fold reduction in potency (51 & 56 – table 
7). 
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Figure 54 - Proposed synthesis of mono-phenol analogue 
 
A synthesis to the mono phenol analogue was devised (Figure 54). Pourmoursavi et al. had 
described the use of benzyl triethylammonium tribromide (BTEAT) to selectively brominate 
a range of substituted phenols.193 Unfortunately attempts at mono bromination using similar 
conditions with benzyl trimethylammonium tribromide (BTMAT), provided a mixture of 
brominated products at room temperature. Efforts to optimise the mono bromination of the 
commercially available benzonitrile (78) were also unsuccessful. Modification of reaction 
temperature, addition order and speed provided a mixture of brominated products that 
could not be easily separated. Alternative brominating agents (Br2, tetrabutylammonium 
tribromide and N-bromosuccinimide) were also trialled to no avail providing mixtures of the 
brominated products; therefore, an alternative synthesis was sought.   
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Figure 55 - Proposed mono-phenol benzaldehyde synthesis 
 
Selective mono-bromination of the benzaldehyde (79) was however successful with the 
BTMAT conditions and the desired product (80) could be isolated in high yield (94%) and on 
scale (Figure 55). A reaction condition screen was performed around the subsequent 
Mizoroki-Heck reaction. It was found that reaction with 1-octene afforded the alkene 
intermediate (81) in 27% yield, utilising conditions reported by Peh et al.194 These conditions 
utilise a N-heterocyclic carbene (NHC) ligand for the palladium catalyst. NHC ligands have 
been shown to have advantages over phosphine ligands: they show higher stability at 
elevated reaction temperatures than bulky phosphine ligands and have strong σ-donating 
properties that aid oxidative addition of the metal into the carbon-halogen bond.195,196 These 
conditions allowed the isolation of the tail derivatised analogue (81). The next step required 
hydrogenation of the alkene double bond, which proved challenging. The benzaldehyde was 
shown to be susceptible to hydrogenation and the resulting benzylalcohol readily underwent 
hydrogenolysis to provide the undesired dimethyl analogue (82) that showed 2 methyl 
signals in the 1H NMR at 2.18 and 2.19. The crude material isolated from this reaction was 
however taken on in synthesis to provide the chlorinated dimethyl analogue 83 
unfortunately due to an error on the purification this compound was not isolated to allow 
for future SAR comparison. Adaption of the synthesis to provide the more attractive 
benzonitrile was devised (Figure 56). 
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Figure 56 - Successful monophenol analogue synthesis 
 
A variety of routes were investigated to interconvert the aldehyde 80 into the nitrile 85. 
Vatèle et al. had reported the facile conversion of primary alcohols to their corresponding 
aldehydes, with subsequent reaction to the nitrile via an aldimine intermediate using TEMPO, 
diacetoxyiodobenzene and ammonium formate in a one-pot procedure.197 Bag et al. had also 
reported the oxidation of an aldimine to the nitrile using diacetoxyiodobenzene.198 
Unfortunately, under both of these conditions the nitrile product 85 was not isolated and the 
material underwent a highly exothermic degradation to unidentified products. This was likely 
due to the phenol, that has previously been reported to react with hyper-valent iodine 
reagents.199,200 Although initial attempts were unsuccessful via the aldimine, there was 
promise in generating the aldoxime with hydroxylamine, and carrying out a subsequent 
dehydration. Conditions reported by De Luca et al,201 describe the reaction between cyanuric 
chloride and DMF to generate a Vilsmeier-like intermediate. This electrophilic intermediate 
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is suggested to undertake nucleophilic attack from the oxygen of the aldoxime, which breaks 
down to generate the nitrile. These reaction conditions successfully provided the nitrile 85 
with an indicative carbon-13 NMR shift at 117.7 ppm and the presence of CN triple bond 
stretch at 2232 cm-1 in the IR spectrum. The nitrile could be cross coupled using the same 
conditions previously identified in the synthesis of aldehyde 81, with similar yields. The vinylic 
intermediate 86 was isolated and confirmed as the trans-alkene from a proton coupling 
constant of 16 Hz. This could be successfully reduced by transfer hydrogenation using 
conditions reported by McMurray.202 Over-reduction of the nitrile was not observed, as the 
quaternary nitrile carbon was still present at 118.4 ppm in the NMR analysis of 87. Final 
electrophilic aromatic chlorination with sulfuryl chloride in diethyl ether was slow, requiring 
the addition of extra equivalents of the chlorinating component and the extension of 
reaction time to provide sufficient material for isolation of compound 88.  
The mono-phenol analogue 88 was isolated successfully through the implementation of the 
synthesis described (Figure 56). Compound 88 was assessed in the 10-point TAO inhibition 
assay and sent for T. b. brucei parasite growth inhibition and mammalian HepG2 cytotoxicity 
assessment at Novartis (Figure 57). Compounds 47 – 53, 57 - 61 and 83 were at this point 
sent to Novartis for evaluation in the same assays, summarised in Table 7. Data generated 
against T. b. brucei showed that the change from aldehyde to nitrile was not as well tolerated 
as in the enzyme inhibition assay. Direct comparison of compounds 47 to CCB (26) and 
compounds 50 to 51 show between 10-100-fold loss in potency against parasite growth with 
the nitrile. In addition, the nitrile did not result in any loss of cytotoxicity in the mammalian 
HepG2 cell and as a result the favourable selectivity profile observed with CCB was 
diminished to 10-100-fold. The replacement of the geranyl chain with a straight n-octyl chain 
correlated to a 10-fold decrease in potency against the enzyme and a 10-fold decrease in 
efficacy against the parasite (47 & 48). Interestingly the potency of the acylated phenol 
analogue (49) showed improved potency in the parasite compared to the enzyme. It was 
hypothesised that the acetyl group was labile, either under assay conditions or due to 
parasite enzyme activity, and so degraded to the more potent CCB (26) in situ.  
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Figure 57 - TAO IC50 and T. b. brucei EC50 assessment of mono-phenol 88, s.d. shown (n = 3). 
 
The mono phenol compound 88 potently inhibited TAO with a pIC50 8.5 (3 nM), which 
correlated to potent inhibition of parasite growth with a pEC50 of 7.6 (27 nM). The compound 
still retained selectivity of parasite inhibition (~ 300-fold) over mammalian HepG2 cells with 
a corresponding pCC50 of 5.1 (7.8 µM). Compound 88 provided a synthetically amenable lead 
that would allow further chemical property exploration and SAR investigation. Comparison 
of this compound to the matched pair 48 was of interest, as removal of the phenol had 
resulted in a 10-fold increase in potency against the enzyme, and also retention of parasite 
growth inhibition, resulting in reasonable selectivity against the parasite over mammalian 
cells. Overall this compound provided a chemically tractable lead, which retained good 
biochemical and cellular potency.  
Chapter 4 - TAO Inhibitor – Lead Compound Identification Conclusions 
The focus of this chapter was to highlight the screening and chemistry efforts aimed at 
identifying a synthetically amenable lead compound. The compounds identified from 
screening the MMV kinetoplastid box initially detected several structurally novel TAO 
inhibitors. Unfortunately, following the confirmation of these compounds activity in 10-point 
TAO inhibition, T. b. brucei parasite growth inhibition and HepG2 cytotoxicity assessment, no 
lead like molecules were identified and no improvements to CCB were observed. Extensive 
exploration of synthetic routes to analogues of CCB had previously been carried out in the 
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SDDC with variable success.178,183 The synthesis of hexa-substituted aromatic systems is not 
trivial, especially with an aim to carry out a late stage diversification of these molecules.203 
The combination of the complex electronic nature of these highly functionalised molecules 
and the steric hindrance of neighbouring substituents limits the viability of using these 
molecules as chemically tractable lead molecules.  
Further analysis of TAO inhibition data of historical compounds challenged the hypothesis 
that both hydrogen-bonding phenols were required for potent TAO inhibition. The synthesis 
of a mono phenol analogue was carried out and confirmed our previous observations 
verifying that the phenol ortho to the aldehyde / nitrile was not required for potent TAO 
inhibition. The synthesis that was developed on route to this compound had potential to be 
used in a late stage diversification strategy, towards additional analogues that would 
facilitate further exploration of SAR and lipophilic tail modification, discussed in chapter 5. 
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Chapter 5 
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Chapter 5 – SAR Exploration of Lipophilic Tail 
5.1 Introduction 
To develop a TAO inhibitor into a potential treatment for HAT it is important to consider the 
target product profile set out by the DNDi (Table 2). Some features of this profile can be 
achieved through astute compound design. Firstly, to effectively treat the second stage of 
the disease it is important that the compound will achieve efficacious concentrations in a 
range of tissues including the brain, so blood brain barrier (BBB) permeability is a 
requirement. An oral dosing strategy is also the preferred route for administration due to 
limited accessibility of health care in sub-Saharan Africa. 
Oral dosing has well studied barriers, which limit effective drug delivery. Solubility and 
dissolution along with absorption, distribution, metabolism and excretion, often referred to 
as ADME, are all important parameters to optimise during the development of orally 
bioavailable drugs.204 There have been many studies that relate compound physicochemical 
properties to ideal pharmacokinetic profiles for oral dosing. Lipinski’s rule of five (RO5) was 
derived from the analysis of approved oral drug molecules and their physicochemical 
parameters. The RO5 states that in order to obtain a compound that has a high chance of 
being orally bioavailable it should not fail more than one of the following parameters: higher 
than 500 molecular weight (MWt), have more than 5 hydrogen bond donors (HBD), more 
than 10 hydrogen bond acceptors (HBA) and a lipophilicity (LogP) above 5.205  
Other studies have looked at the effects of physicochemical properties on measured 
parameters like absorption.40 Palm and co-workers have shown the close relationship that 
polar surface area (PSA) has with human fraction absorbed (F); compounds with PSA of below 
63 Å are > 90% absorbed and compounds with PSA above 140 Å are < 10% absorbed.40 These 
observations have been further employed, along with other calculated parameters like cLogP 
and MWt, in models to predict absorption.206–208  
Similar explorations of the relationship between solubility and physicochemical properties 
have been attempted. However, correlations between high solubility and calculated physical 
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chemical properties are not clear-cut, making predications of solubility from compound 
structure imprecise. Many parameters have to been taken into account, and solubility 
models that contain a measured melting point often predict more accurately.209 More recent 
models have since been developed that include descriptors for structural shape, including 
number of rotational bonds and dihedral angles, which can better predict solubility when 
combined with other physicochemical parameters.210,211  
Metabolism of xenobiotics is a vital mechanism for organism survival, that facilitates the 
excretion of potentially harmful substances from the body. External molecules that are 
absorbed are subjected to a variety of metabolising enzymes in the liver. A large class of 
these enzymes are cytochrome P450 oxidases (CYP), that display recognition for a broad 
range of substrates and facilitates their mono-oxygenation.212 The rate and extent of 
compound metabolism can have a large impact on in vivo efficacy. Compounds that are 
rapidly metabolised and excreted will have a limited capacity to reach and maintain 
efficacious concentrations in the body. Metabolites that arise from enzymatic phase one 
processes such as oxidation, often undergo further 2nd phase metabolism through 
conjugation with molecules such as glucuronic acid. This furnishes the metabolite with polar 
functionality, which allows for efficient elimination and excretion. One common strategy to 
reduce metabolism, is to block the specific site of metabolic liability with a functional group 
that is less reactive or not recognised by metabolic enzymes.213,214 Recent reports of 
metabolic stability improvement strategies have involved utilising specific CYP enzymes to 
bio-transform advanced drug candidates on a preparative scale, then utilise fluorination 
chemistry to transform the oxidised drug molecule into a fluorine blocking group, specific to 
the site of metabolising enzyme action. This resulted in the generation of more metabolically 
stable molecules in some cases. However, the study also showed that stabilisation was only 
effective if the site of metabolism was the predominant weak spot. There are variations in 
metabolic pathways between species, and stability with one species’ CYP enzymes did not 
always correlate to stability across species. It was also highlighted that not all drug molecules 
will be suitable for late stage fluorination, as this depends on the tolerability of other 
functional groups present.215 
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Another general strategy to promote metabolic stability is to lower compound 
lipophilicity,214,216,217 as compounds with higher lipophilicity have been shown to have higher 
affinity for CYP enzymes.218 A common method employed to reduce lipophilicity is to 
introduce polarity into molecules through structural modification such as inclusion of 
heteroatoms and replacement of lipophilic groups.217 Adoption of compound optimisation 
metrics like lipophilic ligand efficiency (LLE) in early drug discovery programs is also becoming 
popular.219 LLE facilitates program advancement through the simultaneous optimisation of 
target potency and lipophilicity. This allows the identification of compounds that attain 
potency through enthalpic protein interactions and not lipophilic entropic interactions, 
reducing the risk of compounds having poor solubility or high metabolism.220 
The design of CNS penetrant compounds requires further optimisation of orally bioavailable 
molecules to permeate the blood brain barrier (BBB). The BBB provides an additional 
obstacle preventing xenobiotics from entering the CNS. The BBB comprises an endothelial 
cell membrane with tight junctions that restricts paracellular diffusion.221 The BBB also 
contains a range of efflux transporters that transport lipophilic molecules back into the blood 
stream, preventing their absorption and protecting the CNS from a variety of toxins.222  
A number of physicochemical properties have been assessed with regards to achieving high 
BBB permeability, previously reviewed by Clark.223 Interestingly, as with intestinal 
permeability predictions, HBD, HBA, PSA, lipophilicity and molecular size all have a correlative 
effect on BBB penetration. It is of note that compounds that have a lipophilicity in the range 
LogD 1-3, have fewer hydrogen bonding atoms (< 5), lower PSA (< 90 Å) and MWt (< 450 Da) 
are more BBB permeable. Further observations that the majority of CNS drugs have high 
permeability, low metabolic clearance and low efflux have recently been developed into a 
model deemed ‘multi-parameter optimisation’ (MPO) for CNS penetration.182,224 In this study 
the physicochemical parameters for a range of CNS approved drugs and CNS drug candidates 
were correlated to measured human liver microsome (HLM) clearance, passive permeability 
and P-glycoprotein (P-gp) efflux. Compounds that had cLogP < 5, cLogD < 4, HBD < 3.5, PSA 
(20-120 Å) and pKa (8 – 10) scored positively (the scoring function changed linearly 
depending on the distance from the cut off parameter). The combined scores for each 
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compound were shown to correlate to the measured clearance, P-gp efflux and passive 
permeability rates. It is interesting to see that the MPO scoring function does not have a 
lower limit for lipophilicity score, as previous studies looking at BBB penetration had 
highlighted that this was an issue for permeability.225 These methods have been 
implemented in CNS drug discovery to attain molecules with improved BBB permeability and 
efficacy.224 It is worth noting that BBB penetration and total brain concentration does not 
infer biological efficacy alone. Total brain concentration often poorly correlates to efficacy in 
pharmacodynamic models. The unbound fraction of drug in the brain has been shown to 
better correlate to in vivo efficacy, making this an important consideration when designing 
new drugs for CNS disorders.226 
Designing TAO inhibitors whilst considering and optimising the physicochemical parameters 
outlined above will facilitate the identification of tool compounds suitable for validating TAO 
as a target to clear trypanosome infections in vivo. It is of interest that the use of 
ascofuranone and glycerol has been shown to clear infections of trypanosomes in mice.227 A 
single oral dose of 200 mg/kg without glycerol was unsuccessful in clearing the infection. 
However, a single dose of ascofuranone at 100 mg/kg with glycerol (3 g/kg) could cure 
parasitaemia. Glycerol could be functioning in two ways in this study. Firstly glycerol can 
inactivate the anaerobic respiratory pathway of glycerol kinase by mass action (discussed in 
chapter 1).135 Secondly glycerol could be acting as an excipient and improve the effective 
concentration of ascofuranone enhancing its efficacy.228 A second study of ascofuranone 
without glycerol was conducted by the same group; here, it was observed that consecutive 
daily dosing of ascofuranone at 100 mg/kg (i.p.) for four days or 400 mg/kg (p.o.) for eight 
days in mice could clear a trypanosome infection.229 Pharmacokinetic data was not reported 
in this study, but a high oral dose did show efficacy in models of the 1st stage of the disease. 
Another interesting observation in this study was that following 3 days of consecutive 
treatment, only short stumpy forms of the parasite were found in the isolated trypanosomes, 
and long slender blood stage forms were not identified. This is important as short stumpy 
forms of the trypanosome are unable to proliferate, and have lost their ability to alter their 
VSG coat expression, and could be subsequently cleared by host immune mechanisms.230,231 
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Obtaining TAO inhibitors with improved pharmacokinetic profiles could improve in vivo 
efficacy, reduce compound burden and improve therapeutic potential. 
 
Figure 58 - Ascofuranone and CCB structural contribution to lipophilicity 
 
Initial calculations of physicochemical properties of ascofuranone and CCB highlight the 
extremely high lipophilicity of both molecules (Figure 58). As previously highlighted, lipophilic 
compounds have a tendency to be highly metabolised,217,218 poorly soluble in aqueous and 
physiological fluids and show off-target promiscuity often resulting in toxic side effects.232,233 
High lipophilicity has also been shown to contribute to a poor MPO CNS score, compounds 
with an MPO > 4 are predicted to permeate the BBB. This effectively penalises highly 
lipophilic compound twice, once for cLogP and once for cLogD, resulting in MPO scores of < 
4 for both ascofuranone and CCB. Further investigation into the contribution of the 
constituent parts of CCB and ascofuranone show that the majority contribution (> 3.5 cLogP) 
to lipophilicity is the tail portion of the molecule (Figure 43). The presence of two hydrogen 
bond donors also affects the CNS MPO score negatively. These aspects of the molecule would 
need to be explored and optimised to identify inhibitors of TAO with improved 
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physicochemical parameters, which would maximise the potential to attain ideal 
pharmacokinetic exposure in vivo for treating African trypanosomiasis infections. 
With the aim to improve the drug likeness and CNS penetration MPO score of the TAO 
inhibitors identified in chapter 4, the physicochemical properties of the synthetically 
amenable lead compound 88 were investigated (Table 12). 
Table 12 - Physicochemical properties and MPO score of compound 88 
 
Compound 
Number 
 PSA 
(Å2) 
HBD Basic pKa cLogD7.4 cLogP MWt 
CNS MPO 
Score 
88 
Value 44 1 - 7.9 5.5 6.3 279 - 
MPO 
score 
1 0.8 1 0 0 1 3.8 
CCB (26) 
Value 58 2 - 7 4.8 6.2 322  
Score 1 0.5 1 0 0 1 3.5 
 
Parameters calculated using Chemaxon Marvin Sketch 17.25.0 and JChem extensions for Knime 
 
Analysis of the physicochemical properties reported in table 12 show that compound 88 is 
penalised for being highly lipophilic, having a cLogP of > 5 and a cLogD7.4 > 4, generating an 
overall CNS MPO score of below 4. This result is similar to the calculated properties of CCB 
(26), which is further penalised in the CNS MPO calculation as it contains two hydrogen bond 
donors. As discussed previously, the main contribution to high lipophilicity in these molecules 
arises from the lipophilic tail. The identification of compound 88 was anticipated to facilitate 
the synthesis of a wider variety of analogues to explore the SAR and reduction of lipophilicity 
in this region. Inspection of the enzyme-inhibitor crystal structure (Figure 59), highlighted 
the lipophilic nature of this part of the inhibitor-binding pocket. No available polar residues 
were present that could be targeted for improving enthalpic interactions between the 
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protein and the ligand. The lipophilic tunnel of TAO was also shown to be narrow at only 7.1 
Å between leucine residues LEU122 and LEU212. This could potentially limit the size of the 
inhibitor that can be accommodated in the binding site. 
 
Figure 59 - Narrow lipophilic tunnel - Leucine residues (LEU122 and LEU212) shown in green, Iron centre shown 
in orange towards the back of TAO inhibitor binding pocket (right), exterior of TAO left, molecular binding surface 
in grey. Image generated from Protein preparation of PDB 3W54 structure using energy minimisation (OPLS3 
forcefield) and receptor binding surface generation in Maestro, Schrodinger drug discovery suite. 3W54 deposited 
by Shiba et al.129 
 
In consideration of this a range of polar tail analogues were designed, focused on minimising 
the steric and electronic impact that these molecules would have on inhibitor binding to TAO 
(Table 13). 
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Table 13 - Designed tail modifications of TAO inhibitors with reduced lipophilicity, Chemaxon v17.25.0 was used 
to calculate properties, utilising consensus model (Chemaxon, Klopp et al. and PhysProp data base) for calculation 
of cLogP and cLogD7.4 
Structure # cLogPa cLogD7.4 
b CNS 
MPO c 
 
26 6.2 4.8 3.5 
 
88 6.3 5.5 3.8 
 
89 3.5 2.7 4.9 
 
90 4.6 3.8 4.1 
 
91 4.5 3.7 4.2 
 
Parameters calculated using Chemaxon Marvin Sketch 17.25.0 and JChem extensions for Knime 
 
5.2.1 Polar Tail Modifications Synthesis 
Analysis of the calculated properties of these designed inhibitors showed that the reduction 
in lipophilicity from these molecules resulted in CNS MPO scores of above 4. If these 
compounds retained inhibitory activity against TAO and parasite growth they would provide 
analogues that had potential for improved CNS penetration over CCB. The synthesis of 
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analogues containing amide, and ether functionality was initially prioritised, as these 
modifications improved the compound lipophilicity profiles to the greatest extent. The 
synthetic route to compound 88 provided a good basis for the synthesis of these analogues 
in the most economical fashion. Electrophilic chlorination of intermediate 85 would enable 
the final synthetic step to be the installation of the tail. 
 
Figure 60 - Chlorination of advanced intermediate 85 
 
Chlorination of 85 to 92 was however, not trivial (Figure 60). The sulfuryl chloride in diethyl 
ether conditions that were previously employed to synthesise compounds 83 and 88 and the 
intermediates 66 and 69 formed product, but an unidentified compound related impurity 
was also produced in around 20% yield. This impurity could not be easily separated through 
crystallisation or chromatography. A variety of electrophilic chlorinating conditions were 
screened, with an aim to identify optimal conditions to provide pure material for 
diversification. The impurity profile was improved in two sets of reaction conditions providing 
the compound in >90% purity: NCS in tetrahydrofuran; or NCS in acetonitrile with 1.1 
equivalents of triethylamine. However, the unidentified impurity was still present at around 
5 – 10%. 
To mitigate the risk of slowing the progression of the project, the synthesis of the des-methyl 
intermediate (94) was performed in parallel (Figure 61). The chlorophenol (93) starting 
material was commercially available and could be readily brominated with 
N-bromosuccinimide in acetonitrile to give 94 in good yield. The 25-fold reduction in TAO 
potency observed with the des-methyl CCB analogue (50 – Table 10) was deemed acceptable 
for future analogue comparison.  
133 
 
Figure 61 – Bromination of des methyl intermediate (94) synthesis 
 
A Mizoroki-Heck coupling was carried out with the methylated intermediate 92,191,192 
utilising the I-Mes NHC catalyst that had previously been identified.195 Some desired product 
was synthesised in the reaction; however, the reaction profile showed the formation of other 
structurally related impurities. The product required isolation by reverse-phase preparative 
high-performance liquid chromatography (HPLC) to provide compound 95 in a low 7% yield. 
Utilising Mizoroki-Heck conditions to install the tail meant that a subsequent reduction of 
the resulting alkene was required. Conducting this reduction via hydrogenation would 
provide the desired saturated carbon chain analogues, although aromatic hydro-
dehalogenation is often observed under hydrogenation conditions and would be a likely side-
reaction of this route. Dehalogenation has been reported to be suppressed when conducting 
the hydrogenation under acidic conditions. However, hydrogenation of 95 in an ethanolic 
HCl solution resulted in the formation of the hydro-dehalogenated product, an intermediate 
that had been previously synthesised (87 - figure 62). 
 
Figure 62 - Mizoroki-Heck installation of lipophilic tail 
 
At this point alternative cross-coupling reactions were investigated to install the tail 
modifications. Li et al. had recently reported the Suzuki-Miyaura cross coupling of 
trialkylboranes with aryl halides, and had showed good utility with a variety of aromatic and 
134 
hetero aromatic substrates.234 A point of interest with this chemistry was that the 
trialkylborane coupling partner could be easily synthesised in situ from the hydroboration of 
a terminal alkene with a solution of borane in THF. The only perceived limitation of this 
chemistry was that there were no examples of substrates containing acidic hydrogens. 
Perhaps unsurprisingly, when attempting these reaction conditions with the free phenol 
intermediates 92 and 94, no product was observed. Li et al. had exemplified an array of 
anisole substrates with high isolated yields, prompting the investigation of protecting the 
phenol and retrying the chemistry (Figure 63).  
 
Figure 63 - Suzuki-Miyaura chemistry to install lipophilic tail, based on Li et al. conditions234 * Formation of 99 
conducted at 100 °C. However, the formation of bis Suzuki coupled material through Cl and Br, led to a reduced 
yield. 
 
Methylation of the intermediate 92 and 94 could be carried out with dimethyl sulphate 
(DMS) in acetone in high yield to provide compounds 96 and 97. Attempting the chemistry 
reported by Li et al. on this substrate proved very successful. Trioctylborane was pre-formed 
by hydroboration of 1-octene with a solution of borane in THF at 0 °C. The excess borane 
reagent was quenched by the addition of water, the arylbromide (96 or 97) was successfully 
Suzuki cross-coupled. This route enabled the installation of the lipophilic tail in a high yield, 
although the phenol was now protected as an anisole (98 and 99) and would require 
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deprotection to provide the desired analogues. The reaction to form the des-methyl 
analogue (99) was conducted at a higher temperature of 100 °C in an attempt to expedite 
the reaction. At this elevated temperature, formation of the bis Suzuki cross-coupled product 
was observed as a major by-product of the reaction. The by-product was formed by the 
reaction of the aryl chloride with a further equivalent of alkyborane and resulted in a lower 
isolated yield of the desired mono-coupled product (99). A range of deprotection conditions 
were screened to remove the anisole and furnish the desired product as the free phenol. The 
best conditions identified were trimethylsilyl chloride (TMS-Cl) and sodium iodide at 80 °C, 
giving the free phenols (88 and 100) in respectable 45-81% yields. With these conditions in 
hand the syntheses of the amide and ether tails were carried out. The des-methyl 
intermediate 94 was used for this initial exploration as the small impurity that was present 
in 92 provided a difficult final purification of each analogue. Suzuki-Miyaura cross-couplings 
were carried out using methyl ester trialkyl boranes that were pre-formed by the 
hydroboration of the corresponding alkene ester with borane in THF. The ester products 101, 
102, 103, 104 were isolated in good yields ranging from 54 – 80%. Two synthetic strategies 
were developed to synthesise the amide analogues (Figure 64). 
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Figure 64 - Amide tail synthesis 
 
The isolated esters (101-104) were initially treated with the demethylation conditions 
(TMS-Cl and sodium iodide) to give the free phenol and free acid products. These molecules 
were poorly soluble in organic solvent and required reverse-phase purification to isolate the 
material at sufficient purity. The acid could be reacted using the amide coupling reagent 
HATU, to provide the final products 109 and 110. The longer chain amides were not isolated 
in sufficient purity from the HATU reactions. Due to the purification difficulties and resulting 
lower yields observed with TMS-Cl, sodium iodide demethylation of the esters (101-104), an 
alternative synthetic route to these amides was investigated. Sabot et al. had reported the 
efficient aminolysis of esters catalysed with the reagent 1,5,7-triazabicyclo[4.4.0]dec-5-ene 
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(TBD) under solvent free conditions.235 In view of using these conditions, ester intermediate 
103 was treated with methylamine and TBD and intermediate 104 with methylamine and 
dimethylamine with TBD, in acetonitrile at room temperature. These reactions provided 
clean conversion to the amide products and were readily isolated in high yields to provide 
compounds 111, 112 and 113. These anisoles could be successfully demethylated using the 
TMS-Cl sodium iodide conditions to provide the other amide analogues (114, 115 and 116). 
The Suzuki-Miyaura cross coupling reaction failed with the ethyl acrylate, possibly due to the 
reduced electron density of the alkene in ethyl acrylate. Studies of the reaction between 
borane and ethyl acrylate have been shown to form an unexpected product. The electron 
withdrawing effect of the ester is thought to direct the borylation to the α carbon, through 
stabilisation of the negative charge of the transition state. This unstable product is reported 
to then undergo a rapid 1,2-rearrangement and yield ethyl propionate upon hydrolysis with 
water (Figure 65).236 
 
Figure 65 - Hydroboration of ethylacrylate reported by Brown et al.236 
 
With the aim to synthesise amide 120 a Mizoroki-Heck cross coupling was utilised. The 
brominated benzonitrile (85) was successfully cross coupled using the I-Mes NHC ligand 
previously identified for the synthesis of 87 and provided the alkene intermediate 117. This 
alkene was successfully hydrogenated to the saturated analogue 118, and then electrophilic 
aromatic chlorination of the phenolic ring using sulfuryl chloride in diethyl ether afforded 
compound 119. The amide (120) was successfully synthesised by treatment with TBD and 
n-butylamine in acetonitrile (Figure 66). 
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Figure 66 - Synthesis of ethyl acrylate analogue 
 
The synthesis of ether containing tail modifications was carried out by a master’s student, 
Thomas Cunningham whilst under my supervision (Figure 67). These analogues proved to be 
more of a synthetic challenge than their amide equivalents. An alternative phenol protection 
was required to enable the successful Suzuki-Miyaura coupling, as the deprotection of the 
aryl ether could not be conducted selectively without the tail alkyl ethers also reacting. A 
small screen of protecting groups highlighted some initial success with acetyl phenol 
protection (121 – Figure 66). Larger silyl protecting groups appeared to restrict the successful 
coupling, as the tri-isopropylsilyl phenol ether provided no product. The acetyl protected 
phenol on the other hand looked to provide approximately 25% conversion to the cross-
coupled phenol analogues directly. The major by-product of this reaction was however the 
deprotected starting material that could not be progressed further with addition of extra 
substrate, catalyst and ligand, or with prolonged reaction times at higher temperatures. The 
desired ether tail analogues (122, 123 and 124) could however be isolated by reverse-phase 
chromatography, albeit in low yield. 
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Figure 67 - Ether tail analogues synthesised by master’s student Thomas Cunningham 
 
5.2.2 Polar Tail Modifications Biological Activity Assessment 
The TAO inhibitory activity of the amide and ether analogues synthesised above were 
assessed in the biochemical ubiquinol assay. Intermediates 87, 95, 98, 99, 119 and 
comparison compound 100 were also assayed for inhibitory activity (data summarised in 
table 14). 
Table 14 - SAR of polar tail modifications 
Structure # TAO (pIC50)a 
T. b. b. 
(pEC50)b 
cLogPc 
 
88 8.5 ± 0.2 7.6 ± 0.1 6.3 
 
87 5.9 ± 0.2 4.9 ± 0.1 5.7 
 
95 8.3 ± 0.2 5.9 ± 0.1 6.0 
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98 < 4.5 < 4.3 6.4 
 
100 7.0 ± 0.1 - 5.8 
 
99 4.6 ± 0.1 - 5.9 
 
109 < 4.5 - 3.0 
 
110 < 4.5 < 4.3 2.9 
 
114 < 4.5 - 3.0 
 
115 5.1 ± 0.1 < 4.3 3.6 
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116 5.5 ± 0.2 < 4.3 3.8 
 
120 5.5 ± 0.2 < 4.3 3.5 
 
122 5.2 ± 0.1 < 4.3 4.1 
 
123 5.6 ± 0.1 4.6 ± 0.1 4.0 
 
124 4.8 ± 0.1  4.7 ± 0.1 4.1 
 
119 5.8 ± 0.1 4.5 ± 0.1 3.2 
 
a Negative log concentration and standard deviation of compounds required for 50% inhibition of trypanosome 
alternative oxidase. b Negative log concentration and standard deviation of compounds required for 50% growth 
inhibition of T. b. brucei Lister427. c Parameters calculated using Chemaxon Marvin Sketch 17.25.0 and JChem 
extensions for Knime 
 
Analysis of the inhibition data generated with these more polar analogues disappointingly 
looked to have significantly reduced TAO inhibition. Assessment of the polar tail analogues 
in the T. b. brucei assay also correlated with poor TAO inhibition. In consideration of these 
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data an alternative option was considered to reduce the lipophilicity of the tail, as minor 
changes in the tail resulted in large reductions in potency. Saimoto et al. had previously 
highlighted that a reduction in carbon chain length was tolerated with the complete CCB 
aromatic head group linked via a trans-alkene. On the other hand, a greater than 100-fold 
loss of potency was observed with tail analogues of 3 carbon atoms or below.128 The 
synthesis of analogues to investigate the required tail length was carried out utilising the 
same cross-coupling chemistry described above. Due to the decrease in potency observed in 
the parasite growth assay with the des-methyl analogues, intermediate 96 was used for this 
exploration. 
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5.3 Tail Chain Length Modifications Synthesis 
 
Figure 68 - Chain length exploration synthesis 
 
Analogues with chain lengths greater than 5 were synthesised via the same cross coupling 
conditions utilised previously to synthesise intermediates 125, 126 and 127, as the alkenes 
were readily available (Figure 68). The alkenes of shorter carbon chains are gaseous at room 
temperature and require specialist reaction equipment for use. These alkenes were also not 
readily available from commercial sources. The methyl analogue (131) was synthesised by a 
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Suzuki-Miyaura cross coupling with trimethylboroxine, using a recently developed palladium 
catalyst dichloro [1,1’- bis(di-tertbutylphosphino)ferrocene]palladium(II) (Pd-118), that has 
shown good activity and application in difficult Suzuki-Miyaura cross couplings.237 The ethyl 
analogue (130) was synthesised using the conditions that had been reported by Li et al. using 
a solution of reagent grade triethyl borane.234 The n-propyl and n-butyl analogues were 
synthesised using the respective alkyl boronic acids with the catalyst conditions utilised for 
the coupling of the tri-alkyl boranes to provide intermediates 128 and 129. Attempted Suzuki 
cross-couplings with Pd-118 and these alky boronic acids were not successful, but 
alkyltrifluoroborates have previously been shown to Suzuki cross-couple well using RuPhos 
and palladium acetate catalyst systems.238 The deprotection of these anisole intermediates 
was carried out using TMS-Cl and NaI, and compounds 132 – 136 and 138 were isolated 
successfully. The ethyl analogue (137) however, was isolated in poor yield due to a technical 
issue upon purification. Compounds 132-136 and 138 were assessed for inhibitory activity of 
TAO and growth inhibition of T. b. brucei, data summarised in table 15. 
5.3.2 Alkyl Chain Length Analogues Biological Activity Assessment 
Table 15 - SAR of chain length analogues 
Structure # TAO (pIC50)a 
T. b. b. 
(pEC50)b 
cLogP 
c 
LLE 
d 
 
88 8.5 ± 0.2 7.6 ± 0.1 6.3 2.2 
 
132 8.5 ± 0.1 6.6 ± 0.1 5.8 2.7 
 
133 8.2 ± 0.1 6.1 ± 0.1 5.4 2.8 
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134 7.8 ± 0.1 5.9 ± 0.1 4.9 2.9 
 
135 7.7 ± 0.1 5.3 ± 0.1 4.5 3.2 
 
136 7.1 ± 0.1 4.7 ± 0.1 4.1 3.0 
 
138 6.2 ± 0.1 4.7 ± 0.1 3.2 3.0 
 
a Negative log concentration and standard deviation of compounds required for 50% inhibition of trypanosome 
alternative oxidase (n = >2). b Negative log concentration and standard deviation of compounds required for 50% 
growth inhibition of T. b. brucei Lister427 (n = >2). c Parameters calculated using Chemaxon Marvin Sketch 17.25.0 
and JChem extensions for Knime. d LLE calculated from TAO pIC50 – cLogP. 
 
Interestingly the inhibition of TAO appeared to track with the decrease in lipophilicity (cLogP) 
and reduction of tail length with a lipophilic ligand efficiency (LLE) of around 3. Lipophilic 
ligand efficiency is a calculated compound metric that is used to optimise and correlate 
compound lipophilicity and potency (pIC50 – cLogP). LLE is useful to help identify potency 
improvements that arise from enthalpic protein ligand interactions such as hydrogen 
bonding or electrostatic contacts, with lead like compounds often achieving an LLE of 4.220 T. 
b. brucei growth inhibition correlated with the observed inhibition of TAO and calculated 
lipophilicity; however, parasite growth inhibition tracked to around a 100-fold decrease from 
the biochemical inhibition of TAO, resulting in LLE in the cellular assay of around 1. 
Compounds with a carbon chain length of 4-5 still showed good inhibition of TAO in the 
low nM range, with parasite growth inhibition of around 1 µM. These compounds also had a 
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cLogP of below 5 and MPO scores of around 4, meaning they were predicted to have 
improved CNS penetration. The shorter chain analogues showed promise, and further 
exploration was carried out with the aim to further improve LLE and identify an optimal tail 
for this class of TAO inhibitor. 
5.4.1 Diverse Tail Analogues Synthesis 
At this point a scale-up of the synthesis of the brominated intermediate 92 was conducted. 
Unfortunately, final purification of this intermediate was not achieved on scale, with the 
close running impurity that had previously been observed co-eluting on chromatography and 
co-crystallising with the desired product. The initial batch of this intermediate (92) also 
contained a small amount of this impurity that provided a challenge for the isolation of the 
final compounds previously synthesised. An alternative synthesis of tail analogues was 
conducted (Figure 69) to circumvent the issues with the isolation of intermediate 92. 
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Figure 69 - Adapted synthesis of tail analogues to overcome impurity profile of chlorination. * Demethylation 
carried out with NaI and TMS-Cl. 
 
The synthesis of analogues 150 – 154 by this method avoided the problematic impurity 
profile of the chlorination reaction. Carrying out the chlorination in the final step yielded a 
single product with no other contaminants. Unfortunately, sp3 di-alkyl boronates 
(cyclohexane, cyclopentane, cyclobutane) failed to cross-couple with these Suzuki coupling 
conditions. To overcome this issue, sp2 alkenyl boronic acids were utilised to furnish cyclic 
tail analogues 163 and 164. The alkenyl cyclopropyl ethene boronic ester was also 
commercially available and was of interest to synthesise to compare with analogues 134, 135 
and 154 (Figure 70). 
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Figure 70 - Cyclic tail analogue synthesis 
 
Both the cyclohexyl (158) and cyclopentyl (159) analogues were synthesised successfully, 
utilising the transfer hydrogenation conditions reported by McMurray et al. to reduce the 
alkene following the Suzuki cross-coupling.202 Under hydrogenation some of the 
cyclopropane ring of 160 was also reduced, resulting in a mixture of desired product and a 
ring opened impurity. Attempts at demethylation of the isolated intermediate 160 resulted 
in the degradation of starting material and no observed product, so an alternative synthesis 
of this analogue was sought (Figure 70).  
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Figure 71 - Synthesis of cyclopropyl ethyl analogue 167 
 
Attempting the Suzuki cross-coupling on the direct phenol bromide intermediate (85) 
showed formation of product 165 at an elevated temperature of 100 °C, 165 could be 
isolated in a reasonable yield of 48%. Transfer hydrogenation of this using the McMurray 
conditions previously employed again provided the desired product 166 but with an impurity 
of the hydrogenated cyclopropane ring. The impurity could be separated with reverse-phase 
chromatography to provide intermediate 166, this was successfully chlorinated with sulfuryl 
chloride to provide analogue 167 (Figure 71). Analogues 150 - 154, 163, 164 and 167 were 
assessed in TAO inhibition and T. b. brucei growth inhibition assays, data summarised in table 
16. 
5.4.2 Diverse Tail Analogues Biological Activity Assessment 
Table 16 - SAR of follow up tail analogues 
Structure # TAO (pIC50)a 
T. b. b. 
(pEC50)b 
cLogP 
c 
 
134 7.8 ± 0.1 5.9 ± 0.1 4.9 
150 
 
150 7.4 ± 0.1 < 4.3 4.4 
 
151 8.0 ± 0.2 6.1 ± 0.1 4.7 
 
152 8.2 ± 0.2 5.5 ± 0.1 5.2 
 
153 6.4 ± 0.1 4.4 ± 0.1 3.6 
 
154 8.1 ± 0.1 6.5 ± 0.1 4.8 
 
163 7.3 ± 0.1 < 4.3 4.8 
 
164 7.8 ± 0.1 4.3 ± 0.1 4.3 
151 
 
167 7.6 ± 0.1 5.6 ± 0.1 4.3 
 
a Negative log concentration and standard deviation of compounds required for 50% inhibition of trypanosome 
alternative oxidase (n = >2). b Negative log concentration and standard deviation of compounds required for 50% 
growth inhibition of T. b. brucei Lister427 (n = >2). c Parameters calculated using Chemaxon Marvin Sketch 
17.25.0 and JChem extensions for Knime. 
 
Analysis of these analogues showed good TAO inhibition profiles and highlighted one 
compound that showed a half log increase in potency for the inhibition of T. b. brucei growth. 
Compound 154, with the isopentyl tail, showed an increase in TAO inhibition that transferred 
to inhibition of parasite growth. This compound had small improvements in calculated 
physicochemical properties, with a cLogP of 4.8 and a cLogD7.4 of 3.8, which resulted in a CNS 
MPO score of 4.2. This compound was of sufficient quality for assessment in more advanced 
parasite-kill kinetic and parasite reversibility assays, to determine the time dependency and 
efficacy of compound treatment. Preliminary solubility and rat microsomal clearance 
turnover were also studied. It was of interest that the benzyl analogue 151 also showed an 
improvement in parasite growth inhibition potency and reduction of lipophilicity. Analogues 
150, 163 and 164 were shown to be active against TAO, but this potency was not retained in 
the parasite growth inhibition assays. The phenol of 150 has an increased acidity, as the 
fluorophenyl substituent is electron withdrawing, lowering the phenolic pKa. This could 
cause a reduction in the compounds’ passive permeability into the parasite, as only un-
ionised compound will be able to passively permeate a cell membrane. This is unlikely to 
explain the loss of potency observed with analogues 163 and 164, as these analogues will 
have similar pKa’s to that of the other alkyl analogues. There may be a number of reasons 
why these analogues are less potent in the trypanosome, including their reduced TAO 
inhibition and lower lipophilicity, that could result in a reduced membrane affinity and 
effective concentration of compound in the parasite inner membrane. The cyclopropylethyl 
152 
(167) and phenethyl (152) analogues showed similar profiles against TAO and parasite 
inhibition, as observed previously. 
5.5.1 Fluorinated Alkyl Chain Analogue Synthesis 
A final attempt was made to reduce the lipophilicity of the tail portion of this chemotype. An 
alternative method to introduce polarity into an alkyl chain is to incorporate a fluorine atom. 
Although fluorine is more lipophilic than hydrogen, the resulting polarity that is introduced 
from the highly electronegative fluorine atom, induces a polarisation of the carbon chain. 
This method has been used to reduce the lipophilicity of alkyl chain containing molecules and 
resulted in the identification of compounds with improved in vitro and in vivo 
pharmacokinetic profiles.239–241 A synthesis to incorporate fluorine atoms into the carbon 
chain of these analogues was devised (Figure 71). 
 
Figure 72 - Synthesis of di-fluoro butyl analogue 171 
 
The butyl alkene containing a terminal ethyl acetal was commercially available and was 
successfully cross-coupled via formation of the trialkyl borane, as previously discussed, to 
form 168. The acetal was converted to the terminal aldehyde in aqueous acid, and isolated 
by extraction into ethyl acetate, then concentration. This crude material was treated with a 
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solution of Deoxo-fluor® to generate the difluorinated intermediate (169). Removal of the 
anisole protecting group and subsequent electrophilic aromatic chlorination, provided the 
desired di-fluorinated butyl tail analogue (171 – Figure 72).  
A synthesis towards a fluorinated analogue of the most potent molecule in the parasite 
growth inhibition assay (compound 154) was also planned (Figure 73), with the aim to 
maintain the parasite growth potency and further reduce the lipophilicity of the molecule. 
The boron pinacol ester of methyl propanoate was available, which was cross-coupled 
utilising the conditions previously identified to provide 172. Compound 172 was then treated 
with two equivalents of methyl magnesium bromide to afford the tertiary alcohol 173. This 
intermediate was fluorinated with Deoxo-fluor® to provide the fluorinated chain analogue 
174. Unfortunately, upon demethylation of the anisole the compound self-cyclised to form 
175, and the desired compound was not isolated. 
 
Figure 73 - Attempted synthesis of fluorinated analogue of 154. 
 
5.5.2 Fluorinated Alkyl Chain Analogue Biological Activity Assessment 
Analogue 171 was assessed in the TAO inhibition assay and in the parasite growth inhibition 
assays with pIC50 (6.7 ± 0.1) and pEC50 (5.3 ± 0.1) respectively. A 10-fold decrease in TAO 
inhibition was observed when comparing this result to the butyl chain analogue (135). This 
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reduction in potency was however not as pronounced in the inhibition of parasite growth, 
with comparable activities observed. The inclusion of these two terminal fluorine atoms had 
resulted in a half log unit reduction of lipophilicity and provided a future avenue for further 
investigation.  
Chapter 5 – SAR Exploration of Lipophilic Tail Conclusions 
An overview of the analogues synthesised in this chapter is highlighted in figure 74. The 
isopentyl analogue 154 showed the most promising LLE profile out of the compounds 
synthesised in this chapter. The isopentyl chain may achieve a lipophilic interaction similar 
to the natural substrate ubiquinol. It is also of interest that the benzylic chain analogue 151 
also showed a marked improvement for inhibition of parasite growth and lower lipophilicity. 
This could provide a further point for future exploration. The aromatic system could be 
substituted further to attain greater binding interactions with TAO. Heteroatoms could also 
be introduced to further reduce the lipophilicity of these compounds. The final compound 
that was of interest is the difluorinated analogue 171. This compound has a reduced 
lipophilicity profile with a similar retention of parasite inhibition. Again, this strategy provides 
another area for future exploration that could be carried out in combination to identify more 
potent and less lipophilic TAO inhibitors.
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Figure 74 – Mean T. b. brucei pEC50, cLogP and LLE Plot of tail modification analogues, LLE 1 = red line, LLE 2 = blue line, LLE 3 = green line. Labelled by compound 
number, and points coloured by mean TAO pIC50 (Green 8.5, lime green 7.5, yellow 6.5, orange 5.5 and red 4.5). cLogP generated using Chemaxon Marvin Sketch 17.25. 
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The focus of this chapter was to explore the lipophilic tail region of the synthetically 
amenable lead compound 88 that was identified in chapter 4. In summary, the introduction 
of polarity by inclusion of heteroatoms and polar functionality was not tolerated, with 
modest changes in structure in this region resulting in a complete loss of activity in both TAO 
inhibition and parasite growth assays. Tail analogue synthesis was optimised to remove a 
persistent impurity and following this the investigation into the tail length was carried out 
showing that adequate parasite inhibition could be attained with shorter carbon chain 
analogues. This highlighted the pentyl chain analogue (134), which retained micromolar 
inhibition of parasite growth with a reduction in cLogP to below 5. Further analogues were 
synthesised to explore more spatially diverse SAR in this region. This identified both the 
isopentyl analogue (154) and the benzyl analogue (151) to have improved LLE profiles, 
potently inhibiting TAO function with resultant parasite growth inhibition at concentrations 
of below 1 µM. Finally, the synthesis of fluorinated alkyl chain analogues was carried out 
resulting in analogue 171. This analogue had a reduced lipophilicity and showed similar 
inhibitory potency in parasite growth assays to its direct matched-pair 135. The isopentyl tail 
compound 154 showed sufficient quality for assessment in more advanced parasite assays, 
the results from these assays will be discussed chapter 7.  
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Chapter 6  
158 
Chapter 6 – Aromatic Head Group Substituent Exploration 
The synthetic exploration of the CCB chemotype had thus far focused on modulating the 
lipophilicity of the tail portion of the molecule. Inclusion of polarity in this region was poorly 
tolerated and resulted in poorly active TAO inhibitors. It was therefore decided to investigate 
alternative substitution vectors from the aromatic ring, with the aim to identify molecules 
that were less lipophilic or that had the potential to improve binding interactions with TAO. 
Evaluation of the TAO : CCB crystal structure (PDB: 3W54) highlighted two vectors that could 
potentially be exploited and will be discussed in the following sections.129 
6.1 Chloro replacement analogues 
Analysis of the data generated from the initial lipophilic tail modification showed that polarity 
was not tolerated in this region of the molecule without loss of potency against TAO and 
therefore loss of parasitic inhibition. An alternative strategy was investigated to introduce 
polar functionality into the molecule and explore the SAR of the aromatic head group. 
Analysis of the TAO inhibitors that had been previously synthesised showed that the chloro 
substituent was required. Comparison of match pairs (26, 53 and 87, 88) indicated a 2.5 log 
drop in potency against TAO for the des-chloro analogues. Apart from removal of the halogen 
atom, no further exploration of the aromatic head group had been reported in the 
literature.128 On review of the protein crystal structure in complex with CCB (PDB:3W54),129 
the chloro substituent looks to occupy the opening of a small channel present in TAO (Figure 
75). 
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Figure 75 - Chloro-substituent exploration PDB: 3W54 structure, prepared and energy minimised using OPLS3 
forcefield, Maestro - Schrodinger drug discovery suite. CCB coloured pink, chloro-atom depicted in Corey Pauling 
and Koltun (CPK) representation (green ball), at opening of small tunnel. 
 
Closer inspection of the channel present in the crystal structure (PDB: 3W54) showed the 
presence of structural water molecules, that form interactions with TAO (Figure 76). This 
channel also has potential to introduce ligand contacts through electrostatic interaction 
(Figure 76 - surface coloured by electrostatic potential – calculated computationally by the 
Poisson-Boltzmann equation). 
 
Figure 76 - Chloro-substituent exploration PDB: 3W54 structure, prepared and energy minimised using OPLS3 
forcefield, Maestro - Schrodinger drug discovery suite. CCB coloured white, with chloro atom in green, surface of 
binding pocket without water removal, coloured by electrostatic potential - red to blue. 
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The chloro atom appeared vital for inhibition of TAO, therefore further analogues were 
planned to investigate whether this interaction could be further exploited to maximise TAO 
ligand interactions. This round of optimisation was initialised following the identification of 
the potent shorter n-pentyl carbon chain analogue 134, and so the first step to facilitate 
exploration of this vector was the preparation of the n-pentyl chain intermediate (177). The 
deprotection of 176 with TMS-I at reflux in MeCN showed reduced conversion to 177 
following lengthy reaction times of 96 h. Performing the reaction at a higher temperature in 
a sealed system in the microwave expediated the reaction to completion after 2 h (Figure 
77). 
 
Figure 77 - Synthesis of n-pentyl intermediate for aromatic chloro head group exploration 
 
With a bulk amount of intermediate 177 in hand, a range of analogues was planned to 
investigate replacement of the chloro atom. Preparation of the bromo analogue (178) by 
electrophilic aromatic bromination was carried out with NBS in acetonitrile. It was 
anticipated that the brominated intermediate (178) would provide access to a range of 
analogues through cross-coupling chemistry (Figure 78). 
 
Figure 78 - Bromination of 177 to provide access to cross-coupled chloro replacement analogues 
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To probe the nature of interaction of the chlorine atom to the protein, the methyl (179), 
ethyl (180) and phenyl (181) analogues were prepared via Suzuki-Miyaura cross-coupling, 
utilising similar reaction conditions to those used to install the tail modifications. The methyl 
compound provides a similar overall lipophilicity profile and is of interest to determine 
whether an electrostatic or lipophilic interaction is being formed with the halogen. A range 
of Buchwald and Ullmann cross-couplings were attempted to furnish the aromatic with 
N-linked heterocycles, unfortunately these were not successful. Attempts at cross-coupling 
178 with heterocyclic boronic acids under these cross-coupling conditions were also 
unsuccessful. A substituted 5-membered heterocycle was of interest, as in silico modelling 
suggested that 2,5-substitution would enable access to the narrow pocket via this vector 
(Figure 79). In particular, 1,3,4-oxadiazoles have recently been shown to provide some of the 
best improvements in compound solubility over other heterocycles.242 
 
Figure 79 – 1,3,4-oxadiazole heterocyclic replacement of aromatic chloro substituent. Virtual molecule (pink) built 
in Maestro – Schrodinger drug discover suite from PDB:3W54 (TAO : CCB crystal structure) and energy 
minimised. Surface generated of binding pocket of TAO. 
 
Following the failure to introduce these heterocycles from cross-coupling chemistries an 
alternative synthetic strategy was sought. The synthesis of 1,3,4-oxadiazoles can be 
performed from the dehydrative cyclisation of diacyl hydrazides at high temperatures.243,244 
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To access these intermediates, synthesis of the ethyl ester of intermediate 178 was carried 
out by palladium mediated carbonylation. The carbonylation of aromatic halides, utilising 
inorganic carbon monoxide sources such as molybdenum hexacarbonyl has been extensively 
reported in the literature.245–247 The use of the catalyst developed by Herrmann and Beller,248 
with Mo(CO)6 and DBU in ethanol provided the ethyl ester (182) in good yield following 
microwave irradiation. Hydrolysis of intermediate 182 required heating at 60 °C for 96 h to 
progress the reaction to completion and isolate the free acid (183). Attempts to form the 
diacyl hydrazide through the formation of the acid chloride or HATU activated ester, then 
reaction with acyl hydrazine were however unsuccessful (Figure 80). 
 
Figure 80 - 1,3,4-oxadiazole synthesis 
 
Introduction of the carboxylic acid in this position also provided the opportunity to introduce 
amidic functionality with an aim to lower the overall lipophilicity of the molecule. Modelling 
of the dimethyl amide looked to also provide a vector to access the narrow tunnel present 
in the TAO : CCB crystal structure (PDB:3W54),129 (Figure 81).  
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Figure 81 - Dimethylamide replacement of aromatic chloro substituent. Virtual molecule (pink) built in Maestro – 
Schrodinger drug discover suite from PDB:3W54 (TAO : CCB crystal structure) and energy minimised. Surface 
generated of binding pocket of TAO – narrow tunnel blue dotted box. 
 
Formation of the acid chloride from intermediate 183 was obtained by reaction with oxalyl 
chloride and a catalytic amount of DMF. The acid chloride was quenched by the addition of 
dimethylamine in THF, to provide the dimethyl amide (184) in good yield (Figure 82).  
 
Figure 82 - Synthesis of dimethyl amide chloro replacement analogue 
 
A final attempt to synthesise a heterocyclic replacement for the chloro substituent was 
attempted. Sangshetti et al. had reported the successful synthesis of 1,3,4-oxadiazoles from 
the reaction of aldehydes with acyl hydrazides, utilising a sodium bisulphite catalyst.249 A 
synthesis to the intermediate benzaldehyde (185) was attempted. Initially, a Vilsmeier-Haack 
reaction was trialled by refluxing intermediate 177 with POCl3 in DMF; no product could be 
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identified from this reaction. An alternative method of formylation was investigated, as 
chemistry developed in 1876 by Reimer and Tiemann had shown the successful formylation 
of phenols using chloroform and sodium hydroxide.250 The Reimer-Tiemann reaction has 
been extensively studied and is understood to react through the formation of an electrophilic 
di-halo carbene species formed from the reaction of chloroform and hydroxide, that is then 
attacked by the electron rich phenol.251 The treatment of intermediate 177 with sodium 
hydroxide and chloroform at reflux showed the formation of the desired formylated product 
(185), albeit with a range of other by-products. Optimisation of this reaction through 
modification of reaction temperature and time provided no improvement in the yield or 
purity of 185. The reaction profile by LCMS showed formation of multiple side products, and 
the reaction never proceeded to completion. Approximately half of the starting material 
could be readily recovered from the chromatographic purification of 185. Unfortunately, the 
subsequent attempts of synthesising heterocycle replacements for the chloro substituent 
from the benzaldehyde were unsuccessful (Figure 83). 
 
Figure 83 - Formation of benzaldehyde intermediate 185 
 
A range of chloro replacement analogues and intermediates had been synthesised (177 - 
185). These compounds were assessed in TAO inhibition and T. b. brucei growth inhibition 
assays before further synthetic exploration was initiated in this area, data summarised in 
Table 17. 
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Table 17 - Chloro replacement analogues 
Structure # TAO (pIC50)a 
T. b. b. 
(pEC50)b 
cLogP 
c 
 
134 7.8 ± 0.1 (LLE 2.9) 
5.9 ± 0.1 
(LLE 1.0) 4.9 
 
177 5.7 ± 0.1 4.4 ± 0.1 4.3 
 
178 8.4 ± 0.1 (LLE 3.3) 
6.5 ± 0.1 
(LLE 1.4) 5.1 
 
179 6.7 ± 0.1 5.1 ± 0.1 4.8 
 
180 6.4 ± 0.1 4.8 ± 0.1 5.3 
 
181 6.0 ± 0.2 < 4.3 6.0 
 
182 - < 4.3 5.3 
166 
 
183 5.0 ± 0.1 < 4.3 4.6 
 
184 5.3 ± 0.1 < 4.3 4.3 
 
185 < 4.5 < 4.3 4.7 
 
a Negative log concentration and standard deviation of compounds required for 50% inhibition of trypanosome 
alternative oxidase (n = >2). b Negative log concentration and standard deviation of compounds required for 50% 
growth inhibition of T. b. brucei Lister427 (n = >2). c Parameters calculated using Chemaxon Marvin Sketch 17.25.0. 
 
Inspection of these data suggested that the introduction of polar functionality was again 
detrimental to potency, particularly in the parasite growth inhibition assay. Introduction of a 
carbonyl ortho to the phenol also provided poorly active compounds (182 - 185) with TAO 
pIC50s below 6. Interestingly, replacement of the chloro atom with other lipophilic moieties 
appeared to be tolerated, with compounds 178 – 181 retaining sub-micro molar inhibition 
profiles of TAO, suggesting that the chloro interactions were predominately lipophilic. This 
potency tracked well with the observed inhibition of T. b. brucei growth apart from the 
phenyl replacement (181), that showed no inhibition of parasite growth. Again, a reduction 
in activity of approximately 1.5 log units was observed from inhibition of TAO to parasite 
growth. A 0.6 pIC50 improvement in TAO inhibition and a 0.6 pEC50 improvement in parasite 
growth inhibition was observed with the bromo analogue (178). This increase in potency was 
driven with only a small 0.2 increase in cLogP, and as a result had a marked 0.4 improvement 
in LLE (compounds 134 and 178 - Table 17). It would be of interest to see if this improvement 
in potency and LLE could be combined with the improvement in potency that were observed 
with the introduction of the isopentyl tail analogue (154). In review of the data in this section, 
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a halogen atom looked to be required for potent TAO inhibition, the introduction of other 
functional groups had resulted in a large detriment to potency, and thus alternative aromatic 
substitutions were explored. 
6.4 Benzonitrile exploration 
Inspection of the parasite growth inhibition data generated thus far had shown a lower 
potency for benzonitrile analogues over the benzaldehyde substituent compounds (47 to 
CCB 26 and 51 to 50). The benzaldehyde analogue containing the shorter n-pentyl chain (187) 
was synthesised to investigate whether this potency observation still held with the mono-
phenol aromatic system. The synthesis of the cyclopropyl ethyl analogue (167) had been 
performed utilising Suzuki-Miyaura cross-coupling of the free phenol with a boronic acid, and 
so this route was successfully implemented to install the n-pentyl chain directly to provide 
186. Subsequent chlorination of 186 with conditions previously utilised provided the desired 
benzaldehyde analogue (187) for matched-pair comparison (Figure 84). 
 
Figure 84 - Synthesis of n-pentyl benzaldehyde analogue 
 
Analogue 187 showed good inhibitory potency of TAO (pIC50 8.7 ± 0.1), that correlated to an 
increased inhibition of T. b. brucei growth (pEC50 6.7 ± 0.2), displaying a six to eight-fold 
improvement in potency in both enzyme and parasite inhibition assays. Due to the superior 
potency observed with these benzaldehyde analogues, the published crystal structure was 
further inspected to ascertain the potential interactions that the benzaldehyde was making 
with TAO (Figure 85). 
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Figure 85 - Aldehyde (left) and Nitrile (right) TAO interactions observed in crystal structure (PDB: 3W54)129 and 
virtual molecule built in Maestro – Schrodinger drug discovery suite energy minimised structure using OPLS3 
forcefield. CCB (white - left), virtual nitrile analogue of CCB (teal - right), protein binding surface (grey), CYS119 
and ARG118 amino acid residues displayed and labelled with hydrogen bonds to aldehyde or nitrile (yellow hash 
lines).  
 
The published crystal structure shows the formation of potential hydrogen bonds with both 
cysteine (CYS119) and arginine (ARG118) residues with the aldehyde (Left - Figure 85). The 
nitrile replacement analogue was predicted to occupy an area further from the arginine 
residue (ARG118) due to the linear orientation and vector from the aromatic ring. The nitrile 
was predicted to retain the hydrogen bond interaction with the cysteine residue, however 
the loss of interaction with ARG118 could help to explain the reduced inhibitory activity of 
TAO (Right – Figure 85). The synthesis of other carbonyl containing analogues was planned, 
to determine whether this interaction could be retained with a more chemically desirable 
functional group. Initially, electrophilic bromination of the methyl ester intermediate (188) 
was attempted. Similar results to the unsuccessful bromination of the benzonitrile 
intermediate (78) were observed, with the formation of a mixture of multiple bromination 
products under these conditions. Carrying out the addition of brominating reagent at lower 
temperatures, and as a dilute solution in reaction solvent, provided no improvement in 
reaction profile. Alternative electrophilic brominating reagents (Br2, NBS, 
dibromoisocyanuric acid and tetrabutyl ammonium tribromide) were also investigated; 
however, these showed similar reaction profiles to BTMAT and did not provide the desired 
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mono brominated analogue in sufficient purity for continuation of the synthesis (Figure 86). 
Therefore, an alternative synthesis to these analogues was sought. 
 
Figure 86 - Attempted bromination of methyl ester intermediate 
 
As selective mono bromination of the benzaldehyde had previously been carried out in good 
yield to provide intermediate 80, this intermediate was used as a starting point for further 
synthetic exploration (Figure 86). Oxidation of the aldehyde to the carboxylic acid (189) was 
performed using Pinnick oxidation conditions.252 This mild oxidation was originally reported 
by Kraus and Roth,253 in the partial synthesis of the natural product verrucarol. Sodium 
chlorite acts as the oxidant to generate the carboxylic acid from the aldehyde, producing 
hypochlorous acid as a by-product. This can further react with other functional groups, so 2-
methyl-2-butene is commonly used as a scavenger to prevent undesired side reactions. 
Intermediate 189 was successfully di-methylated with dimethyl sulphate in acetone, utilising 
potassium carbonate as a base to provide 190. The isopentyl chain was installed via Suzuki-
Miyaura cross coupling, utilising the same conditions that were previously employed to 
append the alkyl chain to provide intermediate 191. This intermediate was doubly de-
protected using chlorotrimethyl silane and sodium iodide in the microwave to provide the 
free phenol and carboxylic acid (192). Electrophilic aromatic chlorination of 192 with sulfuryl 
chloride in diethyl ether as discussed previously, provided the chlorinated intermediate (193). 
This material was used to generate primary (196), secondary methyl (195) and tertiary 
dimethyl (196) amides for comparison to the benzaldehyde analogue (187) (Figure 87). 
170 
 
Figure 87 - Synthesis of benzaldehyde replacement analogues 
 
Analogues 193 – 196 were assessed in TAO and T. b. brucei growth inhibition assays. 
Unfortunately, these analogues showed a large reduction in potency in both assays. The most 
potent analogue was the primary amide (196), which showed 3-fold higher potency than the 
other analogues in the TAO inhibition assay (pIC50 5.8), compared to pIC50s of around 5.2 for 
193 – 195. In review of these data, further synthetic exploration around this functional group 
was deprioritised.  
6.3 Combination compounds 
With deadline limitations approaching for the conclusion of this project, examination of all 
the analogues that had been synthesised around the CCB chemotype was carried out.  This 
highlighted potential amalgamations for some of the successful structural modifications that 
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had been identified. The isopentyl analogue (154), had shown a decrease in lipophilicity and 
an improvement in parasite growth inhibition potency in comparison to the n-pentyl 
analogue (134). Replacement of the chlorine with a bromine atom (178) had also provided 
an analogue with improved potency against TAO, with a minimal increase in lipophilicity. It 
was therefore decided to combine these two structural modifications to ascertain whether 
they could be combined to obtain a molecule that had improved parasite growth inhibition 
potency and LLE profile. 
 
Figure 88 - Synthesis of combination bromo isopentyl analogue (197) 
 
Analogue 197 was successfully synthesised by the electrophilic aromatic bromination of 
intermediate 149 (Figure 88). The compound required further purification by reverse-phase 
chromatography that resulted in a lower than expected yield. Assessment of the biological 
activity of this compound was promising with TAO pIC50 8.3 ± 0.1 and T. b. brucei inhibition 
pEC50 6.9 ± 0.1, correlating to a 0.4 pEC50 increase in potency for parasite growth inhibition 
and a resultant LLE of 2.0. The CNS MPO score for 197 is 3.9 close to the desired score 
required for optimal predicted CNS penetration. The comparison of 197 to the chloro 
analogue however, shows a 0.3 decrease (CNS MPO score 4.2). The increase in lipophilicity 
from the bromine atom has again negatively influenced the cLogP and cLogD7.4 scoring 
functions for the total MPO score. The compound was still regarded to be of sufficient quality 
for assessment in advanced kill kinetic and parasite cure assays at Novartis and in vitro 
pharmacokinetic profiling, that should highlight metabolism and permeability issues of these 
compounds. These data will be discussed in the next and final chapter of this thesis, along 
with comparative data generated with the n-pentyl benzaldehyde (187) and CCB (26) 
analogues.  
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Chapter 6 - Aromatic Head Group Substituent Exploration Summary and 
Conclusions 
The aim of the work performed in this chapter was to explore the SAR of the aromatic 
substituents of the CCB chemotype. A synthesis was developed to allow introduction of 
alternative functionality in place of the chloro and nitrile substituents. Unfortunately, many 
of the analogues synthesised in this exploration resulted in major reductions in inhibition of 
TAO and parasite growth. A highlight of this exploration was the identification of the 
brominated analogue (178) that achieved improved parasite inhibition potency with a minor 
increase in lipophilicity. Bromine atoms can potentially form stronger electrostatic halogen 
bond interactions than chlorine atoms. This arises from the increased size of the σ-hole 
present in bromine due to the electron anisotropy. As halogen atoms increase in size, the σ-
hole becomes larger and more electron deficient allowing stronger electrostatic interactions 
with Lewis bases.254 However, inspection of the crystal structure reported by Shiba et al.129 
(PDB: 3W54) does not identify a Lewis basic amino acid residue to be present in this part of 
TAO, that could potentially form this type of head on interaction. A halogen bond to a water 
molecule present in the narrow channel is observed in the crystal structure 3W54. Structural 
water molecules have previously been observed to partake in protein-water-inhibitor 
binding interactions that result in positive affinities for inhibitors.255 The combination of 
chloro replacement with bromo, and the improvement in potency observed with the 
isopentyl analogue resulted in additive potency improvements for analogue 197. This 
analogue was considered to be of sufficient quality for assessment in further parasite kill 
kinetic and cure assays along with basic in vitro pharmacokinetic profiling assays conducted 
at Novartis. Further exploration into the benzonitrile substituent resulted in the 
identification of compounds with reduced potency against TAO. The aldehyde analogues 
continued to show higher potency against TAO, which correlated to an improvement in 
parasite growth inhibition. The benzaldehyde 187 was therefore also assessed in the 
advanced parasite inhibition and in vitro pharmacokinetic assays. These data will be 
discussed in the concluding chapter. 
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Chapter 7 – Final Compound Profiling, Conclusions and Future Work 
7.1 Final Compound Profiling 
Several interesting TAO inhibitors were identified and characterised over the course of this 
research project. Compound 88 provided a synthetically amenable starting point, to explore 
the lipophilic tail region of the CCB (26) chemotype. Shorter carbon chain tail analogues had 
improved physicochemical properties and retained micromolar parasite growth inhibition. 
Further synthetic exploration of these shorter chain analogues (134 and 135) identified the 
isopentyl analogue 154, a compound with reduced lipophilicity, a significant improvement in 
potency against TAO inhibition and improved parasite growth inhibition.  
The investigation into replacing the chloro substituent highlighted that the larger bromo 
halogen analogue 178 had improved parasite growth inhibition, with only a marginal increase 
in lipophilicity. This compound showed little improvement in CNS MPO score over the natural 
product CCB (26) as the cLogP and cLogD7.4 were still below the parameter scoring limit. 
Synthesis of the combination isopentyl bromo compound 197 was synthesised and 
demonstrated additive potency improvements in the parasite inhibition assay, resulting 
again in a compound with slightly lower lipophilicity, and improvement in LLE. Following 
further exploration of the benzonitrile, it was apparent that the benzaldehyde analogues 
retained higher potency in the parasite inhibition assay. This led to the synthesis of the n-
pentyl benzaldehyde analogue 187 for further assessment in parasite kill kinetic and 
reversibility studies and enabled in in vitro pharmacokinetic profiling which is currently 
ongoing. 
Table 18 - SAR overview of key TAO inhibitors 
Structure # 
TAO 
(pIC50) 
a 
T. b. b. 
(pEC50) 
b 
HepG2 
(pCC50) 
c 
T.b.b 
LLE d 
CNS 
MPO 
e 
 
26 8.5 ± 0.2 
8.4 ± 
0.1 
5.1 ± 
0.1 2.2 3.5 
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88 8.5 ± 0.2 
7.6 ± 
0.1 
5.1 ± 
0.1 1.3 3.8 
 
134 7.8 ± 0.1 
5.9 ± 
0.1 
4.4 ± 
0.1 1.0 3.9 
 
135 7.7 ± 0.1 
5.3 ± 
0.1 - 2.1 4.2 
 
154 8.1 ± 0.1 
6.5 ± 
0.1 
4.1 ± 
0.1 1.7 3.9 
 
178 8.4 ± 0.1 
6.5 ± 
0.1 
4.4 ± 
0.1 1.4 3.8 
 
197 8.3 ± 
0.1 
6.9 ± 
0.1 
- 1.8 3.9 
 
187 8.7 ± 0.1 
6.7 ± 
0.1 - 1.9 4.0 
 
a Negative log concentration and standard deviation of compounds required for 50% inhibition of trypanosome 
alternative oxidase (n = >2). b Negative log concentration and standard deviation of compounds required for 50% 
growth inhibition of T. b. brucei Lister427 (n = >2). c Negative log concentration and standard deviation of 
compounds required for 50% growth inhibition of T. b. brucei Lister427 (n = >2). d Parameters calculated using 
Chemaxon Marvin Sketch 17.25.0. LLE T. b. brucei pEC50 – cLogP. e Calculated in Knime workflow using 
ChemAxon JChem nodes. 
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Analysis of these data indicated that the shorter alkyl chain analogues had a reduced 
cytotoxicity in mammalian HepG2 cells, compared to the more lipophilic, longer alkyl chain 
analogues. An improvement in LLE was observed with the isopentyl chain (154), the bromo 
substituent (178) and the benzaldehyde analogues (187). The benzaldehyde (187) has 
stronger electron-withdrawing properties over the benzonitrile (134), decreasing the 
calculated pKa of the phenol. This decreased the calculated cLogD7.4 by 0.6 units, which 
improves the CNS MPO scoring function. The T. b. brucei LLE and TAO inhibition profiles for 
the TAO inhibitors synthesised over the course of this project are highlighted in figure 88. 
From this plot it is apparent that the later synthesised compounds (154, 178, 187) have 
improved LLE.  The combination of these structural modifications in compound 197 attained 
an LLE of 2. Incorporation of the benzaldehyde moiety together with the structural 
modifications previously identified may improve the LLE to higher than the natural product 
CCB (26), approaching a more desirable LLE value of 3 (Figure 89 - green line).
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Figure 89 - LLE Plot of T. b. brucei growth inhibition activity of all compounds, generated in Vortex. Mean T. b. brucei pEC50, cLogP and LLE Plot of tail modification 
analogues, LLE 1 = red line, LLE 2 = blue line, LLE 3 = green line. Labelled by compound number, and points coloured by mean TAO pIC50 (Green 8.7, lime green 7.5, 
yellow 6.6, orange 5.5 and red 4.5). cLogP generated using Chemaxon Marvin Sketch 17.25.
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7.2 Parasite Kill Kinetics and Reversibility Assessment 
The parasite kill kinetic assay determines the concentration of compound that is required to 
reduce parasite levels over a time course of 6, 24 and 48 h. This data is used to show 
compound cidality, which is determined to be a 1 log order reduction in parasite 
concentration. This assay was conducted by research associates at Novartis. A T. b. brucei 
culture is initiated at a 1 × 105/mL parasite density at 10 concentrations of inhibitor. Parasite 
density is then assessed using cell-titre glow reagent at the time points stated to allow 
analysis of the time dependent inhibition profile and cidality assessment.  The data for 
compounds 26, 134, 154, 178, 187 is summarised in figure 89. Analysis of these data show 
that the kill kinetic profiles of these TAO inhibitors require 24 h to reach maximal inhibition. 
Unfortunately, the TAO inhibitors show poor trypanocidal efficacy in this assay, instead 
showing a trypanonstatic effect. Much higher concentrations of compound are required to 
instigate parasite clearance than was necessary to inhibit parasite growth. A CCB (26) 
concentration of 1.8 µM was required for a cidal response in this assay. This equates to a 
concentration approximately 25 × greater than the concentration required to inhibit 90% of 
parasite growth. These types of inhibition profile are indicative of a non-cidal mechanism of 
action. The target product profile set out by the DNDi (Table 2), highlights the preference for 
progressing trypanocidal compounds into the clinic as potential HAT treatments.65 This data 
suggests that TAO inhibitors predominately act via a trypanostatic mechanism, and would 
therefore be a less desirable class of compounds to progress into further drug development. 
However, TAO inhibition does show a marked increase in potency for the Melarsoprol and 
Pentamidine drug resistant strains.135 Assessment of cidal activity against these drug 
resistant strains may re-new interest in TAO inhibitors for the potential treatment of HAT. 
The data generated here also showed the need for compounds with much higher potency in 
the parasite growth inhibition assays due to the significant decrease observed in the parasite 
kill kinetic assay. Attaining such a high compound concentration in an in vivo setting would 
be difficult especially over the prolonged time period required to attain parasite clearance, 
highlighted in this experiment (Figure 90). The therapeutic window of these compounds 
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would also likely be diminished as CC50 in mammalian HepG2 cells is close to the micromolar 
concentrations that would be required to clear parasite infections.
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Figure 90 - Kill Kinetic data for TAO inhibitors
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These compounds were also assessed in parasite cure reversibility assays, also conducted at 
Novartis. These assays are used to determine the concentration of compound that is 
required to irreversibly clear a parasite culture. In this assay a 1 × 105 per mL of T. b. brucei 
culture is inoculated with inhibitor at 10 concentrations (3-fold serial dilution from 50 µM). 
Each culture is incubated for 48 h with compound at 37 °C, 5% CO2. The supernatant is then 
removed, and the parasites are washed 3-times with media before placing under culture 
conditions for 72 h. Parasites levels are then assessed with celltitre glo® reagent to determine 
the compound concentration required to clear parasites irreversibly. Parasite clearance is 
determined when a response below the limit of detection is observed (Figure 91). 
 
Figure 91 - T. b. brucei reversibility / cure assay 
 
Again, a similar result to the kill kinetic profiles was observed. Very high concentrations of 
TAO inhibitor were required to observe parasite clearance. The benzaldehyde compound 187 
looks to show higher potency for clearance than the direct nitrile comparison 134. The iso-
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pentyl chain analogue (154) and the bromo analogue (178) also showed improved parasite 
clearance profiles in this assay format. The natural product CCB (26) again showed to cure at 
the lowest concentrations; however, this again tracked to a significantly higher concentration 
than that was required to inhibit T. b. brucei growth. These data support the hypothesis that 
TAO inhibition causes a trypanostatic response and that inhibition of TAO does not cause 
cidality of the T. b. brucei parasite. The increase in potency observed with CCB (26) in all of 
the parasite assays could be due to a number of reasons. The compound may be acting on a 
complimentary un-identified inhibition pathway. The higher lipophilicity of CCB may also 
increase compound affinity to the parasites mitochondrial inner-membrane, where TAO is 
located. Unfortunately, the generation of parasite genetic mutants for trypanostatic 
compounds is not trivial and was therefore not pursued at this point to identify alternative 
targets that CCB may be inhibiting through. 
7.2 Conclusions 
Over the duration of this research project robust methods to generate functionally active 
recombinant TAO have been established. This enabled the development of medium 
throughput biochemical assays that were used to identify inhibitors of TAO. With these 
assays in place, the optimisation of drug like properties of compounds similar to the natural 
product CCB (26) was initiated. This highlighted the difficulties of synthesis of hexa-
substituted aromatic molecules. The synthetically amenable mono-phenol analogue (88) was 
identified and found to have good TAO inhibition that correlated to potent T. b. brucei growth 
inhibition. The high lipophilicity observed with 88 and the parent CCB natural product 
contributed to poor physicochemical properties and predicted CNS penetration profiles, so 
a focus was made to identify potent TAO inhibitors that had lower lipophilicity and improved 
predicted CNS penetration profiles. This investigation highlighted that polar functionality was 
not well tolerated in the lipophilic tail portion of CCB based TAO inhibitors, and that shorter 
alkyl chain analogues (134 and 135) retained adequate potency with reduced lipophilicity. 
This instigated the synthesis and evaluation of further diverse tail analogues and identified 
the isopentyl tail compound (154) to have improved activity for inhibiting both TAO and 
T. b. brucei growth, and also lower lipophilicity. Further attempts to lower these TAO 
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inhibitors’ lipophilicity showed that polar functionality was also not tolerated on the chloro 
substituent vector. Evaluation of the bromo intermediate (178) that was synthesised to 
facilitate this exploration showed increased inhibition of TAO, which correlated to a higher 
inhibition of T. b. brucei growth with only a minor increase in lipophilicity. This observation 
led to the synthesis of the iso-pentyl bromo analogue (197), which showed an additive 
potency increase in T. b. brucei inhibition. Replacement of the benzonitrile with amide 
functionality was poorly tolerated and resulted in reduced potency against TAO. On review 
of the data generated with the TAO inhibitors synthesised over the course of this project, it 
was obvious that the benzaldehyde analogues showed higher inhibition of T. b. brucei growth. 
The synthesis and evaluation of the pentyl chain benzaldehyde analogue 187 followed this 
observation. More advanced parasite kill kinetic and reversibility assays were conducted at 
Novartis. Data from these assays showed that the compounds act as trypanostatic inhibitors, 
as a much higher compound concentration is required to cause a cidal response in the 
parasite, compared to the concentration required to inhibit parasite growth. The parasite kill 
kinetic and reversibility assays tracked to the potency trends observed in the T. b. brucei 
growth inhibition assays, with the benzaldehyde (187), bromo analogue (178) and isopentyl 
chain analogue (154) all showing improved concentration responses than the matched pair 
(134). Unfortunately, the trypanostatic response observed with these TAO inhibitors will 
restrict interest in the further development of these compounds, as the desired target 
product profile set out by the DNDi states a preference for development of trypanocidal 
molecules.  
I have successfully synthesised compounds based on the natural product CCB to validate TAO 
as a potential target for the treatment of HAT. TAO inhibitors were synthesised with 
improved calculated physicochemical properties to CCB; however, these compounds were 
shown to be trypanostatic, rather than trypanocidal. These results indicate that TAO 
inhibition is a poor target as a single agent for widespread HAT treatment. 
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7.3 Future Work 
An interest in developing and studying TAO inhibitors may still exist for treating HAT and AAT 
in some cases. In vivo, clearance of T. b. brucei may be improved over what is observed in 
these in vitro assays. In animals, a host immune response can clear infections of T. b. brucei 
that are in an arrested state.229 This is also observed with the trypanostatic compound 
Eflornithine, which was used in the clinic as a monotherapy prior to the introduction of 
combination therapies for treatment of HAT T. b. gambiense infections.60 Combination of 
Eflornithine with the trypanocide Nifurtimox is now the standard of care for T. b. gambiense 
infections. Similarly, the combination of a TAO inhibitor with a trypanocide may also prove 
interesting for treatment of HAT or AAT infections. NECT treatment is not used for treatment 
of T. b. rhodesiense infections as the ornithine decarboxylase enzyme turns over much more 
readily than in T. b. gambiense.64 TAO inhibitors may provide an alternative trypanostatic 
mechanism that could be useful in T. b. rhodesiense treatment. 
Further optimisation of these TAO inhibitors could identify a molecule that has a similar T. b. 
brucei growth inhibition profile to CCB, with lower lipophilicity and an improved predicted 
CNS penetration. The combination compound 197 is currently being tested in the kill kinetic 
and parasite clearance assays. Combination of the structural modifications present in 197 
with the potency improvements observed with the benzaldehyde analogue 187 would likely 
result in a low nanomolar inhibitor of TAO and of T. b. brucei growth. This compound (198) 
would also have an improved CNS MPO score, lower LogD7.4 and lower lipophilicity (Figure 
92).  
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Figure 92 - Design and predicted activity of compound 198 – Predicted potency from pEC50 increment observed 
with benzaldehyde analogue (134 to 187 = 0.8, 47 to 26 = 2.0, 51 to 50 = 1.4). Parameters calculated using 
Chemaxon Marvin Sketch 17.25.0 
 
Compound 198 however, would however contain the benzaldehyde motif. As discussed 
previously, compound metabolism and reactivity would have to be assessed before 
committing to further synthesis of molecules containing the benzaldehyde moiety. 
The TAO inhibitors synthesised may also be of interest for the treatment of other parasitic 
infections. Cryptosporidium parasites are reliant on a similar alternative oxidase for their 
respiratory function, and share approximately 50% sequence homology to TAO.256 An in silico 
homology model built from the FASTA sequence of cryptosporidium homonis and the crystal 
structure of T. b. brucei (PDB: 3W54), shows good homology of the predicted binding site of 
CCB (Figure 93 - Identical residues – red, similar residues – orange and dis-similar residues - 
white).  A range of microsporidian parasites also rely on similar alternative oxidases for their 
function.257 Compounds designed for TAO inhibition may show inhibitory activity against the 
alternative oxidase enzymes of these parasites and provide chemically tractable starting 
points for further development. 
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Figure 93 - Cryptosporidium homonis homology model built on T. b. brucei crystal structure (PDB: 3W54) in Maestro – 
Schrodinger Drug Discovery Suite. Identical residues coloured red, similar residues coloured orange, dis-similar 
residues coloured white, CCB coloured green. 
 
This project has generated several TAO inhibitors that have improved drug like properties 
over the natural product inhibitors colletochlorin B and ascofuranone. The evaluation of 
these molecules in advanced parasite assays has enabled the discovery that TAO inhibition 
causes a trypanostatic response in T. b. brucei parasites. This will be of interest for the future 
development of treatments for HAT and AAT. In consideration of these data, TAO inhibition 
may be deprioritised in preference for trypanocidal compounds. Further in vitro and in vivo 
pharmacokinetic and pharmacodynamic experiments would be required to show that these 
TAO inhibitors could achieve high CNS exposure following oral dosing and are able to clear T. 
b. brucei parasite infections to renew an interest in TAO as a target for treating HAT and AAT. 
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Chapter 8 – Experimental 
General Experimental 
Reactions were performed under an atmosphere of nitrogen unless otherwise stated, using 
anhydrous solvents as purchased or dried over molecular sieves and degassed with nitrogen 
flow. Flash chromatography was performed using pre-packed silica gel cartridges, supplied 
by Biotage, Grace or Teledyne ISCO and performed on ISCO Combiflash RF or Biotage Isolera 
Prime purification systems. Reverse-phase chromatography was performed with pre-packed 
C18 silica carstridges supplied by Grace and purification performed on a Biotage Isolera Prime 
purification system. Proton NMR spectra were recorded at 500 or 600 MHz, on either a 
Varian 500 or 600 spectrometer (at 30 °C) or a Bruker 500 spectrometer (at 25 °C), using the 
residual isotopic solvent shift as an internal reference (CHCl3 δH – 7.27 ppm, DMSO δH – 
2.50 ppm, MeOH δH 3.31 ppm). Chemical shifts are quoted in parts per million (ppm), 
coupling constants are recorded in Hertz (Hz). Carbon 13 NMR were recorded at 125 MHz 
on a Varian 500 or 600 spectrometer or a Bruker 500 spectrometer. Residual isotopic solvent 
shifts were used as an internal reference (CHCl3 δC – 77.00 ppm, DMSO δC – 39.52 ppm). 
Infra-red spectra were recorded on a Perkin Elmer FT-IR Spectrum One spectrometer as a 
neat sample. Absorption maxima are reported in wavenumber (cm-1). Distinguishable and 
significant absorptions were recorded in wave numbers (cm-1), with key stretches identified 
in brackets. LCMS (LCQ) data was recorded on Waters 2695 HPLC using a Waters 2487 UV 
detector and Thermo LCQ ESI-MS, eluting through a Phenomenex Lunar 3 µ C18 column 
(50 mm × 4.6 mm column) with a water to acetonitrile gradient with a formic acid modifier 
(0.1%). LCMS (MDAP) data was recorded on a Shimatzu Prominence Series coupled to a 
LCMS-2020 ESI and APCI mass spectrometer. Samples were eluted through a Phenomenex 
Gemini 5 μ C18 110A 250 mm × 4.6 mm column, using water and acetonitrile gradient with 
a 0.1% formic acid modifier at 1 ml/min and detected at 254 nm. UPLC data was recorded 
on a Waters Acuity UPLC and Waters ZQ ESI mass spectrometer. Samples were eluted 
through a Kinetex 2.6 µ C18 column (50 mm × 2.1 mm), using water and acetonitrile gradient 
with a 0.1% trifluoro acetic acid modifier. High resolution mass-spectrometry (HRMS) data 
was recorded on Bruker Daltonics, Apex III, ESI source: Apollo ESI with methanol as spray 
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solvent. Only molecular ions, fractions from molecular ions and other major peaks are 
reported as mass/charge (m/z) ratios. All reported yields refer to chromatographically and 
spectroscopically pure compounds, unless otherwise specified. Reagents were used as 
supplied from Manchester Organics, Sigma-Aldrich, Acros, Fluorochem, Combi-blocks or 
Tokyo Chemical Industry unless otherwise stated. Compound 27 – 46 were supplied by 
Medicines Malaria Venture (MMV), compounds 26 and 47 – 61 were synthesised by 
members of the Sussex Drug Discovery Centre (SDDC) prior to the start of this project. 
Compounds 72, 73 and 121 – 124 were synthesised by Thomas Cunningham who was a 
Masters’ student under my supervision for his research project.  
2,4-Dihydroxy-6-methylbenzaldehyde (63)258 
 
To a solution of POCl3 (26.3 mL, 282 mmol) in acetonitrile (250 mL) was added DMF (21.8 mL, 
282 mmol) at 0 °C. After 10 min, 5-methylresorcinol (62) (20.0 g, 161 mmol) in 
acetonitrile (200 mL) was added at 0 °C. The reaction mixture was allowed to warm to RT 
and stir for 1 hour before being quenched by addition to water (1000 mL). The solution was 
concentrated under reduced pressure, precipitating a pale-yellow solid. Collection by 
reduced pressure filtration and drying afforded the title compound as a pale-yellow solid 
(19.4 g, 79%): m.p. 118–121 °C, (water / acetonitrile). IR (neat, vmax) cm-1 3086, 1623, 1204. 
1H NMR (500 MHz, D6-DMSO) δH 12.05 (br s, 1H, OH-8/9), 10.67 (br s, 1H, OH-8/9), 10.04 (s, 
1H, CH-10), 6.20 (s, 1H, CH-1), 6.12 (s, 1H, CH-3), 2.44 (s, 3H, CH3-7). 13C NMR (126 MHz, D6-
DMSO) δC 193.4 (CH-10), 165.8 (C4), 165.7 (C2), 145.2 (C6), 113.1 (C5), 111.2 (CH-1), 100.7 
(CH-3), 19.0 (CH3-7). HRMS (ESI-) m/z [M-H]- calculated for C8H7O3 151.0401, found 151.0394. 
LCMS Analytical LCQ, Method 2, tR 3.48 min, [M+H]+ 153.3 m/z, LCMS MDAP, Method 4, tR 
15.14 min, (>95%), [M-H]- 151.1 m/z.  
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2,4-Dihydroxy-6-methylbenzaldoxime (64) 
 
A suspension of 2,4-dihydroxy-6-methylbenzaldehyde (63) (4.25 g, 27.9 mmol) in acetonitrile 
(50 mL) was added hydroxylamine hydrochloride (2.14 g, 30.7 mmol) and heated to reflux 
for 16 h. The cooled reaction was partitioned between water and ethyl acetate. The organic 
layer was separated, washed with brine, dried over MgSO4, filtered and concentrated under 
reduced pressure, to provide the title compound as a pale-yellow solid (4.38 g, 94%). 
m.p. 196.4-200.7 °C. IR (neat, vmax) cm-1 3237, 1609, 1585, 1302, 1149. 1H NMR (500 MHz, 
D6-DMSO) δH 11.12 (s, 1H, OH-8/9/12), 10.65 (s, 1H, OH-8/9/12), 9.68 (s, 1H, OH-8/9/12), 
8.36 (s, 1H, CH-10), 6.16 (s, 1H, CH-1), 6.12 (s, 1H, CH-3), 2.38 (s, 3H, CH3-7). 13C NMR 
(126 MHz, CDCl3) δC 159.7 (C2/4), 159.6 (C2/4), 149.1 (CH-10), 139.5 (C), 110.0 (CH-1), 108.0 
(C5), 101.0 (CH-3), 20.0 (CH3-7). HRMS-ESI m/z [M-H]- calculated for C8H8NO3 166.0510, 
found 166.0505. LCMS Analytical LCQ, Method 3, tR 4.15 min, [M+H]+ 168.1 m/z. LCMS 
Analytical MDAP, Method 4, tR 9.17 min, [M+H]+ 168.0 m/z (>95%). 
2,4-Dihydroxy-6-methylbenzonitrile (65)259 
 
A solution of 2,4-dihydroxy-6-methylbenzaldoxime (64) (3.00 g, 18.0 mmol) in diethyl ether 
(100 mL) was added pyridine (0.97 mL, 11.2 mmol) and cooled to 0 °C. The cooled solution 
was dropwise added thionyl chloride (1.96 mL, 26.9 mmol) over 10 min. To the reaction 
mixture was allowed to warm to rt and stir for 16 h. The reaction was concentrated under 
reduced pressure and the residue dissolved in ethanol (30 mL) and added 2 M NaOH (aq) (20 
mL). The reaction mixture was stirred at rt for 96 h. The reaction mixture was acidified with 
5 M HCl (aq) (20 mL) and extracted with ethyl acetate. The organic layers were separated, 
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washed with brine, dried over MgSO4, filtered and concentrated under reduced pressure. 
The residue was purified by flash silica chromatography. To provide the title compound as a 
pale-yellow solid. (1.82 g, 67%). m.p. 188.8-194.2 °C. IR (neat, vmax) cm-1 3142, 2225, 1749, 
1602, 1468, 1274, 1152. 1H NMR (500 MHz, D6-DMSO) δH 10.65 (s, 1H, OH-8/9), 10.21 (br s, 
1H, OH-8/9), 6.23 (s, 1H, CH-1/3), 6.21 (s, 1H, CH-1/3), (s, 3H, CH3-7). 13C NMR (126 MHz, 
D6-DMSO) δC 162.5 (C2+4), 144.2 (C6), 117.3 (C10), 109.3 (CH-1), 100.3 (CH-3), 91.2 (CH-5), 
20.6 (CH3-7). HRMS-ESI m/z [M-H]- calculated for C8H6NO2 148.0404, found 148.0401. LCMS 
analytical LCQ, Method 2, tR 0.61 min, [M+H]+ - no ionisation. LCMS analytical MDAP, Method 
4, tR 8.58 min, [M-H]- 147.9 m/z (>95%). 
2,4-Dihydroxy-5-chloro-6-methylbenzonitrile (66) 
 
A solution of 2,4-dihydroxy-6-methylbenzonitrile (65) (1.76 g, 11.8 mmol) in diethyl ether 
(10 mL) was cooled to -10 °C, the reaction mixture was dropwise added a solution of sulfuryl 
chloride (0.96 mL, 11.8 mmol) in diethyl ether (10 mL) over 30 min. The reaction mixture was 
allowed to warm to rt and stir for 2 h. To the reaction mixture was added 1 M HCl (aq) and 
extracted with ethyl acetate. The organic layers were separated, washed with brine, dried 
over MgSO4, filtered and concentrated under reduced pressure. The residue was purified by 
recrystallization from methanol, water (8:2) to provide the title compound (1.96 g, 90%). m.p. 
199.2-204.6 °C. IR (neat, vmax) cm-1 3335, 2226, 1592, 1441, 1330, 1274. 1H NMR (500 MHz, 
D6-DMSO) δH 11.07 (s, 1H, OH-8/9), 10.96 (s, 1H, OH-8/9), 6.51 (s, 1H, CH-3), 2.37 (s, 3H, CH3-
7). 13C NMR (126 MHz, D6-DMSO) δC 160.5 (C4), 158.3 (C2), 141.0 (C6), 116.7 (C1), 112.2 
(C10), 101.3 (CH-3), 92.7 (C-5), 19.0 (CH3-7). HRMS-ESI m/z [M-H]- calculated for C8H535ClNO2 
182.0014, found 182.0009. LCMS analytical MDAP, Method 4, tR 15.67 min, [M-H]- 182.0 m/z 
(>95%). 
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2,4-Dihydroxy-5-chloro-6-methylbenzaldehyde (69)149 
 
To a solution of 2,4-dihydroxy-6-methylbenzaldehyde (63) (9.50 g, 62.4 mmol) in diethyl 
ether (300 mL) was drop wise added sulfuryl chloride (5.06 mL, 62.4 mmol) as a solution in 
diethyl ether (20 mL) at -5 °C over 30 min. After 10 min the reaction mixture was allowed to 
warm to rt and stir for 2 h before the addition of petroleum ether (150 mL) and precipitation 
of a pale-yellow solid. Collection by reduced pressure filtration and drying afforded the title 
compound as a pale-yellow solid (5.65 g, 49%): m.p. 172–175 °C (diethyl ether / petroleum 
ether). IR (neat, vmax) cm-1 2981, 1581, 1307, 1256, 1217. 1H NMR (500 MHz, D6-DMSO) δH 
11.93 (br s, 1H, OH-8/9), 11.46 (br s, 1H, OH-8/9), 10.15 (s, 1H, CH-10), 6.40 (s, 1H, CH-3), 
2.55 (s, 3H, CH3-7). 13C NMR (126 MHz, D6-DMSO) δC 193.6 (CH-10), 163.5 (C2), 161.07 (C4), 
141.44 (C6), 113.86 (C1/5), 113.82 (C1/5), 101.46 (C3), 15.49 (CH3-7). HRMS (ESI-) m/z [M-
H]- calculated for C8H635ClO3 185.0011, found 185.0005. LCMS Analytical LCQ, Method 2, tR 
2.62 min, [M+H]+ 187.2 m/z. LCMS MDAP, Method 4, tR 16.89 min, (>95%), [M-H]- 185.0 m/z. 
5-Chloro-3-[[hexyl(methyl)amino]methyl]-2,4-dihydroxy-6-methyl-benzaldehyde 
(71) 
 
A solution of N-methylheptylamine (0.23 mL, 1.30 mmol) in ethanol (5 mL) was added 
paraformaldehyde (40 mg, 1.30 mmol) and heated to 50 °C for 30 min. The solution was 
added 2,4-dihydroxy-5-chloro-6-methylbenzaldehyde (69) (0.20 g, 1.10 mmol) and heated to 
50 °C for 10 min. The reaction mixture was added water and extracted with ethyl acetate. 
The organic layers were separated, washed with brine, dried over MgSO4, filtered and 
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concentrated under reduced pressure. The residue was recrystallized from methanol and 
water (10:1) to provide the title compound as a cream solid (0.226 g, 67%). m.p. 
119.2-121.3 °C. IR (neat, vmax) cm-1 2949, 1715, 1621, 1421, 1249, 1227. 1H NMR (500 MHz, 
CDCl3) δH 13.14 (s, 1H, OH-9), 9.95 (s, 1H, CH-10), 3.99 (s, 2H, CH2-13), 2.75 (t, J = 7.9 Hz, 2H, 
CH2-16), 2.57 (s, 3H, CH3-7/15), 2.50 (s, 3H, CH3-7/15), 1.68 (m, 2H, CH2-17), 1.37-1.29 (m, 
6H, CH2-18/19/20), 0.89 (t, 3H, CH3-21). 13C NMR (126 MHz, CDCl3) δC 191.5 (CH-10), 167.51 
(C2), 162.2 (C4), 139.9 (C6), 110.6 (C1), 110.0 (C5), 104.8 (C3), 56.5 (CH2-16), 53.9 (CH2-13), 
40.3 (CH3-15), 31.4 (CH2-17/18/19/20), 26.5 (CH2-17/18/19/20), 25.7 (CH2-17/18/19/20), 
22.4 (CH2-17/18/19/20), 14.4 (CH3-7), 13.9 (CH3-21). HRMS-ESI m/z [M-H]- calculated for 
C16H2335ClNO3 312.1372, found 312.1359. LCMS analytical MDAP, Method 4, tR 13.28 min, 
[M+H]+ 314.1 m/z (95%). 
2,4-Dihydroxy-3-bromo-5-chloro-6-methylbenzaldehyde (74) 
 
To a solution of 2,4-dihydroxy-5-chloro-6-methylbenzaldehyde (69) (5.50 g, 29.5 mmol) in 
CH2Cl2, methanol (4:1, 150 mL) was added tetrabutylammmonium tribromide (14.9 g, 
31.0 mmol) as a solution in CH2Cl2, methanol (4:1) (20 mL). After 30 min the reaction mixture 
was concentrated under reduced pressure. The residue was dissolved in methanol (55 mL), 
addition of water (110 mL) afforded a pale-yellow precipitate. Collection by reduced pressure 
filtration and drying afforded the title compound as a pale-yellow solid (4.85 g, 62%): m.p. 
169–174 °C, (methanol / water). IR (neat, vmax) cm-1 3179, 1606, 1405, 1273. 1H NMR 
(500 MHz, D6-DMSO) δH 13.16 (s, 1H, OH-8/9), 10.10 (s, 1H, CH-10), 2.58 (s, 3H, CH3-7). 13C 
NMR (126 MHz, D6-DMSO) δC 195.4 (CH-10), 160.3 (C2/4), 157.8 (C2/4), 140.7 (C6), 114.6 
(C1/5), 113.5 (C1/5), 110.0 (C3), 15.1 (CH3-7). HRMS (ESI-) m/z [M-H]- calculated for 
C8H579Br35ClO3 262.9116, found 262.9168. LCMS Analytical LCQ, Method 2, tR 2.97 min, 
[M+H]+ 267.1 m/z, LCMS analytical MDAP, Method 4, tR 19.11 min, (90%) [M-H]- 264.9 m/z. 
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2,4-Dihydroxy-3-bromo-5-chloro-6-methylbenzaldoxime (75) 
 
To a suspension of 2,4-dihydroxy-3-bromo-5-chloro-6-methylbenzaldehyde (74) (4.85 g, 
18.3 mmol) in ethanol (50 mL) was added hydroxylamine hydrochloride (1.90 g, 27.4 mmol). 
After 16 h the resulting precipitate was collected by reduced pressure filtration, washed with 
water and cold ethanol to afford the title compound as a white solid (4.40 g, 86%): m.p. 
231-234 °C, (ethanol / water). IR (neat, vmax) cm-1 3383, 3347, 1605, 1417, 1400, 1189. 1H 
NMR (500 MHz, D6-DMSO) δH 11.87 (br s, 1H, OH-8/9/14), 11.67 (s, 1H, OH-8/9/14), 10.19 
(br s, 1H, OH-8/9/14), 8.53 (s, 1H, CH-10), 2.38 (s, 3H, CH3-7). 13C NMR (126 MHz, D6-DMSO) 
δC 154.6 (C4), 152.0 (C2), 149.4 (CH-10), 135.1 (C6), 113.9 (C1), 109.7 (C5), 98.0 (C3), 16.5 
(CH3-7). HRMS (ESI-) m/z [M-H]- calculated for C8H679Br35ClNO3 277.9225, found 277.9219. 
LCMS Analytical LCQ, Method 2, tR 2.48 min, [M+H]+ 282.5 m/z. LCMS analytical MDAP, 
Method 4, tR 17.41 min, (>95%), [M-H]- 279.9 m/z. 
4-Methyl-5-chloro-6-hydroxy-7-bromo-[1,2]benzisoxazole (76) 
 
To a suspension of 2,4-dihydroxy-3-bromo-5-chloro-6-methylbenzaldoxime (75) (1.13 g, 
4.00 mmol) in diethyl ether (100 mL) was added pyridine (0.65 mL, 8.10 mmol) and SOCl2 at 
0 °C. After 10 min the reaction mixture was allowed to warm to rt. After 16 h the reaction 
mixture was partitioned between ethyl acetate (200 mL) and 1 M HCl (aq) (100 mL). The 
phases were separated, the aqueous phase was extracted with ethyl acetate (3 × 50 mL) and 
the combined organic extracts were washed with brine (50 mL), dried over MgSO4, filtered 
and concentrated under reduced pressure. The residue was purified by flash 
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chromatography (petroleum ether to 30% ethyl acetate in petroleum ether over 25 min) to 
afford the title compound as a white solid (1.01 g, 96%): m.p. 176–181 °C, (petroleum 
ether / ethyl acetate). IR (neat, vmax) cm-1 3202, 1594, 1320, 1194. 1H NMR (500 MHz, 
D6-DMSO) δH 10.97-10.85 (br s, 1H, OH), 9.40 (s, 1H, CH-13), 2.53 (s, 3H, CH3-7). 13C NMR δC 
(126 MHz, D6-DMSO) 158.9 (C4), 152.8 (C2), 147.6 (CH-13), 130.8 (C6), 120.1 (C1), 115.8 (C5), 
88.0 (C3), 17.3 (CH3-7). HMBC – observed between H-13 and C-5. HRMS (ESI-) m/z [M-H]- 
calculated for C8H479Br35ClNO2 259.9119, found 259.9113. LCMS analytical LCQ, Method 3, 
tR 5.78 min, [M+H]+ 264.0 m/z. LCMS analytical MDAP, Method 4, tR 18.37 min, (88%), [M-
H]- 261.9 m/z.  
4-Methyl-5-chloro-6-hydroxy-7-bromo-[1,3]benzoxazole (77) 
 
To a solution of 2,4-dihydroxy-3-bromo-5-chloro-6-methylbenzaldoxime (75) (1.40 g, 
5.0 mmol) in CH2Cl2 and acetonitrile (10:1, 10 mL) was added trifluoroacetic anhydride (2.02 
mL, 12.0 mmol). After heating the reaction mixture by microwave (Biotage® Initiator) for 1 h 
at 100 °C the reaction mixture was diluted with CH2Cl2 (100 mL) and washed with aqueous 
sodium bicarbonate (50 mL), brine (50 mL), dried over MgSO4, filtered and concentrated 
under reduced pressure. The residue was triturated in CH2Cl2 and filtered afford the title 
compound as a tan solid (0.58 g, 45%): m.p. 209–211 °C, (CH2Cl2). IR (neat, vmax) cm-1 3144, 
1384, 1289. 1H NMR (500 MHz, D6-DMSO) δH 10.24 (br s, 1H, OH-8), 8.64 (s, 1H, CH-12), 2.73 
(s, 3H, CH3-7). 13C NMR (126 MHz, D6-DMSO) δC 153.5 (CH-12), 149.1 (C2), 147.2 (C4), 132.8 
(C5), 128.1 (C6), 120.3 (C1), 90.1 (C3), 14.8 (CH3-7). HMBC observed from H-12 to C4 and C5. 
HRMS (ESI-) m/z [M-H]- calculated for C8H479Br35ClNO2 259.9119, found 259.9113. LCMS 
MDAP, Method 4, tR 17.86 min, (>95%), [M-H]- 261.9 m/z. 
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2-Methyl-4-hydroxy-5-bromo-benzaldehyde (80)260 
 
To a solution of 2-methyl-4-hydroxy-benzaldehyde (79) (10.0 g, 73.5 mmol) in CH2Cl2 
(100 mL) and methanol (50 mL) was added a solution of phenyltrimethylammonium 
tribromide (30.1 g, 77.1 mmol) in CH2Cl2: methanol (1:1, 100 mL) at -5 °C. The reaction was 
warmed to ambient temperature and stirred for 16 h. The reaction was concentrated under 
reduced pressure and the residue was added 1 M HCl (aq) (200 mL) to precipitate a white 
solid, the solid was collected by filtration and dried under reduced pressure to give the title 
compound as a cream precipitate (14.7 g, 94%): m.p. 160–165 °C, (methanol / water). IR 
(neat, vmax) cm-1 3063, 1384, 1310. 1H NMR (500MHz, D6-DMSO) δH 11.35 (1H, br s, OH-12), 
9.95 (1H, s, CH-8), 7.91 (1H, s, CH-4), 6.83 (1H, s, CH-1), 2.49 (3H, s, CH3-7). 13C NMR 
(126 MHz, D6-DMSO) δC 190.8 (CH-8), 159.2 (C2), 142.3 (C6), 137.1 (CH-4), 128.0 (C5), 119.1 
(CH-1), 107.4 (C3), 19.1 (CH3-7). HRMS (ESI-) m/z [M-H]- calculated for C8H679BrO2 212.9557, 
found 212.9550. LCMS analytical LCQ, Method 2, tR 2.51 min, [M+H]+ 217.1 m/z. LCMS 
analytical MDAP, Method 4, tR 16.54 min, (94%), [M-H]- 213.0 m/z.  
2-Methyl-4-hydroxy-5-oct-1-enyl-benzaldehyde (81) 
 
A stirring suspension of 
chloro[(1,3-dimesitylimidazol-2-ylidene)(n,n-dimethylbenzylamine)palladium(II)] (0.03 g, 
0.05 mmol), potassium carbonate (0.96 g, 7.0 mmol), 
2-methyl-4-hydroxy-5-bromo benzaldehyde (80) (0.50 g, 2.30 mmol) and 1-octene (0.65 g, 
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0.60 mmol) in N-methyl-2-pyrrollidinone (10 mL) was heated in a sealed vial at 140 °C for 2 h. 
The reaction mixture was cooled to rt, diluted with ethyl acetate (50 mL), washed with water 
(20 mL), LiCl (aq) (0.5 M, 20 mL) and brine (50 mL). The organic phase was separated, dried 
over MgSO4, filtered and concentrated under reduced pressure. The residue was purified by 
flash chromatography (petroleum ether to 15% ethyl acetate in petroleum ether over 
20 min) to afford the title compound as a yellow oil (0.147 g, 26%). 1H NMR (500 MHz, CDCl3) 
δH 10.11 (s, 1H, CH-11), 7.79 (s, 1H, CH-4), 6.69 (s, 1H, CH-1), 6.53 (d J = 16.1, 1H, CH-12), 
6.27 (dt J = 16.1, 6.8 Hz, 1H, CH-13), 6.09 (s, 1H, OH-8), 2.61 (s, 3H, CH3-7), 2.26 (m, 2H, 
CH2-14), 1.56-1.18 (m, 8H, CH2-15/16/17/18) 0.90 (m, 3H, CH3-19). 13C NMR (126 MHz, 
D6-DMSO) δC 191.4 (CH-9), 157.1 (C2), 141.6 (C6), 134.8 (CH-4), 132.4 (CH-13), 127.9 (C5), 
123.4 (C3), 122.6 (CH-12), 118.6 (CH-1), 33.4 (CH2-14/17), 31.7 (CH2-14/17), 29.2 (CH2-
15/16), 28.9 (CH2-15/16), 22.6 (CH2-18), 19.2 (CH3-7), 14.0 (CH3-19). HRMS (ESI-) m/z [M-H]- 
calculated for C16H21O 245.1547, found 245.1539. LCMS analytical LCQ, Method 3, tR 8.14 
min, [M+H]+ 247.2 m/z. LCMS analytical MDAP, Method 4, tR 24.10 min, (94%), [M-H]- 
245.2 m/z. 
4,5-Dimethyl-2-octyl-phenol (82) 
 
Triethylsilane (0.05 g, 0.43 mmol) was added to a solution 
4-hydroxy-2-methyl-5-[(E)-oct-1-enyl]benzaldehyde (81) (0.05 g, 0.20 mmol) and 10% 
palladium on carbon (0.002 g, 0.02 mmol) in ethyl acetate (2 mL). The reaction mixture was 
stirred at rt for 16 h. The reaction mixture was purged with nitrogen and was filtered through 
a pad of celite, the filtrate was partitioned between HCl (aq) (1 M, 10 mL) and ethyl acetate 
(2 x 20 mL). The combined organics were separated, dried over MgSO4, filtered and 
concentrated under vacuum. The residue was purified by flash silica chromatography, eluting 
with petroleum ether to 50% ethyl acetate in petroleum ether to provide the title compound 
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as an orange oil (0.045 g, 95%). 1H NMR (500 MHz, CDCl3) δH 6.86 (s, 1H, CH-6/3), 6.57 (s, 1H, 
CH-6/3), 4.41 (br s, 1H, OH-7), 2.53 (t, J = 7.8 Hz, CH2-8), 2.18 (s, 3H, CH3-16/17), 2.17 (s, 3H, 
CH3-16/17), 1.66-1.55 (m, 2H, CH2-9), 1.40-1.23 (m, 10H, CH2s-10-14) 0.88 (t, J = 6.7 Hz, 3H, 
CH3-15). LCMS - Analytical LCQ (10 min) 30-95% MeCN:Water (0.1% Formic), tR  9.26 min, 
[M+H]+ 235.1 m/z (> 95%). 
2-Methyl-4-hydroxy-5-bromo-aldoxime (84) 
 
A solution of 2-methyl-4-hydroxy-5-bromo-benzaldehyde (80) (6.00 g, 27.9 mmol), in 
acetonitrile (100 mL) was added hydroxylamine hydrochloride (2.33 g, 33.5 mmol). The 
reaction mixture was stirred for 3 h at ambient temperature. The resulting solid collected by 
vacuum filtration. The solid was washed with water (100 mL) and dried under reduced 
pressure to provide the title compound as a white solid (3.79 g, 59%): m.p. 143–146 °C 
(acetonitrile / water). IR (neat, vmax) cm-1, 3352, 1594, 1416, 1265. 1H NMR (500MHz, D6-
DMSO) δH 11.05 (1H, s, OH-12), 10.44 (1H, s, OH-10), 8.15 (1H, s, CH-8), 7.67 (1H, s, CH-4), 
6.77 (1H, s, CH-1), 2.26 (3H, s, CH3-7). 13C NMR (126MHz, D6-DMSO) - δC 154.9 (C-2), 146.4 
(CH-8), 137.5 (C-6), 130.9 (CH-4), 124.4 (C-5), 118.6 (CH-1), 107.3 (C-3), 19.7 (CH3-7). HRMS 
(ESI-) m/z [M-H]- calculated for C8H779BrNO2 227.9666, found 227.9660. LCMS MDAP, 
Method 4, tR 15.15 min, (86%), [M-H]- 229.9 m/z. 
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4-Hydroxy-2-methyl-5-octyl-benzonitrile (85) 
 
A pre-stirred solution of cyanuric chloride (2.53 g, 13.7 mmol), in DMF (50 mL) was added a 
solution of 2-methyl-4-hydroxy-5-bromo-aldoxime (84) (3 g, 13.0 mmol) in DMF (25 mL) over 
15 min. The reaction mixture was stirred at rt for 3 h. The reaction mixture was added water 
(150 mL) and stirred at rt for 1 h. The resulting white solid was collected by filtration and 
dried under vacuum to provide the title compound as a white solid (2.77 g, 90%): m.p. 
194-199 °C (DMF / water). IR (neat, ν̄max) cm-1 3203, 2232, 1595, 1402, 1386, 1260, 1221. 1H 
NMR (500MHz, D6-DMSO) - δH 11.38 (1H, br s, OH-12), 7.90 (1H, s, CH-4), 6.92 (1H, s, CH-1), 
2.49 (3H, s, CH3-7). 13C NMR (126MHz, D6-DMSO) δC 158.6 (C-2), 143.4 (C-6), 137.1 (CH-4), 
117.9 (CH-1), 117.7 (C-8), 107.3 (C-3), 103.8 (C-5), 19.1 (CH3-7). HRMS (ESI-) m/z [M-H]- 
calculated for C8H579BrNO 209.9560, found 209.9554. LCMS analytical LCQ, Method 2, tR 2.43 
min, [M+H]+ 215.0 m/z. LCMS MDAP, Method 4, tR 17.34 min, (>95%), [M-H]- 212.0 m/z. 
4-Hydroxy-2-methyl-5-oct-1-enylbenzonitrile (86) 
 
A stirring suspension of chloro[(1,3-dimesitylimidazol-2-ylidene)(n,n-
dimethylbenzylamine)palladium(II)] (0.03 g, 0.05 mmol), potassium carbonate (0.39 g, 2.83 
mmol), 4-hydroxy-2-methyl-5-octyl-benzonitrile (85) (0.20 g, 0.94 mmol) and 1-octene (1.06 
g, 9.43 mmol) in N-methyl-2-pyrrolidinone (10 mL) was heated in a sealed vial at 140°C for 
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2 h. The reaction mixture was cooled to rt, diluted with ethyl acetate (50 mL), washed with 
HCl (aq) (1 M, 20 mL), LiCl (aq) (0.5 M, 10 mL) and brine (25 mL). The organic phase was 
separated, dried over MgSO4, filtered and concentrated under reduced pressure. The residue 
was purified by flash chromatography (petroleum ether to 10% ethyl acetate in petroleum 
ether over 20 min) to afford the title compound as a clear oil (0.066 g, 28%): 1H NMR 
(500 MHz, CDCl3) δH 7.54 (s, 1H, CH-4), 6.73 (s, 1H, CH-1), 6.45 (d J = 16.0 Hz, 1H, CH-12), 
6.20 (dt J = 16.0 Hz, 7.0 Hz, 1H, CH-13), 5.62 (s, 1H, OH-8), 2.46 (s, 3H, CH3-7), 2.24 (m, 2H, 
CH2-13), 1.56-1.18 (m, 8H, CH2-14/15/16/17) 0.90 (m, 3H, CH3-18). 13C NMR (126MHz, CDCl3) 
δC 155.9 (C-2), 142.1 (C-6), 135.5 (CH-4), 131.9 (CH-12), 123.9 (C-3), 122.0 (C-11), 118.4 
(CH-8), 117.3 (CH-1) 110.0 (C-8), 33.3 (CH2-13/16), 31.7 (CH2-13/16), 29.1 (CH2-14/15), 28.9 
(CH2-14/15), 22.6 (CH2-17), 19.2 (CH3-7), 14.0 (CH3-18). HRMS (ESI-) m/z [M-H]- calculated for 
C16H20NO 242.1541, found 242.1541. LCMS MDAP, Method 4, tR 24.58 min, (91%), [M-H] 
242.2 m/z. 
4-Hydroxy-2-methyl-5-octyl-benzonitrile (87) 
 
A stirring solution of 4-hydroxy-2-methyl-5-oct-1-enylbenzonitrile (86) (0.066 g, 0.27 mmol) 
in ethanol (5 mL) was added 10% palladium on carbon (0.003 g, 0.03 mmol). Triethylsilane 
(0.034 g, 0.05 mmol) was added to the stirring suspension. The reaction was sealed and 
stirred at rt for 2 h. The reaction mixture was filtered through a pad of celite, the filtrate 
concentrated under reduced pressure to provide the title compound as a colourless oil 
(0.064 g, quantitative): IR (neat, vmax) cm-1 3308, 2917, 2848, 2222, 1608, 1415, 1269. 1H 
NMR (500 MHz, CDCl3) δH 7.35 (s, 1H, CH-4), 6.69 (s, 1H, CH-1), 5.47 (s, 1H, OH-10), 2.56 (m, 
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2H, CH2-11), 2.45 (s, 3H, CH3-7), 1.59 (m, 2H, CH2-12), 1.56-1.18 (m, 10H, CH2-
13/14/15/16/17) 0.89 (t, J = 6.7 Hz, 3H, CH3-18). 13C NMR (126 MHz, CDCl3) δC 157.2 (C2), 
141.6 (C6), 134.3 (CH-4), 127.4 (C3), 118.7 (C8), 116.8 (CH-1), 104.3 (C5), 31.8 (CH2-16), 29.4 
(CH2-11), 29.3 (CH2-12/13/14/15), 29.3 (CH2-12/13/14/15), 29.2 (CH2-12/13/14/15), 29.1 
(CH2-12/13/14/15), 22.6 (CH2-17), 20.0 (CH2-7), 14.0 (CH3-18). HRMS (ESI-) m/z [M-H]- 
calculated for C16H22NO 244.1707, found 244.1701. LCMS MDAP, Method 4, tR 25.14 min, 
(93%), [M-H]- 244.2 m/z. 
3-Chloro-4-hydroxy-2-methyl-5-octyl-benzonitrile (88) 
 
A solution of 4-hydroxy-2-methyl-5-octyl-benzonitrile (87) (0.067 g, 0.27 mmol) in diethyl 
ether (5 mL) was added sulfuryl chloride (0.03 mL, 0.33 mmol) and stirred at rt for 16 h. 
Further sulfuryl chloride (0.22 mL, 2.70 mmol) was added and the reaction was stirred at rt 
for 96 h. The reaction was quenched with HCl (aq) (1 M, 20 mL) and extracted with ethyl 
acetate (50 mL). The organic layer was separated, washed with brine, dried over MgSO4, 
filtered and concentrated under reduced pressure. The residue was purified by silica flash 
chromatography, eluting with petroleum ether to 10% ethyl acetate to provide the title 
compound as a yellow gum. (0.021 g, 28%) IR (neat, vmax) cm-1 3360, 2928, 2850, 2222, 1601, 
1473, 1461, 1163. 1H NMR (500 MHz, CDCl3) δH 7.31 (s, 1H, CH-4), 6.08 (s, 1H, OH-10), 2.64 
(t, J = 7.7 Hz, 2H, CH2-11), 2.56 (s, 3H, CH3-7), 1.59 (m, 2H, CH2-12), 1.45-1.20 (m, 10H, CH2-
13/14/15/16/17) 0.91 (t, J = 7.2 Hz, 3H, CH3-18). 13C NMR (126 MHz, CDCl3) δC 153.0 (C2), 
138.2 (C6), 132.2 (CH-4), 128.9 (C3), 121.0 (C8), 118.0 (C1), 110.0 (C5), 31.8 (CH2-16), 29.9 
(CH2-11), 29.3 (CH2-12/13/14/15), 29.3 (CH2-12/13/14/15), 29.2 (CH2-12/13/14/15), 29.1 
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(CH2-12/13/14/15), 22.6 (CH2-17), 18.7 (CH2-7), 14.0 (CH3-18). HRMS (ESI-) m/z [M-H]- 
calculated for C16H2135ClNO 278.1317, found 278.1303. LCMS MDAP, Method 4, tR 26.76 min, 
(>95%), [M-H]- 278.1 m/z. 
5-Bromo-3-chloro-4-hydroxy-benzonitrile (92) 
 
Triethylamine (0.83 mL, 5.97 mmol) was added to a solution of 5-bromo-2-methyl-4-
hydroxybenzonitrile (85) (1.15 g, 5.42 mmol) in acetonitrile (50 mL). 1-chloropyrorolidine-
2,5-dione (1.52 g, 11.38 mmol) was added portion wise to the stirring solution. The reaction 
mixture was added water precipitating a pale-yellow solid, that was collected by filtration to 
provide the title compound (1.11 g, 83%) that was used without further purification. m.p. 
166.0-168.7 °C. IR (neat, vmax) cm-1 3239, 2236, 1581, 1468, 1384, 1294, 1224. 1H NMR 
(500MHz, CDCl3) δH 7.70 (s, 1H, CH-4), 6.39 (s, 1H, OH-10), 2.58 (s, 3H, CH3-7). 13C NMR (126 
MHz, CDCl3) δC 152.5 (C2), 140.9 (C6), 134.4 (CH-4), 122.1 (CH-1), 116.4 (C8), 107.5 (CH-3), 
106.9 (C5), 19.0 (CH3-7). HRMS-ESI m/z [M-H]- calculated for C8H479Br35ClNO 243.9170, found 
243.9165. LCMS - Analytical MDAP 5-95% MeCN:Water (0.1% Formic), tR 18.99 min, [M-H]- 
245.7 m/z (89%) 
3-Bromo-5-chloro-4-hydroxybenzonitrile (94) 
 
N-bromosuccinimide (0.30 g, 1.71 mmol) was added to a solution of 3-chloro-4-
hydroxybenzonitrile (93) (0.25 g, 1.63 mmol) in acetonitrile (5 mL). The reaction mixture was 
added water (15 mL), precipitating a white solid, this was collected by filtration and dried 
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under reduced pressure to provide the title compound as a white solid (0.36 g, 84%). m.p. 
165.9-169.2 °C. IR (neat, vmax) cm-1 3411, 2229, 1471, 1327, 1294, 1245, 1204. 1H NMR 
(500MHz, CDCl3) δH 7.75 (s, 1H, CH-4/6), 7.64 (s, 1H, CH-4/6), 6.37 (s, 1H, OH-8). 13C NMR 
(126 MHz, CDCl3) δC 152.8 (C2), 135.0 (CH-4/6), 132.6 (CH-4/6), 121.7 (C1), 116.3 (C7), 110.9 
(C3), 106.1 (C5). HRMS-ESI m/z [M-H]- calculated for C7H279Br35ClNO 229.9014, found 
231.8984. LCMS - Analytical MDAP 5-95% MeCN:Water (0.1% Formic), tR 18.07 min, [M-H] 
231.9 m/z (> 95%). 
3-Chloro-4-hydroxy-2-methyl-5-oct-1-enylbenzonitrile (95) 
 
A stirring suspension of chloro[(1,3-dimesitylimidazol-2-ylidene)(n,n-
dimethylbenzylamine)palladium(II)] (0.03 g, 0.05 mmol), potassium carbonate (0.39 g, 2.83 
mmol), 4-hydroxy-2-methyl-5-octyl-benzonitrile (92) (0.20 g, 0.94 mmol) and 1-octene (1.06 
g, 9.43 mmol) in N-methyl-2-pyrrolidinone (10 mL) was heated in a sealed vial at 110 °C for 
16 h. The reaction mixture was cooled to rt, diluted with ethyl acetate (50 mL), washed with 
HCl (aq) (1 M, 20 mL), LiCl (aq) (0.5 M, 10 mL) and brine (25 mL). The organic phase was 
separated, dried over MgSO4, filtered and concentrated under reduced pressure. The residue 
was purified by mass directed prep Shimadzu 0-95% MeCN in water (0.1% formic acid) title 
compound as a clear oil (0.008 g, 7%): IR (neat, vmax) cm-1 3321, 2917, 2851, 2228, 1596, 
1468, 1416. 1H NMR (500 MHz, CDCl3) δH 7.56 (s, 1H, CH-4), 6.55 (d, J = 16.1 Hz, 1H, CH-11), 
6.30 (dt, J = 16.1 Hz, 7.0 Hz, 1H, CH-12), 6.20 (s, 1H, OH-10), 2.57 (s, 3H, CH3-7), 2.25 (dt, J = 
7.0 Hz, 7.4 Hz, 2H, CH2-13), 1.49 (m, 2H, CH2-14), 1.42-1.24 (m, 6H, CH2-15/16/17), 0.91 (m, 
3H, CH3-18). 13C NMR (126MHz, CDCl3) δC 151.5 (C2), 138.2 (C6), 135.2 (CH-12), 129.0 (CH-
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4), 124.8 (C3), 122.0 (CH-11), 121.6 (C1), 117.8 (C8), 105.6 (C5), 33.3 (CH2-13), 31.7 (CH2-16), 
29.7 (CH2-14/15), 29.1 (CH2-14/15), 22.6 (CH2-17), 18.8 (CH2-7), 14.1 (CH3-18). HRMS (ESI-) 
m/z [M-H]- calculated for C16H1935ClNO 276.1161, found 276.1152. LCMS MDAP, Method 4, 
tR 26.40 min, (>95%), [M-H]- 276.1 m/z. 
5-Bromo-3-chloro-4-methoxy-benzonitrile (96) 
 
Dimethyl sulphate (0.85 mL, 8.95 mmol) was added to a suspension of 5-bromo-3-chloro-4-
hydroxy-benzonitrile (92) (2.10 g, 8.52 mmol), and potassium carbonate (1.41 g, 10.22 mmol) 
in acetone (80 mL). The reaction mixture was heated to reflux for 3 h, the reaction was cooled 
to rt and added water (160 mL) precipitating a white solid that was collected by filtration to 
give the title compound (2.07 g, 93%). m.p. 118.5-119.8 °C. IR (neat, vmax) cm-1 2229, 1457, 
1372, 1275, 1048, 946. 1H NMR (500 MHz, CDCl3) δ 7.74 (s, 1H, CH-4), 3.94 (s, 3H, CH3-12), 
2.58 (s, 3H, CH3-7). 13C NMR (126 MHz, CDCl3) δC 157.4 (C2), 141.7 (C6), 134.9 (CH-4), 131.3 
(C1), 116.3 (C3), 116.0 (C8), 111.0 (C5), 61.0 (CH3-12), 19.2 (CH3-7). HRMS-ESI m/z no 
ionisation observed with +ve or -ve ion mode LRMS only EI+ 261 m/z. LCMS - Analytical MDAP 
50-95% MeCN:Water (0.1% Formic), tR 15.41 min, [M+H]+ - poor ionisation (>95%). 
3-Bromo-5-chloro-4-methoxybenzonitrile (97) 
 
Dimethyl sulphate (0.15 mL, 1.61 mmol) was added to a suspension of potassium carbonate 
(0.22 g, 1.61 mmol) and 3-bromo-5-chloro-4-hydroxy-benzonitrile (94) (0.30 g, 1.29 mmol) 
in acetone (10 mL). The reaction mixture was heated to reflux for 30 min, cooled to rt and 
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added water (20 mL). The resulting precipitate was collected by filtration and dried under 
reduced pressure to provide the title compound as a white solid (0.29 g, 90%). m.p. 
114.7-116.1 °C. IR (neat, vmax) cm-1 2236, 1539, 1470, 1419, 1272. 1H NMR (500MHz, CDCl3) 
δH 7.78 (s, 1H, CH-4/6), 7.66 (s, 1H, CH-4/6), 3.97 (s, 3H, CH3-12). 13C NMR (126 MHz, CDCl3) 
δC 157.6 (C2), 135.4 (CH-4/6), 133.2 (CH-4/6), 130.4 (C1), 119.5 (C3), 116.0 (C9), 109.9 (C5), 
61.0 (CH3-12). HRMS-ESI m/z [M-H]- calculated for C8H579Br35ClNO 243.9170, found 243.9165. 
LCMS - Analytical MDAP 5-95% MeCN:Water (0.1% Formic), tR 20.90 min, [M+H]+ - no 
ionisation, (>95%). 
3-Chloro-4-methoxy-2-methyl-5-octylbenzonitrile (98) 
 
1-Octene (0.6 mL, 3.84 mmol) was dropwise added to an ice cooled solution of 1 M borane 
in THF (1.44 mL, 1.44 mmol). This solution was warmed to rt and stirred for 15 min. The 
solution was quenched with the addition of water (0.5 mL) and diluted with toluene (2.5 mL). 
Potassium phosphate tribasic (0.44 g, 1.92 mmol), 5-bromo-3-chloro-4-methoxy-2-methyl-
benzonitrile (96) (0.25 g, 0.96 mmol), palladium (II) acetate (0.02 g, 0.02 mmol) and 2-
dicyclohexylphosphino-2’-6’-diisopropoxybiphenyl (0.02 g, 0.05 mmol) were added. The 
reaction mixture stirred at 50 °C for 16 h. The reaction mixture was partitioned between 
water (10 mL) and ethyl acetate (20 mL). The organic layer was separated, dried over MgSO4, 
filtered and concentrated under reduced pressure. The residue was purified by flash silica 
chromatography, eluting with petroleum ether to 10% ethyl acetate followed by purification 
by reverse-phase chromatography 75% MeCN in water to 100% MeCN to provide the title 
compound as a colourless oil, that solidified upon standing (0.18 g, 60%). m.p. 53.9 – 55.2 °C. 
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IR (neat, vmax) cm-1 2913, 2849, 2226, 1468, 1291. 1H NMR (500 MHz, CDCl3) δH 7.36 (s, 1H, 
CH-4), 3.87 (s, 3H, CH3-20), 2.62 (t, J = 7.9 Hz, 2H, CH2-13), 2.57 (s, 3H, CH3-7), 1.61-1.55 (m, 
2H, CH2-14), 1.36-1.27 (m, 10H, CH2s 15-19), 0.89 (t, J = 6.8 Hz, 3H, CH3-20). 13C NMR (126 
MHz, CDCl3) δC 158.2 (C2), 139.4 (C6), 136.3 (C3), 132.0 (CH-4), 129.7 (C1), 117.7 (C11), 109.4 
(C5), 60.9 (CH3-20), 31.8 (CH2-17), 30.2 (CH2-12), 29.7 (CH2-13), 29.4 (CH2 14/15/16), 29.3 
(CH2 14/15/16), 29.1 (CH2 14/15/16), 22.6 (CH2 18), 18.8 (CH3-7), 14.0 (CH3-19). HRMS-ESI 
m/z no ionisation observed with +ve or -ve ion mode LRMS only EI+ 293 m/z. LCMS - Analytical 
MDAP 70-95% MeCN:Water (0.1% Formic), tR 26.07 min, [M+H]+ no ionisation (>95%). 
5-Chloro-4-methoxy-5-octylbenzonitrile (99) 
 
1-Octene (0.40 mL, 2.54 mmol) was dropwise added to an ice cooled solution of 1 M borane 
in THF (0.91 mL, 0.91 mmol). This solution was warmed to rt and stirred for 15 min. The 
solution was quenched with the addition of water (0. 5 mL) and diluted with toluene (2.5 mL). 
Potassium phosphate tribasic (0.43 g, 2.03 mmol), 5-bromo-3-chloro-4-methoxy-
benzonitrile (97) (0.25 g, 1.01 mmol), palladium (II) acetate (0.02 g, 0.03 mmol) and 2-
dicyclohexylphosphino-2’-6’-diisopropoxybiphenyl (0.02 g, 0.05 mmol) were added. The 
reaction mixture sealed and heated 100 °C for 16 h. The reaction mixture was partitioned 
between water (10 mL) and ethyl acetate (20 mL). The organic layer was separated, dried 
over MgSO4, filtered and concentrated under vacuum. The residue was purified by flash silica 
chromatography, eluting with petroleum ether to 10% ethyl acetate followed by purification 
by reverse-phase chromatography 75% MeCN in water to 100% MeCN to provide the title 
compound as a pale brown oil, that solidified upon standing (0.03 g, 11%). m.p. 55.8-58.2 °C. 
IR (neat, vmax) cm-1 2925, 2854, 2232, 1470, 1426, 1275. 1H NMR (500 MHz, CDCl3) δH 7.53 
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(s, 1H, CH-6), 7.40 (s, 1H, CH-4), 3.90 (s, 3H, CH3-19), 2.66 (t, J = 7.9 Hz, 2H, CH2-11), 1.60 (m, 
2H, CH2-12), 1.40 – 1.26 (m, 10H, CH2s-13/1/15/16/17), 0.90 (t, J = 6.8 Hz, 3H, CH3-18). 13C 
NMR (126 MHz, CDCl3) δC 158.2 (C2), 139.7 (C3), 132.4 (CH-4), 131.7 (CH-6), 128.9 (C1), 117.7 
(C7), 108.5 (C5), 61.1 (CH3-19), 31.8 (CH2-16), 30.2 (CH2-12), 30.0 (CH2-11), 29.4 (CH2-
13/14/15), 29.3 (CH2-13/14/15), 29.1 (CH2-13/14/15), 22.6 (CH2-17), 14.0 (CH3-18). HRMS-
ESI m/z [M-H]- calculated for C15H1935ClNO 264.1161, found 264.1153. LCMS - Analytical 
MDAP 5-95% MeCN:Water (0.1% Formic), tR 28.59 min, [M+H]+ no ionisation (94%). 
5-Chloro-4-hydrox-5-octylbenzonitrile (100) 
 
Chlorotrimethyl silane (0.25 mL, 2.00 mmol) was added to a suspension of sodium iodide 
(0.30 g, 2.00 mmol) and 3-chloro-4-methoxy-5-octyl-benzonitrile (0.14 g, 0.50 mmol) in 
acetonitrile (2 mL). The reaction mixture was sealed and heated at 80 °C for 16 h. The 
reaction mixture was partitioned between HCl (aq) (1 M, 20 mL) and ethyl acetate, the 
organics were separated, washed with sodium thiosulfate (aq) (0.1 M, 5 mL), brine (5 mL), 
dried over MgSO4, filtered and concentrated under reduced pressure. The residue was 
purified by reverse-phase chromatography, eluting with water to MeOH, to provide the 
desired product as a pale tan solid (0.060 g, 42%). m.p. 60.1 – 61.8 °C. IR (neat, vmax) cm-1 
3362, 2927, 2849, 2230, 1595, 1471, 1316, 1241, 1168. 1H NMR (500 MHz, CDCl3) δH 7.49 (s, 
1H, CH-6), 7.34 (s, 1H, CH-4), 6.07 (s, 1H, OH-9), 2.66 (m, 2H, CH2-11), 1.59 (m, 2H, CH2-12), 
1.49-1.17 (m, 10H, CH2-13/14//15/16/17), 0.88 (m, 3H, CH3-18). 13C NMR (126 MHz, CDCl3) 
δC 153.4 (C2), 132.9 (C4), 132.2 (CH-1), 130.4 (CH-6), 120.5 (C3), 118.2 (C7), 104.6 (C5), 32.0 
(CH2-16), 30.3 (CH2-11), 29.5 (CH2-13/14/15), 29.5 (CH2-13/14/15), 29.4 (CH2-4), 29.2 (CH2-
13/14/15), 22.8 (CH2, 17), 14.3 (CH3-18). HRMS-ESI m/z [M-H]- calculated for C15H1935ClNO 
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264.1161, found 264.1151. LCMS - Analytical MDAP 50-95% MeCN:Water (0.1% Formic), tR 
21.67 min, [M-H]- 265.0 m/z (> 95%). 
Methyl 4-(3-chloro-5-cyano-2-methoxy-phenyl)butanoate (101) 
 
A solution of 1 M borane in THF (3.04 mL, 3.04 mmol) was added dropwise to a 40% solution 
methyl but-3-enoate in diethyl ether (2.03 g, 8.11 mmol) at 0 °C. This solution was warmed 
to rt and stirred for 15 min. The solution was quenched with the addition of water (1 mL) and 
diluted with toluene (5 mL). Potassium phosphate tribasic (1.17 g, 5.07 mmol), 5-bromo-3-
chloro-4-methoxy-benzonitrile (97) (0.50 g, 2.03 mmol), palladium (II) acetate (0.05 g, 
0.05 mmol) and 2-dicyclohexylphosphino-2’-6’-diisopropoxybiphenyl (0.05 g, 0.10 mmol) 
were added. The reaction mixture was sealed and heated to 50° C for 16 h. The cooled 
reaction mixture was filtered through a pad of celite, the filtrate partitioned between water 
(10 mL) and ethyl acetate (20 mL). The organic layer was separated, dried over MgSO4, 
filtered and concentrated under reduced pressure. The residue was purified by flash silica 
chromatography, eluting with petroleum ether to 15% ethyl acetate followed by purification 
by preparative HPLC 75% MeCN in water to 100% MeCN to provide the title compound as a 
light-yellow oil (0.330 g, 54%). IR (neat, vmax) cm-1 2952, 2231, 1732, 1427, 1276. 1H NMR 
(500 MHz, CDCl3) δH 7.55 (d, J = 2.1 Hz, 1H, CH-4/6), 7.40 (d, J = 2.1 Hz, 1H, CH 4/6), 3.90 (s, 
3H, CH3-11/18), 3.68 (s, 3H, CH3-11/18), 2.70 (t, J = 7.7 Hz, 2H, CH2-12/14), 2.36 (t, J = 7.3 Hz, 
2H, CH2-12/14), 1.92 (m, 2H, CH2-13).13C NMR (126 MHz, CDCl3) δC 158.2 (C2), 139.7 (C3), 
132.4 (CH-4), 131.7 (CH-6), 128.9 (C1), 117.7 (C7), 108.5 (C5), 61.1 (CH3-19), 31.8 (CH2-16), 
30.2 (CH2-12), 30.0 (CH2-11), 29.4 (CH2-13/14/15), 29.3 (CH2-13/14/15), 29.1 (CH2-13/14/15), 
22.6 (CH2-17), 14.0 (CH3-18). HRMS-ESI m/z no ionisation observed with +ve or -ve ion mode 
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LRMS only EI+ 267 m/z. LCMS - Analytical MDAP 30-95% MeCN:Water (0.1% Formic), tR 
18.30 min, [M+H]+ no ionisation (94%). 
Methyl 5-(3-chloro-5-cyano-2-methoxy-phenyl)pentanoate (102) 
 
A solution of 1 M borane in THF (3.04 mL, 3.04 mmol) was added dropwise to a 31% solution 
methyl but-3-enoate in diethyl ether (2.99 g, 8.11 mmol) at 0 °C. This solution was warmed 
to rt and stirred for 15 min. The solution was quenched with the addition of water (1 mL) and 
diluted with toluene (5 mL). Potassium phosphate tribasic (1.17 g, 5.07 mmol), 5-bromo-3-
chloro-4-methoxy-benzonitrile (97) (0.50 g, 2.03 mmol), palladium (II) acetate (0.05 g, 0.05 
mmol) and 2-dicyclohexylphosphino-2’-6’-diisopropoxybiphenyl (0.05 g, 0.10 mmol) were 
added. The reaction mixture was sealed and heated 50 °C for 16 h. The cooled reaction 
mixture was filtered through a pad of celite, the filtrate partitioned between water (10 mL) 
and ethyl acetate (20 mL). The organic layer was separated, dried over MgSO4, filtered and 
concentrated under vacuum. The residue was purified by flash silica chromatography, eluting 
with petroleum ether to 15% ethyl acetate followed by purification by preparative HPLC 75% 
MeCN in water to 100% MeCN to provide the title compound as a light-yellow oil (0.460 g, 
80%). IR (neat, vmax) cm-1 2951, 2233, 1733, 1472, 1275. 1H NMR (500 MHz, CDCl3) δH 7.53 
(s, 1H, CH-6/4), 7.38 (s, 1H, CH-6/4), 3.89 (s, 3H, CH3-9/19), 3.67 (s, 3H, CH3-9/19), 2.67 (m, 
2H, CH2-12/15), 2.35 (m, 2H, CH2-12/15), 1.65 (m, 4H, CH2-13/14). 13C NMR (126 MHz, CDCl3) 
δ 173.8 (C16), 158.2 (C2), 139.9 (C3), 132.4 (C6/4), 132.0 (C6/4), 128.9 (C1), 117.6 (C10), 
108.5 (C5), 61.1 (CH3-9), 51.6 (CH3-19), 33.7 (CH2-15), 29.7 (CH2-12/13), 29.5 (CH2-12/13), 
24.6 (CH2-14). HRMS-ESI m/z no ionisation observed with +ve or -ve ion mode LRMS only EI+ 
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281 m/z. LCMS - Analytical MDAP 30-95% MeCN:Water (0.1% Formic), tR 19.60 min, [M+H]+ 
no ionisation (95%). 
Methyl 6-(3-chloro-5-cyano-2-methoxy-phenyl)hexanoate (103) 
 
A solution of 1 M borane in THF (3.04 mL, 3.04 mmol) was added dropwise to methyl hex-5-
enoate (1.04 g, 8.11 mmol) at 0 °C. This solution was warmed to RT and stirred for 15 min. 
The solution was quenched with the addition of water (1 mL) and diluted with toluene (5 mL). 
Potassium phosphate tribasic (1.17 g, 5.07 mmol), 5-bromo-3-chloro-4-methoxy-
benzonitrile (97) (0.50 g, 2.03 mmol), palladium (II) acetate (0.05 g, 0.05 mmol) and 2-
dicyclohexylphosphino-2’-6’-diisopropoxybiphenyl (0.05 g, 0.10 mmol) were added. The 
reaction mixture was sealed and heated 50 °C for 16 h. The cooled reaction mixture was 
filtered through a pad of celite, the filtrate partitioned between water (10 mL) and ethyl 
acetate (20 mL). The organic layer was separated, dried over MgSO4, filtered and 
concentrated under vacuum. The residue was purified by flash silica chromatography, eluting 
with petroleum ether to 15% ethyl acetate to provide the title compound as a light-yellow 
oil (0.470 g, 78%). IR (neat, vmax) cm-1 2948, 2232, 1733, 1472, 1275. 1H NMR (500 MHz, 
CDCl3) δH 7.53 (s, 1H, CH-6/4), 7.38 (s, 1H, CH-6/4), 3.89 (s, 3H, CH3-9), 3.67 (s, 3H, CH3-20), 
2.65 (m, 2H, CH2-12), 2.32 (m, 2H, CH2-16), 1.70-1.57 (m, 4H, CH2s 13/15), 1.39 (m, CH2-14). 
13C NMR (126 MHz, CDCl3) δc 174.0 (C20), 158.2 (C2), 139.2 (C3), 132.4 (CH-6/4), 131.9 (CH-
6/4), 128.9 (C1), 117.7 (C10), 108.5 (C5), 61.1 (CH3-9), 51.5 (CH3-20), 33.83 (CH2-16), 29.82 
(CH2-12/13/14), 29.80 (CH2-12/13/14), 28.8 (CH2-12/13/14), 24.6 (CH2-15). HRMS-ESI m/z no 
ionisation observed with +ve or -ve ion mode LRMS only EI+ 295 m/z. LCMS - Analytical MDAP 
30-95% MeCN:Water (0.1% Formic), tR 20.99 min, [M+H]+ no mass ion (85%). 
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Methyl 7-(3-chloro-5-cyano-2-methoxy-phenyl)heptanoate (104) 
 
A solution of 1 M borane in THF (3.04 mL, 3.04 mmol) was added dropwise to methyl hept-
6-enoate (1.15 g, 8.11 mmol) at 0 °C. This solution was warmed to rt and stirred for 15 min. 
The solution was quenched with the addition of water (1 mL) and diluted with toluene (5 mL). 
Potassium phosphate tribasic (1.17 g, 5.07 mmol), 5-bromo-3-chloro-4-methoxy-
benzonitrile (97) (0.50 g, 2.03 mmol), palladium (II) acetate (0.05 g, 0.05 mmol) and 2-
dicyclohexylphosphino-2’-6’-diisopropoxybiphenyl (0.05 g, 0.10 mmol) were added. The 
reaction mixture was sealed and heated 50 °C for 16 h. The cooled reaction mixture was 
filtered through a pad of celite, the filtrate partitioned between water (10 mL) and ethyl 
acetate (20 mL). The organic layer was separated, dried over MgSO4, filtered and 
concentrated under vacuum. The residue was purified by flash silica chromatography, eluting 
with petroleum ether to 15% ethyl acetate to provide the title compound as a light-yellow 
oil (0.360 g, 58%). IR (neat, vmax) cm-1 2933, 2232, 1734, 1472, 1276. 1H NMR (500 MHz, 
CDCl3) δH 7.52 (s, 1H, CH-6/4), 7.38 (s, 1H, CH-6/4), 3.88 (s, 3H, CH3-9), 3.66 (s, 3H, CH3-21), 
2.64 (m, 2H, CH2-12), 2.31 (m, 2H, CH2-17), 1.66-1.55 (m, 4H, CH2s-13/16), 1.36 (m, 4H, CH2s 
14/15). 13C NMR (126 MHz, CDCl3) δC 174.3 (C19), 158.4 (C2), 139.6 (C3), 132.6 (CH-6/4), 
132.0 (CH6/4), 129.1 (C1), 117.9 (C10), 108.6 (C5), 61.3 (CH3-9), 51.7 (CH3-21), 34.1 (CH2-17), 
30.14 (CH2-12/13/14/15), 30.08 (CH2-12/13/14/15), 29.2 (CH2-12/13/14/15), 29.0 (CH2-
12/13/14/15), 24.9 (CH2-16). HRMS-ESI m/z [M+Na]+ calculated for C16H2035ClNNaO3 
332.1024, found 332.1019. LCMS - Analytical MDAP 30-95% MeCN:Water (0.1% Formic), tR 
22.46 min, [M+H]+ 310.1 m/z (86%). 
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4-(3-Chloro-5-cyano-2-hydroxy-phenyl)butanoic acid (105) 
 
Sodium iodide (1.12 g, 7.47 mmol) was added to a solution of methyl 4-(3-chloro-5-cyano-2-
methoxy-phenyl)butanoate (101) (0.25 g, 0.93 mmol) and chloro(trimethyl)silane (0.95 mL, 
7.47 mmol) in acetonitrile (5 mL). The reaction mixture was sealed and heated to 80 °C for 
96 h. The cooled reaction mixture was partitioned between sodium thiosulfate (aq) (1 M, 
10 mL) and ethyl acetate (2 x 20 mL). The organic layer was separated, dried over MgSO4, 
filtered and concentrated under reduced pressure. The residue was purified by flash silica 
chromatography, eluting with petroleum ether to ethyl acetate to provide the title 
compound as a colourless waxy solid (0.030 g, 14%). IR (neat, vmax) cm-1 3345, 2569, 2228, 
1691, 1474, 1253. 1H NMR (500 MHz, CDCl3) δH 12.06 (br s, 1H, COOH-15), 10.43 (br s, 1H, 
OH-7), 7.81 (d, J = 2.0 Hz, 1H, CH-6), 7.51 (d, J = 2.0 Hz, 1H, CH-4), 2.61 (t, J = 7.5 Hz, 2H, CH2-
11), 2.19 (t, J = 7.5 Hz, 2H, CH2-13), 1.73 (quintet, J = 7.5 Hz, 2H, CH2-12). 13C NMR (126 MHz, 
CDCl3) δC 174.6 (C14), 155.6 (C2), 133.1 (CH-4), 132.4 (C3), 131.9 (CH-6), 121.6 (C1), 118.7 
(C9), 102.8 (C5), 33.6 (CH2-13), 29.5 (CH2-11), 24.5 (CH2-12). HRMS-ESI m/z [M-H]- calculated 
for C11H935ClNO3 238.0276, found 238.0266. LCMS - Analytical MDAP 30-95% MeCN:Water 
(0.1% Formic), tR 11.53 min, [M-H]- 238.1 m/z (95%). 
213 
5-(3-Chloro-5-cyano-2-hydroxy-phenyl)pentanoic acid (106) 
 
Sodium iodide (1.28 g, 8.52 mmol) was added to a solution of methyl 5-(3-chloro-5-cyano-2-
methoxy-phenyl)pentanoate (102) (0.30 g, 1.06 mmol) and chloro(trimethyl)silane (1.08 mL, 
8.52 mmol) in acetonitrile (5 mL). The reaction mixture was sealed and heated to 80 °C for 
96 h. The cooled reaction mixture was partitioned between sodium thiosulfate (aq) (1 M, 10 
mL) and ethyl acetate (2 x 20 mL). The organic layer was separated, dried over MgSO4, 
filtered and concentrated under reduced pressure. The residue was purified by flash silica 
chromatography, eluting with petroleum ether to ethyl acetate to provide the title 
compound as a colourless waxy solid (0.070 g, 27%). IR (neat, vmax) cm-1 3093, 2867, 2243, 
1723, 1471. 1H NMR (500 MHz, CDCl3) δH 11.98 (br s, 1H, COOH-16), 10.40 (br s, 1H, OH-7), 
7.78 (d, J = 2.0 Hz, 1H, CH-6), 7.53 (d, J = 2.0 Hz, 1H, CH-4), 2.59 (t, J = 7.2 Hz, 2H, CH2-11), 
2.20 (m, 2H, CH2-14), 1.49 (m, 4H, CH2s-12/13). 13C NMR (126 MHz, CDCl3) δC 174.8 (C15), 
155.6 (C2), 133.8 (C4), 133.0 (C3), 131.8 (C6), 121.5 (C1), 118.8 (C9), 102.7 (C5), 33.9 (CH2-
14), 29.8 (CH2-11), 28.7 (CH2-12), 24.5 (CH2-13). HRMS-ESI m/z [M-H]- calculated for 
C12H1135ClNO3 252.0433, found 252.0423. LCMS - Analytical MDAP 30-95% MeCN:Water 
(0.1% Formic), tR 11.53 min, [M-H]- 238.1 m/z (94%). 
214 
6-(3-Chloro-5-cyano-2-hydroxy-phenyl)hexanoic acid (107) 
 
Sodium iodide (1.22 g, 8.11 mmol) was added to a solution of methyl 6-(3-chloro-5-cyano-2-
methoxy-phenyl)hexanoate (103) (0.30 g, 1.01 mmol) and chloro(trimethyl)silane (1.03 mL, 
8.11 mmol) in acetonitrile (5 mL). The reaction mixture was sealed and heated to 80 °C for 
96 h. The cooled reaction mixture was partitioned between sodium thiosulfate (aq) (1 M, 
10 mL) and ethyl acetate (2 x 20 mL). The organic layer was separated, dried over MgSO4, 
filtered and concentrated under reduced pressure. The residue was purified by flash silica 
chromatography, eluting with petroleum ether to ethyl acetate to provide the title 
compound as a colourless waxy solid (0.070 g, 28%). IR (neat, vmax) cm-1 3365, 2943, 2230, 
1699, 1172. 1H NMR (500 MHz, CDCl3) δH 11.97 (br s, 1H, COOH-17), 10.37 (br s, 1H, OH-7), 
7.77 (d, J = 2.0 Hz, 1H, CH-6), 7.53 (d, J = 2.0 Hz, 1H, CH-4), 2.58 (t, J = 7.5 Hz, 2H, CH2-11), 
2.18 (t, J = 7.3 Hz, 2H, CH2-15), 1.49 (m, 4H, CH2s-12/14), 1.27 (m, 2H, CH2-13). 13C NMR (126 
MHz, CDCl3) δC 174.9 (C16), 155.5 (C2), 133.1 (C3), 133.0 (C4), 131.7 (C6), 121.5 (C1), 118.8 
(C9), 102.8 (C5), 34.0 (CH2-15), 30.0 (CH2-11), 29.0 (CH2-12), 28.7 (CH2-13), 24.7 (CH2-14). 
HRMS-ESI m/z [M-H]- calculated for C13H1335ClNO3 266.0589, found 266.0577. LCMS - 
Analytical MDAP 30-95% MeCN:Water (0.1% Formic), tR 13.68 min, [M-H]- 266.2 m/z (93%). 
215 
7-(3-Chloro-5-cyano-2-hydroxy-phenyl)heptanoic acid (108) 
 
Sodium iodide (1.16 g, 7.75 mmol) was added to a solution of methyl 7-(3-chloro-5-cyano-2-
methoxy-phenyl)heptanoate (104) (0.30 g, 0.97 mmol) and chloro(trimethyl)silane (0.98 mL, 
7.75 mmol) in acetonitrile (5 mL). The reaction mixture was sealed and heated to 80 °C for 
96 h. The cooled reaction mixture was partitioned between sodium thiosulfate (aq) (1 M, 10 
mL) and ethyl acetate (2 x 20 mL). The organic layer was separated, dried over MgSO4, 
filtered and concentrated under reduced pressure. The residue was purified by flash silica 
chromatography, eluting with petroleum ether to ethyl acetate to provide the title 
compound as a colourless waxy solid (0.070 g, 26%). IR (neat, vmax) cm-1 3401, 2926, 2227, 
1699, 1473, 1160, 1113. 1H NMR (500 MHz, CDCl3) δH 11.96 (br s, 1H, COOH-18), 10.36 (br s, 
1H, OH-7), 7.77 (d, J = 2.0 Hz, 1H, CH-6), 7.52 (d, J = 2.0 Hz, 1H, CH-4), 2.57 (t, J = 7.6 Hz, 2H, 
CH2-11), 2.18 (t, J = 7.4 Hz, 2H, CH2-16), 1.49 (m, 4H, CH2s-12/15), 1.26 (m, 4H, CH2s-13/14). 
13C NMR (126 MHz, CDCl3) δC 174.9 (C16), 155.5 (C2), 133.2 (C3), 133.0 (C4), 131.7 (C6), 
121.5 (C1), 118.8 (C9), 102.8 (C5), 34.0 (CH2-16), 30.1 (CH2-11), 29.1 (CH2-12), 28.9 (CH2-13), 
28.8 (CH2-14), 24.8 (CH2-15). HRMS-ESI m/z [M-H]- calculated for C14H1535ClNO3 280.0746, 
found 280.0731. LCMS - Analytical MDAP 30-95% MeCN:Water (0.1% Formic), tR 14.92 min, 
[M-H]- 280.2 m/z (95%). 
216 
4-(3-Chloro-5-cyano-2-hydroxy-phenyl)-N-propyl-butanamide (109) 
 
Triethylamine (0.07 mL, 0.52 mmol) was added to a solution of 4-(3-chloro-5-cyano-2-
methoxy-phenyl)butanoic acid (105) (0.05 g, 0.21 mmol), HATU (0.09 g, 0.23 mmol), and 
propylamine (0.03 mL, 0.31 mmol) in acetonitrile (0.5 mL). The reaction was stirred at rt for 
16 h. The reaction mixture was partitioned between ethyl acetate (0.25 mL) and water (0.25 
mL). The organic layer was separated, washed with brine, dried over MgSO4, filtered and 
concentrated under reduced pressure. The residue was purified by flash silica 
chromatography eluting with petroleum ether to ethyl acetate, then further purified by 
reverse-phase chromatography eluting with water to MeOH to provide the title compound 
as a colourless oil, that solidified upon standing (0.020 g, 29%). m.p. 117-119 °C.  IR (neat, 
vmax) cm-1 2933, 2225, 1727, 1601, 1469, 1289. 1H NMR - (500MHz, CDCl3) δH 10.73 (br s, 
1H, OH-9), 7.95 (br t, 1H, NH-16), 7.73 (s, 1H, CH-6), 7.45 (s, 1H, CH-4), 2.97, (m, 2H, CH2-17), 
2.56 (t, J = 7.4 Hz, 2H, CH2-12), 2.04 (t, J = 7.4 Hz, 2H, CH2-14), 1.71 (m, 2H, CH2-13), 1.37 (m, 
2H, CH2-18), 0.81 (t, J = 7.4 Hz, 3H, CH3-19). 13C NMR - (126 MHz, CDCl3) δC 172.0 (C15), 155.4 
(C2), 132.8 (CH-4), 131.9 (C3), 131.4 (CH-6), 121.2 (C1), 118.3 (C8), 102.12 (C5), 40.3 (CH2-
17), 34.3 (CH2-14), 29.1 (CH2-12), 25.0 (CH2-13), 22.3 (CH2-18), 11.4 (CH3-19). HRMS-ESI m/z 
[M+Na]+ calculated for C19H2835ClN3NaO2 303.0871, found 303.0879. LCMS - Analytical MDAP 
30-95% MeCN:Water (0.1% Formic), tR 14.48 min, [M-H]- 281.0 (95%). 
217 
5-(3-Chloro-5-cyano-2-hydroxy-phenyl)-N-ethyl-pentanamide (110) 
 
Triethylamine (0.07 mL, 0.49 mmol) was added to a solution of 5-(3-chloro-5-cyano-2-
hydroxy-phenyl)pentanoic acid (106) (0.05 g, 0.2 mmol), HATU (0.08 g, 0.22 mmol), and 
2 M ethylamine solution in THF (0.02 mL, 0.3 mmol) in acetonitrile (0.5 mL). The reaction was 
stirred at rt for 16 h. The reaction mixture was partitioned between ethyl acetate (0.25 mL) 
and water (0.25 mL). The organic layer was separated, brine, dried over MgSO4, filtered and 
concentrated under reduced pressure. The residue was purified by flash silica 
chromatography eluting with petroleum ether to ethyl acetate in petroleum ether, then 
further purified by reverse phase chromatography eluting with water to MeOH to provide 
the title compound as a colourless oil, that solidified upon standing (0.040 g, 67%). m.p. 
113-115 °C. IR (neat, vmax) cm-1 3353, 2945, 2231, 1649, 1560, 1462, 1174. 1H NMR - 
(500MHz, D6-DMSO) δH 10.16 (br 1H, OH-9), 7.76-7.72 (br m, 2H, CH-6/NH-16), 7.49 (s, 1H, 
CH-4), 3.02 (m, 2H, CH2-17), 2.58 (t, J = 6.3 Hz, 2H, CH2-11), 2.02 (t, J = 6.3 Hz, 2H, CH2-14), 
1.45 (m, 4H, CH2-12/13), 0.96 (t, J = 7.2 Hz, 3H, CH3-18). 13C NMR - (126 MHz, D6-DMSO) δC 
172.1 (C15), 156.0 (C2), 133.0 (C4), 132.9 (C3), 131.7 (C6), 121.6 (C1), 118.9 (C9), 102.1 (C5), 
35.7 (CH2-14), 33.6 (CH2-17), 29.9 (CH2-11), 28.9 (CH2-12), 25.4 (CH2-13), 15.2 (CH3-18). 
HRMS-ESI m/z [M+Na]+ calculated for C14H1735ClN2NaO2 303.0871, found 303.0865. LCMS - 
Analytical MDAP 30-95% MeCN:Water (0.1% Formic), tR 12.21 min, [M-H]- 281.0 (95%). 
218 
6-(3-Chloro-5-cyano-2-methoxy-phenyl)-N-methyl-hexanamide (111) 
 
A solution of 2 M methylamine in THF (1.28 mL, 2.57 mmol) was added to a solution of 1,5,7-
triazabicyclo[4.4.0]dec-5-ene (0.10 g, 0.71 mmol) and methyl 6-(3-chloro-5-cyano-2-
methoxy-phenyl)hexanoate (103) (0.19 g, 0.64 mmol) in acetonitrile (5 mL). The reaction was 
stirred at rt for 112 h. The reaction mixture was partitioned between ethyl acetate (25 mL) 
and water (25 mL). The organic layer was separated, washed with brine, dried over MgSO4, 
filtered and concentrated under reduced pressure. The residue was purified by flash silica 
chromatography eluting with petroleum ether to ethyl acetate to provide the title compound 
as a colourless oil, that solidified upon standing (0.15 g, 80%). m.p. 80-81 °C. IR (neat, vmax) 
cm-1 3300, 2938, 2230, 1639, 1557, 1281.  1H NMR - (500MHz, CDCl3) δH 7.52 (d, J = 2.0 Hz, 
1H, CH-6), 7.37 (d, J = 2.0 Hz, 1H, CH-4), 5.44 (br s, 1H, NH-18), 3.88 (s, 3H, CH3-20), 2.80 (d, 
J = 5.0 Hz, 3H, CH3-19), 2.65 (t, J = 7.6 Hz, 2H, CH2-11), 2.17 (t, J = 7.6 Hz, 2H, CH2-15), 1.68 
(m, 2H, CH2-14), 1.59 (m, 2H, CH2-12), 1.37 (m, 2H, CH2-13). 13C NMR - (126 MHz, CDCl3) δC 
173.5 (C16), 158.4 (C2), 139.4 (C3), 132.6 (CH-4), 132.0 (CH-6), 129.1 (C1), 117.8 (C9), 108.6 
(C5), 61.3 (CH3-20), 36.6 (CH2-15), 30.1 (CH2-11/12), 30.0 (CH2-11/12), 29.1 (CH2-13), 26.4 
(CH2-14), 25.5 (CH3-19). HRMS-ESI m/z [M+Na]+ calculated for C15H1935ClN2NaO2 317.1027, 
found 317.1019. LCMS - Analytical MDAP 30-95% MeCN:Water (0.1% Formic), tR 14.72 min, 
[M+H]+ 295.1 (95%). 
219 
7-(3-Chloro-5-cyano-2-methoxy-phenyl)-N-methyl-heptanamide (112) 
 
A solution of 2 M methylamine in THF (0.24 mL, 0.48 mmol) was added to a solution of 1,5,7-
triazabicyclo[4.4.0]dec-5-ene (0.02 g, 0.17 mmol) and methyl 7-(3-chloro-5-cyano-2-
methoxy-phenyl)heptanoate (104) (0.05 g, 0.16 mmol) in acetonitrile (1 mL). The reaction 
was stirred at rt for 16 h. The reaction mixture was partitioned between ethyl acetate (25 mL) 
and water (25 mL). The organic layer was separated, washed with brine, dried over MgSO4, 
filtered and concentrated under reduced pressure. The residue was purified by flash silica 
chromatography eluting with petroleum ether to ethyl acetate to provide the title compound 
as a colourless oil, that solidified upon standing (0.04 g, 82%). m.p. 95-97 °C. IR (neat, vmax) 
cm-1 3307, 2934, 2231, 1638, 1554, 1465, 1273.  1H NMR - (500MHz, CDCl3) δH 7.52 (d, J = 
2.0 Hz, 1H, CH-4), 7.37 (d, J = 2.0 Hz, 1H, CH-6), 5.41 (br s, 1H, NH-19), 3.88 (s, 3H, CH3-11), 
2.80 (d, J = 5.0 Hz, 3H, CH3-20), 2.64 (t, J = 7.9 Hz, 2H, CH2-12), 2.16 (t, J = 7.6 Hz, 2H, CH2-17), 
1.69-1.52 (m, 4H, CH2-13/16), 1.42-1.28 (m, 4H, CH2-14/15). 13C NMR - (126 MHz, CDCl3) δC 
173.5 (C18), 158.2 (C2), 139.4 (C1), 132.4 (C6), 131.8 (C4), 128.9 (C3), 117.7 (C8), 108.4 (C5), 
61.1 (CH3-11), 36.6 (CH2-17), 30.0 (CH2-12/13), 29.9 (CH2-12/13), 29.1 (CH2-14/15), 29.0 
(CH2-14/15), 26.3 (CH3-20), 25.5 (CH2-16). HRMS-ESI m/z [M+Na]+ calculated for 
C16H2135ClN2NaO2 331.1184, found 331.1176. LCMS - Analytical MDAP 30-95% MeCN:Water 
(0.1% Formic), tR 16.12 min, [M+H]+ 309.1 m/z (95%). 
220 
7-(3-Chloro-5-cyano-2-methoxy-phenyl)-N,N-dimethyl-heptanamide (113) 
 
A solution of 2 M dimethylamine in THF (0.24 mL, 0.17 mmol) was added to a solution of 
1,5,7-triazabicyclo[4.4.0]dec-5-ene (0.02 g, 0.17 mmol) and methyl 7-(3-chloro-5-cyano-2-
methoxy-phenyl)heptanoate (104) (0.05 g, 0.16 mmol) in acetonitrile (1 mL). The reaction 
was stirred at rt for 16 h. The reaction mixture was partitioned between ethyl acetate (25 mL) 
and water (25 mL). The organic layer was separated, washed with brine, dried over MgSO4, 
filtered and concentrated under reduced pressure. The residue was purified by flash silica 
chromatography eluting with petroleum ether to ethyl acetate to provide the title compound 
as a colourless oil (0.040 g, 81%). IR (neat, vmax) cm-1 2931, 2232, 1639, 1468, 1404, 
1272.  1H NMR - (500MHz, CDCl3) δH 7.52 (s, 1H, CH-4), 7.37 (s, 1H, CH-6), 3.88 (s, 3H, CH3-11), 
2.99 (s, 3H, CH3-20/21), 2.94 (s, 3H, CH3-20/21), 2.64 (m, 2H, CH2-12), 2.30 (m, 2H, CH2-17), 
1.70-1.53 (m, 4H, CH2-13/16), 1.43-1.32 (m, 4H, CH2-14/15).13C NMR - (126 MHz, CDCl3) δC 
173.0 (C18), 158.2 (C2), 139.5 (C1), 132.4 (C6), 131.8 (C4), 128.9 (C3), 117.7 (C8), 108.4 (C5), 
61.1 (CH3-11), 37.3 (CH3-20/21), 35.4 (CH3-20/21), 33.2 (CH2-17), 30.1 (CH2-12/13), 29.9 
(CH2-12/13), 29.2 (CH2-14/15), 29.2 (CH2-14/15), 25.0 (CH2-16). HRMS-ESI m/z [M+Na]+ 
calculated for C17H2335ClN2NaO2 345.1340, found 345.1339. LCMS - Analytical MDAP 30-95% 
MeCN:Water (0.1% Formic), tR 18.34 min, [M+H]+ 323.1 m/z (95%). 
221 
6-(3-Chloro-5-cyano-2-hydroxy-phenyl)-N-methyl-hexanamide (114) 
 
Sodium iodide (0.31 g, 2.04 mmol) was added to a solution of 6-(3-chloro-5-cyano-2-
methoxy-phenyl)-N-methyl-hexanamide (111) (0.15 g, 0.51 mmol) and 
chloro(trimethyl)silane (0.26 mL, 2.04 mmol) in acetonitrile (2 mL). The reaction mixture was 
sealed and heated to 80 °C for 16 h. The cooled reaction mixture was partitioned between 
sodium thiosulfate (aq) (1 M, 10 mL) and ethyl acetate (2 x 20 mL). The combined organics 
were separated, dried over MgSO4, filtered and concentrated under vacuum. The residue 
was purified by flash silica chromatography, eluting with CH2Cl2 to 5% methanol in CH2Cl2, 
then further purified by reverse phase flash chromatography eluting with water to methanol 
to provide the title compound as a white solid (0.040 g, 27%). m.p. 123-125 °C. IR (neat, 
vmax) cm-1 3395, 2941, 2226, 1638, 1559, 1291, 1271. 1H NMR (500 MHz, D6-DMSO) δH 
10.37 (br s, 1H, OH-7), 7.76 (s, 1H, CH-6), 7.67 (br s, 1H, NH-17), 7.51 (s, 1H, CH-4), 2.56 (t, 
J = 7.14 Hz, 2H, CH2-11), 2.52 (m, 3H, CH3-19), 2.01 (t, J = 7.2 Hz, CH2-15), 1.47 (m, 4H, 
CH2-12/14), 1.22 (m, 2H, CH2-13). 13C NMR (126 MHz, D6-DMSO) δC 172.9 (C16), 155.6 (C2), 
133.2 (C3), 133.0 (CH-4), 131.7 (CH-6), 121.5 (C1), 118.8 (C9), 102.6 (C5), 35.6 (CH2-15), 29.9 
(CH2-11), 29.0 (CH2-12), 28.8 (CH2-13), 25.8 (CH3-19), 25.5 (CH2-14). HRMS-ESI m/z [M+H]+ 
calculated for C14H1735ClN2NaO2 303.0871, found 303.0865. LCMS - Analytical MDAP 30-95% 
MeCN:Water (0.1% Formic), tR 11.92 min, [M+H]+ 281.0 m/z (95%). 
222 
6-(3-Chloro-5-cyano-2-hydroxy-phenyl)-N-methyl-heptanamide (115) 
 
Sodium iodide (0.08 g, 0.52 mmol) was added to a solution of 6-(3-chloro-5-cyano-2-
methoxy-phenyl)-N-methyl-heptanamide (112) (0.04 g, 0.13 mmol) and 
chloro(trimethyl)silane (0.07 mL, 0.52 mmol) in acetonitrile (1 mL). The reaction mixture was 
sealed and heated to 80 °C for 16 h. The cooled reaction mixture was partitioned between 
sodium thiosulfate (aq) (1 M, 10 mL) and ethyl acetate (2 x 20 mL). The combined organics 
were separated, dried over MgSO4, filtered and concentrated under vacuum. The residue 
was purified by flash silica chromatography, eluting with CH2Cl2 to 5% methanol in CH2Cl2, 
then further purified by reverse phase flash chromatography eluting with water to methanol 
to provide the title compound as a colourless oil (0.002 g, 5%). m.p. 123-125 °C. IR (neat, 
vmax) cm-1 3315, 2935, 2227, 1622, 1474, 1168. 1H NMR (500 MHz, MeOD) δH 7.57 (d, J = 
2.0 Hz, 1H, CH-4), 7.40 (d, J = 2.0 Hz, 1H, CH-6), 2.69 (s, 3H, CH3-19), 2.66 (t, J = 7.4 Hz, 2H, 
CH2-11), 2.16 (t, J = 7.6 Hz, 2H, CH2-16), 1.70-1.50 (m, 4H, CH2-12/15), 1.44-1.22 (m, 4H, 
CH2-13/14). 13C NMR (126 MHz, MeOD) δC 172.4 (C17), 155.2 (C2),132.9 (C1), 132.1 (CH-6), 
130.8 (CH-4), 121.0 (C3), 117.8 (C8), 102.8 (C5), 35.5 (CH2-15), 29.8 (CH2-11), 28.8 (CH2-12), 
28.6 (CH2-13), 25.4 (CH3-19), 24.8 (CH2-14). HRMS-ESI m/z [M+H]+ and [M-H]- poor ionisation, 
LRMS only EI+ 294 m/z. LCMS - Analytical MDAP 30-95% MeCN:Water (0.1% Formic), tR 
13.34 min, [M+H]+ 295.1 m/z (95%). 
223 
6-(3-Chloro-5-cyano-2-hydroxy-phenyl)-N,N-dimethyl-heptanamide (116) 
 
Sodium iodide (0.070 g, 0.500 mmol) was added to a solution of 6-(3-chloro-5-cyano-2-
methoxy-phenyl)-N,N-dimethyl-heptanamide (113) (0.040 g, 0.120 mmol) and 
chloro(trimethyl)silane (0.060 mL, 0.500 mmol) in acetonitrile (1 mL). The reaction mixture 
was sealed and heated to 80 °C for 16 h. The cooled reaction mixture was partitioned 
between sodium thiosulfate (aq) (1 M, 10 mL) and ethyl acetate (2 x 20 mL). The combined 
organics were separated, dried over MgSO4, filtered and concentrated under vacuum. The 
residue was purified by flash silica chromatography, eluting with CH2Cl2 to 5% methanol in 
CH2Cl2, then further purified by reverse phase flash chromatography eluting with water to 
methanol to provide the title compound as a colourless oil (0.005 g, 12%). m.p. 105-107 °C. 
IR (neat, vmax) cm-1 2929, 2222, 1625, 1468, 1158. 1H NMR (500 MHz, CDCl3) δH 7.48 (s, 1H, 
CH-4) 7.31 (s, 1H, CH-6), 6.93 (br s, 1H, OH), 3.00 (s, 3H, CH3-20/19), 2.96 (s, 3H, CH3-20/19), 
2.69-2.59 (m, 2H, CH2-11), 2.34-2.24 (m, 2H, CH2-16),  1.67-1.52 (m, 4H, CH2-15/12), 1.42-
1.29 (m, 4H, CH2-13/14). 13C NMR (126 MHz, CDCl3) δC 173.2 (C17), 153.7 (C2), 132.6 (CH-6), 
132.0 (C1), 130.5 (CH-4), 120.8 (C3), 118.2 (C8), 104.1 (C5), 37.3 (CH3-19/20), 35.5 (CH3-
19/20), 33.1 (CH2-16), 29.9 (CH2-11), 28.83 (CH2-12/13/14), 28.80 (CH2-12/13/14), 28.75 
(CH2-12/13/14), 24.6 (CH2-15). HRMS-ESI m/z [M+H]+ calculated for C16H2135ClN2NaO2 
331.1184, found 331.1183. LCMS - Analytical MDAP 30-95% MeCN:Water (0.1% Formic), tR 
15.22 min, [M+H]+ 309.1 m/z (95%). 
224 
Ethyl-(E)-3-5-cyano-2-hydroxy-4-methylphenyl)prop-2-enoate (117) 
 
Potassium carbonate (0.98 g, 7.07 mmol) was added to a solution of 5-bromo-4-hydroxy-2-
methyl-benzonitrile (85) (0.50 g, 2.36 mmol) and ethyl acrylate (0.77 mL, 7.07 mL) in 1-
methyl-2-pyrrolidinone. [1,3-bis(2,4,6-trimethylphenyl)-2,3-dihydro-1H-imidazol-2-
ylidene]({2-[(dimethylamino)methyl]phenyl})palladiumylium chloride was added to the 
suspension and the reaction was sealed under nitrogen and heated at 100 °C for 48 h. The 
reaction mixture was cooled to rt and diluted with ethyl acetate (50 mL) and filtered through 
a celite pad. The filtrate was washed with HCl (aq) (1 M, 25 mL), LiCl (aq) (0.5 M, 25 mL), 
brine (25 mL), dried over MgSO4 filtered and concentrated under vacuum. The residue was 
purified by flash silica chromatography eluting with petroleum ether to 15% ethyl acetate in 
petroleum ether to provide the title compound as a white solid (0.16 g, 29%). m.p. 
143-147 °C. IR (neat, vmax) cm-1 2923, 2221, 1600, 1274. 1H NMR (500 MHz, 
D6-DMSO) δH 11.30 (br s, 1H, OH-10) 8.07 (s, 1H, CH-1), 7.73 (d, J = 16.0 Hz, 1H, CH-11), 6.90 
(s, 1H, CH-2), 6.70 (d, J = 16.0 Hz, 1H, CH-12), 4.17 (q, J = 7.2 Hz, 2H, CH2-16), 2.38 (s, 3H, 
CH3-7), 1.24 (t, J = 7.2 Hz, 3H, CH3-17). 13C NMR (126 MHz, D6-DMSO) δC 160.9 (C13), 160.6 
(C2), 145.4 (C6), 138.2 (CH-11), 134.4 (CH-4), 120.3 (C3), 119.4 (CH-12), 118.5 (C8), 118.1 
(CH-1), 103.19 (C8), 60.4 (CH2-16), 20.5 (CH3-7), 14.6 (CH3-17). HRMS-ESI m/z [M-H]- 
calculated for C13H12NO3 230.0823, found 230.0814. LCMS - Analytical LCQ 7 min 30-90 Low 
MWt, Rt 3.18 min, [M+H]+ 232.0, Analytical MDAP 30-95% MeCN:Water (0.1% Formic), 
tR 15.24 min, [M+H]+ 230.1 (95%). 
225 
Ethyl 3-(5-cyano-2-hydroxy-4-methyl-phenyl)propanoate (118) 
 
Triethylsilane (0.50 g, 4.32 mmol) was added to a solution ethyl (E)-3-(5-cyano-2-hydroxy-4-
methyl-phenyl)prop-2-enoate (117) (0.10 g, 0.43 mmol) and 10% palladium on carbon (0.004 
g, 0.04 mmol) in ethanol (5 mL). The reaction mixture was stirred at rt for 16 h. Further 
triethylsilane (0.50 g, 4.32 mmol) was added and the reaction mixture was stirred for a 
further 16 h.  The reaction mixture was purged with nitrogen and was filtered through a pad 
of celite, the filtrate was partitioned between HCl (aq) (1 M, 10 mL) and ethyl acetate (2 x 
20 mL). The combined organics were separated, dried over MgSO4, filtered and concentrated 
under vacuum. The residue was purified by flash silica chromatography, eluting with 
petroleum ether to 50% ethyl acetate in petroleum ether to provide the title compound as a 
white solid (0.080 g, 77%). m.p. 78-80 °C. IR (neat, vmax) cm-1 3496, 2927, 2225, 1716, 1199, 
1250, 861. 1H NMR (500 MHz, CDCl3) δH 8.25 (s, 1H, CH-6/4), 7.32 (s, 1H, CH-6/4), 6.80 (s, 1H, 
OH-7), 4.16 (q, J = 7.3 Hz, CH2-16), 2.84 (m, 2H, CH2-11/12), 2.70 (m, 2H, CH2-11/12), 2.44 (s, 
3H, CH3-10), 1.25 (t, J = 7.3 Hz, CH3-17). 13C NMR (126 MHz, CDCl3) δC 175.9 (C13), 158.4 (C2), 
142.5 (C6), 135.1 (CH-4), 125.8 (C3), 119.0 (CH-1), 118.6 (C8), 104.3 (C5), 61.8 (CH2-16), 35.0 
(CH2-12), 24.0 (CH2-11), 20.1 (CH3-10), 14.0 (CH3-17). HRMS-ESI m/z [M+H]+ calculated for 
C13H15NNaO3 256.0944, found 256.0941. LCMS - Analytical MDAP 30-95% MeCN:Water 
(0.1% Formic), tR 14.34 min, [M-H]- 232.1 m/z (95%). 
226 
Ethyl 3-(3-chloro-5-cyano-2-hydroxy-4-methyl-phenyl)propanoate (119) 
 
Sulfuryl chloride (0.02 mL, 0.26 mmol) was added to a solution ethyl 3-(5-cyano-2-hydroxy-
4-methyl-phenyl)propanoate (118) (0.05 g, 0.21 mmol) in diethyl ether (1 mL). The reaction 
mixture was stirred at rt for 96 h. Further sulfuryl chloride (0.02 mL, 0.26 mmol) was added 
and the reaction mixture was stirred for a further 16 h.  The reaction mixture was partitioned 
between HCl (aq) (1 M, 10 mL) and ethyl acetate (2 x 20 mL). The combined organics were 
separated, dried over MgSO4, filtered and concentrated under reduced pressure. The residue 
was purified by flash silica chromatography, eluting with petroleum ether to 25% ethyl 
acetate in petroleum ether to provide the title compound as a white solid (0.043 g, 75%). 
m.p. 92-94 °C. IR (neat, vmax) cm-1 3340, 2997, 2228, 1712, 1210, 1177, 880. 1H NMR (500 
MHz, CDCl3) δH 7.33 (s, 1H, CH-4), 7.03 (s, 1H, OH-7), 4.14 (q, J = 7.1 Hz, 2H, CH2-16), 2.94 (t, 
J = 7.1 Hz, 2H, CH2-12), 2.65 (t, J = 7.1 Hz, 2H, CH2-13), 2.55 (s, 3H, CH3-9), 1.24 (t, J = 7.1 Hz, 
3H, CH3-17). 13C NMR (126 MHz, CDCl3) δC 173.6 (C14), 153.6 (C2), 139.4 (C6), 132.6 (CH-4), 
126.7 (C10), 117.9 (C3), 105.3 (C5), 61.1 (CH2-16), 33.7 (CH2-12/13), 25.3 (CH2-12/13), 18.9 
(CH3-17), 14.2 (CH3-9). HRMS-ESI m/z [M-H]- calculated for C13H13NO3 266.0589, found 
266.0576. LCMS - Analytical MDAP 30-95% MeCN:Water (0.1% Formic), tR 16.74 min, [M-H]- 
265.9 m/z (95%). 
227 
N-Butyl-3-(3-chloro-5-cyano-2-hydroxy-4-methyl-phenyl)propenamide (120) 
 
N-Butylamine (0.03 mL, 0.33 mmol) was added to a solution of 1,5,7-triazabicyclo[4.4.0]dec-
5-ene (0.04 g, 0.26 mmol) and ethyl 3-(3-chloro-5-cyano-2-hydroxy-4-methyl-
phenyl)propanoate (119) (0.04 g, 0.13 mmol) in acetonitrile (0.5 mL). The reaction was 
stirred at rt for 48 h. The reaction mixture was partitioned between ethyl acetate (25 mL) 
and water (25 mL). The organic layer was separated, washed with brine, dried over MgSO4, 
filtered and concentrated under reduced pressure. The residue was purified by flash silica 
chromatography eluting with petroleum ether to 30% ethyl acetate in petroleum ether to 
provide the title compound as a colourless oil, that solidified upon standing (0.012 g, 31%). 
m.p. 141-143 °C. IR (neat, vmax) cm-1 3369, 2928, 2220, 1632, 1562, 1157, 885.  1H NMR - 
(500MHz, CDCl3) δH 10.35 (br s, 1H, OH-7), 7.24 (s, 1H, CH-4), 5.55 (br s, 1H, NH-14), 3.26 (m, 
2H, CH2-15), 2.91 (m, 2H, CH2-11), 2.59 (m, 2H, CH2-12), 2.54 (s, 3H, CH3-20), 1.45 (m, 2H, 
CH2-16), 1.28 (m, 2H, CH2-17), 0.90 (t, J = 7.5 Hz, 3H, CH3-18). 13C NMR - (126 MHz, CDCl3) δC 
173.6 (C13), 155.6 (C2), 140.0 (C6), 132.6 (CH-4), 127.4 (C3), 123.9 (C1), 118.3 (C9), 104.0 
(C5), 39.9 (CH2-15), 36.3 (CH2-12), 31.4 (CH2-16), 25.0 (CH2-11), 19.9 (CH2-17), 18.9 (CH3-20), 
13.6 (CH3-18). HRMS-ESI m/z [M+Na]+ calculated for C15H1935ClN2NaO2 317.1027, found 
317.1019. LCMS - Analytical MDAP 30-95% MeCN:Water (0.1% Formic), tR 16.73 min, [M+H]+ 
295.0 (95%). 
228 
3-Chloro-5-heptyl-4-methoxy-2-methyl-benzonitrile (125) 
 
A solution of 1 M borane in THF (0.43 mL, 0.43 mmol) was added dropwise to 1-heptene 
(0.18 mL, 1.31 mmol) at 0 °C. This solution was warmed to rt and stirred for 15 min. The 
solution was quenched with the addition of water (1 mL) and diluted with toluene (5 mL). 
Potassium phosphate tribasic (0.25 g, 1.15 mmol), 5-bromo-3-chloro-4-methoxy-2-methyl-
benzonitrile (96) (0.10 g, 0.38 mmol), palladium (II) acetate (0.02 g, 0.01 mmol) and 2-
dicyclohexylphosphino-2’-6’-diisopropoxybiphenyl (0.09 g, 0.02 mmol) were added. The 
reaction mixture was sealed and heated 50 °C for 16 h. The cooled reaction mixture was 
filtered through a pad of celite, the filtrate partitioned between water (10 mL) and ethyl 
acetate (20 mL). The organic layer was separated, dried over MgSO4, filtered and 
concentrated under vacuum. The residue was purified by flash silica chromatography, eluting 
with petroleum ether to 15% ethyl acetate, followed by further purification by reverse-phase 
chromatography eluting with 60% MeOH in water to 100% MeOH to provide the title 
compound as a colourless oil (0.040 g, 35%). IR (neat, vmax) cm-1 2927, 2226, 1466, 1286. 1H 
NMR (500 MHz, CDCl3) δH 7.35 (s,1H, CH-6), 3.85 (s, 3H, CH3-12), 2.60 (t, J = 7.9 Hz, 2H, CH2-
13), 2.54 (s, 3H, CH3-9), 1.61-1.50 (m, 2H, CH2-14), 1.38-1.11 (m, 8H, CH2-15/16/17/18), 0.87 
(t, J = 6.7 Hz, 3H, CH3-19). 13C NMR (126 MHz, CDCl3) δC 158.1 (C4), 139.3 (C5), 136.3 (C2), 
132.0 (CH-6), 129.6 (C3), 117.7 (C7), 109.3 (C1), 60.9 (CH3-11), 31.7 (CH2-17), 30.8 (CH2-14), 
29.7 (CH2-13), 29.3 (CH2-15/16) 29.0 (CH2-15/16), 22.6 (CH2-18), 18.8 (CH3-9) 14.1 (CH3-19). 
HRMS-ESI m/z [M+Na]+ and [M-H]- poor ionisation LRMS only EI+ 279 m/z. LCMS - Analytical 
MDAP 50-95% MeCN:Water (0.1% Formic), tR 26.21 min, no ionisation. (95%). 
229 
3-Chloro-5-hexyl-4-methoxy-2-methyl-benzonitrile (126) 
 
A solution of 1 M borane in THF (0.43 mL, 0.43 mmol) was added dropwise to 1-hexene (0.16 
mL, 1.31 mmol) at 0 °C. This solution was warmed to rt and stirred for 15 min. The solution 
was quenched with the addition of water (1 mL) and diluted with toluene (5 mL). Potassium 
phosphate tribasic (0.25 g, 1.15 mmol), 5-bromo-3-chloro-4-methoxy-2-methyl-benzonitrile 
(96) (0.10 g, 0.38 mmol), palladium (II) acetate (0.02 g, 0.01 mmol) and 2-
dicyclohexylphosphino-2’-6’-diisopropoxybiphenyl (0.09 g, 0.02 mmol) were added. The 
reaction mixture was sealed and heated 50 °C for 16 h. The cooled reaction mixture was 
filtered through a pad of celite, the filtrate partitioned between water (10 mL) and ethyl 
acetate (20 mL). The organic layer was separated, dried over MgSO4, filtered and 
concentrated under vacuum. The residue was purified by flash silica chromatography, eluting 
with petroleum ether to 15% ethyl acetate, followed by further purification by reverse-phase 
chromatography eluting with 60% MeOH in water to 100% MeOH to provide the title 
compound as a colourless oil (0.040 g, 43%). IR (neat, vmax) cm-1 2929, 2227, 1466, 1286. 1H 
NMR (500 MHz, CDCl3) δH 7.35 (s, 1H, CH-6), 3.85 (s, 3H, CH3-12), 2.60 (t, J = 7.6 Hz, 2H, CH2-
13), 2.54 (s, 3H, CH3-9), 1.61-1.48 (m, 2H, CH2-14), 1.41-1.17 (m, 6H, CH2-15/16/17), 0.87 (t, 
J = 6.8 Hz, 3H, CH3-18). 13C NMR (126 MHz, CDCl3) δC 158.1 (C4), 139.3 (C5), 136.3 (C2), 132.0 
(CH-6), 129.6 (C3), 117.7 (C1), 109.3 (C7), 60.9 (CH3-12), 31.6 (CH2-16), 30.1 (CH2-14), 29.7 
(CH2-13), 29.1 (CH2-15) 22.5 (CH2-17), 18.8 (CH3-9), 14.0 (CH3-18). HRMS-ESI m/z [M+Na]+ 
and [M-H]- poor ionisation LRMS only EI+ 265 m/z. LCMS - Analytical MDAP 30-95% 
MeCN:Water (0.1% Formic), tR 28.32 min, no ionisation (95%). 
230 
3-Chloro-4-methoxy-2-methyl-5-pentyl-benzonitrile (127) 
 
A solution of 1 M borane in THF (0.43 mL, 0.43 mmol) was added dropwise to 1-pentene 
(0.14 mL, 1.31 mmol) at 0 °C. This solution was warmed to rt and stirred for 15 min. The 
solution was quenched with the addition of water (1 mL) and diluted with toluene (5 mL). 
Potassium phosphate tribasic (0.25 g, 1.15 mmol), 5-bromo-3-chloro-4-methoxy-2-methyl-
benzonitrile (96) (0.10 g, 0.38 mmol), palladium (II) acetate (0.02 g, 0.01 mmol) and 2-
dicyclohexylphosphino-2’-6’-diisopropoxybiphenyl (0.09 g, 0.02 mmol) were added. The 
reaction mixture was sealed and heated 50 °C for 16 h. The cooled reaction mixture was 
filtered through a pad of celite, the filtrate partitioned between water (10 mL) and ethyl 
acetate (20 mL). The organic layer was separated, dried over MgSO4, filtered and 
concentrated under vacuum. The residue was purified by flash silica chromatography, eluting 
with petroleum ether to 15% ethyl acetate, followed by further purification by reverse-phase 
chromatography eluting with 60% MeOH in water to 100% MeOH to provide the title 
compound as a colourless oil (0.03 g, 31%). IR (neat, vmax) cm-1 2931, 2226, 1466, 1287. 1H 
NMR (500 MHz, CDCl3) δH 7.35 (s, 1H, CH-6), 3.85 (s, 3H, CH3-12), 2.60 (t, J = 7.8 Hz, 2H, CH2-
13), 2.55 (s, 3H, CH3-9), 1.57 (t, J = 7.5 Hz, 2H, CH2-14), 1.41-1.18 (m, 4H, CH2-15/16), 0.89 (t, 
J = 6.7 Hz, 3H, CH3-17). 13C NMR (126 MHz, CDCl3) δC 158.1 (C4), 139.4 (C2), 136.3 (C5), 132.0 
(CH-6), 129.6 (C3), 117.8 (C1), 109.3 (C7), 60.9 (CH3-12), 31.5 (CH2-15), 29.9 (CH2-14), 29.7 
(CH2-13), 22.4 (CH2-16), 18.8 (CH3-9), 13.9 (CH3-17). HRMS-ESI m/z [M+Na]+ and [M-H]- poor 
ionisation LRMS only EI+ 251 m/z. LCMS - Analytical MDAP 30-95% MeCN:Water (0.1% 
Formic), tR 26.44 min, no ionisation (95%). 
231 
5-Butyl-3-chloro-4-methoxy-2-methyl-benzonitrile (128) 
 
Palladium (II) acetate (0.02 g, 0.01 mmol) and 2-dicyclohexylphosphino-2’-6’-
diisopropoxybiphenyl (0.09 g, 0.02 mmol) were added to a biphasic mixture of potassium 
phosphate tribasic (0.25 g, 1.15 mmol), 5-bromo-3-chloro-4-methoxy-2-methyl-benzonitrile 
(96) (0.10 g, 0.38 mmol) and 1-butaneboronic acid (0.06 g, 0.58 mmol) in water (1 mL) and 
diluted with toluene (5 mL). The reaction mixture was sealed and heated 50 °C for 16 h. The 
cooled reaction mixture was filtered through a pad of celite, the filtrate partitioned between 
water (10 mL) and ethyl acetate (20 mL). The organic layer was separated, dried over MgSO4, 
filtered and concentrated under vacuum. The residue was purified by flash silica 
chromatography, eluting with petroleum ether to 15% ethyl acetate, followed by further 
purification by reverse-phase chromatography eluting with 60% MeOH in water to 100% 
MeOH to provide the title compound as a colourless oil (0.070 g, 65%). IR (neat, vmax) cm-1 
2944, 2226, 1466, 1285. 1H NMR (500 MHz, CDCl3) δH 7.35 (s, 1H, CH-6), 3.86 (s, 3H, CH3-9), 
2.62 (t, J = 7.7 Hz, 2H, CH2-13), 2.55 (s, 3H, CH3-10), 1.59-1.51 (m, 2H, CH2-14), 1.41-1.31 (m, 
2H, CH2-15), 0.93 (t, J = 6.7 Hz, 3H, CH3-16). 13C NMR (126 MHz, CDCl3) δC 158.1 (C4), 139.4 
(C2), 136.3 (C5), 132.1 (CH-6), 129.7 (C3), 117.8 (C11), 109.3 (C1), 60.9 (CH3-9), 32.3 (CH2-
14), 31.7 (CH2-13), 22.5 (CH2-15), 18.8 (CH3-10), 13.8 (CH3-16). HRMS-ESI m/z [M+Na]+ and 
[M-H]- poor ionisation LRMS only EI+ 237 m/z. LCMS - Analytical MDAP 30-95% MeCN:Water 
(0.1% Formic), tR 24.85 min, no ionisation (95%). 
232 
3-Chloro-4-methoxy-2-methyl-5-propyl-benzonitrile (129) 
 
Palladium (II) acetate (0.02 g, 0.01 mmol) and 2-dicyclohexylphosphino-2’-6’-
diisopropoxybiphenyl (0.09 g, 0.02 mmol) were added to a biphasic mixture of potassium 
phosphate tribasic (0.25 g, 1.15 mmol), 5-bromo-3-chloro-4-methoxy-2-methyl-benzonitrile 
(96) (0.10 g, 0.38 mmol) and 1-propylboronic acid (0.05 g, 0.58 mmol) in water (1 mL) and 
diluted with toluene (5 mL). The reaction mixture was sealed and heated 50 °C for 16 h. The 
cooled reaction mixture was filtered through a pad of celite, the filtrate partitioned between 
water (10 mL) and ethyl acetate (20 mL). The organic layer was separated, dried over MgSO4, 
filtered and concentrated under reduced pressure. The residue was purified by flash silica 
chromatography, eluting with petroleum ether to 15% ethyl acetate, followed by further 
purification by reverse-phase chromatography eluting with 60% MeOH in water to 100% 
MeOH to provide the title compound as a colourless oil (0.07 g, 65%). IR (neat, vmax) cm-1 
2959, 2225, 1465, 1284. 1H NMR (500 MHz, CDCl3) δH 7.35 (s, 1H, CH-6), 3.86 (s, 3H, CH3-9), 
2.60 (t, J = 6.7 Hz, 2H, CH2-13), 2.55 (s, 3H, CH3-10), 1.66-1.56 (m, 2H, CH2-14), 0.96 (t, J = 7.4 
Hz, 3H, CH3-15). 13C NMR (126 MHz, CDCl3) δC 158.2 (C4), 139.4 (C5), 136.0 (C2), 132.1 (CH-
6), 129.7 (C3), 117.8 (C11), 109.3 (C1), 60.9 (CH3-9), 31.7 (CH2-13), 23.3 (CH2-14), 18.9 (CH3-
10), 13.9 (CH3-15). HRMS-ESI m/z [M+Na]+ and [M-H]- poor ionisation LRMS only EI+ 223 m/z. 
LCMS - Analytical MDAP 30-95% MeCN:Water (0.1% Formic), tR 24.85 min, no ionisation 
(95%). 
233 
3-Chloro-5-ethyl-4-methoxy-2-methyl-benzonitrile (130) 
 
Palladium (II) acetate (0.02 g, 0.01 mmol) and 2-dicyclohexylphosphino-2’-6’-
diisopropoxybiphenyl (0.09 g, 0.02 mmol) were added to a biphasic mixture of potassium 
phosphate tribasic (0.20 g, 0.96 mmol), 5-bromo-3-chloro-4-methoxy-2-methyl-benzonitrile 
(96) (0.10 g, 0.38 mmol) and triethylborane (0.42 mL, 0.42 mmol) in water (1 mL) and diluted 
with toluene (5 mL). The reaction mixture was sealed and heated 50 °C for 16 h. The cooled 
reaction mixture was filtered through a pad of celite, the filtrate partitioned between water 
(10 mL) and ethyl acetate (20 mL). The organic layer was separated, dried over MgSO4, 
filtered and concentrated under reduced pressure. The residue was purified by flash silica 
chromatography, eluting with petroleum ether to 15% ethyl acetate, followed by further 
purification by reverse-phase chromatography eluting with 60% MeOH in water to 100% 
MeOH to provide the title compound as a colourless oil (0.020 g, 23%). IR (neat, vmax) cm-1 
2937, 2224, 1468, 1288. 1H NMR (500 MHz, CDCl3) δH 7.37 (s, 1H, CH-6), 3.86 (s, 3H, CH3-9), 
2.75-2.60 (m, 2H, CH2-11), 2.56 (s, 3H, CH3-10), 1.22 (t, J = 7.5 Hz, 3H, CH3-12). 13C NMR (126 
MHz, CDCl3) δC 158.0 (C4), 139.4 (C2), 137.5 (C5), 131.4 (CH-6), 129.6 (C3), 117.8 (C13), 109.5 
(C1), 60.9 (CH3-9), 22.3 (CH2-11), 18.8 (CH3-10), 14.4 (CH3-12). HRMS-ESI m/z [M+Na]+ and 
[M-H]- poor ionisation LRMS only EI+ 209 m/z. LCMS - Analytical MDAP 30-95% MeCN:Water 
(0.1% Formic), tR 21.40 min, no ionisation (95%). 
234 
3-Chloro-4-methoxy-2,5-dimethyl-benzonitrile (131) 
 
Bis[2-(di-tert-butylphosphanyl)cyclopenta-2,4-dien-1-yl]iron; dichloropalladium (0.01 g, 
0.02 mmol) was added to a suspension of potassium phosphate tribasic (0.20 g, 0.96 mmol), 
5-bromo-3-chloro-4-methoxy-2-methyl-benzonitrile (96) (0.10 g, 0.38 mmol) and trimethyl 
boroxine (0.12 mL, 0.42 mmol) in water (0.25 mL) and diluted with acetonitrile (1 mL). The 
reaction mixture was sealed and heated 100 °C for 16 h. The cooled reaction mixture was 
filtered through a pad of celite, the filtrate partitioned between water (10 mL) and ethyl 
acetate (20 mL). The organic layer was separated, dried over MgSO4, filtered and 
concentrated under reduced pressure. The residue was purified by flash silica 
chromatography, eluting with petroleum ether to 15% ethyl acetate, followed by further 
purification by reverse-phase chromatography eluting with 60% MeOH in water to 100% 
MeOH to provide the title compound as a colourless oil (0.040 g, 57%). IR (neat, vmax) cm-1 
2935, 2223, 1468, 1288. 1H NMR (500 MHz, CDCl3) δH 7.35 (s, 1H, CH-6), 3.84 (s, 3H, CH3-9), 
2.55 (s, 3H, CH3-10), 2.29 (s, 3H, CH3-11). 13C NMR (126 MHz, CDCl3) δC 158.3 (C4), 139.5 (C2), 
132.9 (CH-6), 131.5 (C5), 129.6 (C3), 117.6 (C12), 109.2 (C1), 60.2 (CH3-9), 18.8 (CH3-10), 16.0 
(CH3-11). HRMS-ESI m/z [M+Na]+ and [M-H]- poor ionisation LRMS only EI+ 195 m/z. LCMS - 
Analytical MDAP 30-95% MeCN:Water (0.1% Formic), tR 19.52 min, no ionisation (95%). 
3-chloro-5-heptyl-4-hydroxy-2-methyl-benzonitrile (132) 
 
235 
Sodium iodide (0.06 g, 0.43 mmol) was added to a solution of 3-chloro-5-heptyl-4-methoxy-
2-methyl-benzonitrile (125) (0.03 g, 0.11 mmol) and chloro(trimethyl)silane (0.05 mL, 0.43 
mmol) in acetonitrile (1 mL). The reaction mixture was sealed and heated to 80 °C for 16 h. 
The cooled reaction mixture was partitioned between sodium thiosulfate (aq) (1 M, 10 mL) 
and ethyl acetate (2 x 20 mL). The combined organics were separated, dried over MgSO4, 
filtered and concentrated under vacuum. The residue was purified by reverse phase flash 
chromatography eluting with water to methanol to provide the title compound as a 
colourless oil (0.006 g, 22%). IR (neat, vmax) cm-1 3335, 2928, 2225, 1466, 1155. 1H NMR 
(500 MHz, CDCl3) δH 7.30 (s, 1H, CH-6), 6.11 (br s, 1H, OH-8), 2.61 (t, J = 7.5, 2H, CH2-10), 2.54 
(s, 3H, CH3-9), 1.61-1.53 (m, 2H, CH2-11), 1.35-1.22 (m, 8H, CH2-12/13/14/15), 0.88 (t, J = 6.2 
Hz, CH3-16). 13C NMR (126 MHz, CDCl3) δC 153.1 (C4), 138.2 (C2), 132.2 (CH-6), 128.9 (C5), 
121.0 (C3), 118.1 (C17), 105.1 (C1), 31.7 (CH2-14), 30.0 (CH2-10), 29.2 (CH2-12/13) 29.09 
(CH2-11/12/13), 29.06 (CH2-11/12/13), 22.6 (CH2-14), 18.8 (CH3-9), 14.1 (CH3-16). HRMS-ESI 
m/z [M-H]- calculated for C15H1935ClNO 264.1161, found 264.1152. LCMS - Analytical MDAP 
30-95% MeCN : Water (0.1% Formic), tR 25.68 min, [M-H]- 264.0 (95%). 
  
236 
3-Chloro-5-hexyl-4-hydroxy-2-methyl-benzonitrile (133) 
 
Sodium iodide (0.09 g, 0.60 mmol) was added to a solution of 3-chloro-5-hexyl-4-methoxy-
2-methyl-benzonitrile (126) (0.04 g, 0.15 mmol) and chloro(trimethyl)silane (0.08 mL, 0.60 
mmol) in acetonitrile (1 mL). The reaction mixture was sealed and heated to 80 °C for 16 h. 
The cooled reaction mixture was partitioned between sodium thiosulfate (aq) (1 M, 10 mL) 
and ethyl acetate (2 x 20 mL). The combined organics were separated, dried over MgSO4, 
filtered and concentrated under vacuum. The residue was purified by reverse phase flash 
chromatography eluting with water to methanol to provide the title compound as a 
colourless oil (0.017 g, 45%). IR (neat, vmax) cm-1 3339, 2932, 2223, 1601, 1466, 1163. 1H 
NMR (500 MHz, CDCl3) δH 7.29 (s, 1H, CH-6), 6.18 (br s, 1H, OH-8), 2.61 (t, J = 7.8 Hz, 2H, CH2-
10), 2.53 (s, 3H, CH3-9), 1.61-1.50 (m, 2H, CH2-11), 1.38-1.23 (m, 6H, CH2-12/13/14), 0.92-
0.84 (m, 3H, CH3). 13C NMR (126 MHz, CDCl3) δC 153.1 (C4), 138.2 (C2), 132.2 (CH-6), 128.9 
(C5), 121.0 (C3), 118.1 (C16), 105.0 (C1), 31.6 (CH2-13), 30.0 (CH2-10), 29.0 (CH2-11), 28.9 
(CH2-12), 22.6 (CH2-14), 18.8 (CH3-9), 14.1 (CH3-15). HRMS-ESI m/z [M-H]- calculated for 
C14H1735ClNO 250.1004, found 250.0995. LCMS - Analytical MDAP 30-95% MeCN:Water 
(0.1% Formic), tR 24.09 min, [M-H]- 249.9 m/z (95%). 
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3-Chloro-4-hydroxy-2-methyl-5-pentyl-benzonitrile (134) 
 
Sodium iodide (0.06 g, 0.40 mmol) was added to a solution of 3-chloro-4-methoxy-2-methyl-
5-pentyl-benzonitrile (127) (0.03 g, 0.1 mmol) and chloro(trimethyl)silane (0.05 mL, 0.40 
mmol) in acetonitrile (1 mL). The reaction mixture was sealed and heated to 80 °C for 16 h. 
The cooled reaction mixture was partitioned between sodium thiosulfate (aq) (1 M, 10 mL) 
and ethyl acetate (2 x 20 mL). The combined organics were separated, dried over MgSO4, 
filtered and concentrated under vacuum. The residue was purified by reverse phase flash 
chromatography eluting with water to methanol to provide the title compound as a 
colourless oil (0.003 g, 13%). IR (neat, vmax) cm-1 3334, 2931, 2226, 1600, 1468, 1158. 1H 
NMR (500 MHz, CDCl3) δH 7.30 (s, 1H, CH-6), 6.10 (br s, 1H, OH-8), 2.62 (t, J = 7.8 Hz, 2H, CH2-
10), 2.54 (s, 3H, CH3-9), 1.65-1.52 (m, 2H, CH2-11), 1.37-1.27 (m, 4H, CH2s-11/13), 0.89 (t, J 
= 6.8 Hz, 3H, CH3-14). 13C NMR (126 MHz, CDCl3) δC 153.1 (C4), 138.2 (C2), 132.2 (CH-6), 
128.9 (C5), 121.0 (C3), 118.1 (C15), 105.1 (C1), 31.4 (CH2-12), 29.9 (CH2-10), 28.8 (CH2-11), 
22.4 (CH2-13), 18.8 (CH3-9), 14.0 (CH3-14). HRMS-ESI m/z [M-H]- calculated for C13H1535ClNO 
236.0848, found 236.0840. LCMS - Analytical MDAP 30-95% MeCN:Water (0.1% Formic), 
tR 22.41 min, [M-H]- 235.9 m/z (95%). 
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5-Butyl-3-chloro-4-hydroxy-2-methyl-benzonitrile (135) 
 
Sodium iodide (0.13 g, 0.84 mmol) was added to a solution of 5-butyl-3-chloro-4-methoxy-
2-methyl-benzonitrile (128) (0.05 g, 0.21 mmol) and chloro(trimethyl)silane (0.11 mL, 0.84 
mmol) in acetonitrile (1 mL). The reaction mixture was sealed and heated to 80 °C for 16 h. 
The cooled reaction mixture was partitioned between sodium thiosulfate (aq) (1 M, 10 mL) 
and ethyl acetate (2 x 20 mL). The combined organics were separated, dried over MgSO4, 
filtered and concentrated under vacuum. The residue was purified by reverse phase flash 
chromatography eluting with water to methanol to provide the title compound as a 
colourless oil (0.029 g, 61%). 1H NMR (500 MHz, CDCl3) δH 7.29 (s, 1H, CH-6), 6.22 (br s, 1H, 
OH-8), 2.61 (t, J = 7.8 Hz, 2H, CH2-10), 2.53 (s, 3H, CH3-9), 1.60-1.50 (m, 2H, CH2-11), 
1.40-1.29 (m, 2H, CH2-12), 0.92 (t, J = 7.3 Hz, 3H, CH3-13). 13C NMR (126 MHz, CDCl3) δC 153.2 
(C4), 138.2 (C2), 132.1 (CH-6), 128.9 (C5), 121.1 (C3), 118.1 (C14), 105.0 (C1), 31.2 (CH2-11), 
29.6 (CH2-12), 22.3 (CH2-12), 18.7 (CH3-9), 13.8 (CH3-13). HRMS-ESI m/z [M-H]- calculated for 
C12H1335ClNO 222.0691, found 222.0685. LCMS - Analytical MDAP 30-95% MeCN:Water 
(0.1% Formic), tR 20.71 min, [M-H]- 221.9 m/z (95%). 
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3-Chloro-4-hydroxy-2-methyl-5-propyl-benzonitrile (136) 
 
Sodium iodide (0.13 g, 0.89 mmol) was added to a solution of 3-chloro-4-methoxy-2-methyl-
5-propyl-benzonitrile (129) (0.05 g, 0.22 mmol) and chloro(trimethyl)silane (0.11 mL, 0.89 
mmol) in acetonitrile (1 mL). The reaction mixture was sealed and heated to 80 °C for 16 h. 
The cooled reaction mixture was partitioned between sodium thiosulfate (aq) (1 M, 10 mL) 
and ethyl acetate (2 x 20 mL). The combined organics were separated, dried over MgSO4, 
filtered and concentrated under vacuum. The residue was purified by reverse phase flash 
chromatography eluting with water to methanol to provide the title compound as a 
colourless oil (0.022 g, 46%). IR (neat, vmax) cm-1 3319, 2930, 2227, 1599, 1470, 1166. 1H 
NMR (500 MHz, CDCl3) δH 7.29 (s, 1H, CH-6), 6.21 (br s, 1H, OH-8), 2.60 (t, J = 7.7 Hz, 2H, CH2-
10), 2.53 (s, 3H, CH3-9), 1.62-1.56 (m, 2H, CH2-11), 0.94 (t, J = 7.3 Hz, 3H, CH3-12). 13C NMR 
(126 MHz, CDCl3) δC 153.2 (C4), 138.3 (C5), 132.2 (CH-6), 128.7 (C5), 121.1 (C3), 118.1 (C13), 
105.0 (C1), 31.9 (CH2-10), 22.2 (CH2-11), 18.8 (CH3-9), 13.7 (CH3-12). HRMS-ESI m/z [M-H]- 
calculated for C11H1135ClNO 208.0535, found 208.0528. LCMS - Analytical MDAP 30-95% 
MeCN:Water (0.1% Formic), tR 18.93 min, [M-H]- 207.9 m/z (95%). 
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3-Chloro-4-hydroxy-2,5-dimethyl-benzonitrile (138) 
 
Sodium iodide (0.11 g, 0.72 mmol) was added to a solution of 3-chloro-4-methoxy-2,5-
dimethyl-benzonitrile (131) (0.04 g, 0.18 mmol) and chloro(trimethyl)silane (0.09 mL, 0.72 
mmol) in acetonitrile (1 mL). The reaction mixture was sealed and heated to 80 °C for 16 h. 
The cooled reaction mixture was partitioned between sodium thiosulfate (aq) (1 M, 10 mL) 
and ethyl acetate (2 x 20 mL). The combined organics were separated, dried over MgSO4, 
filtered and concentrated under vacuum. The residue was purified by reverse phase flash 
chromatography eluting with water to methanol to provide the title compound as a 
colourless oil (0.015 g, 33%). IR (neat, vmax) cm-1 3325, 2222, 1602, 1475, 1240, 1160. 1H 
NMR (500 MHz, CDCl3) δH 7.29 (s, 1H, CH-6), 6.21 (br s, 1H, OH-8), 2.53 (s, 3H, CH3-9), 2.25 
(s, 3H, CH3-10). 13C NMR (126 MHz, CDCl3) δC 153.4 (C4), 138.3 (C2), 132.8 (CH-6), 124.2 (C5), 
120.8 (C3), 118.0 (C11), 104.9 (C1), 18.7 (CH3-9), 15.9 (CH3-10). HRMS-ESI m/z [M-H]- 
calculated for C9H735ClNO 180.0222, found 180.0217. LCMS - Analytical MDAP 30-95% 
MeCN:Water (0.1% Formic), tR 15.35 min, [M-H]- 179.9 m/z (95%). 
5-Bromo-4-methoxy-2-methyl-benzonitrile (139)261 
 
Dimethyl sulphate (0.19 mL, 1.98 mmol) was added to a suspension of potassium carbonate 
(0.29 g, 2.08 mmol) and 5-bromo-4-hydroxy-2-methyl-benzonitrile (85) (0.40 g 1.89 mmol) 
241 
in acetone (10 mL). The reaction mixture was heated to reflux for 1 h. The cooled reaction 
mixture was diluted with water (30 mL) and the resulting solid was filtered and air dried to 
provide the title compound as an off white solid (0.41 g, 95%). m.p. 88-90 °C. IR (neat, vmax) 
cm-1 2223, 1686, 1594, 1488, 1258. 1H NMR (500 MHz, D6-DMSO) δH 7.99 (s, 1H, CH-4), 7.20 
(s, 1H, CH-1), 3.91 (s, 3H, CH3-11), 2.44 (s, 3H, CH3-7). 13C NMR (126 MHz, D6-DMSO) δC 159.2 
(C2), 144.3 (C6), 136.5 (CH-4), 117.5 (C3), 114.7 (CH-1), 108.5 (C8), 105.2 (C5), 57.3 (CH3-11), 
20.5 (CH3-7). HRMS-ESI m/z [M+Na]+ and [M-H]- poor ionisation LRMS only EI+ 225 / 227 m/z 
(Br isotope). LCMS - Analytical MDAP 30-95% MeCN:Water (0.1% Formic), tR 20.20 min, no 
mass ion (95%). 
5-(3-Fluorophenyl)-4-methoxy-2-methyl-benzonitrile (140) 
 
Palladium (II) acetate (0.003 g, 0.01 mmol), and 2-dicyclohexylphosphino-2’-6’-
diisopropoxybiphenyl (0.01 g, 0.02 mmol) was added to a mixture of K3PO4 (0.29 g, 1.33 
mmol), 5-bromo-4-methoxy-2-methyl-benzonitrile (139) (0.10 g, 0.44 mmol) and 
3-fluorophenyl boronic acid (0.10 g, 0.66 mmol) in toluene (2 mL) and heated to 100 °C for 
1 h. The reaction mixture was partitioned between CH2Cl2 (10 mL), and HCl (aq) (1 M, 10 mL), 
the chlorinated layer was separated through a phase separator and concentrated under 
reduced pressure. The residue was purified by flash silica chromatography, eluting with 
heptane to 20% ethyl acetate in heptane, to provide the title compound as a white solid 
(0.096 g, 90%). m. p. 107-108 °C. IR (neat, vmax) cm-1 2924, 2209, 1600, 1471, 1255. 1H NMR 
(500 MHz, CDCl3) δH 7.52 (s, 1H, CH-6), 7.38 (dt, J = 8.1 Hz, 6.2 Hz, 1H, CH-14), 7.23-7.18 (m, 
2H, CH-13/17), 7.05 (tdd, J = 8.4 Hz, 2.6 Hz, 1.0 Hz, 1H, CH-15), 6.87 (s, 1H, CH3), 3.87 (s, 3H, 
CH3-10), 2.59 (s, 3H, CH3-11). 13C NMR (126 MHz, CDCl3) δC 162.5 (d, J = 246 Hz, C16), 159.4 
(C4), 144.0 (C2), 138.4 (d, J = 8 Hz, C12), 134.4 (CH-6), 129.7 (d, J = 8 Hz, CH-14), 128.1 (d, J 
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= 3 Hz, C5), 124.9 (d, J = 4 Hz, CH-13), 118.3 (C7), 116.5 (d, J = 22 Hz, CH-15), 114.6 (d, J = 21 
Hz, CH-17), 112.8 (CH-3), 104.8 (C1), 55.8 (CH3-10), 20.8 (CH3-11). HRMS-ESI m/z [M+Na]+ 
calculated for C15H12FNNaO 264.0795, found 264.0799. LCMS - Analytical UPLC 5-95% 
MeCN:Water (0.1% TFA), tR 0.88 min, [M+H]+ 242.5 m/z (95%). 
5-Benzyl-4-methoxy-2-methyl-benzonitrile (141) 
 
Palladium (II) acetate (0.003 g, 0.01 mmol), and 2-dicyclohexylphosphino-2’-6’-
diisopropoxybiphenyl (0.01 g, 0.02 mmol) was added to a mixture of K3PO4 (0.29 g, 1.33 
mmol), 5-bromo-4-methoxy-2-methyl-benzonitrile (139) (0.10 g, 0.44 mmol) and 2-benzyl-
4,4,5,5-tetramethyl-1,3,2-dioxaborolane (0.14 g, 0.66 mmol) in toluene (2 mL) and water 
(0.2 mL) and heated to 100 °C for 1 h. The reaction mixture was partitioned between CH2Cl2 
(10 mL), and HCl (aq) (1 M, 10 mL), the chlorinated layer was separated through a phase 
separator and concentrated under reduced pressure. The residue was purified by flash silica 
chromatography, eluting with heptane to 20% ethyl acetate in heptane, and further purified 
by reverse-phase (C18) chromatography eluting with 20% MeCN in water to 95% MeCN in 
water to provide the title compound as a white solid upon concentration (0.022 g, 21%). m. 
p. 111-112 °C. IR (neat, vmax) cm-1 3302, 2922, 2223, 1600, 1454, 1170. 1H NMR (500 MHz, 
CDCl3) δH 7.36-7.17 (m, 6H, CH-6/14/15/16/17/18), 6.77 (s, 1H, CH-3), 3.93 (s, 2H, CH2-12), 
3.89 (s, 3H, CH3-11), 2.54 (s, 3H, CH3-9). 13C NMR (126 MHz, CDCl3) δC 160.4 (C4), 142.5 (C2), 
139.6 (C13), 133.8 (CH-6), 128.9 (CH-14/18), 128.5 (CH-15/17&C5), 126.3 (CH-16), 118.8 (C7), 
111.9 (CH-3), 104.0 (C1), 55.6 (CH3-10), 35.2 (CH2-12), 20.7 (CH3-9). HRMS-ESI m/z [M+Na]+ 
calculated for C16H15NNaO 260.1046, found 260.1047. LCMS - Analytical UPLC 5-95% 
MeCN:Water (0.1% TFA), tR 0.90 min, [M+H]+ 238.4 m/z (95%). 
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4-Methoxy-2-methyl-5-(2-phenylethyl)benzonitrile (142) 
 
Palladium (II) acetate (0.003 g, 0.01 mmol), and 2-dicyclohexylphosphino-2’-6’-
diisopropoxybiphenyl (0.01 g, 0.02 mmol) was added to a mixture of K3PO4 (0.29 g, 1.33 
mmol), 5-bromo-4-methoxy-2-methyl-benzonitrile (139) (0.10 g, 0.44 mmol) and 
2-phenylethylboronic acid (0.10 g, 0.66 mmol) in toluene (2 mL) and heated to 100 °C for 1 h. 
The reaction mixture was partitioned between CH2Cl2 (10 mL), and HCl (aq) (1 M, 10 mL), the 
chlorinated layer was separated through a phase separator and concentrated under reduced 
pressure. The residue was purified by flash silica chromatography, eluting with heptane to 
20% ethyl acetate in heptane, to provide the title compound as a colourless oil (0.085 g, 76%). 
IR (neat, vmax) cm-1 2927, 2216, 1607, 1501, 1457, 1256. 1H NMR (500 MHz, CDCl3) δH 7.31-
7.24 (m, 3H, CH-6&16&18), 7.22-7.12 (m, 3H, CH-15&17&19), 6.72 (CH-3), 3.85 (s, 3H, 11), 
2.90-2.80 (m, 4H, CH2s-12&13), 2.51 (s, 3H, CH3-9). 13C NMR (126 MHz, CDCl3) δC 160.6 (C4), 
142.2 (C2/14), 141.5 (C2/14), 133.5 (CH-6), 128.7 (C5/CH-16/18/CH-15/19), 128.4 (C5/CH-
16/18/CH-15/19), 128.3 (C5/CH-16/18/CH-15/19), 126.0 (CH-17), 118.8 (C7), 111.7 (CH-3), 
103.8 (C1), 55.5 (CH3-11), 35.7 (CH2-13), 31.6 (CH2-12) 20.6 (CH3-9). HRMS-ESI m/z [M+Na]+ 
calculated for C17H17NNaO 274.1202, found 274.1211. LCMS - Analytical UPLC 5-95% 
MeCN:Water (0.1% TFA), tR 0.95 min, [M+H]+ 252.4 m/z (95%). 
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5-Ethyl-4-methoxy-2-methyl-benzonitrile (143) 
 
Palladium (II) acetate (0.01 g, 0.06 mmol), and 2-dicyclohexylphosphino-2’-6’-
diisopropoxybiphenyl (0.06 g, 0.12 mmol) was added to a mixture of K3PO4 (1.52 g, 
7.17 mmol), 5-bromo-4-methoxy-2-methyl-benzonitrile (139) (0.54 g, 2.39 mmol) and 
ethylboronic acid (0.27 g, 3.58 mmol) in toluene (10 mL) and heated to 100 °C for 16 h. The 
reaction mixture was partitioned between CH2Cl2 (50 mL), and HCl (aq) (1 M, 50 mL), the 
chlorinated layer was separated through a phase separator and concentrated under reduced 
pressure. The residue was purified by flash silica chromatography, eluting with heptane to 
20% ethyl acetate in heptane, to provide the title compound as a colourless oil (0.41 g, 98%). 
IR (neat, vmax) cm-1 2968, 2217, 1610, 1502, 1459, 1253. 1H NMR (500 MHz, CDCl3) δH 7.33 
(s, 1H, CH-6), 6.70 (s, 1H, CH-3), 3.85 (s, 3H, CH3-13), 2.57 (q, J = 7.5, 2H, CH2-11), 2.50 (s, 3H, 
CH3-9), 1.16 (t, J = 7.5 Hz, 3H, CH3-12). 13C NMR (126 MHz, CDCl3) δC 160.5 (C4), 141.8 (C2), 
132.4 (CH-6), 131.13 (C5), 119.0 (C7), 111.6 (CH-3), 103.8 (C1), 55.4 (CH3-13), 22.5 (CH2-11), 
20.6 (CH3-9), 13.6 (CH3-9). HRMS-ESI m/z [M+Na]+ and [M-H]- poor ionisation LRMS only EI+ 
175 m/z. LCMS - Analytical MDAP 30-95% MeCN:Water (0.1% Formic), tR 20.07 min, no mass 
ion (95%). 
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5-Isopentyl-4-methoxy-2-methyl-benzonitrile (144) 
 
Palladium (II) acetate (0.003 g, 0.01 mmol), and 2-dicyclohexylphosphino-2’-6’-
diisopropoxybiphenyl (0.01 g, 0.02 mmol) was added to a mixture of K3PO4 (0.23 g, 
1.11 mmol), 5-bromo-4-methoxy-2-methyl-benzonitrile (139) (0.10 g, 0.44 mmol) and 
isopentylboronic acid (0.08 g, 0.66 mmol) in toluene (2 mL) and heated to 100 °C for 1 h. The 
reaction mixture was partitioned between CH2Cl2 (10 mL), and HCl (aq) (1 M, 10 mL), the 
chlorinated layer was separated through a phase separator and concentrated under reduced 
pressure. The residue was purified by flash silica chromatography, eluting with heptane to 
20% ethyl acetate in heptane, to provide the title compound as a colourless oil (0.084 g, 87%). 
IR (neat, vmax) cm-1 2953, 2218, 1609, 1461, 1255. 1H NMR (500 MHz, CDCl3) δH 7.32 (s, 1H, 
CH-6), 6.70 (s, 1H, CH-3),  3.85 (s, 3H, CH3-11), 2.55 (t, J = 8.1 Hz, 2H, CH2-12), 2.50 (s, 3H, 
CH3-9), 1.61-1.54 (m, 1H, CH-14), 1.45-1.37 (m, 2H, CH2-13), 0.93 (d, J = 6.6 Hz, 6H, CH3's - 
15 & 16). 13C NMR (126 MHz, CDCl3) δC 160.6 (C4), 141.7 (C2), 133.2 (CH-6), 130.1 (C5), 119.0 
(C7), 111.7 (CH-3), 103.8 (C1), 55.5 (CH3-11), 38.6 (CH2-13), 27.9 (CH-14), 27.2 (CH2-12), 22.5 
(CH3's - 15 & 16), 20.6 (CH3-9). HRMS-ESI m/z [M+Na]+ calculated for C14H19NNaO 240.1359, 
found 240.1357. LCMS - Analytical UPLC 5-95% MeCN:Water (0.1% TFA), tR 1.00 min, [M+H]+ 
218.4 m/z (95%). 
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5-(3-Fluorophenyl)-4-hydroxy-2-methyl-benzonitrile (145) 
 
Iodo(trimethyl)silane (0.11 mL, 0.78 mmol) was added to a solution of 5-(3-fluorophenyl)-4-
methoxy-2-methyl-benzonitrile (140) (0.075 g, 0.31 mmol) in acetonitrile (1 mL). The 
reaction mixture was sealed and heated to 90 °C in the microwave (Biotage Initiator®) for 
1 h. The cooled reaction mixture was partitioned between sodium thiosulfate (aq) (0.1 M, 
10 mL) and CH2Cl2 (2 x 20 mL). The chlorinated layers were separated through a phase 
separator and concentrated under reduced pressure. The residue was purified by flash silica 
chromatography eluting with heptane to 40% ethyl acetate in heptane to provide the title 
compound as a white solid (0.070 g, 99%). m.p. 157-159 °C. IR (neat, vmax) cm-1 3225, 2223, 
1578, 1390. 1H NMR (500 MHz, CDCl3) δH 7.54-7.47 (m, 2H, CH-6&14), 7.26-7.21 (m, 1H, CH-
13), 7.21-7.13 (m, 2H, CH-15&16), 6.94 (s, 1H, CH-3), 5.65 (s, 1H, OH-11), 2.56 (s, 3H, CH3-9). 
13C NMR (126 MHz, CDCl3) δC 163.2 (d, J = 248 Hz, C17), 155.8 (C4), 144.1 (C2), 137.0 (d, J = 
8 Hz, C12), 134.6 (CH-6), 131.2 (d, J = 8 Hz, C14), 125.6 (d, J = 2 Hz, C5), 124.5 (d, J = 3 Hz, 
C13), 118.1 (C7), 117.9 (CH-3), 116.2 (d, J = 21 Hz, C15), 115.7 (d, J = 21 Hz, C16), 105.2 (C1), 
20.3 (CH3-9). HRMS-ESI m/z [M+Na]+ calculated for C14H10FNNaO 250.0639, found 250.0638. 
LCMS - Analytical UPLC 2-98% MeCN:Water (0.1% TFA), tR 0.76 min, [M+H]+ 228.3 m/z (95%). 
  
247 
5-Benzyl-4-hydroxy-2-methyl-benzonitrile (146) 
 
Iodo(trimethyl)silane (0.03 mL, 0.19 mmol) was added to a solution of 5-benzyl-4-methoxy-
2-methyl-benzonitrile (141) (0.022 g, 0.09 mmol) in acetonitrile (1 mL). The reaction mixture 
was sealed and heated to 175 °C in the microwave (Biotage Initiator®) for 2 h. The cooled 
reaction mixture was partitioned between sodium thiosulfate (aq) (0.1 M, 10 mL) and CH2Cl2 
(2 x 20 mL). The chlorinated layers were separated through a phase separator and 
concentrated under reduced pressure. The residue was purified by flash silica 
chromatography eluting with heptane to 40% ethyl acetate in heptane to provide the title 
compound as a white solid (0.021 g, 99%). m.p. 148-149 °C. IR (neat, vmax) cm-1 3286, 2923, 
2221, 1504, 1265. 1H NMR (500 MHz, CDCl3) δH 7.40-7.28 (m, 2H, CH-6/13/17/14/16/15), 
7.28-7.14 (m, 2H, CH-6/13/17/14/16/15), 6.70 (s, 1H, CH-3), 5.22 (s, 1H, OH-10), 3.94 (s, 2H, 
CH2-11), 2.46 (s, 3H, CH3-9). 13C NMR (126 MHz, CDCl3) δC 157.2 (C4), 142.5 (C2), 138.4 (C12), 
135.0 (CH-3), 128.9 (CH-13/17), 128.6 (CH-14/16), 126.8 (CH-15), 125.8 (C5), 118.5 (C7), 
117.3 (CH-3), 104.7 (C1), 35.6 (CH2-11), 20.1 (CH3-9). HRMS-ESI m/z [M+Na]+ calculated for 
C15H13NNaO 246.0889, found 246.0892. LCMS - Analytical UPLC 2-98% MeCN:Water (0.1% 
TFA), tR 0.76 min, [M+H]+ 224.4 m/z (95%). 
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4-Hydroxy-2-methyl-5-(2-phenylethyl)benzonitrile (147) 
 
Iodo(trimethyl)silane (0.11 mL, 0.75 mmol) was added to a solution of 4-methoxy-2-methyl-
5-(2-phenylethyl)benzonitrile (142) (0.075 g, 0.30 mmol) in acetonitrile (1 mL). The reaction 
mixture was sealed and heated to 90 °C in the microwave (Biotage Initiator®) for 1 h. The 
cooled reaction mixture was partitioned between sodium thiosulfate (aq) (0.1 M, 10 mL) and 
CH2Cl2 (2 x 20 mL). The chlorinated layers were separated through a phase separator and 
concentrated under reduced pressure. The residue was purified by flash silica 
chromatography eluting with heptane to 40% ethyl acetate in heptane to provide the title 
compound as a white solid (0.054 g, 76%). m.p. 108-109 °C. IR (neat, vmax) cm-1 3329, 2925, 
2218, 1608, 1264. 1H NMR (500 MHz, CDCl3) δH 7.34-7.29 (m, 3H, CH-6&16/17), 7.27-7.16 
(m, 3H, CH-14/16/18), 6.69 (s, 1H, CH-3), 5.17 (s, 1H, OH-10), 2.95-2.86 (m, 4H, CH2s-11&12), 
2.47 (s, 3H, CH3-9). 13C NMR (126 MHz, CDCl3) δC 157.2 (C4), 142.0 (C2), 141.1 (C13), 134.64 
(CH-6), 128.6 (CH-16/17/14/18), 128.4 (CH-16/17/14/18), 126.3 (C5), 118.6 (C7), 117.0 (CH-
3), 104.5 (C1), 35.8 (CH2-12), 31.6 (CH2-11), 20.1 (CH3-9). HRMS-ESI m/z [M+Na]+ calculated 
for C16H15NNaO 260.1046, found 260.1046. LCMS - Analytical UPLC 2-98% MeCN:Water 
(0.1% TFA), tR 0.82 min, [M+H]+ 238.4 m/z (95%). 
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5-Ethyl-4-hydroxy-2-methyl-benzonitrile (148) 
 
Chloro(trimethyl)silane (1.16 mL, 9.13 mmol) was added to a suspension of 5-ethyl-4-
methoxy-2-methyl-benzonitrile (143) (0.40 g, 2.28 mmol) and sodium iodide (1.37 g, 
9.13 mmol) in acetonitrile (10 mL). The reaction mixture was sealed and heated to 80 °C for 
16 h. The cooled reaction mixture was partitioned between sodium thiosulfate (aq) (0.1 M, 
100 mL) and ethyl acetate (2 x 100 mL). The combined organic layers were dried over MgSO4, 
filtered and concentrated under reduced pressure. The residue was purified by flash silica 
chromatography eluting with heptane to 40% ethyl acetate in heptane to provide the title 
compound as a white solid (0.204 g, 55%). m.p. 99-100 °C. IR (neat, vmax) cm-1 3277, 2221, 
1610, 1409, 1255. 1H NMR (500 MHz, CDCl3) δH  7.35 (s, 1H, CH-6), 6.70 (s, 1H, CH-3), 6.02 
(br s, 1H, OH-10), 2.59 (q, J = 7.6 Hz, 2H, CH2-11), 2.44 (s, 3H, CH3-9), 1.21 (t, J = 7.6 Hz, 3H, 
CH3-12). 13C NMR (126 MHz, CDCl3) δC 157.5 (C4), 141.7 (C2), 133.5 (CH-6), 128.8 (C5), 118.9 
(C7), 116.7 (CH-3), 103.9 (C1), 22.2 (CH2-11), 20.0 (CH3-9), 14.2 (CH3-12). HRMS-ESI m/z [M-
H]- calculated for C10H10NO 160.0768, found 160.0766. LCMS - Analytical MDAP 30-95% 
MeCN:Water (0.1% Formic), tR 16.02 min, [M-H]- 160.1 m/z (95%). 
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4-Hydroxy-5-isopentyl-2-methyl-benzonitrile (149) 
 
Iodo(trimethyl)silane (0.75 mL, 5.25 mmol) was added to a solution of 4-methoxy-5-
isopentyl-2-methyl-benzonitrile (144) (0.290 g, 1.31 mmol) in acetonitrile (4 mL). The 
reaction mixture was sealed and heated to 90 °C in the microwave (Biotage Initiator®) for 
1 h. The cooled reaction mixture was partitioned between sodium thiosulfate (aq) (0.1 M, 
10 mL) and CH2Cl2 (2 x 20 mL). The chlorinated layers were separated through a phase 
separator and concentrated under reduced pressure. The residue was purified by flash silica 
chromatography eluting with heptane to 40% ethyl acetate in heptane to provide the title 
compound as a white solid (0.225 g, 84%). m.p. 69-71 °C. IR (neat, vmax) cm-1 3253, 2953, 
2223, 1607, 1416, 1267. 1H NMR (500 MHz, CDCl3) δH 7.37 (s, 1H, CH-6), 6.70 (s, 1H, CH-3), 
5.38 (s, 1H, OH-10), 2.61-2.55 (m, 2H, CH2-11), 2.47 (s, 3H, CH-9), 1.67-1.56 (m, 1H, CH-13), 
1.52-1.45 (m, 2H, CH2-12), 0.97 (d, J = 6.7 Hz, 6H, CH3's-14&15). 13C NMR (126 MHz, CDCl3) 
δC 157.1 (C4). 141.6 (C2), 134.2 (CH-6), 127.6 (C5), 118.8 (C7), 116.8 (CH-3), 104.4 (C1), 38.5 
(CH2-12), 27.8 (CH-13), 27.0 (CH2-11), 22.5 (CH3's-14&15), 20.0 (CH3-9). HRMS-ESI m/z 
[M+Na]+ calculated for C13H17NNaO 226.1202, found 226.1202. LCMS - Analytical UPLC 2-
98% MeCN:Water (0.1% TFA), tR 0.86 min, [M+H]+ 204.4 m/z (95%). 
  
251 
5-(3-Fluorophenyl)-4-hydroxy-2-methyl-benzonitrile (150) 
 
Sulfuryl chloride (0.02 mL, 0.39 mmol) was added to a solution of 5-(3-fluorophenyl)-4-
hydroxy-2-methyl-benzonitrile (145) (0.04 g, 0.18 mmol) in diethyl ether (1 mL) and stirred 
for 16 h. The reaction mixture was partitioned between HCl (aq) (1 M, 5 mL) and CH2Cl2 
(2 x 10 mL). The chlorinated layers were separated through a phase separator and 
concentrated under reduced pressure. The residue was purified by flash silica 
chromatography eluting with heptane to 40% ethyl acetate in heptane to provide the title 
compound as a white solid (0.026 g, 56%). m.p. 193-194 °C. IR (neat, vmax) cm-1 3314, 2923, 
2227, 1594, 1461, 1398, 1291. 1H NMR (500 MHz, CDCl3) δH 7.55 (s, 1H, CH-6), 7.50-7.41 (m, 
1H, CH-16), 7.34-7.27 (m, 2H, CH-15&17), 7.17-7.09 (m, 1H, CH-13), 6.29 (s, 1H, OH-11), 2.66 
(s, 3H, CH3-9). 13C NMR (126 MHz, CDCl3) δC 162.6 (d, J = 230.4 Hz, CF-14), 152.0 (C4), 140.4 
(C2), 137.2 (d, J = 8 Hz, C12), 132.8 (CH-6), 130.2 (d, J = 8 Hz, CH-16), 126.7 (d, J = 2 Hz, C5), 
124.7 (d, J = 3 Hz, CH-17), 122.0 (C3 - observed HMBC), 117.5 (C7), 116.2 (d,  J = 23 Hz, CH-
15), 115.4 (d, J = 21 Hz, CH-13), 106.1 (C1), 19.1 (CH3-9). HRMS-ESI m/z [M-H]- calculated for 
C14H835ClFNO 260.0284, found 260.0275. LCMS - Analytical UPLC 2-98% MeCN:Water (0.1% 
TFA), tR 0.82 min, no mass ion observed, (95%). 
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5-Benzyl-3-chloro-4-hydroxy-2-methyl-benzonitrile (151) 
 
Sulfuryl chloride (0.01 mL, 0.18 mmol) was added to a solution of 5-benzyl-4-hydroxy-2-
methyl-benzonitrile (146) (0.02 g, 0.09 mmol) in diethyl ether (1 mL) and stirred for 16 h. The 
reaction mixture was partitioned between HCl (aq) (1 M, 5 mL) and CH2Cl2 (2 x 10 mL). The 
chlorinated layers were separated through a phase separator and concentrated under 
reduced pressure. The residue was purified by flash silica chromatography eluting with 
heptane to 40% ethyl acetate in heptane to provide the title compound as a white solid 
(0.017 g, 74%). m.p. 151-153 °C. IR (neat, vmax) cm-1 3320, 2226, 1595, 1414, 1240, 1157. 
1H NMR (500 MHz, CDCl3) δH 7.37-7.30 (m, 2H, CH-14/16), 7.30-7.16 (m, 4H, CH-6/15/13/17), 
6.20 (br, 1H, OH-11), 4.01 (s, 2H, CH2-12), 2.58 (s, 3H, CH3-9). 13C NMR (126 MHz, CDCl3) δC 
153.0 (C4), 138.9 (C2), 138.6 (C12), 132.7 (CH-6), 128.9 (CH-13/17), 128.7 (CH-14/16), 127.6 
(C5), 126.7 (CH-15), 121.3 (C3), 117.9 (C7), 105.4 (C1), 35.8 (CH2-11), 18.9 (CH3-9). HRMS-ESI 
m/z [M+Na]+ calculated for C15H1235ClNNaO 280.0500, found 280.0502. LCMS - Analytical 
UPLC 2-98% MeCN:Water (0.1% TFA), tR 0.83 min, [M+H]+ 258.4 m/z, (95%). 
3-Chloro-4-hydroxy-2-methyl-5-(2-phenylethyl)benzonitrile (152) 
 
Sulfuryl chloride (0.04 mL, 0.50 mmol) was added to a solution of 4-hydroxy-2-methyl-5-(2-
phenylethyl)benzonitrile (147) (0.05 g, 0.21 mmol) in diethyl ether (1 mL) and stirred for 16 h. 
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The reaction mixture was partitioned between HCl (aq) (1 M, 5 mL) and CH2Cl2 (2 x 10 mL). 
The chlorinated layers were separated through a phase separator and concentrated under 
reduced pressure. The residue was purified by flash silica chromatography eluting with 
heptane to 40% ethyl acetate in heptane to provide the title compound as a white solid 
(0.037 g, 65%). m.p. 144-145 °C. IR (neat, vmax) cm-1 3304, 2923, 2228, 1600, 1320,1164. 1H 
NMR (500 MHz, CDCl3) δH 7.34-7.29 (m, 2H, CH-16/18), 7.27-7.16 (m, 4H, CH-6/17/15/19), 
6.16 (OH-11), 3.00-2.88 (m, 4H, CH2-12&13), 2.58 (s, 3H, CH3-9). 13C NMR (126 MHz, CDCl3) 
δC 153.1 (C4), 141.0 (C14), 138.7 (C2), 132.4 (CH-6), 128.5 (CH's-15/16/18/19), 128.4 (CH-
15/16/18/19), 127.8 (C5), 126.2 (CH-17), 121.2 (C3), 118.0 (C7), 105.2 (C1), 35.3 (CH2-13), 
32.2 (CH2-12), 18.9 (CH3-9). HRMS-ESI m/z [M-H]- calculated for C16H1335ClNO 270.0691, 
found 270.0682. LCMS - Analytical UPLC 2-98% MeCN:Water (0.1% TFA), tR 0.89 min, poor 
ionisation – no mass ion observed, (> 95%). 
3-Chloro-5-ethyl-4-hydroxy-2-methyl-benzonitrile (153) 
 
Sulfuryl chloride (0.1 mL, 1.16 mmol) was added to a solution of 5-ethyl-4-hydroxy-2-methyl-
benzonitrile (148) (0.085 g, 0.53 mmol) in diethyl ether (1 mL) and stirred for 16 h. The 
reaction mixture was partitioned between HCl (aq) (1 M, 5 mL) and CH2Cl2 (2 x 10 mL). The 
chlorinated layers were separated through a phase separator and concentrated under 
reduced pressure. The residue was purified by flash silica chromatography eluting with 
heptane to 40% ethyl acetate in heptane to provide the title compound as a white solid 
(0.046 g, 45%). m.p. 95-97 °C. IR (neat, vmax) cm-1 3336, 2966, 2219, 1601, 1413, 1313, 1166. 
1H NMR (500 MHz, CDCl3) δH 7.32 (s, 1H, CH-6), 6.14 (s, 1H, OH-11), 2.66 (q, J = 7.6 Hz, 2H, 
CH2-12), 2.54 (s, 3H, CH3-9), 1.21 (t, J = 7.6 Hz, 3H, CH3-13). 13C NMR (126 MHz, CDCl3) δC 
153.0 (C4), 138.3 (C2), 131.4 (CH-6), 130.1 (C5), 121.0 (C3), 118.1 (C7), 105.2 (C1), 23.1 (CH2-
254 
12), 18.8 (CH3-9), 13.4 (CH3-13). HRMS-ESI m/z [M-H]- calculated for C10H935ClNO 194.0378, 
found 194.0375. LCMS - Analytical MDAP 30-95% MeCN:Water (0.1% Formic), tR 21.64 min, 
[M-H]- 193.95 m/z (> 95%). 
3-Chloro-4-hydroxy-5-isopentyl-2-methyl-benzonitrile (154) 
 
Sulfuryl chloride (0.16 mL, 2.06 mmol) was added to a solution of 4-hydroxy-5-isopentyl-2-
methyl-benzonitrile (149) (0.175 g, 0.86 mmol) in diethyl ether (2 mL) and stirred for 16 h. 
The reaction mixture was partitioned between HCl (aq) (1 M, 5 mL) and CH2Cl2 (2 x 10 mL). 
The chlorinated layers were separated through a phase separator and concentrated under 
reduced pressure. The residue was purified by flash silica chromatography eluting with 
heptane to 40% ethyl acetate in heptane to provide the title compound as a white solid 
(0.185 g, 90%). m.p. 82-83 °C. IR (neat, vmax) cm-1 3303, 2957, 2227, 1603, 1471,1319, 1245, 
1170. 1H NMR (500 MHz, CDCl3) δH 7.34 (s, 1H, CH-6), 6.11 (s, 1H, OH-11), 2.66 (m, 2H, CH2-
12), 2.57 (s, 3H, CH3-9), 1.62 (m, 1H, CH-14), 1.49 (m, 2H, CH2-13), 0.97 (d, J = 6.6 Hz, 6H, 
CH3-15&16). 13C NMR (126 MHz, CDCl3) δC 153.0 (C4), 138.2 (C2), 132.1 (CH-6), 129.1 (C5), 
121.1 (C3), 118.1 (C7), 105.2 (C1), 38.3 (CH2-13), 27.9 (CH2-12), 27.8 (CH-14), 22.5 (CH2s-
15&16), 18.8 (CH3-9). HRMS-ESI m/z [M-H]- calculated for C13H1535ClNO 236.0848, found 
236.0840. LCMS - Analytical UPLC 2-98% MeCN:Water (0.1% Formic), tR 0.92 min, [M+H]+ 
238.3 m/z (95%). 
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 5-(Cyclohexen-1-yl)-4-methoxy-2-methyl-benzonitrile (155) 
 
Palladium (II) acetate (0.006 g, 0.03 mmol), and 2-dicyclohexylphosphino-2’-6’-
diisopropoxybiphenyl (0.025 g, 0.06 mmol) was added to a mixture of K3PO4 (0.59 g, 
2.76 mmol), 5-bromo-4-methoxy-2-methyl-benzonitrile (139) (0.25 g, 1.11 mmol) and 
cyclohexen-1-yl boronic acid (0.21 g, 1.66 mmol) in toluene (5 mL) and heated to 100 °C for 
16 h. The reaction mixture was partitioned between CH2Cl2 (10 mL), and HCl (aq) (1 M, 10 mL), 
the chlorinated layer was separated through a phase separator and concentrated under 
reduced pressure. The residue was purified by flash silica chromatography, eluting with 
heptane to 20% ethyl acetate in heptane, to provide the title compound as a yellow solid 
(0.187 g, 74%). m.p. 70-72 °C. IR (neat, vmax) cm-1 2928, 2214, 1604, 1452, 1256. 1H NMR 
(500 MHz, CDCl3) δH 7.36 (s, 1H, CH-6), 6.74 (s, 1H, CH-3), 5.78 (tt, J = 3.8, 1.7 Hz, 1H, CH-17), 
3.87 (s, 3H, CH3-11), 2.53 (s, 3H, CH3-9), 2.30 (m, 2H, CH2-13), 2.20 (m, 2H, CH2-16), 1.78-
1.65 (m, 4H, CH2s-14&15). 13C NMR (126 MHz, CDCl3) δC 159.9 (C4), 142.5 (C2), 135.6 (C12), 
133.3 (CH-6), 132.3 (C5), 127.6 (CH-17), 118.7 (C7), 112.2 (CH-3), 104.1 (C1), 55.6 (CH3-11), 
28.6 (CH2-13), 25.6 (CH-16), 22.8 (CH2-14/15), 22.0 (CH2-14/15) 20.6 (CH3-9). HRMS-ESI m/z 
[M+Na]+ calculated for C15H17NNaO 250.1202, found 250.1206. LCMS - Analytical UPLC 2-
98% MeCN:Water (0.1% TFA), tR 0.95 min, [M+H]+ 228.4 m/z, (95%). 
5-(Cyclopenten-1-yl)-4-methoxy-2-methyl-benzonitrile (156) 
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Palladium (II) acetate (0.006 g, 0.03 mmol), and 2-dicyclohexylphosphino-2’-6’-
diisopropoxybiphenyl (0.025 g, 0.06 mmol) was added to a mixture of K3PO4 (0.59 g, 
2.76 mmol), 5-bromo-4-methoxy-2-methyl-benzonitrile (139) (0.25 g, 1.11 mmol) and 
cyclopenten-1-yl boronic acid (0.19 g, 1.66 mmol) in toluene (5 mL) and heated to 100 °C for 
16 h. The reaction mixture was partitioned between CH2Cl2 (10 mL), and HCl (aq) (1 M, 10 mL), 
the chlorinated layer was separated through a phase separator and concentrated under 
reduced pressure. The residue was purified by flash silica chromatography, eluting with 
heptane to 20% ethyl acetate in heptane, to provide the title compound as a yellow solid 
(0.212 g, 89%). m.p. 106-107 °C. IR (neat, vmax) cm-1 2902, 2211, 1601, 1457, 1251. 1H NMR 
(500 MHz, CDCl3) δH 7.48 (s, 1H, CH-6), 6.79 (s, 1H, CH-3), 6.48-6.45, (m, 1H, CH-13), 3.93 (s, 
3H, CH3-11), 2.76-2.69 (m, 2H, CH2-16), 2.61-2.54 (m, 5H, CH2-14 & CH3-9), 1.98 (tt, J = 8.3, 
7.0 Hz, CH2-15). 13C NMR (126 MHz, CDCl3) δC 160.4 (C4), 142.1 (C2), 137.2 (C12), 132.5 (CH-
6), 132.1 (CH-13), 125.0 (C5), 118.8 (C7), 112.2 (CH-3), 104.1 (C1), 55.5 (CH3-11), 35.0 (CH2-
16), 34.0 (CH2-14), 22.7 (CH2-15), 20.6 (CH3-9). HRMS-ESI m/z [M+Na]+ calculated for 
C14H15NNaO 236.1046, found 236.1043. LCMS - Analytical UPLC 2-98% MeCN:Water (0.1% 
TFA), tR 0.92 min, [M+H]+ 214.4 m/z, (95%). 
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5-[(E)-2-Cyclopropylvinyl]-4-methoxy-2-methyl-benzonitrile (157) 
 
Palladium (II) acetate (0.006 g, 0.03 mmol), and 2-dicyclohexylphosphino-2’-6’-
diisopropoxybiphenyl (0.025 g, 0.06 mmol) was added to a mixture of K3PO4 (0.59 g, 
2.76 mmol), 5-bromo-4-methoxy-2-methyl-benzonitrile (139) (0.25 g, 1.11 mmol) and [(E)-
2-cyclopropylvinyl]-(1,1,2,2-tetramethylpropoxy)boronic acid (0.35 g, 1.66 mmol) in toluene 
(5 mL) and water (0.5 mL) and heated to 100 °C for 16 h. The reaction mixture was 
partitioned between CH2Cl2 (10 mL), and HCl (aq) (1 M, 10 mL), the chlorinated layer was 
separated through a phase separator and concentrated under reduced pressure. The residue 
was purified by flash silica chromatography, eluting with heptane to 20% ethyl acetate in 
heptane, to provide the title compound as a yellow solid (0.209 g, 88%). m.p. 60-62 °C. IR 
(neat, vmax) cm-1 2213, 1606, 1459, 1259. 1H NMR (500 MHz, CDCl3) δH 7.55 (s, 1H, CH-6), 
6.74 (s, 1H, CH-3), 6.67, (d, J = 15.8 Hz, 1H, CH-12), 5.73 (dd, J = 15.8, 9.0 Hz, 1H, CH-13), 3.90 
(s, 3H, CH3-11), 2.52 (s, 3H, CH3-9), 1.60 (m, 1H, CH-14), 0.91-0.79 (m, 2H, CH2-15 & 16), 0.59-
0.50 (m, 2H, CH2-15&16). 13C NMR (126 MHz, CDCl3) δC 158.9 (C4), 141.9 (C2), 137.4 (CH-13), 
130.0 (CH-6), 125.7 (C5), 120.0 (CH-12), 118.7 (C7), 112.1 (CH-3), 104.4 (C1) , 55.6 (CH3-11), 
20.7 (CH3-9), 15.0 (CH-14), 7.5 (CH2-15&16). HRMS-ESI m/z [M+Na]+ calculated for 
C14H15NNaO 236.1046, found 236.1048. LCMS - Analytical UPLC 2-98% MeCN:Water (0.1% 
TFA), tR 0.89 min, [M+H]+ 214.4 m/z, (95%). 
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5-Cyclohexyl-4-methoxy-2-methyl-benzonitrile (158) 
 
Triethylsilane (0.06 mL, 0.03 mmol) was added dropwise to a suspension of 5-(cyclohexen-1-
yl)-4-methoxy-2-methyl-benzonitrile (155) (0.16 g, 0.70 mmol and palladium on carbon (10%, 
0.08 g, 0.07 mmol) in ethanol (5 mL) stirred at rt for 16 h. The reaction mixture was filtered 
through a pad of celite and washed through with ethanol (2 × 10 mL), the filtrate was 
concentrated under reduced pressure. The residue was purified by flash silica 
chromatography, eluting with heptane to 20% ethyl acetate in heptane, to provide the title 
compound as a white solid (0.145 g, 90%). m.p. 94-96 °C. IR (neat, vmax) cm-1 2924, 2214, 
1603, 1455, 1249. 1H NMR (500 MHz, CDCl3) δH 7.39 (s, 1H, CH-6), 6.73 (s, 1H, CH-3), 3.88 (s, 
3H, CH3-11), 2.89 (tt, J = 11.0, 3.1 Hz, 1H, CH-12), 2.52 (s, 3H, CH3-9), 1.88-1.78 (m, 5H, CH2s 
13/17/14/16/15), 1.48-1.20 (m, 4H, CH2s 13/17/14/16), 1.03-0.94 (m, 1H, CH2-15). 13C NMR 
(126 MHz, CDCl3) δC 159.9 (C4), 141.4 (C2), 134.9 (C5), 130.7 (CH-6), 119.1 (C7), 111.6 (CH-
3), 104.0 (C1), 55.5 (CH3-11), 36.3 (CH-12), 33.0 (CH2s-13/17), 26.9 (CH2s-13/14/16), 26.2 
(CH2s-13/14/16), 20.5 (CH3-9). HRMS-ESI m/z [M+Na]+ calculated for C15H19NNaO 252.1359, 
found 252.1358. LCMS - Analytical UPLC 2-98% MeCN:Water (0.1% TFA), tR 1.01 min, [M+H]+ 
230.4 m/z, (95%). 
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5-Cyclopentyl-4-methoxy-2-methyl-benzonitrile (159) 
 
Triethylsilane (0.06 mL, 0.03 mmol) was added dropwise to a suspension of 5-(cyclopenten-
1-yl)-4-methoxy-2-methyl-benzonitrile (156) (0.15 g, 0.70 mmol and palladium on carbon 
(10%, 0.08 g, 0.07 mmol) in ethanol (5 mL) stirred at rt for 16 h. The reaction mixture was 
filtered through a pad of celite and washed through with ethanol (2 × 10 mL), the filtrate was 
concentrated under reduced pressure. The residue was purified by flash silica 
chromatography, eluting with heptane to 20% ethyl acetate in heptane, to provide the title 
compound as a colourless oil (0.12 g, 79%). IR (neat, vmax) cm-1 2950, 2217, 1608, 1501, 
1458, 1251. 1H NMR (500 MHz, CDCl3) δH 7.41 (s, 1H, CH-6), 6.73 (s, 1H, CH-3), 3.88 (s, 3H, 
CH3-11), 3.25 (p, J = 8.6, 2H, CH-12), 2.06-1.97 (m, 2H, CH2-13/16), 1.85-1.64 (m, 4H, 
CH2-14&15), 1.56-1.46 (m, 2H, CH2-13/16). 13C NMR (126 MHz, CDCl3) δC 160.6 (C4), 141.5 
(C2), 133.3 (C5), 130.6 (CH-6), 119.1 (C7), 111.7 (CH-3), 103.9 (C1), 55.5 (CH3-11), 38.6 
(CH-12), 32.7 (CH2s-13&16), 25.2 (CH2s-14&15), 20.5 (CH3-9). HRMS-ESI m/z [M+Na]+ 
calculated for C14H17NNaO 238.1202, found 238.1202. LCMS - Analytical UPLC 2-98% 
MeCN:Water (0.1% TFA), tR 0.96 min, [M+H]+ 216.4 m/z, (95%). 
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5-Cyclopentyl-4-methoxy-2-methyl-benzonitrile (160) 
 
Triethylsilane (0.06 mL, 0.03 mmol) was added dropwise to a suspension of 5-(2-
cyclopropylethyl)-4-methoxy-2-methyl-benzonitrile (157) (0.15 g, 0.70 mmol and palladium 
on carbon (10%, 0.08 g, 0.07 mmol) in ethanol (5 mL) stirred at rt for 16 h. The reaction 
mixture was filtered through a pad of celite and washed through with ethanol (2 × 10 mL), 
the filtrate was concentrated under reduced pressure. The residue was purified by flash silica 
chromatography, eluting with heptane to 20% ethyl acetate in heptane, to provide the title 
compound as a colourless oil (0.125 g, 83%). IR (neat, vmax) cm-1 2926, 2217, 1609, 1503, 
1459, 1255. 1H NMR (500 MHz, CDCl3) δH 7.36 (s, 1H, CH-6), 6.72 (s, 1H, CH-3), 3.88 (s, 3H, 
CH3-11), 2.68 (t, J = 7.6 Hz, 2H, CH2-12), 2.53 (s, 3H, CH3-9), 1.49-1.42 (m, 2H, CH2-13), 0.74-
0.64 (m, 1H, CH-14), 0.46-0.41 (m, 2H, CH2-15/16), 0.06-0.01 (m, 2H, CH2-15/16). 13C NMR 
(126 MHz, CDCl3) δC 160.6 (C4). 141.9 (C2), 133.4 (CH-6), 129.6 (C5), 119.0 (C7), 111.7 (CH-
3), 103.7 (C1), 55.5 (CH3-11), 34.4 (CH2-13), 29.6 (CH2-12), 20.6 (CH3-9), 10.8 (CH-14), 4.5 
(CH2-15/16). HRMS-ESI m/z [M+Na]+ calculated for C14H17NNaO 238.1202, found 238.1203. 
LCMS - Analytical UPLC 2-98% MeCN:Water (0.1% TFA), tR 0.94 min, [M+H]+ 216.4 m/z, (> 
95%). 
  
261 
5-Cyclohexyl-4-hydroxy-2-methyl-benzonitrile (161) 
 
Iodo(trimethyl)silane (0.12 mL, 0.82 mmol) was added to a solution of 5-cyclohexyl-4-
methoxy-2-methyl-benzonitrile (158) (0.075 g, 0.33 mmol) in acetonitrile (1 mL). The 
reaction mixture was sealed and heated to 90 °C in the microwave (Biotage Initiator®) for 
1 h. The cooled reaction mixture was partitioned between sodium thiosulfate (aq) (0.1 M, 
10 mL) and CH2Cl2 (2 x 20 mL). The chlorinated layers were separated through a phase 
separator and concentrated under reduced pressure. The residue was purified by flash silica 
chromatography eluting with heptane to 40% ethyl acetate in heptane to provide the title 
compound as a white solid (0.05 g, 71%). m.p. 158-159 °C. IR (neat, vmax) cm-1 3249, 2927, 
2223, 1609, 1411, 1258. 1H NMR (500 MHz, CDCl3) δH 7.41 (s, 1H, CH-6), 6.69 (s, 1H, CH-3), 
5.29 (s, 1H, OH-10), 2.77 (tt, J = 11.5, 3.1 Hz, 1H, CH-11), 2.47 (s, 3H, CH3-9), 1.92-1.84 (m, 
4H, CH2-12/16), 1.83-1.76 (m, 1H, CH-14), 1.49-1.23 (m, 5H, CH2-13/15&CH-14). 13C NMR 
(126 MHz, CDCl3) δC 156.4 (C4), 141.2 (C2), 132.3 (C5), 131.7 (CH-6), 118.9 (C7), 116.9 (CH-
3), 104.7 (C1), 36.7 (CH-11), 32.8 (CH2-12/16), 26.8 (CH2-13/15), 26.1 (CH2-14), 20.0 (CH3-9). 
HRMS-ESI m/z [M+Na]+ calculated for C14H17NNaO 238.1202, found 238.1204. LCMS - 
Analytical UPLC 2-98% MeCN:Water (0.1% TFA), tR 0.85 min, [M+H]+ 216.4 m/z (95%). 
  
262 
5-Cyclopentyl-4-hydroxy-2-methyl-benzonitrile (162) 
 
Iodo(trimethyl)silane (0.12 mL, 0.87 mmol) was added to a solution of 5-cyclopentyl-4-
methoxy-2-methyl-benzonitrile (159) (0.075 g, 0.35 mmol) in acetonitrile (1 mL). The 
reaction mixture was sealed and heated to 90 °C in the microwave (Biotage Initiator®) for 1 
h. The cooled reaction mixture was partitioned between sodium thiosulfate (aq) (0.1 M, 10 
mL) and CH2Cl2 (2 x 20 mL). The chlorinated layers were separated through a phase separator 
and concentrated under reduced pressure. The residue was purified by flash silica 
chromatography eluting with heptane to 40% ethyl acetate in heptane to provide the title 
compound as a white solid (0.07 g, 99%). m.p. 96-97 °C. IR (neat, vmax) cm-1 3254, 2949, 
2224, 1609, 1412, 1286. 1H NMR (500 MHz, CDCl3) δH 7.43 (s, 1H, CH-6), 6.70 (s, 1H, CH-3), 
5.36 (s, 1H, OH-10), 3.17 (p, J = 8.5 Hz, 1H, CH-11), 2.47 (s, 3H, CH3-9), 2.11-2.03 (m, 2H, CH2-
12/15), 1.88-1.67 (m, 4H, CH2-12/15, 13/14), 1.62-1.53 (m, 2H, CH2-13/14). 13C NMR (126 
MHz, CDCl3) δC 157.1 (C4), 141.4 (C2), 131.6 (CH-6), 130.7 (C5), 118.9 (C7), 116.9 (CH-3), 
104.5 (C1), 38.5 (CH-11), 32.6 (CH2-12&15), 25.2 (CH2-13&14), 20.0 (CH3-9). HRMS-ESI m/z 
[M+Na]+ calculated for C13H15NNaO 224.1046, found 224.1044. LCMS - Analytical UPLC 2-
98% MeCN:Water (0.1% TFA), tR 0.80 min, [M+H]+ 202.4 m/z (> 95%). 
  
263 
3-Chloro-5-cyclohexyl-4-hydroxy-2-methyl-benzonitrile (163) 
 
Sulfuryl chloride (0.04 mL, 0.44 mmol) was added to a solution of 5-cyclohexyl-4-hydroxy-2-
methyl-benzonitrile (161) (0.04 g, 0.19 mmol) in diethyl ether (2 mL) and stirred for 16 h. The 
reaction mixture was partitioned between HCl (aq) (1 M, 5 mL) and CH2Cl2 (2 x 10 mL). The 
chlorinated layers were separated through a phase separator and concentrated under 
reduced pressure. The residue was purified by flash silica chromatography eluting with 
heptane to 40% ethyl acetate in heptane to provide the title compound as a white solid 
(0.031 g, 67%). m.p. 165-166 °C. IR (neat, vmax) cm-1 3289, 2919, 2229, 1601, 1415, 1163. 
1H NMR (500 MHz, CDCl3) δH 7.37 (s, 1H, CH-6), 6.13 (s, 1H, OH-11), 2.93 (tt, J = 11.7, 2.9 Hz, 
1H, CH-12), 2.57 (s, 3H, CH3-9), 1.91-1.85 (m, 4H, CH2-13/17/14/16), 1.82-1.76 (m, 1H, CH2-
15), 1.50-1.22 (m, 5H, CH2-13/14/15/16/17). 13C NMR (126 MHz, CDCl3) δC 152.4 (C4), 137.9 
(C2), 133.8 (C5), 129.6 (CH-6), 121.1 (C3), 118.3 (C7), 105.4 (C1), 37.5 (CH-12), 32.6 (CH2s-
13&17), 26.7 (CH2s-14&16), 26.1 (CH2s-15), 18.8 (CH2-15). HRMS-ESI m/z [M-H]- calculated 
for C14H1535ClNO 248.0848, found 248.0840. LCMS - Analytical UPLC 2-98% MeCN:Water 
(0.1% Formic), tR 0.93 min, poor ionisation, no mass ion observed (95%). 
  
264 
3-Chloro-5-cyclopentyl-4-hydroxy-2-methyl-benzonitrile (164) 
 
Sulfuryl chloride (0.04 mL, 0.44 mmol) was added to a solution of 5-cyclopentyl-4-hydroxy-
2-methyl-benzonitrile (162) (0.04 g, 0.2 mmol) in diethyl ether (2 mL) and stirred for 16 h. 
The reaction mixture was partitioned between HCl (aq) (1 M, 5 mL) and CH2Cl2 (2 x 10 mL). 
The chlorinated layers were separated through a phase separator and concentrated under 
reduced pressure. The residue was purified by flash silica chromatography eluting with 
heptane to 40% ethyl acetate in heptane to provide the title compound as a white solid 
(0.028 g, 60%). m.p. 102-104 °C. IR (neat, vmax) cm-1 3294, 2943, 2227, 1602, 1473, 1318, 
1164. 1H NMR (500 MHz, CDCl3) δH 7.37 (s, 1H, CH-6), 6.13 (s, 1H, OH-11), 3.27 (p, J = 8.5 Hz, 
1H, CH-12), 2.55 (s, 3H, CH3-9), 2.09-2.01 (m, 2H, CH2-13/16), 1.59-1.42 (m, 4H, CH2-
13/16/14/15), 1.59-1.49 (m, 2H, CH2-14/15). 13C NMR (126 MHz, CDCl3) δC 153.0 (C4), 138.0 
(C2), 132.4 (C5), 129.7 (CH-6), 121.1 (C3), 118.3 (C7), 105.2 (C1), 39.5 (CH-12), 32.5 (CH2-
13&16), 25.2 (CH2-14&15), 18.8 (CH3-9). HRMS-ESI m/z [M-H]- calculated for C13H1335ClNO 
234.0691, found 234.0683. LCMS - Analytical UPLC 2-98% MeCN:Water (0.1% Formic), tR 
0.88 min, poor ionisation, no mass ion observed (95%). 
  
265 
5-[(E)-2-Cyclopropylvinyl]-4-hydroxy-2-methyl-benzonitrile (165) 
 
Palladium (II) acetate (0.013 g, 0.06 mmol), and 2-dicyclohexylphosphino-2’-6’-
diisopropoxybiphenyl (0.055 g, 0.12 mmol) was added to a mixture of K3PO4 (1.25 g, 
5.90 mmol), 5-bromo-4-hydroxy-2-methyl-benzonitrile (85) (0.50 g, 2.36 mmol) and [(E)-2-
cyclopropylvinyl]-(1,1,2,2-tetramethylpropoxy)boronic acid (0.73 mL, 3.54 mmol) in toluene 
(8 mL) and water (0.8 mL) and heated to 100 °C for 16 h. The reaction mixture was 
partitioned between CH2Cl2 (10 mL), and HCl (aq) (1 M, 10 mL), the chlorinated layer was 
separated through a phase separator and concentrated under reduced pressure. The residue 
was purified by flash silica chromatography, eluting with heptane to 20% ethyl acetate in 
heptane, to provide the title compound as a yellow solid (0.226 g, 48%). m.p. 109-111 °C. IR 
(neat, vmax) cm-1 3309, 2221, 1602, 1413, 1265. 1H NMR (500 MHz, CDCl3) δH 7.49 (s, 1H, 
CH-6), 6.70 (s, 1H, CH-3), 6.53, (d, J = 15.9 Hz, CH-11), 5.87 (br s, 1H, OH-10), 5.70 (dd, J = 
15.9, 9.1 Hz, 1H, CH-12), 2.44 (s, 3H, CH3-9), 1.65-1.57 (m, 1H, CH-13), 0.90-0.84 (m, 2H, CH2-
14/15), 0.58-0.53 (m, 2H, CH2-14/15). 13C NMR (126 MHz, CDCl3) δC 156.1 (C4), 141.8 (C2), 
138.8 (CH-12), 131.4 (CH-6), 124.0 (C5), 119.5 (CH-11), 118.7 (C7), 117.3 (CH-3), 104.2 (C1), 
20.1 (CH3-9), 15.0 (CH-13), 7.55 (CH2-14/15). LCMS - Analytical MDAP LCMS 30-95% 
MeCN:Water (0.1% Formic), tR 17.18 min, [M-H]- 198.1 m/z, (95%). 
  
266 
5-Cyclopentyl-4-hydroxy-2-methyl-benzonitrile (166) 
 
Triethylsilane (0.17 mL, 1.05 mmol) was added dropwise to a suspension of 5-[(E)-2-
cyclopropylvinyl]-4-hydroxy-2-methyl-benzonitrile (165) (0.20 g, 1.00 mmol and palladium 
on carbon (10%, 0.010 g, 0.10 mmol) in ethanol (5 mL) stirred at rt for 16 h. The reaction 
mixture was filtered through a pad of celite and washed through with ethanol (2 × 10 mL), 
the filtrate was concentrated under reduced pressure. The residue was purified by flash silica 
chromatography, eluting with heptane to 20% ethyl acetate in heptane, then further purified 
by reverse-phase chromatography, eluting with 60% methanol in water to 95% methanol in 
water to provide the title compound as a white solid (0.060 g, 30%). m.p. 92-93 °C. IR (neat, 
vmax) cm-1 3290, 2221, 1608, 1411, 1263. 1H NMR (500 MHz, CDCl3) δH 7.36 (s, 1H, CH-6), 
6.69 (s, 1H, CH-3), 5.48 (br s, 1H, OH-10), 2.67 (t, J = 7.5 Hz, 2H, CH2-11), 2.45 (s, 3H, CH3-9), 
1.52-1.46 (m, 2H, CH2-12), 0.73-0.65 (m, 1H, CH-13), 0.47-0.43 (m, 2H, CH2-14&15), 0.07-
0.03 (m, 2H, CH2-14'&15'). 13C NMR (126 MHz, CDCl3) δC 157.3 (C4), 141.7 (C2), 134.5 (CH-6), 
127.0 (C5), 118.7 (C7), 116.9 (CH-3), 104.3 (C1), 34.4 (CH2-12), 29.3 (CH2-11), 20.03 (CH3-9), 
10.6 (CH-13), 4.55 (CH2-14&15). HRMS-ESI m/z [M+Na]+ and [M-H]- poor ionisation LRMS 
only EI+ 201 m/z. LCMS - Analytical MDAP 30-95% MeCN:Water (0.1% Formic), tR 18.25 min, 
[M-H] 200.1 m/z, (95%). 
  
267 
3-Chloro-5-(2-cyclopropylethyl)-4-hydroxy-2-methyl-benzonitrile (167) 
 
Sulfuryl chloride (0.09 mL, 1.12 mmol) was added to a solution of 5-(2-cyclopropylethyl)-4-
hydroxy-2-methyl-benzonitrile (166) (0.045 g, 0.22 mmol) in diethyl ether (2 mL) and stirred 
for 16 h. The reaction mixture was partitioned between HCl (aq) (1 M, 5 mL) and CH2Cl2 
(2 x 10 mL). The chlorinated layers were separated through a phase separator and 
concentrated under reduced pressure. The residue was purified by flash silica 
chromatography eluting with heptane to 40% ethyl acetate in heptane to provide the title 
compound as a white solid (0.048 g, 91%). m.p. 89-91 °C. IR (neat, vmax) cm-1 3334, 2922, 
2223, 1419, 1242, 1169. 1H NMR (500 MHz, CDCl3) δH  7.32 (s, 1H, CH-6), 6.10 (s, 1H, OH-11), 
2.74 (t, J = 7.6 Hz, 2H, CH2-12), 2.55 (s, 3H, CH3-9), 1.51-1.46 (m, 2H, CH-14), 0.72-0.64 (m, 
1H, CH-14), 0.46-0.40 (m, 2H, CH2-14&15), 0.08-0.01 (m, 2H, CH2-14'&15').13C NMR (126 
MHz, CDCl3) δC 153.1 (C4), 138.3 (C2), 132.4 (CH-6), 128.6 (C5), 121.0 (C3), 118.1 (C7), 105.1 
(C1), 34.1 (CH2-13), 30.2 (CH2-12), 18.8 (CH3-9), 10.6 (CH-14), 4.5 (CH2-15&16). HRMS-ESI 
m/z [M-H]- calculated for C13H1335ClNO 234.0691, found 234.0681. LCMS - Analytical MDAP 
30-95% MeCN:Water (0.1% Formic), tR 20.66 min, [M-H]- 234.05 m/z, (95%). 
  
268 
5-(4,4-Diethoxybutyl)-4-methoxy-2-methyl-benzonitrile (168) 
 
A solution of 1 M borane in THF (1.00 mL, 1.00 mmol) was added dropwise to 4,4-
diethoxybut-1-ene (0.56 mL, 3.32 mmol) at 0 °C. This solution was warmed to rt and stirred 
for 15 min. The solution was quenched with the addition of water (1 mL) and diluted with 
toluene (5 mL). Potassium phosphate tribasic (1.17 g, 5.53 mmol), 5-bromo-4-methoxy-2-
methyl-benzonitrile (139) (0.50 g, 2.21 mmol), palladium (II) acetate (0.012 g, 0.06 mmol) 
and 2-dicyclohexylphosphino-2’-6’-diisopropoxybiphenyl (0.05 g, 0.11 mmol) were added. 
The reaction mixture was sealed and heated 50 °C for 16 h. The cooled reaction mixture was 
filtered through a pad of celite, the filtrate partitioned between water (10 mL) and ethyl 
acetate (20 mL). The organic layer was separated, dried over MgSO4, filtered and 
concentrated under vacuum. The residue was purified by flash silica chromatography, eluting 
with petroleum ether to 15% ethyl acetate, followed by further purification by reverse-phase 
chromatography eluting with 60% MeOH in water to 100% MeOH to provide the title 
compound as a colourless oil (0.376 g, 58%). IR (neat, vmax) cm-1 2932, 2218, 1610, 1503, 
1459, 1256. 1H NMR (500 MHz, CDCl3) δH 7.31 (s, 1H, CH-6), 6.69 (s, 1H, CH-3), 4.48 (m, 1H, 
CH-15), 3.84 (s, 3H, CH3-9), 3.62 (m, 2H, CH2-18/19), 3.47 (m, 2H, CH2-18/19), 2.57 (m, 2H, 
CH2-12), 2.49 (s, 3H, CH3-7), 1.62 (m, 4H, CH2s-13/14), 1.19 (t, J = 7.0 Hz, 6H, CH3's-20/21). 
13C NMR (126 MHz, CDCl3) δC 160.6 (C4), 142.0 (C2), 133.3 (CH-6), 129.3 (C5), 118.9 (C10), 
111.7 (CH-3), 103.8 (C1), 102.7 (CH-15), 61.0 (CH2-18/19), 55.4 (CH3-9), 33.2 (CH2-14), 29.1 
(CH2-12), 24.5 (CH2-13), 20.6 (CH3-7), 15.3 (CH3-20/21). HRMS-ESI m/z [M+Na]+ and [M-H]- 
poor ionisation LRMS only EI+ 291 m/z. LCMS - Analytical MDAP 30-95% MeCN:Water (0.1% 
Formic), tR 21.79 min, no ionisation (95%). 
269 
5-(4,4-difluorobutyl)-4-methoxy-2-methyl-benzonitrile (169) 
 
HCl (aq) (1 M, 1.17 mL, 5.83 mmol) was added to a solution of 5-(4,4-diethoxybutyl)-4-
methoxy-2-methyl-benzonitrile (168) (0.17 g, 0.58 mmol) in tetrahydrofuran (5 mL) and 
stirred at rt for 2 h. The reaction mixture was diluted with water (20 mL) and extracted with 
ethyl acetate (2 × 30 mL), the organics were separated, dried over MgSO4, filtered and 
concentrated under reduced pressure. The residue was dissolved in CH2Cl2 (3 mL) and 
transferred to a PTFE flask, a solution of bis(2-methoxyethyl)aminosulfur trifluoride (50% 
solution in toluene, 0.37 mL, 0.99 mmol) was added and the reaction sealed. Ethanol (5 µL) 
was added and the reaction was stirred at rt for 16 h. The reaction mixture was quenched 
with the addition of saturated NaHCO3 (aq) (30 mL) and stirred at rt for 1 h. The resulting 
biphasic mixure was partitioned between water (20 mL) and CH2Cl2 (2 × 50 mL). The 
combined chlorinated layers were dried over MgSO4, filtered and concentrated under 
vacuum. The residue was purified by flash silica chromatography, eluting with petroleum 
ether to 15% ethyl acetate to provide the title compound as a waxy white solid (0.094 g, 67%). 
m.p. 64-66 °C. IR (neat, vmax) cm-1 2945, 2217, 1610, 1502, 1456, 1257. 1H NMR (500 MHz, 
CDCl3) δH 7.30 (s, 1H, CH-6), 6.72 (s, 1H, CH-3), 5.80 (tt, J = 56.8 Hz, 4.4 Hz, 1H, CH-15), 3.85 
(s, 3H, CH3-11), 2.60 (t, J = 7.6 Hz, 2H, CH2-12), 2.50 (s, 3H, CH3-9), 1.90-1.62 (m, 4H, CH2s-
13/14). 13C NMR (126 MHz, CDCl3) δC 160.6 (C4), 142.4 (C2), 133.4 (CH-6), 128.4 (C5), 118.7 
(C7), 117.1 (t, J = 238.6 Hz, CH-15), 111.9 (CH-3), 103.9 (C1), 55.5 (CH3-11), 33.5 (t, J = 21.2 
Hz, CH2-14), 28.8 (CH2-12), 21.9 (t, J = 5.7 Hz, CH2-13), 20.6 (CH3-9). HRMS-ESI m/z [M+Na]+ 
and [M-H]- poor ionisation LRMS only EI+ 239 m/z. LCMS - Analytical MDAP 30-95% 
MeCN:Water (0.1% Formic), tR 19.87 min, no ionisation (95%). 
270 
5-(4,4-difluorobutyl)-4-hydroxy-2-methyl-benzonitrile (170) 
 
Chloro(trimethyl)silane (0.05 mL, 0.37 mmol) was added to a suspension of 5-(4,4-
difluorobutyl)-4-methoxy-2-methyl-benzonitrile (169) (0.022 g, 0.09 mmol) and sodium 
iodide (0.20 g, 1.34 mmol) in acetonitrile (1 mL). The reaction mixture was sealed and heated 
to 80 °C for 16 h. The cooled reaction mixture was partitioned between sodium thiosulfate 
(aq) (0.1 M, 100 mL) and ethyl acetate (2 x 100 mL). The combined organic layers were dried 
over MgSO4, filtered and concentrated under reduced pressure. The residue was purified by 
flash silica chromatography eluting with heptane to 30% ethyl acetate in heptane to provide 
the title compound as a white solid (0.016 g, 77%). m.p. 82-83 °C. IR (neat, vmax) cm-1 3275, 
2947, 2226, 1610, 1412, 1268. 1H NMR (500 MHz, CDCl3) δH 7.32 (s, 1H, CH-6), 7.24 (br s, 1H, 
OH-10), 6.74 (s, 1H, CH-3), 5.82 (tt, J = 56.8 Hz, 4.3 Hz, 1H, CH-14), 2.63 (t, J = 7.5 Hz, 2H, 
CH2-11), 2.43 (s, 3H, CH3-9), 1.92-1.69 (m, 4H, CH2s-13/14). 13C NMR (126 MHz, CDCl3) δC 
158.3 (C4), 142.1 (C2), 134.4 (CH-6), 126.7 (C5), 118.8 (C7), 117.2 (t, J = 239 Hz, C-14), 116.9 
(CH-3), 103.2 (C1), 33.5 (t, J = 20.9 Hz, CH2-13), 28.6 (CH2-11), 21.9 (t, J = 5.5 Hz, CH2-12), 
14.1 (CH3-9). HRMS-ESI m/z [M-H]- calculated for C12H12F2NO 224.0892, found 224.0887. 
LCMS - Analytical MDAP 30-95% MeCN:Water (0.1% Formic), tR 16.83 min, [M-H]- 
223.95 m/z (95%). 
  
271 
3-Chloro-5-(4,4-difluorobutyl)-4-hydroxy-2-methyl-benzonitrile (171) 
 
Sulfuryl chloride (0.02 mL, 0.26 mmol) was added to a solution of 5-(4,4-difluorobutyl)-4-
hydroxy-2-methyl-benzonitrile (170) (0.02 g, 0.09 mmol) in diethyl ether (1 mL) and stirred 
for 16 h. The reaction mixture was partitioned between HCl (aq) (1 M, 5 mL) and CH2Cl2 (2 x 
10 mL). The chlorinated layers were separated through a phase separator and concentrated 
under reduced pressure. The residue was purified by flash silica chromatography eluting with 
heptane to 40% ethyl acetate in heptane to provide the title compound as a white solid 
(0.009 g, 33%). m.p. 91-92 °C. 1H NMR (500 MHz, CDCl3) δH 7.31 (s, 1H, CH-6), 6.15 (s, 1H, 
OH-11), 5.83 (tt, J = 56.6 Hz, & 4.3 Hz, 1H, CH-15), 2.70 (t, J = 7.5 Hz, 2H, CH2-12), 2.56 (s, 3H, 
CH3-9), 1.97-1.74 (m, 4H, CH2-13&14). 13C NMR (126 MHz, CDCl3) δC 153.1 (C4), 138.9 (C2), 
132.3 (CH-6), 127.4 (C5), 117.8 (C7), 117.0 (t, J = 238 Hz, CH-15), 105.4 (C1), 33.5 (t, J = 21 
Hz, CH2-14), 29.4 (CH2-12), 21.6 (CH2-13), 18.8 (CH3-9). HRMS-ESI m/z [M-H]- calculated for 
C12H1135ClF2NO 258.0503, found 258.0495. LCMS - Analytical MDAP 30-95% MeCN:Water 
(0.1% Formic), tR 22.48 min, [M-H]- 257.95 m/z, (95%). 
  
272 
3-(5-Cyano-2-methoxy-4-methyl-phenyl)propanoate (172) 
 
Palladium (II) acetate (0.062 g, 0.28 mmol), and 2-dicyclohexylphosphino-2’-6’-
diisopropoxybiphenyl (0.26 g, 0.55 mmol) was added to a mixture of K3PO4 (7.04 g, 
33.18 mmol), 5-bromo-4-methoxy-2-methyl-benzonitrile (139) (2.50 g, 11.06 mmol) and 
methyl 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propanoate (3.55 g, 16.59 mmol) in 
toluene (15 mL) and water (2 mL) and heated to 60 °C for 96 h. The reaction mixture was 
partitioned between CH2Cl2 (10 mL), and HCl (aq) (1 M, 10 mL), the chlorinated layer was 
separated through a phase separator and concentrated under reduced pressure. The residue 
was purified by flash silica chromatography, eluting with heptane to 20% ethyl acetate in 
heptane, to provide the title compound as a colourless oil (0.226 g, 48%). m.p. 109-111 °C. 
IR (neat, vmax) cm-1 3345, 2219, 1612, 1437. 1H NMR (500 MHz, CDCl3) δH 7.34 (s, 1H, CH-6), 
6.72 (s, 1H, CH-3), 3.86 (s, 3H, CH3-11), 3.67 (s, 3H, CH3-17), 2.88 (t, J = 7.6 Hz, 2H, CH2-12), 
2.57 (t, J = 7.6 Hz, 2H, CH2-13), 2.50 (s, 3H, CH3-9). 13C NMR (126 MHz, CDCl3) δC 173.2 (C14), 
160.6 (C4), 142.7 (C2), 133.5 (CH-6), 127.4 (C5), 118.6 (C7), 111.8 (CH-3), 104.0 (C1), 55.5 
(CH3-11), 51.6 (CH3-17), 33.4 (CH2-12), 25.3 (CH2-13), 20.6 (CH3-9). HRMS-ESI m/z [M+Na]+ 
and [M-H]- poor ionisation LRMS only EI+ 233 m/z. LCMS - Analytical MDAP LCMS 30-95% 
MeCN:Water (0.1% Formic), tR 16.74 min, [M+H]+ 233.95 m/z, (95%). 
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5-(3-Hydroxy-3-methyl-butyl)-4-methoxy-2-methyl-benzonitrile (173) 
 
A solution of methylmagnesium bromide (3 M, 0.21 mL, 0.62 mmol), was added to a solution 
of 3-(5-cyano-2-methoxy-4-methyl-phenyl)propanoate (172) (0.07 g, 0.30 mmol) in 
tetrahydrofuran (0.5 mL) at -78 °C. The reaction mixture was warmed to rt and stirred for 
2 h. The reaction mixture was quenched with the addition of HCl (aq), (1 M, 5 mL) and 
extracted with ethyl acetate (2 × 20 mL). The combined organic layers were dried over MgSO4, 
filtered and concentrated under reduced pressure. The residue was purified by flash silica 
chromatography, eluting with heptane to 20% ethyl acetate in heptane, to provide the title 
compound as an orange oil (0.062 g, 89%). IR (neat, vmax) cm-1 3436, 2968, 2218, 1610, 1503, 
1461, 1256. 1H NMR (500 MHz, CDCl3) δH 7.31 (s, 1H, CH-3), 6.70 (s, 1H, CH-6), 3.84 (s, 3H, 
CH3-11), 2.65-2.60 (m, 2H, CH2-12), 2.47 (s, 3H, CH3-9), 1.69-1.64 (m, 2H, CH2-13), 1.26 (s, 
6H, CH3's-15&16). 13C NMR (126 MHz, CDCl3) δC 160.5 (C4), 142.0 (C2), 133.1 (CH-6), 129.7 
(C5), 118.8 (C7), 111.8 (CH-3), 103.8 (C1), 70.8 (C14), 55.5 (CH3-11), 43.3 (CH2-13), 29.2 
(CH3's-15&16), 24.4 (CH2-12), 20.5 (CH3-9). HRMS-ESI m/z [2M+Na]+ calculated for 
C28H38N2NaO4 489.2724, found 489.2751 (dimer adduct). LCMS - Analytical MDAP LCMS 30-
95% MeCN:Water (0.1% Formic), tR 14.99 min, [M+Na]+ 257.00 m/z, (95%). 
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5-(3-Fluoro-3-methyl-butyl)-4-methoxy-2-methyl-benzonitrile (174) 
 
A solution of bis(2-methoxyethyl)aminosulfur trifluoride (50% solution in toluene, 0.37 mL, 
0.99 mmol) was added to a solution of 5-(3-hydroxy-3-methyl-butyl)-4-methoxy-2-methyl-
benzonitrile (173) (0.40 g, 1.71 mmol) in CH2Cl2 (8 mL) and the reaction was sealed. Ethanol 
(5 µL) was added and the reaction was stirred at rt for 16 h. The reaction mixture was 
quenched with the addition of saturated NaHCO3 (aq) (30 mL) and stirred at rt for 1 h. The 
resulting biphasic mixture was partitioned between water (20 mL) and CH2Cl2 (2 × 50 mL). 
The combined chlorinated layers were dried over MgSO4, filtered and concentrated under 
vacuum. The residue was purified by flash silica chromatography, eluting with petroleum 
ether to 15% ethyl acetate to provide the title compound as a colourless oil (0.34 g, 84%). IR 
(neat, vmax) cm-1 2970, 2218, 1609, 1503, 1459, 1255. 1H NMR (500 MHz, CDCl3) δH 7.33 (s, 
1H, CH-6), 6.72 (s, 1H, CH-3), 3.86 (s, 3H, CH3-10), 2.68-2.62 (m, 2H, CH2-12), 2.50 (s, 3H, 
CH3-9), 1.86-1.77 (m, 2H, CH2-13), 1.40 (d, J = 21.4 Hz, 6H, CH3's- 15&16). 13C NMR (126 MHz, 
CDCl3) δC 160.5 (C4), 142.2 (C2), 133.1 (CH-6) 129.1 (C5), 118.7 (C7), 111.8 (CH-3), 103.9 (C1), 
95.2 (d, J = 166 Hz, C14), 55.5 (CH3-11), 40.9 (d, J = 23 Hz, CH2-13), 26.6 (d, J = 25 Hz, CH3's-
15&16), 24.1 (d, J = 6 Hz, CH2-12), 20.6 (CH3-9). HRMS-ESI m/z [M+Na]+ and [M-H]- poor 
ionisation LRMS only EI+ 235 m/z. LCMS - Analytical MDAP 30-95% MeCN:Water (0.1% 
Formic), tR 20.98 min, [M+H+MeCN]+ 277.0 m/z (95%). 
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2,2,7-Trimethylchromane-6-carbonitrile (175) 
 
Chloro(trimethyl)silane (0.73 mL, 5.78 mmol) was added to a suspension of 5-(3-fluoro-3-
methyl-butyl)-4-methoxy-2-methyl-benzonitrile (174) (0.34 g, 1.44 mmol) and sodium iodide 
(0.87 g, 5.78 mmol) in acetonitrile (4 mL). The reaction mixture was sealed and heated to 
130 °C in the microwave (Biotage Initiator®) for 2 h. The cooled reaction mixture was 
partitioned between sodium thiosulfate (aq) (0.1 M, 100 mL) and ethyl acetate (2 x 100 mL). 
The combined organic layers were dried over MgSO4, filtered and concentrated under 
reduced pressure. The residue was purified by flash silica chromatography eluting with 
heptane to 30% ethyl acetate in heptane to provide the title compound as a colourless oil 
(0.12 g, 42%). IR (neat, vmax) cm-1 2934, 2217, 1619, 1562, 1495, 1449, 1291, 1251. 1H NMR 
(500 MHz, CDCl3) δH 7.30 (s, 1H, CH-7), 6.67 (s, 1H, CH-10), 2.74 (t, J = 6.8 Hz, 2H, CH2-4), 
2.42 (s, 3H, CH3-13), 1.80 (t, J = 6.8 Hz, 2H, CH2-3), 1.34 (s, 6H, CH3's-11&12).13C NMR (126 
MHz, CDCl3) δC 157.7 (C6), 141.3 (C9), 134.0 (CH-7), 119.3 (C5), 118.9 (C14), 118.8 (CH-10), 
103.4 (C8), 75.6 (CH2-4), 32.3 (CH2-3), 26.8 (CH3's-11&12), 21.7 (CH2-4), 20.1 (CH3-13). HRMS-
ESI m/z [M+Na]+ and [M-H]- poor ionisation LRMS only EI+ 201 m/z. LCMS - Analytical MDAP 
30-95% MeCN:Water (0.1% Formic), tR 20.65 min, [M+H+MeCN]+ 242.95 m/z (95%). 
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4-Methoxy-2-methyl-5-pentyl-benzonitrile (176) 
 
Palladium (II) acetate (0.10 g, 0.44 mmol), and 2-dicyclohexylphosphino-2’-6’-
diisopropoxybiphenyl (0.41 g, 0.88 mmol) was added to a mixture of K3PO4 (18.78 g, 
88.47 mmol), 5-bromo-4-methoxy-2-methyl-benzonitrile (139) (8.00 g, 35.39 mmol) and n-
pentylboronic acid (6.16 g, 53.08 mmol) in toluene (200 mL) and heated to 100 °C for 1 h. 
The reaction mixture was filtered through a pad of celite and the filtrate was partitioned 
between ethyl acetate (300 mL), and HCl (aq) (1 M, 150 mL), the organic layer was separated 
an the aqueous layer was re-extracted with ethyl acetate (2 × 200 mL). The combined organic 
layers were dried over MgSO4, filtered and concentrated under reduced pressure. The 
residue was purified by flash silica chromatography, eluting with heptane to 20% ethyl 
acetate in heptane to provide the title compound as a yellow oil (7.80 g, 90%). m. p. 111-
112 °C. IR (neat, vmax) cm-1 2929, 2218, 1609, 1503, 1460, 1209, 1255. 1H NMR (500 MHz, 
CDCl3) δH 7.34 (s, 1H, CH-6), 6.73 (s, 1H, CH-3), 3.88 (s, 3H, CH3-11), 2.59-2.54 (m, 2H, CH2-12), 
2.53 (s, 3H, CH3-9), 1.59-1.51 (m, 2H, CH2-13), 1.40-1.27 (m, 4H, CH2s-14&15), 0.92 (t, 
J = 7.1 Hz, 3H, CH3-16). 13C NMR (126 MHz, CDCl3) δC 160.6 (C4), 141.8 (C2), 133.3 (CH-6), 
130.0 (C5), 119.0 (C7), 111.7 (CH-3), 103.7 (C1), 55.5 (CH3-11), 31.6 (CH2-14), 29.3 (CH2-12), 
29.0 (CH2-13), 22.5 (CH2-15), 20.6 (CH3-16), 14.0 (CH3-9). HRMS-ESI m/z [M+Na]+ calculated 
for C14H19NNaO 240.1359, found 240.1362. LCMS - Analytical UPLC 5-95% MeCN:Water 
(0.1% TFA), tR 1.01 min, [M+H]+ 218.4 m/z (95%). 
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4-Hydroxy-2-methyl-5-pentyl-benzonitrile (177) 
 
Iodo(trimethyl)silane (3.01 mL, 21.17 mmol) was added to a solution of 4-methoxy-2-methyl-
5-pentyl-benzonitrile (176) (2.30 g, 10.58 mmol) in acetonitrile (30 mL). The reaction mixture 
was sealed and heated to 90 °C in the microwave in 2 vials (Biotage Initiator®) for 2 h. The 
cooled RM’s were combined and partitioned between sodium thiosulfate (aq) (0.1 M, 
100 mL) and CH2Cl2 (2 x 200 mL). The chlorinated layers were separated through a phase 
separator and concentrated under reduced pressure. The residue was purified by flash silica 
chromatography eluting with heptane to 30% ethyl acetate in heptane to provide the title 
compound as a white solid (2.20 g, 99%). m.p. 68-70 °C. IR (neat, vmax) cm-1 3303, 2926, 
2219, 1608, 1413, 1261. 1H NMR (500 MHz, CDCl3) δH 7.34 (s, 1H, CH-6), 6.67 (s, 1H, CH-3), 
5.24 (s, 1H, OH-10), 2.55 (t, J = 7.8 H, 2H, CH2-11), 2.45 (s, 3H, CH3-9), 1.63-1.53 (m, 2H, CH2-
12), 1.38-1.28 (m, 4H, CH2-13&14), 0.90 (t, J = 6.9 Hz, 3H, CH3-15). 13C NMR (126 MHz, CDCl3) 
δC 157.0 (C4), 141.7 (C2), 143.3 (CH-6), 127.2 (C5), 118.7 (C7), 116.8 (CH-3), 104.4 (C1), 31.5 
(CH2-13), 29.1 (CH2-11), 29.0 (CH2-12), 22.5 (CH2-14), 20.0 (CH3-9), 14.0 (CH3-15). HRMS-ESI 
m/z [M+Na]+ calculated for C13H17NNaO 226.1202, found 226.1202. LCMS - Analytical UPLC 
2-98% MeCN:Water (0.1% TFA), tR 0.85 min, [M+H]+ 204.4 m/z (95%). 
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3-Bromo-4-hydroxy-2-methyl-5-pentyl-benzonitrile (178) 
 
N-Bromosuccinimide (1.96 g, 11.00 mmol) was added to a solution of 4-hydroxy-2-methyl-5-
pentyl-benzonitrile (177) (2.13 g, 10.48 mmol) in acetonitrile (50 mL). The reaction mixture 
was stirred at rt for 10 min. The reaction mixture was partitioned between HCl (aq) (1 M, 
150 mL) and CH2Cl2 (2 × 200 mL), the chlorinated layers were combined and concentrated 
under reduced pressure. The residue was purified by flash silica chromatography eluting with 
heptane to 30% ethyl acetate in heptane to provide the title compound as a pale yellow solid 
(2.65 g, 90%). m.p. 74-75 °C. IR (neat, vmax) cm-1 3333, 2932, 2225, 1598, 1464, 1147. 1H 
NMR (500 MHz, CDCl3) δH 7.36 (s, 1H, CH-6), 6.12 (s, 1H, OH-10), 2.66 (t, J = 7.8 Hz, 2H, CH2-
11), 2.61 (s, 3H, CH3-9), 1.66-1.51 (m, 2H, CH2-12), 1.42-1.30 (m, 3H, CH2s-13&14), 0.92 (t, J 
= 6.8 Hz, 3H, CH3-15). 13C NMR (126 MHz, CDCl3) δC 153.9 (C4), 140.1 (C2), 132.9 (CH-6), 
128.8 (C5), 118.2 (C7), 113.9 (C3), 105.3 (C1), 31.5 (CH2-13), 30.2 (CH2-12), 28.8 (CH2-11), 
22.5 (CH2-14), 21.9 (CH3-9), 14.0 (CH3-15). HRMS-ESI m/z [M+Na]+ calculated for 
C13H1679BrNNaO 304.0307, found 304.0305. LCMS - Analytical UPLC 2-98% MeCN:Water 
(0.1% TFA), tR 0.95 min, [M+H]+ 282.3 m/z (95%). 
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4-Hydroxy-2,3-dimethyl-5-pentyl-benzonitrile (179) 
 
Palladium (II) acetate (0.002 g, 0.01 mmol), and 2-dicyclohexylphosphino-2’-6’-
diisopropoxybiphenyl (0.01 g, 0.02 mmol) was added to a mixture of K3PO4 (0.10 g, 
0.49 mmol), 3-bromo-4-hydroxy-2-methyl-5-pentyl-benzonitrile (178) (0.055 g, 0.19 mmol) 
and trimethylboroxine (0.072 g, 0.58 mmol) in toluene (1 mL) and water (0.1 mL) and heated 
to 100 °C for 16 h. The reaction mixture was partitioned between CH2Cl2 (10 mL), and HCl (aq) 
(1 M, 10 mL), the chlorinated layer was separated through a phase separator and 
concentrated under reduced pressure. The residue was purified by flash silica 
chromatography, eluting with heptane to 25% ethyl acetate in heptane to provide the title 
compound as a white solid upon concentration (0.041 g, 98%). m. p. 81-82 °C. IR (neat, vmax) 
cm-1 3339, 2926, 2224, 1567, 1463, 1199. 1H NMR (500 MHz, CDCl3) δH 7.26 (s, 1H, CH-6), 
5.12 (OH-11), 2.60-2.54 (m, 2H, CH2-12), 2.47 (s, 3H, CH3-9), 2.21 (s, 3H, CH3-10), 1.65-1.58 
(m, 2H, CH2-13), 1.41-1.32 (m, 4H, CH2-14&15), 0.95-0.90 (m, 3H, CH3-16). 13C NMR (126 
MHz, CDCl3) δC 155.4 (C4), 139.7 (C2), 131.3 (CH-6), 126.2 (C5), 123.2 (C3), 119.5 (C7), 104.6 
(C1), 31.5 (CH2-14), 29.6 (CH2-12), 28.9 (CH2-13), 22.5 (CH2-15), 18.3 (CH3-9), 14.0 (CH3-16), 
12.0 (CH3-10). HRMS-ESI m/z [M+Na]+ calculated for C14H19NNaO 240.1359, found 240.1359. 
LCMS - Analytical UPLC 2-98% MeCN:Water (0.1% TFA), tR 0.89 min, [M+H]+ 218.5 m/z 
(> 95%). 
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3-Ethyl-4-hydroxy-2-methyl-5-pentyl-benzonitrile (180) 
 
Palladium (II) acetate (0.001 g, 0.005 mmol), and 2-dicyclohexylphosphino-2’-6’-
diisopropoxybiphenyl (0.003 g, 0.01 mmol) was added to a mixture of K3PO4 (0.056 g, 
0.26 mmol), 3-bromo-4-hydroxy-2-methyl-5-pentyl-benzonitrile (178) (0.037 g, 0.13 mmol) 
and ethylboronic acid (0.015 g, 0.20 mmol) in toluene (0.5 mL) and water (0.05 mL) and 
heated to 100 °C for 16 h. The reaction mixture was partitioned between CH2Cl2 (10 mL), and 
HCl (aq) (1 M, 10 mL), the chlorinated layer was separated through a phase separator and 
concentrated under reduced pressure. The residue was purified by flash silica 
chromatography, eluting with heptane to 25% ethyl acetate in heptane to provide the title 
compound as a white solid upon concentration (0.012 g, 40%). m. p. 96-97 °C. IR (neat, vmax) 
cm-1 3349, 2929, 2222, 1567, 1463, 1265, 1194. 1H NMR (500 MHz, CDCl3) δH 7.24 (s, 1H, CH-
6), 5.15 (s, 1H, OH-12), 2.68 (q, J = 7.6 Hz, 2H, CH2-10), 2.54 (t, J = 7.8 Hz, 2H, CH2-13), 2.47 
(s, 3H, CH3-9), 1.63-1.56 (m, 2H, CH2-14), 1.38-1.31 (m, 4H, CH2s-15&16), 1.13 (t, J = 7.6 Hz, 
3H, CH3-11), 0.91 (t, J = 6.7 Hz, 3H, CH3-17). 13C NMR (126 MHz, CDCl3) δC 155.0 (C4), 139.1 
(C2), 131.5 (CH-6), 129.3 (C3), 126.3 (C5), 119.5 (C7), 104.9 (C1), 31.5 (CH2-15), 29.5 (CH2-
13), 28.8 (CH2-14), 22.5 (CH2-16), 19.8 (CH2-10). 17.4 (CH3-9), 14.0 (CH3-17), 13.01 (CH3-11). 
HRMS-ESI m/z [M-H]- calculated for C15H20NO 230.1550, found 230.1542. LCMS - Analytical 
MDAP 30-95% MeCN:Water (0.1% Formic), tR 22.35 min, [M-H]- 230.1 m/z (95%). 
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4-Hydroxy-2-methyl-5-pentyl-3-phenyl-benzonitrile (181) 
 
Palladium (II) acetate (0.001 g, 0.005 mmol), and 2-dicyclohexylphosphino-2’-6’-
diisopropoxybiphenyl (0.004 g, 0.01 mmol) was added to a mixture of K3PO4 (0.094 g, 
0.44 mmol), 3-bromo-4-hydroxy-2-methyl-5-pentyl-benzonitrile (178) (0.05 g, 0.18 mmol) 
and phenylboronic acid (0.032 g, 0.27 mmol) in toluene (0.75 mL) and heated to 100 °C for 
16 h. The reaction mixture was partitioned between CH2Cl2 (10 mL), and HCl (aq) (1 M, 10 mL), 
the chlorinated layer was separated through a phase separator and concentrated under 
reduced pressure. The residue was purified by flash silica chromatography, eluting with 
heptane to 25% ethyl acetate in heptane, and further purified by reverse-phase 
chromatography, eluting with 30% MeCN in water to 95% MeCN to provide the title 
compound as a white solid upon concentration (0.014 g, 28%). m. p. 124-125 °C. IR (neat, 
vmax) cm-1 3350, 2930, 2225, 1600, 1450, 1150. 1H NMR (500 MHz, CDCl3) δH 7.61-7.55 (m, 
2H, CH-12&14), 7.55-7.47 (m, 1H, CH-13), 7.42 (s, 1H, CH-6), 7.30-7.25 (m, 2H, CH-11&15), 
5.18 (s, 1H, OH-16), 2.63 (t, J = 7.8 Hz, 2H, CH2-17), 2.23 (s, 3H, CH3-9), 1.68-1.59 (m, 2H, CH2-
18), 1.42-1.33 (m, 4H, CH2s-19&20), 0.96-0.89 (m, 3H, CH3-21). 13C NMR (126 MHz, CDCl3) δC 
154.4 (C4), 139.1 (C2), 133.6 (C10), 133.3 (CH-6), 130.2 (CH-11&15), 130.0 (CH-12&14), 
129.1 (CH-13), 128.7 (C3), 127.9 (C5), 119.2 (C7), 104.5 (C1), 31.6 (CH2-19), 29.7 (CH2-17), 
29.0 (CH2-18), 22.5 (CH2-20), 18.8 (CH3-9), 14.0 (CH3-21). HRMS-ESI m/z [M+Na]+ calculated 
for C19H21NNaO 302.1515, found 302.1517. LCMS - Analytical UPLC 2-98% MeCN:Water 
(0.1% Formic), tR 1.01 min, [M+H]+ 280.5 m/z (95%). 
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Ethyl 5-cyano-2-hydroxy-6-methyl-3-pentyl-benzoate (182) 
 
1,8-Diazabicyclo[5.4.0]undec-7-ene (0.28 mL, 1.86 mmol) was added to a suspension of  
trans-Bis(acetato)bis[o-(di-o-tolylphosphino)benzyl]dipalladium(II) (0.041 g, 0.04 mmol), 
molybdenum hexacarbonyl (0.23 g, 0.89 mmol) and 3-bromo-4-hydroxy-2-methyl-5-pentyl-
benzonitrile (178) in ethanol (7.5 mL) and heated to 100 °C for 1 h. The reaction mixture was 
partitioned between CH2Cl2 (50 mL), and HCl (aq) (1 M, 20 mL), the chlorinated layer was 
separated through a phase separator and concentrated under reduced pressure. The residue 
was purified by flash silica chromatography, eluting with heptane to 25% ethyl acetate in 
heptane to provide the title compound as a colourless oil (0.38 g, 78%). IR (neat, vmax) cm-1 
2928, 2219, 1627, 1436, 1227, 1297. 1H NMR (500 MHz, CDCl3) δH 12.15 (s, 1H, OH-15), 7.48 
(s, 1H, CH-6), 4.50 (q, J = 7.2 Hz, 2H, CH2-13), 2.77 (s, 3H, CH3-9), 2.63 (t, J = 7.7 Hz, 2H, CH2-
15), 1.65-1.57 (m, 2H, CH2-17), 1.48 (t, J = 7.2 Hz, 3H, CH3-14), 1.41-1.23 (m, 4H, CH2s-18&19), 
0.95-0.88 (m, 3H, CH3-20). 13C NMR (126 MHz, CDCl3) δC 171.2 (C10), 164.1 (C4), 143.6 (C2), 
137.1 (CH-6), 130.7 (C5), 118.8 (C7), 112.9 (C3), 105.0 (C1), 62.5 (CH2-13), 31.6 (CH2-18), 29.4 
(CH2-16), 28.5 (CH2-17), 22.5 (CH2-19), 21.7 (CH3-9), 14.1 (CH3-14), 14.0 (CH3-20). HRMS-ESI 
m/z [M+Na]+ calculated for C16H21NNaO3 298.1414, found 298.1416. LCMS - Analytical UPLC 
2-98% MeCN:Water (0.1% Formic), tR 1.06 min, [M+H]+ 276.4 m/z (95%). 
283 
5-Cyano-2-hydroxy-6-methyl-3-pentyl-benzoic acid (183) 
 
NaOH (aq) (4 M, 5.00 mL, 20.00 mmol) was added to a solution of ethyl 5-cyano-2-hydroxy-
6-methyl-3-pentyl-benzoate (182) (0.50 g, 1.82 mmol) in methanol (2 mL) and 
tetrahydrofuran (10 mL) and heated to 60 °C for 120 h. The reaction mixture was partitioned 
between CH2Cl2 (50 mL), and NaOH (aq) (2 M, 20 mL), the chlorinated layer was washed with 
NaOH (aq) (2 M, 20 mL) the combined aqueous layers were acidified with HCl (aq) (5 M) to 
pH 1 and extracted with ethyl acetate (2 × 50 mL). The organics were dried over MgSO4, 
filtered and concentrated under reduced pressure to provide the title compound as a white 
solid (0.43 g, 99%). m.p. 186-188 °C. IR (neat, vmax) cm-1 3176, 2214, 1605, 1555, 1437, 1381, 
1262. 1H NMR (500 MHz, CDCl3) δH 7.23 (s, 1H, CH-6), 7.19-6.98 (br, 2H, OH-12&13), 2.69 (s, 
3H, CH3-9), 2.44 (t, J = 7.7 Hz, 2H, CH2-14), 1.56-1.45 (m, 2H, CH2-15), 1.37-1.2 (m, 4H, CH2-
16&17), 0.87 (t, J = 7.0 Hz, 3H, CH3-18). 13C NMR (126 MHz, CDCl3) δC 170.9 (C10), 169.5 (C4 
observed in HMBC), 143.9 (C2), 133.4 (CH-6), 129.6 (C5), 121.0 (C7), 118.1 (C3), 98.3 (C1), 
31.6 (CH2-16), 29.7 (CH2-14), 28.7 (CH2-15), 22.5 (CH2-17), 20.7 (CH3-9), 14.4 (CH3-9). HRMS-
ESI m/z [M+Na]+ calculated for C14H17NNaO3 270.1101, found 270.1106. LCMS - Analytical 
UPLC 2-98% MeCN:Water (0.1% Formic), tR 0.89 min, poor ionisation, no mass ion observed 
(95%). 
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5-Cyano-2-hydroxy-N,N,6-trimethyl-3-pentyl-benzamide (184) 
 
Oxalyl chloride (0.01 mL, 0.12 mmol) was added to a suspension of 5-cyano-2-hydroxy-6-
methyl-3-pentyl-benzoic acid (183) (0.02 g, 0.08 mmol) in CH2Cl2 (0.5 mL), the reaction was 
added 1 drop of N,N-dimethylformamide. Once gas evolution had ceased, the reaction was 
added a solution of dimethylamine (2 M, 0.16 mL, 0.32 mmol) and stirred at rt for 16 h. The 
reaction mixture was partitioned between CH2Cl2 (20 mL), and HCl (aq) (1 M, 5 mL), the 
chlorinated layer was separated through a phase-separator and concentrated under reduced 
pressure. The residue was purified by flash silica chromatography eluting with heptane to 
25% ethyl acetate in heptane to provide the title compound as a white solid (0.017 g, 77%). 
m.p. 87-89 °C. IR (neat, vmax) cm-1 2925, 2217, 1580, 1460, 1399, 1321, 1259. 1H NMR (500 
MHz, CDCl3) δH 8.70 (br, 1H, OH-15), 7.28 (s, 1H, CH-6), 3.29-2.73 (br m, 6H, CH3-13&14), 
2.50-2.34 (m, 5H, CH2-16&CH3-9), 1.53-1.41 (m, 2H, CH2-17), 1.41-1.16 (m, 4H, CH2-18&19), 
0.91 (t, J = 7.0 Hz, 3H, CH3-20). 13C NMR (126 MHz, CDCl3) δC 169.3 (C10), 155.2 (C4), 137.5 
(C2), 134.3 (CH-6), 130.6 (C5), 123.9 (C3), 118.4 (C7), 104.6 (C1), 38.1 (br, CH3-13/14), 35.1 
(br, CH3-13/14), 31.5 (CH2-18), 29.3 (CH2-16), 28.8 (CH2-17), 22.4 (CH2-19), 17.9 (CH3-9), 14.0 
(CH3-20). HRMS-ESI m/z [M+Na]+ calculated for C16H22NNaO2 297.1573, found 297.1579. 
LCMS - Analytical UPLC 2-98% MeCN:Water (0.1% Formic), tR 0.75 min, [M+H]+ 275.4 m/z 
(95%). 
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3-Formyl-4-hydroxy-2-methyl-5-pentyl-benzonitrile (185) 
 
NaOH (aq) (4 M, 1.22 mL, 4.87 mmol) was added to a solution of 4-hydroxy-2-methyl-5-
pentyl-benzonitrile (177) (0.20 g, 0.97 mmol) in CHCl3 (3 mL), the reaction was heated at 
100 °C in the microwave for 1 h. The reaction mixture was partitioned between CH2Cl2 
(50 mL), and HCl (aq) (1 M, 30 mL), the chlorinated layer was separated through a phase-
separator and concentrated under reduced pressure. The residue was purified by flash silica 
chromatography eluting with heptane to 25% ethyl acetate in heptane to provide the title 
compound as a white solid (0.054 g, 24%). m.p. 85-87 °C. 1H NMR (500 MHz, CDCl3) δH 12.75 
(s, 1H, OH-12), 10.37 (s, 1H, CH-10), 7.55 (s, 1H, CH-6), 2.83 (s, 3H, CH3-9), 2.64 (t, J = 7.8 Hz, 
2H, CH2-13), 1.68-1.54 (m, 2H, CH2-14), 1.43-1.30 (m, 4H, CH2s-15&16), 0.93 (t, J = 6.6 Hz, 
CH3-17). 13C NMR (126 MHz, CDCl3) δC 195.0 (C10), 164.6 (C4), 144.7 (C2), 139.4 (CH-6), 131.7 
(C5), 118.0 (C3), 117.8 (C7), 104.5 (C1), 31.5 (CH2-15), 28.7 (CH2-13), 28.5 (CH2-14), 22.5 
(CH2-16), 16.1 (CH3-9), 14.00 (CH3-17). HRMS-ESI m/z [M-H]- calculated for C14H16NO2 
230.1187, found 230.1179. LCMS - Analytical UPLC 2-98% MeCN:Water (0.1% Formic), tR 
0.95 min, poor ionisation, no mass ion (95%). 
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4-Hydroxy-2-methyl-5-pentyl-benzaldehyde (187) 
 
Palladium (II) acetate (0.20 g, 0.87 mmol), and 2-dicyclohexylphosphino-2’-6’-
diisopropoxybiphenyl (0.81 g, 1.74 mmol) was added to a mixture of K3PO4 (18.5 g, 87.2 
mmol), 5-bromo-4-hydroxy-2-methyl-benzaldehyde (80) (7.50 g, 34.9 mmol) and 
n-pentylboronic acid (6.07 g, 52.3 mmol) in toluene (150 mL) and water (15 mL) and heated 
to 85 °C for 96 h. The reaction mixture was filtered through a pad of celite and the filtrate 
was partitioned between ethyl acetate (300 mL), and HCl (aq) (1 M, 150 mL), the organic 
layer was separated, and the aqueous layer was re-extracted with ethyl acetate (2 × 200 mL). 
The combined organic layers were dried over MgSO4, filtered and concentrated under 
reduced pressure. The residue was purified by flash silica chromatography, eluting with 
heptane to 20% ethyl acetate in heptane to provide the title compound as an orange oil 
(1.60 g, 22%). IR (neat, vmax) cm-1 3131, 2927, 1650, 1574, 1430, 1394, 1258. 1H NMR 
(500 MHz, CDCl3) δH 10.08 (s, 1H, CH-7), 7.59 (s, 1H, CH-6), 6.64 (s, 1H, CH-3), 6.34 (br m, 1H, 
OH-10), 2.75-2.55 (m, 5H, CH2-11 & CH3-9), 1.66-1.58 (m, CH2-12), 1.36-1.30 (m, 4H, 
CH2s-13/14), 0.91-0.86 (m, 3H, CH3-15). 13C NMR (126 MHz, CDCl3) δC 192.2 (CH-7), 158.8 
(C4), 141.2 (C2), 134.8 (CH-6), 127.5 (C1), 118.1 (CH-3), 113.0 (C5), 31.6 (CH2-13), 29.23 
(CH2-12), 29.17 (CH2-11), 22.5 (CH2-14), 19.1 (CH3-9), 14.0 (CH3-15). HRMS-ESI m/z [M-H]- 
calculated for C13H17O2 205.1234, found 205.1230. LCMS - Analytical MDAP 30-95% 
MeCN:Water (0.1% Formic), tR 19.70 min, [M-H]- 205.1 m/z (95%). 
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3-Chloro-4-hydroxy-2-methyl-5-pentyl-benzaldehyde (188) 
 
Sulfuryl chloride (1.18 mL, 14.5 mmol) was added to a solution of 4-hydroxy-2-methyl-5-
pentyl-benzaldehyde (187) (1.00 g, 4.85 mmol) in diethyl ether (20 mL) and stirred for 30 min 
at rt. The reaction mixture was partitioned between HCl (aq) (1 M, 50 mL) and ethyl acetate 
(2 x 100 mL). The organic layers were combined, dried over MgSO4, filtered and concentrated 
under reduced pressure. The residue was purified by flash silica chromatography eluting with 
heptane to 30% ethyl acetate in heptane to provide the title compound as a yellow solid 
(0.98 g, 84%). m.p. 69-71 °C. IR (neat, vmax) cm-1 3228, 2918, 1674, 1600, 1549, 1320, 1223. 
1H NMR (500 MHz, CDCl3) δH 10.11 (s, 1H, CH-7), 7.55 (s, 1H, CH-6), 6.24 (s, 1H, OH-11), 2.71-
2.65 (m, 5H, CH3-9& CH2-12), 1.66-1.60 (m, 2H, CH2-13), 1.36-1.30 (m, 4H, CH2s-14&15), 0.90 
(t, J = 6.8 Hz, 3H, CH3-16). 13C NMR (126 MHz, CDCl3) δC 190.8 (C7), 153.8 (C4), 137.2 (C2), 
132.5 (CH-6), 128.0 (C3/5), 127.9 (C3/5), 122.0 (C1), 31.6 (CH2-14), 30.0 (CH2-12), 29.0 (CH2-
13), 22.5 (CH2-15), 15.2 (CH3-9), 14.00 (CH3-16). HRMS-ESI m/z [M-H]- calculated for 
C13H1635ClO2 239.0844, found 239.0838. LCMS - Analytical MDAP 30-95% MeCN:Water (0.1% 
Formic), tR 21.88 min, [M-H]- 239.0 m/z, (95%). 
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5-Bromo-4-hydroxy-2-methyl-benzoic acid (189) 
 
Sodium chlorite (2.94 g, 26.0 mmol) was added to a solution of 5-bromo-4-hydroxy-2-methyl-
benzaldehyde (80) (4.00 g, 18.6 mmol) and sodium phosphate monobasic (3.01 g, 
25.1 mmol) in t-BuOH (50 mL), 2-methyl-2-butene (1.98 mL, 18.6 mmol) and water (5 mL), 
and stirred at rt for 2 h. The reaction mixture was partitioned between HCl (aq) (1 M, 50 mL) 
and ethyl acetate (2 x 100 mL). The organic layers were combined, dried over MgSO4, filtered 
and concentrated under reduced pressure to provide the title compound as a tan solid (4.31 
g, 99%). m.p. 182-184 °C. IR (neat, vmax) cm-1 2931, 2635, 1672, 1596,1554, 1434, 1271. 1H 
NMR (500 MHz, D6-DMSO) δH 12.59 (br s, 1H, OH-9), 10.87 (br s, 1H, OH-11), 7.94 (s, 1H, CH-
6), 6.80 (s, 1H, CH-3), 2.42 (s, 3H, CH3-10). 13C NMR (126 MHz, D6-DMSO) δC 167.3 (C7), 157.5 
(C4), 141.9 (C2), 136.0 (CH-6), 122.4 (C1), 119.2 (CH-3), 106.3 (C5), 21.9 (CH3-10). HRMS-ESI 
m/z [M+Na]+ and [M-H]- poor ionisation LRMS only EI+ 230 / 232 m/z (Br isotope). LCMS - 
Analytical MDAP 30-95% MeCN:Water (0.1% Formic), tR 11.01 min, [M-H]- 228.9 m/z, (95%). 
Methyl 5-bromo-4-methoxy-2-methyl-benzoate (190) 
 
Dimethyl sulphate (1.02 mL, 10.8 mmol) was added to a suspension of potassium carbonate 
(1.87 g, 13.5 mmol) and 5-bromo-4-hydroxy-2-methyl-benzoic acid (189) (1.25 g 5.41 mmol) 
in acetone (50 mL). The reaction mixture was stirred at rt for 16 h, then diluted with water 
(200 mL) and the resulting solid was filtered and purified by flash silica chromatography 
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eluting with petroleum ether to 30% ethyl acetate in petroleum ether to provide the title 
compound as an off white solid (0.86 g, 61%). m.p. 93-95 °C. IR (neat, vmax) cm-1 2946, 1712, 
1593, 1315, 1233. 1H NMR (500 MHz, CDCl3) δH 8.15 (s, 1H, CH-6), 6.71 (s. 1H, CH-3), 3.93 (s, 
3H, CH3-13), 3.86 (s, 3H, CH3-10), 2.59 (s, 3H, CH3-11). 13C NMR (126 MHz, CDCl3) δC 166.3 
(C7), 158.3 (C4), 142.5 (C2), 135.8 (CH-6), 122.6 (C1), 114.5 (CH-3), 108.1 (C5), 56.3 (CH3-13), 
51.7 (CH3-10), 22.2 (CH3-11). HRMS-ESI m/z [M+Na]+ and [M-H]- poor ionisation LRMS only 
EI+ 258 / 260 m/z (Br isotope). LCMS - Analytical MDAP 30-95% MeCN:Water (0.1% Formic), 
tR 19.56 min, [M-H]- 258.9 m/z (95%). 
Methyl 5-isopentyl-4-methoxy-2-methyl-benzoate (191) 
 
Palladium (II) acetate (0.052 g, 0.23 mmol), and 2-dicyclohexylphosphino-2’-6’-
diisopropoxybiphenyl (0.216 g, 0.46 mmol) was added to a mixture of K3PO4 (3.93 g, 18.53 
mmol), methyl 5-bromo-4-methoxy-2-methyl-benzoate (190) (2.40 g, 9.26 mmol) and 
(3-methylbutyl)boronic acid (1.61 g, 13.89 mmol) in toluene (50 mL) and heated to 100 °C 
for 3 h. The reaction mixture was filtered through a pad of celite and partitioned between 
ethyl acetate (100 mL), and HCl (aq) (1 M, 50 mL), the organic layer was separated, dried over 
MgSO4, filtered and concentrated under reduced pressure. The residue was purified by flash 
silica chromatography, eluting with heptane to 15% ethyl acetate in heptane, to provide the 
title compound as a yellow oil (1.99 g, 86%). IR (neat, vmax) cm-1 2952, 1712, 1445, 1253, 
1141. 1H NMR (500 MHz, CDCl3) δH 7.74 (s, 1H, CH-6), 6.65 (s, 1H, CH-3), 3.85 (s, 6H, 
CH3-10&13), 2.60 (s, 3H, CH3-11), 2.59-2.55 (m, 2H, CH2-14), 1.60-1.58 (m, 1H, CH-16), 1.47-
1.41 (m, 2H, CH2-15), 0.94 (d, J = 6.6 Hz, 6H, CH3-17&18). 13C NMR (126 MHz, CDCl3) δC 167.8 
(C7), 160.1 (C4), 140.5 (C2), 132.3 (CH-6), 128.8 (C5), 120.9 (C1), 113.1 (CH-3), 55.3 
(CH3-10/13), 51.4 (CH3-10/13), 39.0 (CH2-15), 28.0 (CH-16), 27.4 (CH2-14), 22.6 (CH3-17&18), 
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22.2 (CH3-11). HRMS-ESI m/z [M+Na]+ and [M-H]- poor ionisation LRMS only EI+ 250 m/z. 
LCMS - Analytical MDAP 30-95% MeCN:Water (0.1% Formic), tR 26.11 min, [M-H]- 251.1 m/z 
(95%). 
4-hydroxy-5-isopentyl-2-methyl-benzoic acid (192) 
 
Chloro(trimethyl)silane (0.81 mL, 6.39 mmol) was added to a suspension of methyl 5-
isopentyl-4-methoxy-2-methyl-benzoate (191) (0.40 g, 1.60 mmol) and sodium iodide (0.96 g, 
6.39 mmol) in acetonitrile (2.4 mL). The reaction mixture was sealed and heated to 130 °C 
for 1 h. The cooled reaction mixture was partitioned between HCl (aq) (1 M, 50 mL) and ethyl 
acetate (2 x 50 mL). The combined organic layers were dried over MgSO4, filtered and 
concentrated under reduced pressure. The residue was purified by flash silica 
chromatography eluting with heptane to 50% ethyl acetate in heptane to provide the title 
compound as a white solid (0.116 g, 33%). m.p. 119-122 °C. IR (neat, vmax) cm-1 2956, 1679, 
1567, 1447, 1398, 1273, 1210, 1150. 1H NMR (500 MHz, CDCl3) δH 7.92 (s, 1H, CH-6), 6.63 (s, 
1H, CH-3), 2.62-2.55 (m, 5H, CH2-12 & CH3-10), 1.66-1.58 (m, 1H, CH-14), 1.53-1.47 (m, 2H, 
CH2-13) 0.95 (d, J = 6.6 Hz, 6H, CH3-15&16).13C NMR (126 MHz, CDCl3) δC 173.0 (C7), 157.5 
(C4), 141.8 (C2), 134.3 (CH-6), 126.4 (C5), 120.3 (C1, 118.4 (CH-3), 38.7 (CH2-13), 27.9 
(CH-14), 27.1 (CH2-12), 22.5 (CH3-15&16) 22.0 (CH3-9). HRMS-ESI m/z [M+Na]+ and [M-H]- 
poor ionisation LRMS only EI+ 222 m/z. LCMS - Analytical MDAP 30-95% MeCN:Water (0.1% 
Formic), tR 15.57 min, [M-H]- 221.1 m/z, (95%). 
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3-Chloro-4-hydroxy-5-isopentyl-2-methyl-benzoic acid (193) 
 
Sulfuryl chloride (0.14 mL, 1.75 mmol) was added to a solution of 4-hydroxy-2-methyl-5-
pentyl-benzaldehyde (192) (0.13 g, 0.58 mmol) in diethyl ether (2 mL) and stirred at rt for 
1 h. The reaction mixture was partitioned between HCl (aq) (1 M, 20 mL) and ethyl acetate 
(2 x 50 mL). The organic layers were combined, dried over MgSO4, filtered and concentrated 
under reduced pressure. The residue was purified by flash silica chromatography eluting with 
heptane to 50% ethyl acetate in heptane to provide the title compound as a white solid 
(0.136 g, 91%). m.p. 116-118 °C. IR (neat, vmax) cm-1 3470, 2954, 1674, 1604, 1395, 1270, 
1157. 1H NMR (500 MHz, CDCl3) δH 12.28-11.53 (br, 1H, OH-9), 7.83 (s, 1H, CH-6), 6.13 (br s, 
1H, OH-11), 2.70 (s, 3H, CH3-10), 2.69-2.64 (m, 2H, CH2-13), 1.64-1.57 (m, 1H, CH-15), 1.53-
1.47 (m, 2H, CH2-14), 0.95 (d, J = 6.6 Hz, 6H, CH3's-16 & 17). 13C NMR (126 MHz, CDCl3) δC 
172.1 (C7), 153.0 (C4), 137.5 (C2), 131.8 (CH-6), 127.43 (C5), 122.0 (C3), 121.3 (C1), 38.5 
(CH2-14), 28.0 (CH2-13), 27.9 (CH-15), 22.5 (CH3's-16 & 17), 18.0 (CH3-9). HRMS-ESI m/z 
[M+Na]+ and [M-H]- poor ionisation LRMS only EI+ 256 m/z. LCMS - Analytical MDAP 30-95% 
MeCN:Water (0.1% Formic), tR 17.97 min, [M-H]- 255.0 m/z, (95%). 
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3-Chloro-4-hydroxy-5-isopentyl-N,N,2-trimethyl-benzamide (194) 
 
Triethylamine (0.05 mL, 0.35 mmol) was added to a solution of 3-chloro-4-hydroxy-5-
isopentyl-2-methyl-benzoic acid (193) (0.03 g, 0.12 mmol), dimethylamine hydrochloride 
(0.014 g, 0.18 mmol) and 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-
b]pyridinium 3-oxid hexafluorophosphate (0.053 g, 0.14 mmol) in acetonitrile (0.75 mL) and 
stirred at rt for 16 h. The reaction mixture was partitioned between HCl (aq) (1 M, 20 mL) 
and ethyl acetate (2 x 50 mL). The organic layers were combined, dried over MgSO4, filtered 
and concentrated under reduced pressure. The residue was purified by flash silica 
chromatography eluting with heptane to 40% ethyl acetate in heptane, and further purified 
by reverse-phase chromatography (C18) eluting with 50% MeOH in water to 100% MeOH to 
provide the title compound as a white solid (0.014 g, 42%). m.p. 111-113 °C. IR (neat, vmax) 
cm-1 2942, 1603, 1390, 1134, 1054. 1H NMR (500 MHz, CDCl3) δH 6.86 (s, 1H, CH-6), 5.91 (s, 
1H, OH-14), 3.11 (s, 3H, CH3-10/11), 2.83 (s, 3H, CH3-10/11), 2.60 (t, J = 7.9 Hz, 2H, CH2-15), 
2.25 (s, 3H, CH3-12), 1.61-1.53 (m, 1H, CH-17), 1.48-1.42 (m, 2H, CH2-16), 0.92 (d, J = 6.6 Hz, 
6H, CH3's-18&19). 13C NMR (126 MHz, CDCl3) δC 170.9 (C7), 149.6 (C4), 130.1 (C2), 129.4 (C1), 
128.3 (C5), 125.5 (CH-6), 121.1 (C3), 38.59 (CH3-10/11/CH2-16), 38.55 (CH3-10/11/CH2-16), 
34.7 (CH3-10/11), 28.1 (CH2-15), 27.8 (CH-17), 22.5 (CH3-18&19), 16.9 (CH3-12). HRMS-ESI 
m/z [M+Na]+ and [M-H]- poor ionisation LRMS only EI+ 283 m/z. LCMS - Analytical MDAP 30-
95% MeCN:Water (0.1% Formic), tR 17.33 min, [M-H]- 282.1 m/z, (95%). 
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3-Chloro-4-hydroxy-5-isopentyl-N,2-dimethyl-benzamide (195) 
 
Triethylamine (0.05 mL, 0.35 mmol) was added to a solution of 3-chloro-4-hydroxy-5-
isopentyl-2-methyl-benzoic acid (193) (0.03 g, 0.12 mmol), methylamine hydrochloride 
(0.012 g, 0.18 mmol) and 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-
b]pyridinium 3-oxid hexafluorophosphate (0.053 g, 0.14 mmol) in acetonitrile (0.75 mL) and 
stirred at rt for 16 h. The reaction mixture was partitioned between HCl (aq) (1 M, 20 mL) 
and ethyl acetate (2 x 50 mL). The organic layers were combined, dried over MgSO4, filtered 
and concentrated under reduced pressure. The residue was purified by flash silica 
chromatography eluting with heptane to 40% ethyl acetate in heptane, and further purified 
by reverse-phase chromatography (C18) eluting with 50% MeOH in water to 100% MeOH to 
provide the title compound as a white solid (0.012 g, 38%). m.p. 204-206 °C. IR (neat, vmax) 
cm-1 3377, 2952, 1623, 1387, 1317, 1162. 1H NMR (500 MHz, CDCl3) δH 7.06 (s, 1H, CH-6), 
5.82 (s, 1H, OH/NH), 5.68 (br s, 1H, OH/NH), 2.98 (s, 3H, CH3-10), 2.61 (t, J = 8.1 Hz, 2H, 
CH2-14), 2.43 (s, 3H, CH3-11), 1.67-1.54 (m, 1H (over integration from water peak), CH-16), 
1.50-1.39 (m, 2H, CH2-15), 0.94 (d, J = 6.8 Hz, 6H, CH3's-17&18). 13C NMR (126 MHz, CDCl3) 
δC 170.1 (C7), 150.3 (C4), 132.2 (C2), 129.8 (C3), 127.6 (C5), 126.6 (CH-6), 121.5 (C1), 38.7 
(CH2-13), 28.1 (CH2-14), 27.9 (CH-16), 26.7 (CH3-10), 22.5 (CH3's-17&18), 17.2 (CH3-11). 
HRMS-ESI m/z [M+Na]+ and [M-H]- poor ionisation LRMS only EI+ 269 m/z. LCMS - Analytical 
MDAP 30-95% MeCN:Water (0.1% Formic), tR 15.85 min, [M-H]- 268.1 m/z, (95%). 
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3-Chloro-4-hydroxy-5-isopentyl-2-methyl-benzamide (196) 
 
Triethylamine (0.05 mL, 0.35 mmol) was added to a solution of 3-chloro-4-hydroxy-5-
isopentyl-2-methyl-benzoic acid (193) (0.03 g, 0.12 mmol), ammonium chloride (0.009 g, 
0.18 mmol) and 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid 
hexafluorophosphate (0.053 g, 0.14 mmol) in acetonitrile (0.75 mL) and stirred at rt for 16 h. 
The reaction mixture was partitioned between HCl (aq) (1 M, 20 mL) and ethyl acetate (2 x 
50 mL). The organic layers were combined, dried over MgSO4, filtered and concentrated 
under reduced pressure. The residue was purified by flash silica chromatography eluting with 
heptane to 40% ethyl acetate in heptane, and further purified by reverse-phase 
chromatography (C18) eluting with 50% MeOH in water to 100% MeOH to provide the title 
compound as a white solid (0.012 g, 38%). m.p. 167-169 °C. IR (neat, vmax) cm-1 3376, 3193, 
2952, 1630, 1385, 1161. 1H NMR (500 MHz, CDCl3) δH 7.17 (s, 1H, CH-6), 5.90 (s, 1H, OH-12), 
5.72 (br, 2H, NH2-9), 2.63 (t, J = 7.9 Hz, 2H, CH2-13), 2.49 (s, 3H, CH3-10), 1.65-1.56 (m, 1H 
(over intergrated with water peak), CH-15), 1.50-1.44 (m, 2H, CH2-14), 0.94 (d, J = 6.6 Hz, 6H, 
CH3's-16&17). 13C NMR (126 MHz, CDCl3) δC 171.2 (C7), 150.8 (C4), 132.6 (C2), 128.3 (C1), 
127.6 (C5), 127.0 (CH-6), 121.8 (C3), 38.7 (CH2-14), 28.1 (CH2-13), 27.9 (CH-15), 22.5 (CH3's-
16&17), 17.3 (CH3-10). HRMS-ESI m/z [M+Na]+ and [M-H]- poor ionisation LRMS only EI+ 255 
m/z. LCMS - Analytical MDAP 30-95% MeCN:Water (0.1% Formic), tR 14.50 min, [M-H]- 
256.0 m/z, (95%). 
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3-Bromo-4-hydroxy-5-isopentyl-2-methyl-benzonitrile (197) 
 
N-Bromosuccinimide (0.048 g, 0.27 mmol) was added to a solution of 4-hydroxy-5-isopentyl-
2-methyl-benzonitrile (149) (0.05 g, 0.25 mmol) in acetonitrile (1 mL). The reaction mixture 
was stirred at rt for 10 min. The reaction mixture was partitioned between HCl (aq) (1 M, 
10 mL) and CH2Cl2 (2 × 20 mL), the chlorinated layers were combined and concentrated 
under reduced pressure. The residue was purified by flash silica chromatography eluting with 
heptane to 30% ethyl acetate in heptane, and further purified by reverse-phase 
chromatography eluting with 30% MeCN in water to 100% MeCN to provide the title 
compound as a white solid (0.029 g, 42%). m.p. 91-92 °C. IR (neat, vmax) cm-1 3310, 2934, 
2221, 1598, 1464, 1410, 1320, 1246, 1153. 1H NMR (500 MHz, CDCl3) δH 7.36 (s, 1H, CH-6), 
6.14 (br s, 1H, OH-4), 2.67 (t, J = 8.0 Hz, 2H, CH2-12), 2.76 (s, 3H, CH3-9), 1.66-1.55 (m, 1H, 
CH-14), 1.52-1.44 (m, 2H, CH2-13), 0.96 (d, J = 6.7 Hz 6H, CH3's-15&16). 13C NMR (126 MHz, 
CDCl3) δC 154.0 (C4), 140.0 (C2), 132.8 (CH-6), 129.0 (C5), 118.1 (C7), 113.9 (C3), 105.3 (C1), 
38.3 (CH2-13), 28.2 (CH2-12), 27.7 (CH-14), 22.5 (CH3's-15&16), 22.0 (CH3-9). HRMS-ESI m/z 
[M+Na]+ calculated for C13H1679BrNNaO 304.0307, found 304.0308. LCMS - Analytical UPLC 
2-98% MeCN:Water (0.1% TFA), tR 0.93 min, poor ionisation, no mass ion observed (95%).  
  
296 
Bibliography 
(1)  World Health Organisation. Control and surveillance of human African 
trypanosomiasis; Geneva, 2013. 
(2)  Steverding, D. The history of African trypanosomiasis. Parasit Vectors 2008, 1 (3). 
(3)  Bruce, D. Preliminary report on the tsetse fly disease or nagana in Zululand. Bennet & 
Davis. Durban 1895, 28. 
(4)  Cox, F. E. . History of sleeping sickness (African trypanosomiasis). Infect. Dis. Clin. North 
Am. 2004, 18 (2), 231–245 DOI: 10.1016/j.idc.2004.01.004. 
(5)  Schultz, C. D. M. G. Image Public Health Image Library - 613. 1970. 
(6)  Fevre, E. M.; Wissmann, B. V.; Welburn, S. C.; Lutumba, P. The Burden of Human 
African Trypanosomiasis. PLoS Negl. Trop. Dis. 2008, 2 (12), e333 DOI: 
10.1371/journal.pntd.0000333. 
(7)  Lejon, V.; Bentivoglio, M.; Franco, J. R. Human African trypanosomiasis. Handb. Clin. 
Neurol. 2013, 114 (0), 169–181 DOI: 10.1016/B978-0-444-53490-3.00011-X. 
(8)  Buguet, A.; Bisser, S.; Josenando, T.; Chapotot, F.; Cespuglio, R. Sleep structure: A new 
diagnostic tool for stage determination in sleeping sickness. Acta Trop. 2005, 93 (1), 
107–117 DOI: 10.1016/j.actatropica.2004.10.001. 
(9)  Magnus, E.; Vervoort, T.; Van Meirvenne, N. A card-agglutination test with stained 
trypanosomes (C.A.T.T.) for the serological diagnosis of T. B. gambiense 
trypanosomiasis. Ann Soc Belg Med Trop. 1978, 58 (3), 169–176. 
(10)  Hasker, E.; Mitashi, P.; Baelmans, R.; Lutumba, P.; Jacquet, D.; Lejon, V.; Kande, V.; 
Declercq, J.; Van Der Veken, W.; Boelaert, M. A new format of the CATT test for the 
detection of Human African Trypanosomiasis, designed for use in peripheral health 
facilities. Trop. Med. Int. Heal. 2010, 15 (2), 263–267 DOI: 10.1111/j.1365-
3156.2009.02446.x. 
(11)  WHO. Cases of sleeping sickness drop to lowest level in 75 years 
http://www.who.int/trypanosomiasis_african/cases_drop_to_lowest_since_75_year
s/en/ (accessed Jul 3, 2017). 
(12)  Nmorsi, O. P. G.; Isaac, C.; Igbinosa, I. B.; Umukoro, D. O.; Aitaikuru, D. P. Human 
African trypanosomiasis in endemic focus of Abraka, Nigeria. Asian Pac. J. Trop. Med. 
2010, 3 (6), 448–450 DOI: 10.1016/S1995-7645(10)60107-1. 
(13)  Medicines Sans Frontiers. CAR: MSF denounces violence as teams are forced to 
suspend activities in Batangafo http://www.msf.org.uk/article/car-msf-denounces-
violence-teams-are-forced-suspend-activities-batangafo (accessed May 26, 2015). 
297 
(14)  Gilleman, Q.; Buscher, P.; Mertens, P.; Lecipteux, T. Development of a Rapid Diagnostic 
Test for active case detection in sleeping sickness contro: recHAT Sero-Strip. In Poster 
presented at ISNTD-d3 Proceedings of the 3rd International Society of Neglected 
Tropical Diseases conference, 20-21 May 2015, London, UK; 2015. 
(15)  Checchi, F.; Filipe, J. a N.; Barrett, M. P.; Chandramohan, D. The natural progression of 
Gambiense sleeping sickness: what is the evidence? PLoS Negl. Trop. Dis. 2008, 2 (12), 
e303 DOI: 10.1371/journal.pntd.0000303. 
(16)  Fairlamb, A. H. Chemotherapy of human African trypanosomiasis: Current and future 
prospects. Trends in Parasitology. 2003, pp 488–494. 
(17)  Lambrecht, F. L. Trypanosomes and Hominid Evolution. Bioscience 1985, 35 (10), 640–
646 DOI: 10.2307/1309990. 
(18)  African Animal Trypanosomiasis - Fact Sheet; 2009. 
(19)  Van Vinh Chau, N.; Buu Chau, L.; Desquesnes, M.; Herder, S.; Phu Huong Lan, N.; 
Campbell, J. I.; Van Cuong, N.; Yimming, B.; Chalermwong, P.; Jittapalapong, S.; et al. 
A Clinical and Epidemiological Investigation of the First Reported Human Infection 
With the Zoonotic Parasite Trypanosoma evansi in Southeast Asia. Clin. Infect. Dis. 
2016, 62, ciw052 DOI: 10.1093/cid/ciw052. 
(20)  Nagana Disease information -PAAT 
http://www.fao.org/ag/againfo/programmes/en/paat/disease.html 
http://www.fao.org/ag/againfo/programmes/en/paat/disease.html (accessed Mar 16, 
2015). 
(21)  Uilenberg, G. A field guide for THE DIAGNOSIS, TREATMENT AND PREVENTION OF 
AFRICAN ANIMAL TRYPANOSOMOSIS; FOOD AND AGRICULTURE ORGANIZATION OF 
THE UNITED NATIONS: Rome, 1998. 
(22)  OIE. OIE Terrestrial Manual 2013 Trypanosomosis (tsetse-transmitted). 
www.oie.int/fileadmin/Home/eng/...in.../TRYPANO_TSETSE.pdf. 2013, pp 1–11. 
(23)  Mihok, S.; Otieno, L. H.; Tarimo, C. S. Trypanosome infection rates in tsetse flies 
(Diptera: Glossinidae) and cattle during tsetse control operations in the Kagera River 
region of Rwanda. Bulletin of Entomological Research. 1992, p 361. 
(24)  McCord, P. F.; Messina, J. P.; Campbell, D. J.; Grady, S. C. Tsetse fly control in Kenya’s 
spatially and temporally dynamic control reservoirs: A cost analysis. Appl. Geogr. 2012, 
34 (517), 189–204 DOI: 10.1016/j.apgeog.2011.11.005. 
(25)  Ruggiero, M. A.; Gordon, D. P.; Orrell, T. M.; Bailly, N.; Bourgoin, T.; Brusca, R. C.; 
Cavalier-Smith, T.; Guiry, M. D.; Kirk, P. M. A higher level classification of all living 
organisms. PLoS One 2015, 10 (4), 1–60 DOI: 10.1371/journal.pone.0119248. 
(26)  Shapiro, T. A.; Englund, P. T. The structure and replication of kinetoplast DNA. Annu. 
298 
Rev. Microbiol. 1995, 49, 117–143 DOI: 10.1146/annurev.mi.49.100195.001001. 
(27)  Magez, S.; Radwanska, M. Trypanosomes and Trypanosomiasis; Magez, S., Radwanska, 
M., Eds.; Springer, 2014. 
(28)  Gruby, M. Recherches et observations sur une nouvelle espece d’hematozoaire, 
Trypanosoma sanguinis. C. R. Hebd. Seances Acad. Sci. 1843, t.17, 1134. 
(29)  Vertommen, D.; Roy, J. Van; Szikora, J.; Rider, M. H.; Michels, P. A. M.; Opperdoes, F. 
R. Differential expression of glycosomal and mitochondrial proteins in the two major 
life-cycle stages of Trypanosoma brucei. Mol Biochem Parasitol. 2008, 158, 189–201 
DOI: 10.1016/j.molbiopara.2007.12.008. 
(30)  Sbicego, S.; Vassella, E.; Kurath, U.; Blum, B.; Roditi, I. The use of transgenic 
Trypanosoma brucei to identify compounds inducing the differentiation of 
bloodstream forms to procyclic forms. 1999, 104, 311–322. 
(31)  Masocha, W.; Kristensson, K. Passage of parasites across the blood-brain barrier. 
Virulence 2012, 3 (2), 202–212. 
(32)  Amin, D. N.; Vodnala, S. K.; Masocha, W.; Sun, B.; Kristensson, K.; Rottenberg, M. E. 
Distinct toll-like receptor signals regulate cerebral parasite load and interferon α/β 
and tumor necrosis factor α-dependent T-cell infiltration in the brains of trypanosoma 
brucei-infected mice. J. Infect. Dis. 2012, 205 (2), 320–332 DOI: 10.1093/infdis/jir734. 
(33)  Masocha, W.; Rottenberg, M. E.; Kristensson, K. Migration of African trypanosomes 
across the blood-brain barrier. Physiol. Behav. 2007, 92 (1–2), 110–114 DOI: 
10.1016/j.physbeh.2007.05.045. 
(34)  Horn, D.; McCulloch, R. Molecular mechanisms underlying the control of antigenic 
variation in African trypanosomes. Current Opinion in Microbiology. 2010, pp 700–705. 
(35)  Morrison, L. J.; Marcello, L.; McCulloch, R. Antigenic variation in the African 
trypanosome: molecular mechanisms and phenotypic complexity. Cell. Microbiol. 
2009, 11 (12), 1724–1734 DOI: 10.1111/j.1462-5822.2009.01383.x. 
(36)  La Greca, F.; Magez, S. Vaccination against trypanosomiasis: Can it be done or is the 
trypanosome truly the ultimate immune destroyer and escape artist? Human Vaccines. 
2011, pp 1225–1233. 
(37)  da Silva, A. J.; Moser, M. PHIL_3184 HAT lifecycle. CDC - DPDx 2003. 
(38)  Ravina, E. The Evolution of Drug Discovery: From Traditional Medicines to Modern 
Drugs; Wiley-VCH, 2011. 
(39)  Kuzoe, F. a. Current situation of African trypanosomiasis. Acta Trop. 1993, 54 (3–4), 
153–162. 
299 
(40)  Palm, K.; Stenberg, P.; Luthman, K.; Artursson1, P. Polar molecular surface properties 
predict the intestinal absorption of drugs in humans. Pharm. Res. 1997, 14 (5), 568–
571 DOI: 10.1023/A:1012188625088. 
(41)  Hou, T. J.; Zhang, W.; Xia, K.; Qiao, X. B.; Xu, X. J. ADME evaluation in drug discovery. 
5. Correlation of caco-2 permeation with simple molecular properties. J. Chem. Inf. 
Comput. Sci. 2004, 44 (5), 1585–1600 DOI: 10.1021/ci049884m. 
(42)  Hou, T. J.; Xu, X. J. ADME Evaluation in Drug Discovery. 3. Modeling Blood-Brain Barrier 
Partitioning Using Simple Molecular Descriptors. J. Chem. Inf. Comput. Sci. 2003, 43 
(6), 2137–2152 DOI: 10.1021/ci034134i. 
(43)  Fairlamb,  a H.; Bowman, I. B. Trypanosoma brucei: maintenance of concentrated 
suspensions of bloodstream trypomastigotes in vitro using continuous dialysis for 
measurement of endocytosis. Exp. Parasitol. 1980, 49 (3), 366–380 DOI: 
10.1016/0014-4894(80)90072-7. 
(44)  Willson, M.; Callens, M.; Kuntz, D. a; Perie, J.; Opperdoes, F. R. Synthesis and activity 
of inhibitors highly specific for the glycolytic enzymes from Trypanosoma brucei. Mol. 
Biochem. Parasitol. 1993, 59 (2), 201–210 DOI: 10.1016/0166-6851(93)90218-M. 
(45)  Wang, C. C. Molecular Mechanisms and Therapeutic Approaches to the Treatment of 
African Trypanosomiasis. Annu. Rev. Pharmacol. Toxicol. 1995, 35 (1), 93–127 DOI: 
10.1146/annurev.pa.35.040195.000521. 
(46)  Pépin, J.; Milord, F. The treatment of human African trypanosomiasis. Adv. Parasitol. 
1994, 33, 1–47 DOI: 1016/S0065-308X(08)60410-8. 
(47)  SCHAFTINGEN, E.; OPPERDOES, F. R.; HERS, H.-G. Effects of various metabolic 
conditions and of the trivalent arsenical melarsen oxide on the intracellular levels of 
fructose 2,6-bisphosphate and of glycolytic intermediates in Trypanosoma brucei. Eur. 
J. Biochem. 1987, 166 (3), 653–661 DOI: 10.1111/j.1432-1033.1987.tb13563.x. 
(48)  Carter, N. S.; Fairlamb, A. H. Arsenical-resistant trypanosomes lack an unusual 
adenosine transporter. Nature 1993, 361 (6408), 173–176 DOI: 10.1038/361173a0. 
(49)  Barrett, M. P.; Fairlamb, A. H. The biochemical basis of arsenical-diamidine 
crossresistance in African trypanosomes. Parasitol. Today 1999, 15 (4), 136–140 DOI: 
10.1016/S0169-4758(99)01414-3. 
(50)  Baker, N.; de Koning, H. P.; Mäser, P.; Horn, D. Drug resistance in African 
trypanosomiasis: the melarsoprol and pentamidine story. Trends Parasitol. 2013, 29 
(3), 110–118 DOI: 10.1016/j.pt.2012.12.005. 
(51)  Shapiro, T. a; Englund, P. T. Selective cleavage of kinetoplast DNA minicircles 
promoted by antitrypanosomal drugs. Proc. Natl. Acad. Sci. U. S. A. 1990, 87 (3), 950–
954 DOI: 10.1073/pnas.87.3.950. 
300 
(52)  Bray, P. G.; Barrett, M. P.; Ward, S. a.; De Koning, H. P. Pentamidine uptake and 
resistance in pathogenic protozoa: Past, present and future. Trends Parasitol. 2003, 
19 (5), 232–239 DOI: 10.1016/S1471-4922(03)00069-2. 
(53)  Midgley, I.; Fitzpatrick, K.; Taylor, L. M.; Houchen, T. L.; Henderson, S. J.; Wright, S. J.; 
Cybulski, Z. R.; John, B. a; Mcburney, A.; Boykin, D. W.; et al. Pharmacokinetics and 
Metabolism of the Prodrug DB289 ( 2 , 5-Bis [ 4- ( N-methoxyamidino ) phenyl ] furan 
Monomaleate ) in Rat and Monkey and Its Conversion to the Antiprotozoal / Antifungal 
Drug DB75 ( 2 , 5-Bis ( 4-guanylphenyl ) furan Dihydrochloride ). Drug Metab. Dispos. 
2007, 35 (6), 955–967 DOI: 10.1124/dmd.106.013391.treatments. 
(54)  Thuita, J. K.; Wolf, K. K.; Murilla, G. a.; Bridges, A. S.; Boykin, D. W.; Mutuku, J. N.; Liu, 
Q.; Jones, S. K.; Gem, C. O.; Ching, S.; et al. Chemotherapy of Second Stage Human 
African Trypanosomiasis: Comparison between the Parenteral Diamidine DB829 and 
Its Oral Prodrug DB868 in Vervet Monkeys. PLoS Negl. Trop. Dis. 2015, 9 (2), e0003409 
DOI: 10.1371/journal.pntd.0003409. 
(55)  Wenzler, T.; Boykin, D. W.; Ismail, M. a.; Hall, J. E.; Tidwell, R. R.; Brun, R. New 
treatment option for second-stage African sleeping sickness: In vitro and in vivo 
efficacy of aza analogs of DB289. Antimicrob. Agents Chemother. 2009, 53 (10), 4185–
4192 DOI: 10.1128/AAC.00225-09. 
(56)  Poulin, R.; Lu, L.; Ackermann, B.; Bey, P.; Pegg,  a. E. Mechanism of the irreversible 
inactivation of mouse ornithine decarboxylase by ??-difluoromethylornithine. 
Characterization of sequences at the inhibitor and coenzyme binding sites. J. Biol. 
Chem. 1992, 267 (1), 150–158. 
(57)  Willert, E.; Phillips, M. a. Regulation and function of polyamines in African 
trypanosomes. Trends in Parasitology. Elsevier Ltd 2012, pp 66–72. 
(58)  Krauth-Siegel, R. L.; Comini, M. a. Redox control in trypanosomatids, parasitic protozoa 
with trypanothione-based thiol metabolism. Biochimica et Biophysica Acta - General 
Subjects. 2008, pp 1236–1248. 
(59)  Vincent, I. M.; Creek, D.; Watson, D. G.; Kamleh, M. a.; Woods, D. J.; Wong, P. E.; 
Burchmore, R. J. S.; Barrett, M. P. A molecular mechanism for eflornithine resistance 
in African trypanosomes. PLoS Pathog. 2010, 6 (11), 1–9 DOI: 
10.1371/journal.ppat.1001204. 
(60)  Burri, C.; Brun, R. Eflornithine for the treatment of human African trypanosomiasis. 
Parasitol. Res. 2003, 90 Supp 1, S49-52 DOI: 10.1007/s00436-002-0766-5. 
(61)  Alirol, E.; Schrumpf, D.; Amici Heradi, J.; Riedel, A.; De Patoul, C.; Quere, M.; Chappuis, 
F. Nifurtimox-eflornithine combination therapy for second-stage gambiense human 
African trypanosomiasis: Médecins Sans Frontières experience in the Democratic 
Republic of the Congo. Clin. Infect. Dis. 2013, 56 (2), 195–203 DOI: 10.1093/cid/cis886. 
301 
(62)  Hall, B. S.; Bot, C.; Wilkinson, S. R. Nifurtimox activation by trypanosomal type I 
nitroreductases generates cytotoxic nitrile metabolites. J. Biol. Chem. 2011, 286 (15), 
13088–13095 DOI: 10.1074/jbc.M111.230847. 
(63)  Yun, O.; Priotto, G.; Tong, J.; Flevaud, L.; Chappuis, F. NECT is next: implementing the 
new drug combination therapy for Trypanosoma brucei gambiense sleeping sickness. 
PLoS Negl. Trop. Dis. 2010, 4 (5), e720 DOI: 10.1371/journal.pntd.0000720. 
(64)  Iten, M.; Mett, H.; Evans, A.; Enyaru, J. C.; Brun, R.; Kaminsky, R. Alterations in 
ornithine decarboxylase characteristics account for tolerance of Trypanosoma brucei 
rhodesiense to D,L-alpha-difluoromethylornithine. Antimicrob. Agents Chemother. 
1997, 41 (9), 1922–1925. 
(65)  DNDi. A fatal disease threatening millions in sub-Saharan Africa - HAT - Fact sheet. 
2011, No. 1, 50055 DOI: 10.1371/journal.pmed.0050055. 
(66)  Eperon, G.; Balasegaram, M.; Potet, J.; Mowbray, C.; Valverde, O.; Chappuis, F. 
Treatment options for second-stage gambiense human African trypanosomiasis. 
Expert Rev. Anti. Infect. Ther. 2014, 12 (11), 1407–1417 DOI: 
10.1586/14787210.2014.959496. 
(67)  Jennings, F. W.; Urquhart, G. M. The use of the 2 substituted 5-nitroimidazole, 
Fexinidazole (Hoe 239) in the treatment of chronic T. brucei infections in mice. Z. 
Parasitenkd. 1983, 69 (5), 577–581 DOI: 10.1007/BF00926669. 
(68)  Kaiser, M.; Bray, M. a.; Cal, M.; Trunz, B. B.; Torreele, E.; Brun, R. Antitrypanosomal 
activity of fexinidazole, a new oral nitroimidazole drug candidate for treatment of 
sleeping sickness. Antimicrob. Agents Chemother. 2011, 55 (12), 5602–5608 DOI: 
10.1128/AAC.00246-11. 
(69)  Viodé, C. E.; Bettache, N.; Cenas, N.; Krauth-Siegel, R. L.; Chauvière, G. E.; Bakalara, N.; 
Périé, J. Enzymatic reduction studies of nitroheterocycles. Biochem. Pharmacol. 1999, 
57 (5), 549–557 DOI: 10.1016/S0006-2952(98)00324-4. 
(70)  Wilkinson, S. R.; Taylor, M. C.; Horn, D.; Kelly, J. M.; Cheeseman, I. A mechanism for 
cross-resistance to nifurtimox and benznidazole in trypanosomes. Proc. Natl. Acad. Sci. 
U. S. A. 2008, 105 (13), 5022–5027 DOI: 10.1073/pnas.0711014105. 
(71)  Torreele, E.; Trunz, B. B.; Tweats, D.; Kaiser, M.; Brun, R.; Mazué, G.; Bray, M. a.; Pécoul, 
B. Fexinidazole - a new oral nitroimidazole drug candidate entering clinical 
development for the treatment of sleeping sickness. PLoS Negl. Trop. Dis. 2010, 4 (12), 
1–15 DOI: 10.1371/journal.pntd.0000923. 
(72)  Mesu, V. K. B. K.; Kalonji, W. M.; Bardonneau, C.; Mordt, O. V.; Blesson, S.; Simon, F.; 
Delhomme, S.; Bernhard, S.; Kuziena, W.; Lubaki, J.-P. F.; et al. Oral fexinidazole for 
late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal 
multicentre, randomised, non-inferiority trial. Lancet (London, England) 2018, 391 
302 
(10116), 144–154 DOI: 10.1016/S0140-6736(17)32758-7. 
(73)  Fexinidazole in Human African Trypanosomiasis Due to T.b. Gambiense at Any Stage 
https://www.clinicaltrials.gov/ct2/show/NCT03025789?term=Fexinidazole&rank=3 
(accessed May 18, 2018). 
(74)  Mäser, P.; Wittlin, S.; Rottmann, M.; Wenzler, T.; Kaiser, M.; Brun, R. Antiparasitic 
agents: New drugs on the horizon. Curr. Opin. Pharmacol. 2012, 12 (5), 562–566 DOI: 
10.1016/j.coph.2012.05.001. 
(75)  Jacobs, R.; Nare, B.; Wring, S.; Bacchi, C.; Brun, R.; Plattner, J.; Beaudet, B.; Bowling, 
T.; Chen, D.; Gaukel, E.; et al. Efficacy and Pharmacokinetics of SCYX-7158 ( AN5568 ): 
a Novel and Potent Oxaborole-6-Carboxamide Selected as a Pre-Clinical Candidate for 
Once- Daily Oral Treatment for Stage 2 Human African Trypanosomiasis 
http://r4d.dfid.gov.uk/Output/185784/. 
(76)  Wring, S.; Gaukel, E.; Nare, B.; Jacobs, R.; Beaudet, B.; Bowling, T.; Mercer, L.; Bacchi, 
C.; Yarlett, N.; Randolph, R.; et al. Pharmacokinetics and pharmacodynamics utilizing 
unbound target tissue exposure as part of a disposition-based rationale for lead 
optimization of benzoxaboroles in the treatment of Stage 2 Human African 
Trypanosomiasis. Parasitology 2014, 141 (1), 104–118 DOI: 
10.1017/S003118201300098X. 
(77)  DNDi. Clinical Trial SCYX-7158 launch announcement http://www.dndi.org/media-
centre/press-releases/1169-oxa-phasei.html (accessed Apr 8, 2015). 
(78)  Prospective Study on Efficacy and Safety of SCYX-7158 in Patients Infected by Human 
African Trypanosomiasis Due to T.b. Gambiense (OXA002) 
https://www.clinicaltrials.gov/ct2/show/NCT03087955?term=SCYX-7158&rank=1 
(accessed May 18, 2018). 
(79)  Bernardes, L. S. C.; Zani, C. L.; Carvalho, I. Trypanosomatidae diseases: from the 
current therapy to the efficacious role of trypanothione reductase in drug discovery. 
Curr. Med. Chem. 2013, 20 (21), 2673–2696 DOI: 10.2174/0929867311320210005. 
(80)  Bharate, S. B.; Khan, S. I.; Yunus, N. a M.; Chauthe, S. K.; Jacob, M. R.; Tekwani, B. L.; 
Khan, I. a; Singh, I. P. Antiprotozoal and antimicrobial activities of O-alkylated and 
formylated acylphloroglucinols. Bioorganic Med. Chem. 2007, 15 (1), 87–96 DOI: 
10.1016/j.bmc.2006.10.006. 
(81)  Brand, S.; Norcross, N. R.; Thompson, S.; Harrison, J. R.; Smith, V. C.; Robinson, D. A.; 
Torrie, L. S.; McElroy, S. P.; Hallyburton, I.; Norval, S.; et al. Lead Optimization of a 
Pyrazole Sulfonamide Series of Trypanosoma brucei N -Myristoyltransferase 
Inhibitors: Identification and Evaluation of CNS Penetrant Compounds as Potential 
Treatments for Stage 2 Human African Trypanosomiasis. J. Med. Chem. 2014 DOI: 
10.1021/jm500809c. 
303 
(82)  Ferrins, L.; Gazdik, M.; Rahmani, R.; Varghese, S.; Sykes, M. L.; Jones, A. J.; Avery, V. 
M.; White, K. L.; Ryan, E.; Charman, S. A.; et al. Pyridyl benzamides as a novel class of 
potent inhibitors for the kinetoplastid Trypanosoma brucei. J. Med. Chem. 2014 DOI: 
10.1021/jm500191u. 
(83)  Frearson, J. a; Brand, S.; McElroy, S. P.; Cleghorn, L. a T.; Smid, O.; Stojanovski, L.; Price, 
H. P.; Guther, M. L. S.; Torrie, L. S.; Robinson, D. a; et al. N-myristoyltransferase 
inhibitors as new leads to treat sleeping sickness. Nature 2010, 464 (7289), 728–732 
DOI: 10.1038/nature08893. 
(84)  Grady, R. W.; Bienen, E. J.; Clarkson, A. B. Esters of 3,4-dihydroxybenzoic acid, highly 
effective inhibitors of the sn-glycerol-3-phosphate oxidase of Trypanosoma brucei 
brucei. Mol. Biochem. Parasitol. 1986, 21 (1), 55–63 DOI: 10.1016/0166-
6851(86)90079-4. 
(85)  Grady, R. W.; Bienen, E. J.; Dieck, H. A.; Saric, M.; Clarkson, A. B. N-n-alkyl-3,4-
dihydroxybenzamides as inhibitors of the trypanosome alternative oxidase: Activity in 
vitro and in vivo. Antimicrob. Agents Chemother. 1993, 37 (5), 1082–1085 DOI: 
10.1128/AAC.37.5.1082. 
(86)  Nihei, C.; Fukai, Y.; Kita, K. Trypanosome alternative oxidase as a target of 
chemotherapy. Biochim. Biophys. Acta 2002, 1587 (2–3), 234–239. 
(87)  Ott, R.; Chibale, K.; Anderson, S.; Chipeleme, A.; Chaudhuri, M.; Guerrah, A.; Colowick, 
N.; Hill, G. C. Novel inhibitors of the trypanosome alternative oxidase inhibit 
Trypanosoma brucei brucei growth and respiration. Acta Trop. 2006, 100 (3), 172–184 
DOI: 10.1016/j.actatropica.2006.10.005. 
(88)  Sharma, S.; Singha, U. K.; Chaudhuri, M. Role of Tob55 on mitochondrial protein 
biogenesis in Trypanosoma brucei. Mol. Biochem. Parasitol. 2010, 174 (2), 89–100 
DOI: 10.1016/j.molbiopara.2010.07.003. 
(89)  Woodring, J. L.; Patel, G.; Erath, J.; Behera, R.; Lee, P. J.; Leed, S. E.; Rodriguez, A.; 
Sciotti, R. J.; Mensa-Wilmot, K.; Pollastri, M. P. Evaluation of aromatic 6-substituted 
thienopyrimidines as scaffolds against parasites that cause trypanosomiasis, 
leishmaniasis, and malaria. Med. Chem. Commun. 2015, 6 (2), 339–346 DOI: 
10.1039/C4MD00441H. 
(90)  Price, H. P. Myristoyl-CoA:Protein N-Myristoyltransferase, an Essential Enzyme and 
Potential Drug Target in Kinetoplastid Parasites. J. Biol. Chem. 2003, 278 (9), 7206–
7214 DOI: 10.1074/jbc.M211391200. 
(91)  Peterson, C.; Grinnage-Pulley, T. 
http://www.merckvetmanual.com/mvm/circulatory_system/blood_parasites/trypan
osomiasis.html 
http://www.merckvetmanual.com/mvm/circulatory_system/blood_parasites/trypan
osomiasis.html (accessed May 13, 2016). 
304 
(92)  Dolan, R. B.; Okech, G.; Alushula, H.; Mutugi, M.; Stevenson, P.; Sayer, P. D.; Njogu, A. 
R. Homidium bromide as a chemoprophylactic for cattle trypanosomiasis in Kenya. 
Acta Trop. 1990, 47 (3), 137–144 DOI: 10.1016/0001-706X(90)90019-V. 
(93)  Browning, C. H.; Morgan, G. T.; Robb, J. V. M.; Walls, L. P. The trypanocidal action of 
certain phenanthridinium compounds. J. Pathol. Bacteriol. 1938, 46 (1), 203–204 DOI: 
10.1002/path.1700460121. 
(94)  WATKINS, T. I.; WOOLFE, G. Effect of Changing the Quaternizing Group on the 
Trypanocidal Activity of Dimidium Bromide. Nature 1952, 169 (4299), 506. 
(95)  Wagner, T. E. Proceedings of the Research Symposium on Complexes of Biologically 
Active Substances with Nucleic Acids and Their Modes of Action: Held at the Walter 
Reed Army Institute of Research Washington, 16--19 March 1970; Hahn, F. E., Ed.; 
Springer Berlin Heidelberg: Berlin, Heidelberg, 1971; pp 152–162. 
(96)  Delespaux, V.; Dekoning, H. Drugs and drug resistance in African trypanosomiasis. 
Drug Resist. Updat. 2007, 10 (1–2), 30–50 DOI: 10.1016/j.drup.2007.02.004. 
(97)  Geerts, S. African bovine trypanosomiasis: the problem of drug resistance. Parasitol. 
Today 2001, 17 (1), 25–28 DOI: 10.1016/S0169-4758(00)01827-5. 
(98)  Shiferaw, S.; Muktar, Y.; Belina, D. A review on trypanocidal drug resistance in Ethiopia. 
2015, 7 (May), 58–66 DOI: JPVB2015.0190. 
(99)  Peregrine, A. S.; Mamman, M. Pharmacology of diminazene: a review. Acta Trop. 1993, 
54 (3–4), 185–203 DOI: 10.1016/0001-706X(93)90092-P. 
(100)  BAUER, F. [Trypanosomiasis and babesiasis in Africa and their treatment with the new 
preparation berenil]. Zeitschrift für Tropenmedizin und Parasitol. 1955, 6 (2), 129–140. 
(101)  Hu, S. H.; Weisz, K.; James, T. L.; Shafer, R. H. H-NMR studies on d(GCTTAAGC)2 and 
its complex with berenil. Eur. J. Biochem. 1992, 204 (1), 31–38 DOI: 10.1111/j.1432-
1033.1992.tb16602.x. 
(102)  DAMPER, D.; PATTON, C. L. Pentamidine Transport and Sensitivity in brucei -Group 
Trypanosomes*. J. Protozool. 1976, 23 (2), 349–356 DOI: 10.1111/j.1550-
7408.1976.tb03787.x. 
(103)  Boibessot, I.; Turner, C. M. R.; Watson, D. G.; Goldie, E.; Connel, G.; McIntosh, A.; Grant, 
M. H.; Skellern, G. G. Metabolism and distribution of phenanthridine trypanocides in 
Trypanosoma brucei. Acta Trop. 2002, 84 (3), 219–228 DOI: 10.1016/S0001-
706X(02)00188-2. 
(104)  Whitelaw, D. D.; Bell, I. R.; Holmes, P. H.; Moloo, S. K.; Hirumi, H.; Urquhart, G. M.; 
Murray, M. Isometamidium chloride prophylaxis against Trypanosoma congolense 
challenge and the development of immune responses in Boran cattle. Vet. Rec.  1986, 
118 (26), 722–726 DOI: 10.1136/vr.118.26.722. 
305 
(105)  Delespaux, V.; Geysen, D.; Majiwa, P. A. O.; Geerts, S. Identification of a genetic marker 
for isometamidium chloride resistance in Trypanosoma congolense. Int. J. Parasitol. 
2005, 35 (2), 235–243 DOI: 10.1016/j.ijpara.2004.11.009. 
(106)  CURD, F. H. S.; DAVEY, D. G. Antrycide, a new trypanocidal drug. Br. J. Pharmacol. 
Chemother. 1950, 5 (1), 25–32. 
(107)  ORMEROD, W. E. The mode of action of antrycide. Br. J. Pharmacol. Chemother. 1951, 
6 (2), 325–333. 
(108)  ORMEROD, W. E. A study of resistance to antrycide in a strain of Trypanosoma 
equiperdum. Br. J. Pharmacol. Chemother. 1952, 7 (4), 674–684. 
(109)  ORMEROD, W. E.; SHAW, J. J. A STUDY OF GRANULES AND OTHER CHANGES IN PHASE-
CONTRAST APPEARANCE PRODUCED BY CHEMOTHERAPEUTIC AGENTS IN 
TRYPANOSOMES. Br. J. Pharmacol. Chemother. 1963, 21 (2), 259–272 DOI: 
10.1111/j.1476-5381.1963.tb01525.x. 
(110)  ORMEROD, W. E. A study of cytoplasmic inclusions in Trypanosoma lewisi and their 
relationship to the formation of antibody. J. Gen. Microbiol. 1959, 21 (1), 287–294 DOI: 
10.1099/00221287-21-2-287. 
(111)  Liao, D.; Shen, J. Studies of quinapyramine-resistance of Trypanosoma brucei evansi 
in China. Acta Trop. 2010, 116 (3), 173–177 DOI: 10.1016/j.actatropica.2010.08.016. 
(112)  Freund, Y. R.; Akama, T.; Sanders, V.; Bu, W.; Jacob, J.; Easom, E.; Gillingwater, K.; Brun, 
R.; Napier, G. B.; Witty, M.; et al. Leveraging an Oxaborole in Clinical Trials for HAT to 
Develop Novel Compounds to Treat Animal African Trypanosomosis ( AAT ). Anacor 
Active in 12 Neglected Disease Research Programs and has a Long History with PDPs 
and the BMGF. In ISCTRC; Khartoum, Sudan, 2013. 
(113)  Clarkson,  a. B.; Bienen, E. J.; Pollakis, G.; Grady, R. W. Respiration of bloodstream 
forms of the parasite Trypanosoma brucei brucei is dependent on a plant-like 
alternative oxidase. J. Biol. Chem. 1989, 264 (30), 17770–17776. 
(114)  Opperdoes, F. R.; Borst, P.; Bakker, S.; Leene, W. Localization of glycerol-3-phosphate 
oxidase in the mitochondrion and particulate NAD+-linked glycerol-3-phosphate 
dehydrogenase in the microbodies of the bloodstream form to Trypanosoma brucei. 
Eur. J. Biochem. 1977, 76 (1), 29–39 DOI: 10.1111/j.1432-1033.1977.tb11567.x. 
(115)  Minagawa, N.; Yabu, Y.; Kita, K.; Nagaid, K.; Ohtab, N.; Meguro, K.; Sakajo, S.; 
Yoshimoto, A. An antibiotic , ascofuranone , specifically inhibits respiration and in vitro 
growth of long slender bloodstream forms of Trypanosoma brucei brucei. Mol. 
Biochem. Parasitol. 1996, 81 (1), 127–136. 
(116)  Chaudhuri, M.; Ott, R. D.; Hill, G. C. Trypanosome alternative oxidase: from molecule 
to function. Trends in Parasitology. October 2006, pp 484–491. 
306 
(117)  Chaudhuri, M.; Ajayi, W.; TEMPLE, S.; Hill, G. C. Identification and partial purification 
of a stage-specific 33 kDa mitochondrial protein as the alternative oxidase of the 
Trypanosoma brucei brucei bloodstream trypomastigotes. J. Eukaryot. Microbiol. 
1995, 42 (5), 467–472 DOI: 10.1111/j.1550-7408.1995.tb05892.x. 
(118)  Chaudhuri, M.; Hill, G. C. Cloning, sequencing, and functional activity of the 
Trypanosoma brucei brucei alternative oxidase. Mol. Biochem. Parasitol. 1996, 83 (1), 
125–129 DOI: 10.1016/S0166-6851(96)02754-5. 
(119)  Grant, P. T.; Sargent, J. R. L-alpha-Glycerophosphate dehydrogenase, a component of 
an oxidase system in Trypanosoma rhodesiense. Biochem. J. 1961, 81 (1959), 206–214. 
(120)  Kido, Y.; Sakamoto, K.; Nakamura, K.; Harada, M.; Suzuki, T.; Yabu, Y.; Saimoto, H.; 
Yamakura, F.; Ohmori, D.; Moore, A.; et al. Purification and kinetic characterization of 
recombinant alternative oxidase from Trypanosoma brucei brucei. Biochim. Biophys. 
Acta - Bioenerg. 2010, 1797 (4), 443–450 DOI: 10.1016/j.bbabio.2009.12.021. 
(121)  Fukai, Y.; Nihei, C.; Kawai, K.; Yabu, Y.; Suzuki, T.; Ohta, N.; Minagawa, N.; Nagai, K.; 
Kita, K. Overproduction of highly active trypanosome alternative oxidase in Escherichia 
coli heme-deficient mutant. Parasitol. Int. 2003, 52 (3), 237–241 DOI: 10.1016/S1383-
5769. 
(122)  Nihei, C.; Fukai, Y.; Kawai, K.; Osanai, A.; Yabu, Y.; Suzuki, T.; Ohta, N.; Minagawa, N.; 
Nagai, K.; Kita, K. Purification of active recombinant trypanosome alternative oxidase. 
FEBS Lett. 2003, 538 (1–3), 35–40 DOI: 10.1016/S0014-5793(03)00120-0. 
(123)  Nakayashiki, T.; Nishimura, K.; Tanaka, R.; Inokuchi, H. Partial inhibition of protein 
synthesis accelerates the synthesis of porphyrin in heme-deficient mutants of 
Escherichia coli. Mol. Gen. Genet. 1995, 249 (2), 139–146 DOI: 10.1007/BF00290359. 
(124)  Chaudhuri, M.; Ajayi, W.; Hill, G. C. Biochemical and molecular properties of the 
Trypanosoma brucei alternative oxidase. Mol. Biochem. Parasitol. 1998, 95 (1), 53–68. 
(125)  Kido, Y.; Shiba, T.; Inaoka, D. K.; Sakamoto, K.; Nara, T.; Aoki, T.; Honma, T.; Tanaka, A.; 
Inoue, M.; Matsuoka, S.; et al. Crystallization and preliminary crystallographic analysis 
of cyanide-insensitive alternative oxidase from Trypanosoma brucei brucei. Acta 
Crystallogr. Sect. F. Struct. Biol. Cryst. Commun. 2010, 66 (Pt 3), 275–278 DOI: 
10.1107/S1744309109054062. 
(126)  Fukai, Y.; Amino, H.; Hirawake, H.; Yabu, Y.; Ohta, N.; Minagawa, N.; Sakajo, S.; 
Yoshimoto,  a; Nagai, K.; Takamiya, S.; et al. Functional expression of the 
ascofuranone-sensitive Trypanosoma brucei brucei alternative oxidase in the 
cytoplasmic membrane of Escherichia coli. Comp. Biochem. Physiol. C. Pharmacol. 
Toxicol. Endocrinol. 1999, 124 (2), 141–148. 
(127)  Mogi, T.; Ui, H.; Shiomi, K.; Omura, S.; Miyoshi, H.; Kita, K. Antibiotics LL-Z1272 
identified as novel inhibitors discriminating bacterial and mitochondrial quinol 
307 
oxidases. Biochim. Biophys. Acta 2009, 1787 (2), 129–133 DOI: 
10.1016/j.bbabio.2008.11.016. 
(128)  Saimoto, H.; Kido, Y.; Haga, Y.; Sakamoto, K.; Kita, K. Pharmacophore identification of 
ascofuranone, potent inhibitor of cyanide-insensitive alternative oxidase of 
Trypanosoma brucei. J. Biochem. 2013, 153 (3), 267–273 DOI: 10.1093/jb/mvs135. 
(129)  Shiba, T.; Kido, Y.; Sakamoto, K.; Inaoka, D. K.; Tsuge, C.; Tatsumi, R.; Takahashi, G.; 
Balogun, E. O.; Nara, T.; Aoki, T.; et al. Structure of the trypanosome cyanide-
insensitive alternative oxidase. Proc. Natl. Acad. Sci. 2013, 110 (12), 4580–4585 DOI: 
10.1073/pnas.1218386110. 
(130)  Nakamura, K.; Fujioka, S.; Fukumoto, S.; Inoue, N.; Sakamoto, K.; Hirata, H.; Kido, Y.; 
Yabu, Y.; Suzuki, T.; Watanabe, Y.; et al. Trypanosome alternative oxidase, a potential 
therapeutic target for sleeping sickness, is conserved among Trypanosoma brucei 
subspecies. Parasitol. Int. 2010, 59 (4), 560–564 DOI: 10.1016/j.parint.2010.07.006. 
(131)  Shibaa, T.; Kita, K.; Harada, S. Crystal structure of the trypanosome cyanide-insensitive 
alternative oxidase. Spring 8 Res. Front. Life Sci. Stuctural Biol. 2013, 10–11. 
(132)  Siedow, J. N.; Umbach, A. L.; Moore, A. L. The active site of the cyanide-resistant 
oxidase from plant mitochondria contains a binuclear iron center. FEBS Lett. 1995, 362 
(1), 10–14 DOI: 10.1016/0014-5793(95)00196-G. 
(133)  Tsuda, A.; Witola, W. H.; Ohashi, K.; Onuma, M. Expression of alternative oxidase 
inhibits programmed cell death-like phenomenon in bloodstream form of 
Trypanosoma brucei rhodesiense. Parasitol. Int. 2005, 54 (4), 243–251 DOI: 
10.1016/j.parint.2005.06.007. 
(134)  Fang, J.; Beattie, D. S. Alternative oxidase present in procyclic Trypanosoma brucei 
may act to lower the mitochondrial production of superoxide. Arch. Biochem. Biophys. 
2003, 414 (2), 294–302 DOI: 10.1016/S0003-9861(03)00196-6. 
(135)  Jeacock, L.; Baker, N.; Wiedemar, N.; Mäser, P.; Horn, D. Aquaglyceroporin-null 
trypanosomes display glycerol transport defects and respiratory-inhibitor sensitivity. 
PLoS Pathog. 2017, 13 (3), 1–16 DOI: 10.1371/journal.ppat.1006307. 
(136)  Edwards, D. L.; Rosenberg, E.; Maroney, P. A. Induction of cyanide-insensitive 
Respiration in Neuropora crassa*. J. Biochem. 1974, 249 (11), 3551–3556. 
(137)  Lambowitz, A. M.; Slayman, C. W. Cyanide-resistant respiration in Neurospora crassa. 
J. Bacteriol. 1971, 108 (3), 1087–1096. 
(138)  Clarkson, A.; Brohn, F. Trypanosomiasis: an approach to chemotherapy by the 
inhibition of carbohydrate catabolism. Science (80-. ). 1976, 194 (4261), 204–206 DOI: 
10.1126/science.986688. 
(139)  Opperdoes, F. R.; Borst, P.; Fonck, K. The potential use of inhibitors of glycerol-3-
308 
phosphate oxidase for chemotherapy of African trypanosomiasis. FEBS Lett. 1976, 62 
(2), 169–172 DOI: 10.1016/0014-5793(76)80045-2. 
(140)  Bakker, B. M.; Michels, P. a M.; Opperdoes, R.; Westerhoff, H. V; Opperdoes, F. R. CELL 
BIOLOGY AND METABOLISM : What Controls Glycolysis in Bloodstream Form 
Trypanosoma brucei ? What Controls Glycolysis in Bloodstream Form Trypanosoma 
brucei ?*. 1999, 274 (21), 14551–14559. 
(141)  Hosokawa, T.; Sawada, M.; Ando, K. Isolation and Structure of Ascofuranone and 
Ascofuranol antibiotics with hypolipidemic activity. J. Antibiot. (Tokyo). 1973, 5 (I), 
676–680. 
(142)  Sasaki, H.; Okutomi, T.; Hosokawa, T.; Nawata, Y.; Ando, K. Ascofuranone, a new 
antibiotic from ascochyta viciae. Tetrahedron Lett. 1972, 13 (25), 2541–2544 DOI: 
10.1016/S0040-4039(01)84869-3. 
(143)  Tamura, G.; Suzuki, S.; Takatsuki, A.; Ando, K.; Arima, K. Ascochlorin, a new antibiotic, 
found by the paper-disc agar-diffusion method. I. Isolation, biological and chemical 
properties of ascochlorin. (Studies on antiviral and antitumor antibiotics. I). J. Antibiot. 
(Tokyo). 1968, 21 (9), 539–544 DOI: 10.7164/antibiotics.21.539. 
(144)  Mori, K.; Fujioka, T. Synthesis of (±)-ascofuranone, in antibiotic with hypolipidemic and 
antitumor protective properties. Tetrahedron Lett. 1983, 24 (14), 1547–1548 DOI: 
10.1016/S0040-4039(00)81705-0. 
(145)  Mori, K.; Takechi, S. Synthesis of the natural enantiomers of ascochlorin, ascofuranone 
and ascofuranol. Tetrahedron 1985, 41 (15), 3049–3062 DOI: 10.1016/S0040-
4020(01)96657-8. 
(146)  Magae, J.; Nagai, K.; Ando, K.; Tamura, G. Differentiation of Mouse and Human 
Myeloid Leukemia Cells Induced by an Antitumor Antibiotic, Ascofuranone. Agric. Biol. 
Chem. 1988, 52 (12), 3143–3147 DOI: 10.1080/00021369.1988.10869194. 
(147)  Fukai, Y.; Nihei, C.; Yabu, Y.; Suzuki, T.; Ohta, N.; Minagawa, N.; Nagai, K.; Kita, K. Strain-
specific difference in amino acid sequences of trypanosome alternative oxidase. 
Parasitol. Int. 2002, 51 (2), 195–199. 
(148)  Kosuge, Y.; Suzuki, A.; Tamura, S. Structures of Colletochlorin C, Colletorin A and 
Colletorin C from Colletotrichum nicotianae. Agric. Biol. Chem. 1974, 38 (6), 1265–
1267 DOI: 10.1080/00021369.1974.10861322. 
(149)  Mori, K.; Sato, K. A general synthetic method for prenylated phenols of microbial origin. 
Tetrahedron 1982, 38 (9), 1221–1225 DOI: 10.1016/0040-4020(82)85107-7. 
(150)  Takahashi, N.; Osada, H.; Numao, N.; Saimoto, H.; Kawabata, T.; Hiyama, T. 
Differentiation induction of human promyelocytic leukemia cells with colletochlorin B 
and its analogues. Chem. Pharm. Bull. (Tokyo). 1988, 36 (1), 452–455 DOI: 
309 
10.1248/cpb.36.452. 
(151)  Meco Navas, A.; Ebiloma, G. U.; Martín Domínguez, A.; Martínez Benayas, I.; cueto 
diaz, E.; Alhejely, A. S.; Balogun, E. O.; Saito, M.; Matsui, M.; Arai, N.; et al. SAR of 4-
Alkoxybenzoic Acid Inhibitors of the Trypanosome Alternative Oxidase. ACS Med. 
Chem. Lett. 2018, acsmedchemlett.8b00282 DOI: 10.1021/acsmedchemlett.8b00282. 
(152)  Ebiloma, G. U.; Ayuga, T. D.; Balogun, E. O.; Gil, L. A.; Donachie, A.; Kaiser, M.; Herraiz, 
T.; Inaoka, D. K.; Shiba, T.; Harada, S.; et al. Inhibition of trypanosome alternative 
oxidase without its N-terminal mitochondrial targeting signal (ΔMTS-TAO) by cationic 
and non-cationic 4-hydroxybenzoate and 4-alkoxybenzaldehyde derivatives active 
against T. brucei and T. congolense. Eur. J. Med. Chem. 2018, 150, 385–402 DOI: 
10.1016/j.ejmech.2018.02.075. 
(153)  Fueyo González, F. J.; Ebiloma, G. U.; Izquierdo García, C.; Bruggeman, V.; Sánchez 
Villamañán, J. M.; Donachie, A.; Balogun, E. O.; Inaoka, D. K.; Shiba, T.; Harada, S.; et 
al. Conjugates of 2,4-Dihydroxybenzoate and Salicylhydroxamate and Lipocations 
Display Potent Antiparasite Effects by Efficiently Targeting the Trypanosoma brucei 
and Trypanosoma congolense Mitochondrion. J. Med. Chem. 2017, 60 (4), 1509–1522 
DOI: 10.1021/acs.jmedchem.6b01740. 
(154)  Rosano, G. L.; Ceccarelli, E. A. Recombinant protein expression in Escherichia coli: 
advances and challenges. Front. Microbiol. 2014, 5 (APR), 1–17 DOI: 
10.3389/fmicb.2014.00172. 
(155)  Hanahan, D. Studies on transformation of Escherichia coli with plasmids. J. Mol. Biol. 
1983, 166 (4), 557–580 DOI: 10.1016/S0022-2836(83)80284-8. 
(156)  Goh, S.; Good, L. Plasmid selection in Escherichia coli using an endogenous essential 
gene marker. BMC Biotechnol. 2008, 8 (1), 61 DOI: 10.1186/1472-6750-8-61. 
(157)  Lewis, M. The lac repressor. C. R. Biol. 2005, 328 (6), 521–548 DOI: 
10.1016/j.crvi.2005.04.004. 
(158)  Rigaut, G.; Shevchenko, A.; Rutz, B.; Wilm, M.; Mann, M.; Séraphin, B. A generic 
protein purification method for protein complex characterization and proteome 
exploration. Nat. Biotechnol. 1999, 17 (10), 1030–1032 DOI: 10.1038/13732. 
(159)  Ajayi, W. U.; Chaudhuri, M.; Hill, G. C. Site-directed mutagenesis reveals the 
essentiality of the conserved residues in the putative diiron active site of the 
trypanosome alternative oxidase. J. Biol. Chem. 2002, 277 (10), 8187–8193 DOI: 
10.1074/jbc.M111477200. 
(160)  Oganesyan, N.; Ankoudinova, I.; Kim, S.-H.; Kim, R. Effect of osmotic stress and heat 
shock in recombinant protein overexpression and crystallization. Protein Expr. Purif. 
2007, 52 (2), 280–285 DOI: 10.1016/j.pep.2006.09.015. 
310 
(161)  Blackwell, J. R.; Horgan, R. A novel strategy for production of a highly expressed 
recombinant protein in an active form. FEBS Lett. 1991, 295 (1–3), 10–12 DOI: 
10.1016/0014-5793(91)81372-F. 
(162)  Andersson, M. E.; Nordlund, P. A revised model of the active site of alternative oxidase. 
FEBS Lett. 1999, 449 (1), 17–22 DOI: S0014-5793(99)00376-2 [pii]. 
(163)  Towbin, H.; Staehelin, T.; Gordon, J. Electrophoretic transfer of proteins from 
polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. 
Natl. Acad. Sci. 1979, 76 (9), 4350–4354 DOI: 10.1073/pnas.76.9.4350. 
(164)  Cardoza, J. D.; Parikh, J. R.; Ficarro, S. B.; Marto, J. A. Mass spectrometry-based 
proteomics: qualitative identification to activity-based protein profiling. Wiley 
Interdiscip. Rev. Syst. Biol. Med. 2012, 4 (2), 141–162 DOI: 10.1002/wsbm.166. 
(165)  Affourtit, C.; Albury, M. S.; Crichton, P. G.; Moore, A. L. Exploring the molecular nature 
of alternative oxidase regulation and catalysis. FEBS Lett. 2002, 510 (3), 121–126 DOI: 
10.1016/S0014-5793(01)03261-6. 
(166)  Wilson, K.; Walker, J. Principles and Techniques of Practical Biochemistry; Principles 
and Techniques of Practical Biochemistry; Cambridge University Press, 2000. 
(167)  Suzuki, T.; Nihei, C.; Yabu, Y.; Hashimoto, T.; Suzuki, M.; Yoshida, A.; Nagai, K.; 
Hosokawa, T.; Minagawa, N.; Suzuki, S.; et al. Molecular cloning and characterization 
of Trypanosoma vivax alternative oxidase (AOX) gene, a target of the trypanocide 
ascofuranone. Parasitol. Int. 2004, 53 (3), 235–245 DOI: 10.1016/j.parint.2004.02.001. 
(168)  Hoefnagel, M.; Rich, P. R.; Zhang, Q.; Wiskich, J. T. Substrate Kinetics of the Plant 
Mitochondrial Alternative Oxidase and the Effects of Pyruvate. Plant Physiol. 1997, 
115 (3), 1145–1153. 
(169)  Johnson, K. A.; Goody, R. S. The Original Michaelis Constant: Translation of the 1913 
Michaelis–Menten Paper. Biochemistry 2011, 50 (39), 8264–8269 DOI: 
10.1021/bi201284u. 
(170)  Lineweaver, H.; Burk, D. The Determination of Enzyme Dissociation Constants. J. Am. 
Chem. Soc. 1934, 56 (3), 658–666 DOI: 10.1021/ja01318a036. 
(171)  Ranaldi, F.; Vanni, P.; Giachetti, E. What students must know about the determination 
of enzyme kinetic parameters. Biochem. Educ. 1999, 27 (2), 87–91 DOI: 
10.1016/S0307-4412(98)00301-X. 
(172)  Hoefnagel, M.; Rich, P. R.; Zhang, Q.; Wiskich, J. T. Substrate Kinetics of the Plant 
Mitochondrial Alternative Oxidase and the Effects of Pyruvate. Plant Physiol. 1997, 
115 (3), 1145–1153. 
(173)  YOSHIKAWA, S.; ORII, Y. The Inhibition Mechanism of the Cytochrome Oxidase 
Reaction. J. Biochem. 1972, 71 (5), 859–872. 
311 
(174)  Brooks, H. B.; Geeganage, S.; Kahl, S. D.; Montrose, C.; Sittampalam, S.; Smith, M. C.; 
Weidner, J. R. Basics of Enzymatic Assays for HTS; 2004. 
(175)  Iversen PW, Beck B, Chen YF,  et al. HTS Assay Validation. Assay Guidance Manual. 
Bethesda (MD): Eli Lilly & Company and the National Center for Adv 
https://www.ncbi.nlm.nih.gov/books/NBK83783/ (accessed May 5, 2018). 
(176)  Simeonov, A.; Davis, M. I. Interference with Fluorescence and Absorbance Assay 
Guidance Manual. In Assay Guidance Manual; 2015; pp 1–12. 
(177)  Dahlin, J. L.; Walters, M. A. The essential roles of chemistry in high-throughput 
screening triage. Future Med. Chem. 2014, 6 (11), 1265–1290 DOI: 10.4155/fmc.14.60. 
(178)  West, R. A.; O’Doherty, O. G.; Askwith, T.; Atack, J.; Beswick, P.; Laverick, J.; Paradowski, 
M.; Pennicott, L. E.; Rao, S. P. S.; Williams, G.; et al. African trypanosomiasis: Synthesis 
&amp; SAR enabling novel drug discovery of ubiquinol mimics for trypanosome 
alternative oxidase. Eur. J. Med. Chem. 2017, 141, 676–689 DOI: 
10.1016/j.ejmech.2017.09.067. 
(179)  Pryde, D. C.; Dalvie, D.; Hu, Q.; Jones, P.; Obach, R. S.; Tran, T.-D. Aldehyde Oxidase: 
An Enzyme of Emerging Importance in Drug Discovery. J. Med. Chem. 2010, 53 (24), 
8441–8460 DOI: 10.1021/jm100888d. 
(180)  Kalgutkar, A. S. Liabilities Associated with the Formation of “Hard” Electrophiles in 
Reactive Metabolite Trapping Screens. Chem. Res. Toxicol. 2017, 30 (1), 220–238 DOI: 
10.1021/acs.chemrestox.6b00332. 
(181)  Casey, M. L.; Kemp, D. S.; Paul, K. G.; Cox, D. D. Physical organic chemistry of 
benzisoxazoles. I. Mechanism of the base-catalyzed decomposition of benzisoxazoles. 
J. Org. Chem. 1973, 38 (13), 2294–2301 DOI: 10.1021/jo00953a006. 
(182)  Wager, T. T.; Hou, X.; Verhoest, P. R.; Villalobos, A. Moving beyond Rules: The 
Development of a Central Nervous System Multiparameter Optimization (CNS MPO) 
Approach To Enable Alignment of Druglike Properties. ACS Chem. Neurosci. 2010, 1 
(6), 435–449 DOI: 10.1021/cn100008c. 
(183)  O’Doherty, O. G. Synthesis of novel trypanosome alternative oxidase inhibitors for the 
treatment of African trypanosomiasis, University of Sussex, 2016. 
(184)  Vilsmeier, A.; Haack, A. Über die Einwirkung von Halogenphosphor auf Alkyl-
formanilide. Eine neue Methode zur Darstellung sekundärer und tertiärer p -
Alkylamino-benzaldehyde. Berichte der Dtsch. Chem. Gesellschaft (A B Ser. 1927, 60 
(1), 119–122 DOI: 10.1002/cber.19270600118. 
(185)  Masilamani, D.; Rogie, M. M. Sulfuryl Chloride as a Reagent for Selective Chlorination 
of Symmetrical Ketones and Phenols. J. Org. Chem. 1981, 46 (11), 4486–4489 DOI: 
10.1021/jo00335a033. 
312 
(186)  Harder, E.; Damm, W.; Maple, J.; Wu, C.; Reboul, M.; Xiang, J. Y.; Wang, L.; Lupyan, D.; 
Dahlgren, M. K.; Knight, J. L.; et al. OPLS3: A Force Field Providing Broad Coverage of 
Drug-like Small Molecules and Proteins. J. Chem. Theory Comput. 2016, 12 (1), 281–
296 DOI: 10.1021/acs.jctc.5b00864. 
(187)  Kalkhambkar, R. G.; Yuvaraj, H. Triflic Anhydride: A Mild Reagent for Highly Efficient 
Synthesis of 1,2-Benzisoxazoles, Isoxazolo, and Isothiazolo Quinolines Without 
Additive or Base. Synth. Commun. 2014, 44 (4), 547–555 DOI: 
10.1080/00397911.2013.821617. 
(188)  Thomas, B.; George, J.; Sugunan, S. Synthesis of benzoxazole via the Beckmann 
rearrangement of salicylaldoxime on protonated zeolites: A green continuous process. 
Ind. Eng. Chem. Res. 2009, 48 (2), 660–670 DOI: 10.1021/ie800913q. 
(189)  Miyaura, N.; Suzuki, A. Stereoselective synthesis of arylated (E)-alkenes by the reaction 
of alk-1-enylboranes with aryl halides in the presence of palladium catalyst. J. Chem. 
Soc. Chem. Commun. 1979, No. 19, 866 DOI: 10.1039/c39790000866. 
(190)  Miyaura, N.; Yamada, K.; Suzuki, A. A new stereospecific cross-coupling by the 
palladium-catalyzed reaction of 1-alkenylboranes with 1-alkenyl or 1-alkynyl halides. 
Tetrahedron Lett. 1979, 20 (36), 3437–3440 DOI: 10.1016/S0040-4039(01)95429-2. 
(191)  Mizoroki, T.; Mori, K.; Ozaki, A. Arylation of Olefin with Aryl Iodide Catalyzed by 
Palladium. Bull. Chem. Soc. Jpn. 1971, 44 (2), 581–581 DOI: 10.1246/bcsj.44.581. 
(192)  Heck, R. F.; Nolley, J. P. Palladium-catalyzed vinylic hydrogen substitution reactions 
with aryl, benzyl, and styryl halides. J. Org. Chem. 1972, 37 (14), 2320–2322 DOI: 
10.1021/jo00979a024. 
(193)  Pourmousavi, S. A.; Salehi, P. Synthesis of Benzyl Triethyl Ammonium Tribromide and 
Its Application as a Highly Efficient and Regioselective Reagent for the Bromination of 
Activated Aromatic Compounds. Acta Chim. Slov. 2009, 3 (56), 734–739. 
(194)  Peh, G.-R.; Kantchev, E. A. B.; Zhang, C.; Ying, J. Y. N-heterocycle carbene (NHC)-ligated 
cyclopalladated N,N-dimethylbenzylamine: a highly active, practical and versatile 
catalyst for the Heck-Mizoroki reaction. Org. Biomol. Chem. 2009, 7 (10), 2110–2119 
DOI: 10.1039/b821892g. 
(195)  Herrmann, W. A.; Köcher, C. N-Heterocyclic Carbenes. Angew. Chemie Int. Ed. English 
1997, 36 (20), 2162–2187 DOI: 10.1002/anie.199721621. 
(196)  Hadei, N.; Kantchev, E. A. B.; O’Brie, C. J.; Organ, M. G. Electronic Nature of N-
Heterocyclic Carbene Ligands: Effect on the Suzuki Reaction. Org. Lett. 2005, 7 (10), 
1991–1994 DOI: 10.1021/ol050471w. 
(197)  Vatèle, J.-M. One-Pot Oxidative Conversion of Alcohols into Nitriles by Using a 
TEMPO/PhI(OAc)2/NH4OAc System. Synlett 2014, 25 (09), 1275–1278 DOI: 10.1055/s-
313 
0033-1341124. 
(198)  Bag, S.; Tawari, N. R.; Degani, M. S. A new, mild and high yielding protocol for the 
preparation of nitriles from aldehydes using iodosobenzene diacetate in aqueous 
ammonia. Arkivoc 2009, 2009 (14), 118–123. 
(199)  Tamura, Y.; Yakura, T.; Tohma, H.; Ki-kuchi, K.; Kita, Y. Hypervalent Iodine Oxidation of 
p -Alkoxy- and Related Phenols: A Facile and Efficient Synthesis of p -Quinones. 
Synthesis (Stuttg). 1989, 1989 (02), 126–127 DOI: 10.1055/s-1989-27170. 
(200)  Pouységu, L.; Sylla, T.; Garnier, T.; Rojas, L. B.; Charris, J.; Deffieux, D.; Quideau, S. 
Hypervalent iodine-mediated oxygenative phenol dearomatization reactions. 
Tetrahedron 2010, 66 (31), 5908–5917 DOI: 10.1016/j.tet.2010.05.078. 
(201)  De Luca, L.; Giacomelli, G.; Porcheddu, A. Beckmann Rearrangement of Oximes under 
Very Mild Conditions. J. Org. Chem. 2002, 67 (17), 6272–6274 DOI: 
10.1021/jo025960d. 
(202)  Mandal, P. K.; McMurray, J. S. Pd-C-induced catalytic transfer hydrogenation with 
triethylsilane. J. Org. Chem. 2007, 72 (17), 6599–6601 DOI: 10.1021/jo0706123. 
(203)  Suzuki, S.; Segawa, Y.; Itami, K.; Yamaguchi, J. Synthesis and characterization of 
hexaarylbenzenes with five or six different substituents enabled by programmed 
synthesis. Nat. Chem. 2015, 7 (3), 227–233 DOI: 10.1038/nchem.2174. 
(204)  Zhu, L.; Lu, L.; Wang, S.; Wu, J.; Shi, J.; Yan, T.; Xie, C.; Li, Q.; Hu, M.; Liu, Z. Oral 
Absorption Basics. In Developing Solid Oral Dosage Forms; Elsevier, 2017; pp 297–329. 
(205)  Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and 
computational approaches to estimate solubility and permeability in drug discovery 
and development settings. Adv. Drug Deliv. Rev. 1997, 23 (1–3), 3–25 DOI: 
10.1016/S0169-409X(96)00423-1. 
(206)  Egan, W. J.; Merz, K. M.; Baldwin, J. J. Prediction of drug absorption using multivariate 
statistics. J. Med. Chem. 2000, 43 (21), 3867–3877 DOI: 10.1021/jm000292e. 
(207)  Ghose, A. K.; Herbertz, T.; Salvino, J. M.; Mallamo, J. P. Knowledge-based 
chemoinformatic approaches to drug discovery. Drug Discov. Today 2006, 11 (23–24), 
1107–1114 DOI: 10.1016/j.drudis.2006.10.012. 
(208)  Zmuidinavicius, D.; Didziapetris, R.; Japertas, P.; Avdeef, A.; Petrauskas, A. 
Classification Structure-Activity Relations (C-SAR) in Prediction of Human Intestinal 
Absorption. J. Pharm. Sci. 2003, 92 (3), 621–633 DOI: 10.1002/JPS.10321. 
(209)  Bergström, C. A. S.; Norinder, U.; Luthman, K.; Artursson, P. Experimental and 
Computational Screening Models for Prediction of Aqueous Drug Solubility. Pharm. 
Res. 2002, 19 (2), 182–188 DOI: 10.1023/A:1014224900524. 
314 
(210)  Chen, X.; Cho, S. J.; Li, Y.; Venkatesh, S. Prediction of aqueous solubility of organic 
compounds using a quantitative structure–property relationship. J. Pharm. Sci. 2002, 
91 (8), 1838–1852 DOI: 10.1002/jps.10178. 
(211)  Ishikawa, M.; Hashimoto, Y. Improvement in Aqueous Solubility in Small Molecule 
Drug Discovery Programs by Disruption of Molecular Planarity and Symmetry. J. Med. 
Chem. 2011, 54 (6), 1539–1554 DOI: 10.1021/jm101356p. 
(212)  Zanger, U. M.; Schwab, M. Cytochrome P450 enzymes in drug metabolism: Regulation 
of gene expression, enzyme activities, and impact of genetic variation. Pharmacol. 
Ther. 2013, 138 (1), 103–141 DOI: 10.1016/j.pharmthera.2012.12.007. 
(213)  Zhang, Z.; Tang, W. Drug metabolism in drug discovery and development. Acta Pharm. 
Sin. B 2018, No. 17 DOI: 10.1016/j.apsb.2018.04.003. 
(214)  Di, L.; Kerns, E. H.; Di, L.; Kerns, E. H. Chapter 11 – Metabolic Stability; 2016. 
(215)  Obach, R. S.; Walker, G. S.; Brodney, M. A. Biosynthesis of fluorinated analogs of drugs 
using human cytochrome P450 enzymes followed by deoxyfluorination and 
quantitative nuclear magnetic resonance spectroscopy to improve metabolic stability. 
Drug Metab. Dispos. 2016, 44 (5), 634–646 DOI: 10.1124/dmd.116.069310. 
(216)  Di, L.; Kerns, E. H. Lipophilicity. Drug-like Prop.  concepts, Struct. Des. methods from 
ADME to Toxic. Optim. 2016, 39–50 DOI: 10.1016/B978-0-12-801076-1.00005-8. 
(217)  Nassar, A.-E. F.; Kamel, A. M.; Clarimont, C. Improving the decision-making process in 
the structural modification of drug candidates: enhancing metabolic stability. Drug 
Discov. Today 2004, 9 (23), 1020–1028 DOI: 10.1016/S1359-6446(04)03280-5. 
(218)  Lewis, D. F. V.; Jacobs, M. N.; Dickins, M. Compound lipophilicity for substrate binding 
to human P450s in drug metabolism. Drug Discov. Today 2004, 9 (12), 530–537 DOI: 
10.1016/S1359-6446(04)03115-0. 
(219)  Freeman-Cook, K. D.; Hoffman, R. L.; Johnson, T. W. Lipophilic efficiency: the most 
important efficiency metric in medicinal chemistry. Future Med. Chem. 2013, 5 (2), 
113–115 DOI: 10.4155/fmc.12.208. 
(220)  Shultz, M. D. The thermodynamic basis for the use of lipophilic efficiency (LipE) in 
enthalpic optimizations. Bioorg. Med. Chem. Lett. 2013, 23 (21), 5992–6000 DOI: 
10.1016/j.bmcl.2013.08.030. 
(221)  Westergaard, E.; Brightman, M. W. Transport of proteins across normal cerebral 
arterioles. J. Comp. Neurol. 1973, 152 (1), 17–44 DOI: 10.1002/cne.901520103. 
(222)  Löscher, W.; Potschka, H. Blood-brain barrier active efflux transporters: ATP-binding 
cassette gene family. NeuroRX 2005, 2 (1), 86–98 DOI: 10.1602/neurorx.2.1.86. 
(223)  Clark, D. E. In silico prediction of blood–brain barrier permeation. Drug Discov. Today 
315 
2003, 8 (20), 927–933 DOI: 10.1016/S1359-6446(03)02827-7. 
(224)  Wager, T. T.; Hou, X.; Verhoest, P. R.; Villalobos, A. Central Nervous System 
Multiparameter Optimization Desirability: Application in Drug Discovery. ACS Chem. 
Neurosci. 2016, 7 (6), 767–775 DOI: 10.1021/acschemneuro.6b00029. 
(225)  Pardridge, W. M. The blood-brain barrier: Bottleneck in brain drug development. 
NeuroRX 2005, 2 (1), 3–14 DOI: 10.1602/neurorx.2.1.3. 
(226)  Di, L.; Kerns, E. H. Blood-Brain Barrier. In Drug-Like Properties; Elsevier, 2016; pp 141–
159. 
(227)  Yabu, Y.; Minagawa, N.; Kita, K.; Nagai, K.; Honma, M.; Sakajo, S.; Koide, T.; Ohta, N.; 
Yoshimoto, A. Oral and intraperitoneal treatment of Trypanosoma brucei brucei with 
a combination of ascofuranone and glycerol in mice. Parasitol. Int. 1998, 47 (2), 131–
137 DOI: 10.1016/S1383-5769(98)00011-7. 
(228)  Narang, A. S.; Mantri, R. V.; Raghavan, K. S. Excipient compatibility and functionality; 
Elsevier Inc., 2016. 
(229)  Yabu, Y.; Yoshida, A.; Suzuki, T.; Nihei, C.; Kawai, K.; Minagawa, N.; Hosokawa, T.; Nagai, 
K.; Kita, K.; Ohta, N. The efficacy of ascofuranone in a consecutive treatment on 
Trypanosoma brucei brucei in mice. Parasitol. Int. 2003, 52 (2), 155–164 DOI: 
10.1016/S1383-5769(03)00012-6. 
(230)  Herman, M.; Pérez-Morga, D.; Schtickzelle, N.; Michels, P. A. M. Turnover of 
glycosomes during life-cycle differentiation of Trypanosoma brucei. Autophagy 2008, 
4 (3), 294–308 DOI: 10.4161/auto.5443. 
(231)  Amiguet-Vercher, A.; Pérez-Morga, D.; Pays, A.; Poelvoorde, P.; Van Xong, H.; Tebabi, 
P.; Vanhamme, L.; Pays, E. Loss of the mono-allelic control of the VSG expression sites 
during the development of Trypanosoma brucei in the bloodstream. Mol. Microbiol. 
2004, 51 (6), 1577–1588 DOI: 10.1111/j.1365-2958.2003.03937.x. 
(232)  Hughes, J. D.; Blagg, J.; Price, D. A.; Bailey, S.; Decrescenzo, G. A.; Devraj, R. V.; 
Ellsworth, E.; Fobian, Y. M.; Gibbs, M. E.; Gilles, R. W.; et al. Physiochemical drug 
properties associated with in vivo toxicological outcomes. Bioorg. Med. Chem. Lett. 
2008, 18 (17), 4872–4875 DOI: 10.1016/j.bmcl.2008.07.071. 
(233)  Di, L.; Kerns, E. H. Solubility. In Drug-Like Properties; Elsevier, 2016; pp 61–93. 
(234)  Li, H.; Zhong, Y.-L.; Chen, C.; Ferraro, A. E.; Wang, D. A Concise and Atom-Economical 
Suzuki–Miyaura Coupling Reaction Using Unactivated Trialkyl- and Triarylboranes with 
Aryl Halides. Org. Lett. 2015, 17 (14), 3616–3619 DOI: 10.1021/acs.orglett.5b01720. 
(235)  Sabot, C.; Kumar, K. A.; Meunier, S.; Mioskowski, C. A convenient aminolysis of esters 
catalyzed by 1,5,7-triazabicyclo[4.4.0]dec-5-ene (TBD) under solvent-free conditions. 
Tetrahedron Lett. 2007, 48 (22), 3863–3866 DOI: 10.1016/j.tetlet.2007.03.146. 
316 
(236)  Brown, H. C.; Keblys, K. A. Hydroboration. XXII. The Reaction of Unsaturated Esters 
with Diborane and Disiamylborane. J. Am. Chem. Soc. 1964, 86 (9), 1795–1801 DOI: 
10.1021/ja01063a029. 
(237)  Colacot, T. J.; Shea, H. A. Cp 2 Fe(PR 2 ) 2 PdCl 2 (R = i -Pr, t -Bu) Complexes as Air-
Stable Catalysts for Challenging Suzuki Coupling Reactions. Org. Lett. 2004, 6 (21), 
3731–3734 DOI: 10.1021/ol048598t. 
(238)  Dreher, S. D.; Lim, S. E.; Sandrock, D. L.; Molander, G. A. Suzuki-miyaura cross-coupling 
reactions of primary alkyltrifluoroborates with aryl chlorides. J. Org. Chem. 2009, 74 
(10), 3626–3631 DOI: 10.1021/jo900152n. 
(239)  Miller, E. J.; Mays, S. G.; Baillie, M. T.; Howard, R. B.; Culver, D. G.; Saindane, M.; Pruett, 
S. T.; Holt, J. J.; Menaldino, D. S.; Evers, T. J.; et al. Discovery of a Fluorinated Enigmol 
Analog with Enhanced in Vivo Pharmacokinetic and Anti-Tumor Properties. ACS Med. 
Chem. Lett. 2016, 7 (5), 537–542 DOI: 10.1021/acsmedchemlett.6b00113. 
(240)  Zhou, Y.; Wang, J.; Gu, Z.; Wang, S.; Zhu, W.; Aceña, J. L.; Soloshonok, V. A.; Izawa, K.; 
Liu, H. Next Generation of Fluorine-Containing Pharmaceuticals, Compounds 
Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New 
Structural Trends and Therapeutic Areas. Chem. Rev. 2016, 116 (2), 422–518 DOI: 
10.1021/acs.chemrev.5b00392. 
(241)  Huchet, Q. A.; Kuhn, B.; Wagner, B.; Kratochwil, N. A.; Fischer, H.; Kansy, M.; Zimmerli, 
D.; Carreira, E. M.; Müller, K. Fluorination Patterning: A Study of Structural Motifs That 
Impact Physicochemical Properties of Relevance to Drug Discovery. J. Med. Chem. 
2015, 58 (22), 9041–9060 DOI: 10.1021/acs.jmedchem.5b01455. 
(242)  Ritchie, T. J.; Macdonald, S. J. F.; Peace, S.; Pickett, S. D.; Luscombe, C. N. The 
developability of heteroaromatic and heteroaliphatic rings – do some have a better 
pedigree as potential drug molecules than others? Medchemcomm 2012, 3 (9), 1062 
DOI: 10.1039/c2md20111a. 
(243)  Patel, K. D.; Prajapati, S. M.; Panchal, S. N.; Patel, H. D. Review of Synthesis of 1,3,4-
Oxadiazole Derivatives. Synth. Commun. 2014, 44 (13), 1859–1875 DOI: 
10.1080/00397911.2013.879901. 
(244)  Tokumaru, K.; Johnston, J. N. A convergent synthesis of 1,3,4-oxadiazoles from acyl 
hydrazides under semiaqueous conditions. Chem. Sci. 2017, 8 (4), 3187–3191 DOI: 
10.1039/c7sc00195a. 
(245)  Wu, X.; Ekegren, J. K.; Larhed, M. Microwave-Promoted Aminocarbonylation of Aryl 
Iodides, Aryl Bromides, and Aryl Chlorides in Water. Organometallics 2006, 25 (6), 
1434–1439 DOI: 10.1021/om051044p. 
(246)  Pineiro, M.; Dias, L. D.; Damas, L.; Aquino, G. L. B.; Calvete, M. J. F.; Pereira, M. M. 
Microwave irradiation as a sustainable tool for catalytic carbonylation reactions. 
317 
Inorganica Chim. Acta 2017, 455, 364–377 DOI: 10.1016/j.ica.2016.06.043. 
(247)  Roberts, B.; Liptrot, D.; Alcaraz, L.; Luker, T.; Stocks, M. J. Molybdenum-mediated 
carbonylation of aryl halides with nucleophiles using microwave irradiation. Org. Lett. 
2010, 12 (19), 4280–4283 DOI: 10.1021/ol1016965. 
(248)  Herrmann, W. A.; Brossmer, C.; Reisinger, C.-P.; Riermeier, T. H.; Öfele, K.; Beller, M. 
Palladacycles: Efficient New Catalysts for the Heck Vinylation of Aryl Halides. Chem. - 
A Eur. J. 1997, 3 (8), 1357–1364 DOI: 10.1002/chem.19970030823. 
(249)  Sangshetti, J. N.; Chabukswar, A. R.; Shinde, D. B. Microwave assisted one pot 
synthesis of some novel 2,5-disubstituted 1,3,4-oxadiazoles as antifungal agents. 
Bioorg. Med. Chem. Lett. 2011, 21 (1), 444–448 DOI: 10.1016/j.bmcl.2010.10.120. 
(250)  Reimer, K.; Tiemann, F. Ueber die Einwirkung von Chloroform auf Phenole und 
besonders aromatische Oxysäuren in alkalischer Lösung. Berichte der Dtsch. Chem. 
Gesellschaft 1876, 9 (2), 1268–1278 DOI: 10.1002/cber.18760090270. 
(251)  Wynberg, H. The reimer-tiemann reaction. Chem. Rev. 1960, 60 (2), 169–184 DOI: 
10.1021/cr60204a003. 
(252)  Bal, B. S.; Childers, W. E.; Pinnick, H. W. Oxidation of α,β-un saturated aldehydes. 
Tetrahedron 1981, 37 (11), 2091–2096 DOI: 10.1016/S0040-4020(01)97963-3. 
(253)  Kraus, G. A.; Roth, B. toward Verrucarol. 2. 1980, 05, 4825–4830 DOI: 
10.1021/jo01312a004. 
(254)  Wilcken, R.; Zimmermann, M. O.; Lange, A.; Joerger, A. C.; Boeckler, F. M. Principles 
and Applications of Halogen Bonding in Medicinal Chemistry and Chemical Biology. J. 
Med. Chem. 2013, 56 (4), 1363–1388 DOI: 10.1021/jm3012068. 
(255)  Huang, K.; James, M. N. G.; Lu, W.; Laskowski, M.; Anderson, S. Water molecules 
participate in proteinase‐inhibitor interactions: Crystal structures of Leu18, Ala18, and 
Gly18variants of turkey ovomucoid inhibitor third domain complexed with 
Streptomyces griseus proteinase B. Protein Sci. 1995, 4 (10), 1985–1997 DOI: 
10.1002/pro.5560041004. 
(256)  Roberts, C. W.; Roberts, F.; Henriquez, F. L.; Akiyoshi, D.; Samuel, B. U.; Richards, T. A.; 
Milhous, W.; Kyle, D.; McIntosh, L.; Hill, G. C.; et al. Evidence for mitochondrial-derived 
alternative oxidase in the apicomplexan parasite Cryptosporidium parvum: a potential 
anti-microbial agent target. Int. J. Parasitol. 2004, 34 (3), 297–308 DOI: 
10.1016/j.ijpara.2003.11.002. 
(257)  Williams, B. A. P.; Elliot, C.; Burri, L.; Kido, Y.; Kita, K.; Moore, A. L.; Keeling, P. J. A Broad 
Distribution of the Alternative Oxidase in Microsporidian Parasites. PLoS Pathog. 2010, 
6 (2), e1000761 DOI: 10.1371/journal.ppat.1000761. 
(258)  Rodriguez, R.; Moses, J. E.; Adlington, R. M.; Baldwin, J. E. A new and efficient method 
318 
for o-quinone methide intermediate generation: application to the biomimetic 
synthesis of the benzopyran derived natural products (±)-lucidene and (±)-alboatrin. 
Org. Biomol. Chem. 2005, 3 (19), 3488 DOI: 10.1039/b508972g. 
(259)  Harris, T. M.; Harris, C. M.; Oster, T. A.; Brown, L. E.; Lee, J. Y. C. Biomimetic syntheses 
of pretetramides.  2.  A synthetic route based on a preformed D ring. J. Am. Chem. Soc. 
1988, 110 (18), 6180–6186 DOI: 10.1021/ja00226a037. 
(260)  Jiang, J. A.; Du, J. L.; Liao, D. H.; Wang, Z. G.; Ji, Y. F. Efficient Co(OAc)2-catalyzed 
aerobic oxidation of EWG-substituted 4-cresols to access 4-hydroxybenzaldehydes. 
Tetrahedron Lett. 2014, 55 (8), 1406–1411 DOI: 10.1016/j.tetlet.2013.12.077. 
(261)  Yokokawa, F.; Nilar, S.; Noble, C. G.; Lim, S. P.; Rao, R.; Tania, S.; Wang, G.; Lee, G.; 
Hunziker, J.; Karuna, R.; et al. Discovery of Potent Non-Nucleoside Inhibitors of Dengue 
Viral RNA-Dependent RNA Polymerase from a Fragment Hit Using Structure-Based 
Drug Design. J. Med. Chem. 2016, 59 (8), 3935–3952 DOI: 
10.1021/acs.jmedchem.6b00143. 
 
  
319 
 
 
 
 
 
Appendix 
Research paper
African trypanosomiasis: Synthesis & SAR enabling novel drug
discovery of ubiquinol mimics for trypanosome alternative oxidase
Ryan A. West a, 1, Oran G. O'Doherty a, 1, Trevor Askwith a, John Atack a, b, Paul Beswick a,
Jamie Laverick a, Michael Paradowski a, Lewis E. Pennicott a, Srinivasa P.S. Rao c,
Gareth Williams a, Simon E. Ward a, b, *
a Sussex Drug Discovery Centre, University of Sussex, Brighton, BN1 9QJ, UK
b Medicines Discovery Institute, Cardiff University, Park Place, Cardiff, CF10 3AT, UK
c Novartis Institutes for Tropical Diseases, 5300 Chiron Way, California, 94608-2916, USA
a r t i c l e i n f o
Article history:
Received 3 July 2017
Received in revised form
13 September 2017
Accepted 29 September 2017
Available online xxx
Keywords:
Antiprotozoal agents
Oxidoreductase
Medicinal chemistry
Synthesis design
a b s t r a c t
African trypanosomiasis is a parasitic disease affecting 5000 humans and millions of livestock animals in
sub-Saharan Africa every year. Current treatments are limited, difﬁcult to administer and often toxic
causing long term injury or death in many patients. Trypanosome alternative oxidase is a parasite
speciﬁc enzyme whose inhibition by the natural product ascofuranone (AF) has been shown to be
curative in murine models. Until now synthetic methods to AF analogues have been limited, this has
restricted both understanding of the key structural features required for binding and also how this
chemotype could be developed to an effective therapeutic agent. The development of 3 amenable novel
synthetic routes to ascofuranone-like compounds is described. The SAR generated around the AF che-
motype is reported with correlation to the inhibition of T. b. brucei growth and corresponding selectivity
in cytotoxic assessment in mammalian HepG2 cell lines. These methods allow access to greater synthetic
diversiﬁcation and have enabled the synthesis of compounds that have and will continue to facilitate
further optimisation of the AF chemotype into a drug-like lead.
© 2017 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).
1. Introduction
African Trypanosomiasis is a parasitic protozoan infection in
mammals spread by the tsetse ﬂy (Glossina) [1]. It is exclusively
found in 36 sub-Saharan African countries between 14!N and 20!S
[2]. Trypanosoma brucei gambiense and T. b. rhodesiense cause the
chronic western and acute eastern infections respectively, these
two species have developed strategies to neutralize the immunity
conferred by apolipoprotein A1, a trypanosomal lytic factor (TLF) in
normal human sera [3], and evade host immune response by
antigenic variation of their variant surface glycoprotein coat [4]. 60
million people are at risk of human African trypanosomiasis (HAT)
with 5000 new cases reported annually [5,6]. Stage 1 of the disease
is haemolymphatic [7], subsequent penetration into the brain gives
rise to stage 2 where meningoencephalitis and neuronal
destruction produce a diverse range of symptoms including motor
neuropathy, psychiatric disorders, sensory disturbances and the
characteristic disruption of the diurnal cycle causing lethargy and
insomnia that gives the disease its sleeping sickness title [8].
Without chemotherapeutic intervention the disease progresses to
coma and death in almost all cases [9]. The high morbidity is
evinced by the 1.79 million disability-adjusted life years (DALYs)
calculated for HAT, over ﬁve times greater than that for the related
disease leishmaniasis [10]. This infection is not limited to humans;
animal African trypanosomiasis (AAT) is the single largest infection
of cattle in Africa necessitating 35 million doses of trypanocidal
agents, costing up to 140 million USD annually and impacting
nutrition, livelihoods and development across sub-Saharan Africa.
[11,12] Different trypanosome species affect cattle, predominantly
T. vivax, T. evansi and T. congolense [13]. AAT is less often fatal but its
characteristic anaemia [14] severely impairs the health and pro-
ductivity of cattle.
Current treatments for HAT are far from ideal: stage 1 treat-
ments pentamidine and suramin (Fig. 1) only treat one subspecies
(T.b. gambiense and T.b. rhodesiense respectively) and require
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intravenous/intramuscular (IV/IM) administration [15]. Similarly
stage 2 is limited to nifurtimox-eﬂornithine combination therapy
(NECT) and melarsoprol where NECT is ineffective in treating T.b.
rhodesiense infection [15]. All current treatments are of limited
utility due to signiﬁcant toxicities; the organoarsenide melarsoprol
even causes reactionary encephalitis in 10% of patients and death in
5%. [16,17] The treatments all require clinicians for IV/IM injections
[15], which is a major practical impediment for a diffuse population
over a sizable portion of continental Africa. Drug resistance for
melarsoprol and pentamidine has been increasingly observed [18]
and has been linked to mutated aquaglyceroproteins both in vitro
and in ﬁeld isolates, required for trypanosomal uptake of the
compounds [19].
With such poor therapeutics currently available, it is imperative
that new, improved drug agents are discovered. An excellent target
for drug development is trypanosome alternative oxidase (TAO).
TAO is a ubiquinol dependent terminal oxidase required for the
long slender blood stream trypanosomes aerobic glucose meta-
bolism converting oxygen into water [20]. It is a 38 kDa cyanide-
insensitive mitochondrial inner-leaf protein with a di-iron core
which is key for enzymatic activity [21]. Many factors make it an
exciting drug development target: 1) TAO is expressed in only
parasitic organisms with no mammalian homologues [22]; 2)
biochemical assays are well established [23]; 3) the crystal struc-
ture has been determined [24]; 4) inhibition of TAO has demon-
strated clear trypanocidal action [25]; 5) existence of potent natural
product inhibitors of TAO, in particular ascofuranone (AF) with
Ki ¼ 0.13 nM [26]; 6) demonstration of efﬁcacy with ascofuranone
in vitro and murine in vivo models [25,27].
However, ascofuranone-like inhibitors have many undesirable
qualities associated with their chemical structure. In particular, the
electron rich aromatic ring, pendant aldehyde, phenols and lipo-
philic side chain contribute to the rapid observed clearance, low
oral bioavailability and potential toxicity of this class. Furthermore,
structure activity relationships (SAR) published around the geranyl
tail clearly demonstrate that its effects are almost entirely due to
non-speciﬁc lipophilic interactions.
Although TAO represents an attractive target for treating HAT,
no real progress has been made in the development of potential
drug agents from this chemical start point, despite the fact that AF
has been known for over 20 years to be a potent inhibitor both
in vitro and in vivo. [27,28] One of the major bottlenecks to this
progress has been lack of versatility of the available synthetic
routes to these templates. There are only a handful of published
synthetic methods, all suffering from linear sequence of steps
resulting in poor overall yields [29]. [30] Additionally, our group has
not been able to reproduce all of the chemistry reported to date.
One key limitation of the current methodologies is that they rely on
pre-formation of the penta-substituted aromatic head group,
which is low-yielding and has limited potential for SAR expansion.
The subsequent addition of the side chain is also capricious and low
yielding. The reported deprotonation [31] with KOH followed by
addition of geranyl bromide yielded only 5% product whilst other
non-prenyl bromides preferably undergo O-alkylation. The selec-
tion of an appropriate protecting group for the bis-phenol 2 proved
challenging as some silicon ethers or esters are labile in the pres-
ence of the ortho-aldehyde. The reported double SEM [32] protec-
tion of phenols in compound 3with subsequent tail-chain addition
via lithium halogen exchange was poor yielding, and subsequent
removal of the SEM ethers proved impossible. Compound 2 does
not undergo palladium-mediated coupling reactions, presumably
due to the exposed phenols. Suzuki coupling is possible with
methylated phenols but deprotection remains an impasse.
We report here a series of novel, simpliﬁed and improved syn-
thetic routes to AF-like compounds. Two of the routes we have
developed allow facile diversiﬁcation of the head group that con-
fers activity as well as alteration of the tail. We also report TAO
inhibition data for the molecules prepared during these synthetic
investigations. This will build upon the existing SAR platform
around the active head group to help inform future development of
AF-like TAO inhibitors for HAT.
2. Results and discussion
2.1. Synthetic chemistry
Previous attempts to deprotect the bis-protected phenol ethers
(Fig. 2) was found to only remove protecting groups ortho to the
aldehyde. This was likely due to an enhanced bidentate chelation of
Lewis acids available to this motif, this chelation could destabilise
the etheric C-O bond and allow for its removal. To take advantage of
this, Lewis-acid mediated cationic rearrangement of the prenyl
chain was employed [33]. It was necessary to mask the para phenol
as the acetate, to enable the rearrangement, as the unprotected
para phenol substrate did not rearrange. Compound 5 was rear-
ranged to give colletochlorin B (CCB-6) a proven trypanocide and
potent TAO inhibitor (IC50e2 nM) in a yield which, although
modest, was a signiﬁcant improvement over past reports. This
chemistry was subsequently employed to generate compounds in
the following SAR investigation (see Scheme 1).
Exploiting the reactivity of the phenolic functionality had
proven successful and was explored further. When starting from
orcinol, double protection of the phenols as MOM ethers was
required to allow the reaction of alkyl bromides via lithiation and
subsequent electrophilic aromatic substitution (exempliﬁed by
DMF in Scheme 2) in excellent yields. This alkylationwas attempted
with the geranyl chain, giving an overall 48% yield via sequential
one-pot additions. However, removal of the protecting groups was
again challenging yielding only 15% product. This method for
addition of the sidechain takes advantage of the symmetrical
starting material thus removing the regioselectivity issues from the
subsequent additions.
Further lithiation chemistry gave access to differentiated core
structures through more ﬂexible synthetic routes, however sub-
sequent optimisation was required to improve both overall yields
and increase structural diversity (Scheme 3). Starting from the
Fig. 1. Current HAT treatments. Fig. 2. Ascofuranone and previous synthetic starting points.
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diketone, various tails were installed, including those amenable to
late stage diversiﬁcation. Protection as the enol methyl ether 14 or
15 ensured clean formation of the desired enolate. This readily
underwent substitution at the a-carbon. Oxidation by DDQ and
subsequent de-protection afforded the AF-like analogues 18 and 19.
A range of diverse analogues have been prepared with the
chemistry described and are currently under biological investiga-
tion, data will be reported in future publications. These synthetic
methods represent a signiﬁcant improvement over previously re-
ported methodologies and allow access to a range of diverse, novel
AF-analogues. This work will facilitate the exploration of this che-
motype to generate more drug like TAO inhibitors for future
development.
2.2. Protein expression and puriﬁcation
Recombinant TAO was expressed in Rosetta2® E. coli by
transformation of plasmid containing complementary DNA for the
overexpression of His-tagged trypanosome alternative oxidase,
obtained from Anthony Moore, University of Sussex. Subsequent
culture in LB broth, containing 120 g/L sorbitol and 250 mM
betaine, 50 mg/mL ampicillin and 35 mg/mL chloramphenicol,
grown at 37 !C until OD600 0.2 then grown at 18 !C until OD600 0.6
was reached. The culture was induced with the addition of Iso-
propyl b-D-1-thiogalactopyranoside 500 mM ﬁnal concentration
and the cultures continued overnight at 18 !C. The E. coli pellet was
isolated by centrifugation 10000g for 20 min at 4 !C (Beckman
Coulter Avanti J26S, JLA9.1000 rotor). Lysis was carried out by re-
suspension of the pellet in 50 mL of lysis buffer (50 mM Tris HCl,
20% (w/v) sucrose pH 7.4, 1 protease inhibitor cocktail tablet and
2 mL of Benzonase/DNAse® Sigma) and sonication (Sonics Vibracell,
13 mm probe, 35% intensity, 180 s, 5 s pulses). Cell debris and un-
broken cells were removed by centrifugation (Beckman Coulter
Avanti J26S, JA 25.50 rotor, 8000 g, 10 min, 4 !C) to provide the
supernatant as the crude fraction for further puriﬁcation.
Fractionation of the E. coli inner membranes was performed by
isopycnic centrifugation. The crude supernatant was overlaid onto
45% sucrose solution (3# 20mL, 50mM TrisHCl, 45% (w/v) sucrose,
pH 7.4) and ultra-centrifuged (Beckman Coulter L-80, SW28,
141000 rcf max, 1 h, 4 !C) to isolate the E. coli inner membranes as
the buoyant supernatant fraction. The supernatant from this was
diluted 1:1 (50 mM Tris HCl, pH 7.4) to give a 15e20% sucrose so-
lution reducing the density of the media and enabling the sedi-
mentation of the inner membranes as a pellet by further
ultracentrifugation (Beckman Coulter L-80, SW28, 141000 rcf max,
1 h, 4 !C). The inner membrane pellet was solubilised by re-
suspension with octylglucopyranoside (OG) buffer (37 mL, 50 mM
TrisHCl, 1.4% OG (w/v), 20% glycerol (v/v), 200 mM MgSO4, pH 7.4)
followed by ultra-centrifugation (Beckman Coulter L-80, SW28,
141000 rcf max, 1 h, 4 !C) to remove non solubilised protein and
debris. Puriﬁcation of the solubilsed membrane fraction was per-
formed by cobalt afﬁnity chromatography (TALON® resin). The
column was equilibrated with buffer (50 mL, 20 mM Tris HCl, 1.4%
OG, 20% glycerol, 100 mM MgSO4 pH 7.4). The resin was incubated
with the solubilised supernatant for 30 min on a roller shaker at
4 !C. The ﬂow throughwas collected and the resinwaswashedwith
buffer 1 (2# 50 mL 20mM TrisHCl, 20 mM imidazole, 0.042% (w/v)
n-dodecyl-b-D-maltopyranoside (DDM), 20% (v/v) glycerol, 50 mM
MgSO4, pH 7.4) and buffer 2 (1 # 50 mL 20 mM TrisHCl, 160 mM
imidazole, 0.042% (w/v) n-dodecyl-b-D-maltopyranoside (DDM),
20% (v/v) glycerol, 50 mM MgSO4, pH 7.4). rTAO was then eluted
with elution buffer (10# 10 mL 20 mM TrisHCl, 200 mM imidazole,
0.042% (w/v) n-dodecyl-b-D-maltopyranoside (DDM), 20% (v/v)
glycerol, 50 mM MgSO4, 60 mM NaCl, pH 7.4). Concentration of
these fractions through a 10 kDa molecular weight cut off Amicon
Ultra-15 ﬁlter unit provided TAO enzyme for use in absorbance
inhibition assay, lane 2 Fig. 4. AOX conﬁrmed in Western Blot
analysis using Polyclonal Ab from Agrisera (raised against plant
AOX1/AOX2 (AS04 054) >70% homology to TAO) (lane 3 Fig. 3).
Both bands observed at 37 kDa and 74 kDa in SDS-PAGE (lane 2)
were conﬁrmed to be rTAO by in-gel trypsin digest and analysis by
protein mass spec (data not shown).
2.3. TAO activity assay
The assessment of enzymatic activity of puriﬁed rTAO was car-
ried out by monitoring the production of 1-ubiquinone from the
substrate 1-ubiquinol. This modiﬁed substrate was used over the
endogenous substrate as it has a higher aqueous solubility and al-
lows assessment of enzyme activity at higher substrate concen-
trations. The measurement of 1-ubiquinone productionwas carried
out kinetically by absorbance readings at the substrates lambda
Scheme 1. Lewis acid catalysed synthesis: a) NEt3, AcCl, CH2Cl2, 68%; b) geranyl bro-
mide, K2CO3, KI, DMF, 50%; c) Florisil, toluene, 28%; d) NaOH, THF/MeOH, 97%.
Scheme 2. Ortho-lithiation syntheses: a) NaH, MOMCl, DMF, 93%; b) 1) n-BuLi, geranyl
bromide, THF 2) n-BuLi, DMF, 48%; c) n-BuLi, bromooctane, THF, 0 !C, 95%; d) ethylene
glycol, mw 160 !C, 98%; e) POCl3, DMF, 96%; f) SO2Cl2, CH2Cl2, quant.
Scheme 3. Diversiﬁable synthesis: a) NaH, tBu-acrylate, DMF, 80 !C, 95%, b) octanal, L-
proline, NaBH3CN, EtOH, quant; c) SO4Me2, NaH, THF, 95%; d) LDA, methyl formate,
THF, $78 !C, 64%; e) DDQ, CH2Cl2, 84%.
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max at 278 nm over time. Measurements were taken using assay
buffer containing detergent C10E8 previously identiﬁed in assay
optimisation experiments reported by Kido et al. [23] and 50 mM
Tris buffer.
The Michalis-Menten kinetics of the puriﬁed enzyme was
measured to determine the most suitable substrate concentration
for use in screening activities. Interestingly we observed a Km of
16.5 mM which is notably lower than previous reports [23,34].
Within our experiments we observed that kinetic measurements of
product formation at high substrate concentrations (>250 mM)
showed substantial rates of turnover. This was also observed in
control experiments of substrate turnover without enzyme. If
background subtractions of substrate turnover without enzyme
were not performed calculations of Km showed to be in line with
the previously reported ﬁgures for Km (A - Fig. 4). We therefore
carried out background subtractions of turnoverwithout enzyme at
each concentration of substrate to generate Michalis-Menten Km
calculations of enzyme alone (B - Fig. 4).
In IC50 determination and in screening activities ﬁnal concen-
trations of 3 nM of puriﬁed rTAOwere usedwith 15 mM1-ubiquinol
for a sufﬁcient window to assess the inhibitory activity of syn-
thesised analogues. Using a substrate concentration close to the
measured Km also enables the identiﬁcation of competitive, non-
competitive and uncompetitive types of inhibitors. We carried
out ten-point IC50 determinations with puriﬁed rTAO protein to try
to understand the action of these compounds. Example data for the
natural product CCBe 6 is shown below (Fig. 5). With correlation to
the ex vivo of inhibition of the growth of T. b. brucei. (Fig. 6).
To understand the mechanism of TAO inhibition by
Fig. 3. SDS-PAGE and Western analysis of rTAO with Quick Coomassie stain (Generon
QC154201/008). 1 Molecular weight markers, 2 Concentrated puriﬁed rTAO protein, 3
WB 100 ng protein load. Polyclonal Ab from Agrisera (raised against plant AOX1/AOX2
(AS04 054) >70% homology to TAO).
Fig. 4. Michalis-Menten kinetics of rTAO. Data plotted is the mean of 3 independent
experiments each with triplicate points for each condition. The error plotted is the SEM
of the 3 independent experiments. The relative background turnover of substrate
without enzyme was subtracted from each condition internally generated within each
experiment in triplicate. 3 nM of puriﬁed rTAO was used. Graph generated in GraphPad
Prism®.
Fig. 5. IC50 data for colletochlorin B from 4 parameter logistic regression of 10 point
inhibitory concentration data. Data from 3 independent experiments reported con-
centrations run in duplicate per experiment, SEM plotted of experiments. 3 nM of
puriﬁed rTAO was used.
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colletochlorin B, more thorough experiments were performed,
measuring the velocity of 1-ubiquinol turn over with increasing
concentrations of colletochlorin B at different concentrations of
substrate (Fig. 7). Interestingly this data suggests a mixed type non-
competitive inhibition proﬁle with regard to 1-ubiquinol substrate,
that is in accordance with previous reports by Kido et al. [23] The
apparent afﬁnity of 1-ubiquinol is not affected by increasing con-
centrations of inhibitor as the calculated Km remains similar with
increasing inhibitor concentration. Furthermore the Vmax is
reduced with increasing inhibitor concentration, which together
with the Km observation are suggestive of non-competitive binding
with regards to 1-ubiquinol.
2.4. Structure-activity relationships
At the outset of our research, there was not only a lack of robust
synthetic routes to AF analogues but the basic SAR around the ar-
omatic head group was under explored. Consequently, it was un-
clear which substituents were necessary for activity. Interestingly
chlorination at R2 contributes a great deal to the inhibition of TAO.
The des-chloro modiﬁcations to compounds 6 and 20e26 (Table 1)
result in a reduction of 1e3 pIC50 units of potency against the
enzyme, and diminishes selectivity for the growth of the trypano-
some. Compound 23 shows 30 fold selectivity for inhibition of
trypanosome growth compared to that of compound 6 that shows
>500 fold selectivity over HepG2 cytotoxicity. Similarly the pres-
ence of a methyl group at R3 contributes signiﬁcantly to the inhi-
bition of TAO albeit to a lesser extent than that of chloro at R2.
Compound 21 shows reduced inhibition of TAO that results in lower
efﬁcacy for trypanosome growth inhibition and consequently re-
duces the selectivity against themammalian HepG2 cell to ~60 fold.
Previously published work had shown that electron with-
drawing groups were preferred at R4 [26]. Our results conﬁrm this
with the exception of compound 30 where R4 is methyl. Direct
comparison to compound 20 shows an order loss in potency sug-
gesting that it is not only electron withdrawing groups could be
tolerated in this position. Interestingly replacement of the benzal-
dehyde with nitrile 29 and 30 appeared to be a well-tolerated
modiﬁcation showing similar inhibition against TAO, however a
drop in efﬁcacy was observed against the trypanosome (see
Table 2). One further divergence from the reported pharmacophore
is compound 33 where the hydrogen bond donor of the phenol of
C5 has been removed whilst retaining a modest inhibition of TAO,
suggesting that the interaction with the enzyme at this position
may not be via an essential hydrogen bond (see Fig. 8). This is
supported by inhibition data of compound 35 where the point of
Fig. 6. IC50 data for concentration of colletochlorin B required to inhibit 50% growth of
T. b. brucei Lister427, following incubation with compound for 48 h. Growth inhibition
was measured by quantifying ATP levels. 4 parameter logistic regression of 10 point
inhibitory concentration data. Data from 3 independent experiments reported con-
centrations run in duplicate per experiment, SEM plotted of experiments.
Fig. 7. Michalis-Menten inhibitor kinetics of rTAO, in presence of increasing concen-
tration of inhibitor CCB. Data plotted is the mean of 3 independent experiments each
with triplicate points for each condition. The error plotted is the SEM of the 3 inde-
pendent experiments. The relative background turnover of substrate without enzyme
was subtracted from each condition internally generated within each experiment in
triplicate. 2 nM of puriﬁed rTAO was used. Graph generated in GraphPad Prism®.
Table 1
Summary of modiﬁcations to the aromatic head group.
# R1 R2 R3 TAO inhibition (pIC50)a T.b.b. Growth
Inhibition
(pIC50)b
HepG2 Cytotox
(pCC50)c
6 OH Cl Me 8.4 ± 0.3 8.5 ± 0.1 5.1 ± 0.1
20 OAc Cl Me 6.5 ± 0.2 7.4 ± 0.7 4.8 ± 0.1
21 OH Cl H 7.0 ± 0.2 6.6 ± 0.1 <4.8
22 OAc Cl H 6.3 ± 0.1 6.2 ± 0.1 4.6 ± 0.1
23 OH H Me 5.5 ± 0.2 5.8 ± 0.1 4.4 ± 0.1
24 OAc H Me 5.4 ± 0.1 e e
25 OH H H 5.4 ± 0.2 e e
26 OAc H H 5.5 ± 0.1 e e
27 H Cl H 5.4 ± 0.1 e e
28 OH H OH 5.5 ± 0.1 e e
a Negative log concentration and standard deviation of compounds required for
50% inhibition of trypanosome alternative oxidase.
b Negative log concentration and standard deviation of compounds required for
50% growth inhibition of T. b. brucei Lister427.
c Negative log concentration and standard deviation of compounds required for
50% growth inhibition of HepG2 cell line.
Fig. 8. Dimethoxy analogue.
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attachment of the lipophilic tail was explored. The compound
retains activity against TAO supporting the hypothesis that the
necessity for a hydrogen bond donor at R5 is not a requirement for
TAO inhibition. Ether-linked tails could thus reasonably represent a
group of underexplored TAO inhibitors that are more synthetically
amenable (see Table 3).
In general a reasonable correlation was observed between the
inhibition of TAO and the inhibition of growth of the parasite. The
OAc masked phenol in compound 20 showed higher inhibitory
activity against T. b. brucei than expected. This higher than expected
potency could be from the cleavage of the acetate to the free phenol
compound 6 under the conditions of the assay. The majority of the
compounds synthesised showed greater than 20 fold selectivity for
T. b. brucei growth inhibition over mammalian HepG2 cytotoxicity.
In general compounds that showed more potent inhibition of TAO
showed better a better selectivity index over mammalian HepG2
cells (see Table 3).
3. Conclusions
Despite current efforts, HAT remains a considerable threat to the
health and well-being of those infected. Currently available treat-
ments are far from safe with increasing incidences of drug resis-
tance being reported. Ascofuranone was described as a nanomolar
inhibitor of TAO in the late 1990s [27], however exploitation of this
opportunity has been severely limited due to the availability of
robust synthetic routes to these molecules. With the potential to
assist future drug development of the ascofuranone chemotype we
present 3 novel and versatile synthetic approaches, together with
the SAR ﬁndings developed during our synthetic exploration. These
routes offer signiﬁcantly improved yields over previous methods
and importantly, allow late stage diversiﬁcation of the crucial ar-
omatic head group that is responsible for both the afﬁnity for the
enzyme and the undesirable, non-drug-like functionality. The SAR
presented builds on that previously published [26], demonstrating
that the aromatic pharmacophore is more amenable to alteration
than previously reported. These synthetic and SAR ﬁndings provide
the foundations for onward exploitation of this chemotype towards
novel treatments for HAT via inhibition of TAO and our onward
investigation further aims to develop CNS drug-like leads from
these challenging chemical starting points.
4. Experimental section
Experimental Details. ChemAxon Calculator Plugins were used
for structure property prediction and calculation (clogP), Marvin
15.5.4, 2015, ChemAxon (http://www.chemaxon.com). All com-
mercial reagents were purchased from Sigma-Aldrich, Alfa Aesar,
Apollo Scientiﬁc, Fluorochem or Tokyo Chemical Industry and of
the highest available purity. Unless otherwise stated, chemicals
were used as supplied without further puriﬁcation. Anhydrous
solvents were purchased from Acros (AcroSeal™) or Sigma-Aldrich
(SureSeal™) and were stored under nitrogen. 40e60 petrol ether
refers to the fraction with a boiling point between 40 !C and 60 !C.
Anhydrous solvents and reagents were used as purchased. Thin
layer chromatography (TLC) was carried out using glass plates pre-
Table 2
Summary of modiﬁcations to the aldehyde.
# R1 R3 R4 TAO inhibition (pIC50)a T.b.b. Growth inhibition (pIC50)b HepG2 Cytotox
(pCC50)c
29 OH Me CN 8.4 ± 0.2 6.4 ± 0.1 4.9 ± 0.1
6 OH Me C¼O 8.5 ± 0.3 8.4 ± 0.1 5.1 ± 0.1
20 OAc Me C¼O 6.5 ± 0.2 7.4 ± 0.7 4.8 ± 0.1
30 OAc Me Me 5.7 ± 0.1 e e
21 OH H C¼O 7.0 ± 0.2 6.6 ± 0.1 <4.8
31 OH H CN 7.6 ± 0.3 5.2 ± 0.1 4.4 ± 0.1
32 OH H C¼NOH 6.1 ± 0.3 5.7 ± 0.1 5.0 ± 0.1
a Negative log concentration and standard deviation of compounds required for 50% inhibition of trypanosome alternative oxidase.
b Negative log concentration and standard deviation of compounds required for 50% growth inhibition of T. b. brucei Lister427.
c Negative log concentration and standard deviation of compounds required for 50% growth inhibition of HepG2 cell line.
Table 3
Alkylation of phenols.
# R1 R5 TAO inhibition (pIC50)a T.b.b. Growth inhibition (pIC50)b HepG2 Cytotox
(pCC50)c
34 O-Geranyl OH 6.0 ± 0.1 5.5 ± 0.1 4.7 ± 0.1
35 OH O-Geranyl 6.6 ± 0.2 4.9 ± 0.1 5.0 ± 0.1
a Negative log concentration and standard deviation of compounds required for 50% inhibition of trypanosome alternative oxidase.
b Negative log concentration and standard deviation of compounds required for 50% growth inhibition of T. b. brucei Lister427.
c Negative log concentration and standard deviation of compounds required for 50% growth inhibition of HepG2 cell line.
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coated with Merck silica gel 60 F254. Melting points were deter-
mined using an OptiMelt apparatus and are uncorrected. Proton
nuclearmagnetic resonance spectrawere recorded at 500MHz on a
Varian VNMRS 500 MHz spectrometer (at 30 !C), using residual
isotopic solvent (CHCl3, dH¼ 7.27 ppm, DMSO dH¼ 2.50 ppm,MeOH
dH ¼ 3.31 ppm) as an internal reference. Chemical shifts are quoted
in parts per million (ppm). Coupling constants (J) are recorded in
Hertz (Hz). Carbon nuclear magnetic resonance spectra were
recorded at 125 MHz on a Varian 500 MHz spectrometer and are
proton decoupled, using residual isotopic solvent (CHCl3,
dC ¼ 77.00 ppm, DMSO dC ¼ 39.52 ppm, MeOH dC ¼ 49.00 ppm) as
an internal reference. Proton and carbon spectra assignments are
supported by DEPT editing. Chemical shifts (dC) are quoted in ppm.
High resolutionmass spectrometry (HRMS) data (ESI) was recorded
on Bruker Daltonics, Apex III, ESI source: Apollo ESI with methanol
as spray solvent. Onlymolecular ions, fractions frommolecular ions
and other major peaks are reported as mass/charge (m/z) ratios.
LCMS data was recorded on a Waters 2695 HPLC using a Waters
2487 UV detector and a Thermo LCQ ESI-MS. Samples were eluted
through a Phenomenex Lunar 3 mm C18 50 mm # 4.6 mm column,
using water and acetonitrile acidiﬁed by 0.1% formic acid at 1 ml/
min and detected at 254 nm. The gradient employed was a 7 min
method 30e90%MeCN over a 5 min gradient, held at 90%MeCN for
1 min, then re-equilibrated to 30% MeCN over 1 min. All experi-
ments were carried out under an inert atmosphere of N2 unless
otherwise stated.
Absorbance Assay. 1-Ubiquinol turnover was measured by
recording the increase in absorbance at 278 nm (Greiner 96-well
UV star ﬂat bottom plates with BMG PHERAstar FS photo spec-
trometer) to monitor the increase of 1-Ubiquinone concentration
kinetically over 6 min with puriﬁed rTAO (3 nM), The Michalis-
Menten derived Km of 1-Ubiquinol showed to be 16.5 mM, kinetic
measurements at high (>250 mM) concentrations of substrate
showed higher rates of enzyme product formation, this was also
observed with high substrate concentrations without enzyme. It
was therefore necessary to carry out a background subtraction of
substrate turnover without enzyme to generate accurate Michalis-
Menten Km calculations. A ﬁnal concentration of 15 mM 1-
Ubiquinol was used under the following conditions: 50 mM Tris-
HCl; 0.05% (w/v) C10E8; pH 7.4; 25 !C). The sigmoidal curve of
the inhibitionwas observed by 10-point 3 fold serial dilution of test
compounds to generate IC50 values.
Growth inhibition assays. Bloodstream form Trypanosoma
brucei brucei Lister 427 parasites were continuously passaged in
HMI-9 medium formulated from IMDM medium (Invitrogen), 10%
heat-inactivated fetal bovine serum, 10% Serum Plus medium
supplement (SAFC Biosciences), 1 mM hypoxanthine (Sigma-
Aldrich), 50 mM bathocuproine disulfonic acid (Sigma-Aldrich),
1.5 mM cysteine (Sigma-Aldrich), 1 mM pyruvic acid (Sigma-
Aldrich), 39 mg/mL thymidine (Sigma-Aldrich), and 14 mL/L beta-
mercapthoethanol (Sigma-Aldrich); all concentrations of added
components refer to that in complete HMI-9medium. The parasites
were cultured in 10 mL of HMI-9 medium in T75 CELL-STAR tissue
culture ﬂasks at 37 !C/5% CO2.
To determine growth inhibitory potency of compounds against
T. b. brucei bloodstream form parasites, 200 nL of 10-point, 3 fold
serially diluted compounds in DMSO were transferred to the wells
of white, solid bottom 384-well plates (Greiner Bio-One) by either
Echo 555 acoustic liquid handling system or Mosquito. Then, 104 of
T. b. brucei parasites in 40 mL of HMI-9 mediumwere added to each
well, and the plates were incubated for 48 h at 37 !C in 5% CO2
incubators. Parasite numbers in individual plate wells were deter-
mined through quantiﬁcation of intracellular ATP amount. The
CellTiter-Glo luminescent cell viability reagent (Promega) was
added to plate wells, and ATP-dependent luminescence signal was
measured on Tecan M1000 plate Reader after 30 min incubation.
Suramin an anti-trypanosomal drug was used positive control and
DMSO was used as negative control. pIC50 values were calculated
using Graph Pad Prism software by plotting the luminescence
values in sigmoidal dose response curves. Suramin was used as a
positive control in screening. (pIC50e6.7 ± 0.1).
Hep-G2 Cytotoxicity Assay. Human hepatocellular carcinoma
(HepG2) cells were obtained from ATCC and grown in RPMI media.
25 mL of 1.6 # 104 cells/mL were dispensed into sterile 384 well
Griener clear plates and incubated at 37 !C in 5% CO2 incubator for
24 h. Once the cells adhered, 125 nL of 10-point, 3 fold serially
diluted compounds in DMSO were transferred on to cells. After
incubating for additional 96 h at 37 !C in 5% CO2 incubator, cells
were added with CCK-8 reagent to each well. Plates were further
incubated for 3 h followed by absorbance reading at 450 nM using
Envision reader. Absorbance values were used for determination of
cytotoxic concentration (pCC50) required to inhibit 50% growth.
Purmycin was used as positive control in screening
(pIC50e6.3 ± 0.1).
4.1. Synthesis
4.1.1. 2-Chloro-5-{[(2E)-3,7-dimethylocta-2,6-dien-1-yl]oxy}-4-
formyl-3-methylphenyl acetate (5)
To a suspension of 3-chloro-4,6-dihydroxy-2-
methylbenzaldehyde (4) [35] [36] (11.8 g, 63.2 mmol) in DCM
(300 mL) was added trimethylamine (8.8 mL, 63.2 mmol) at room
temperature. This mixture was stirred for 15 min during which
time the suspension had dissolved. Acetyl chloride (4.5 mL,
63.3 mmol) was added to the reaction mixture dropwise at room
temperature over 20 min and this was stirred for a further 5 h.
Deionised water (200 mL) was added and the phases were sepa-
rated. The aqueous layer was extracted with ethyl acetate
(3 # 100 mL) and the combined organic extracts were dried over
magnesium sulfate, ﬁltered and concentrated under reduced
pressure. Puriﬁcation 2 times by ﬂash column chromatography
(100 g silica), eluting with a gradient of petrol ether: ethyl acetate
(95: 5) to (90: 10), gave 2-chloro-4-formyl-5-hydroxy-3-
methylphenyl acetate as an off-white solid (9.9 g, 68%): Rf 0.46
(10% ethyl acetate/90% 40e60 petrol ether); 1H NMR (500 MHz,
Chloroform-d) d 12.16 (s, 1H), 10.31 (s, 1H), 6.70 (s, 1H), 2.68 (s, 3H),
2.37 (s, 3H).
To a solution of 2-chloro-4-formyl-5-hydroxy-3-methylphenyl
acetate (1.30 g, 5.7 mmol) and geranyl bromide (1.35 mL,
6.8 mmol) in dimethylformamide (10 mL) was added potassium
iodide (85 mg, 0.6 mmol) followed by potassium carbonate (2.35 g,
17.1 mmol). The reaction mixture was stirred at room temperature
for 16 h before being diluted with deionised water (50 mL). This
mixture was extracted with diethyl ether (3 # 30 mL) and the
combined organic extracts were dried over magnesium sulfate,
ﬁltered and concentrated under reduced pressure. Puriﬁcation by
ﬂash column chromatography (25 g silica), eluting with a gradient
of petrol ether: ethyl acetate (100: 0) to (90: 10), gave the title
compound as a yellow oil (1.04 g, 50%) and 4-chloro-5-{[(2E)-3,7-
dimethylocta-2,6-dien-1-yl]oxy}-2-formyl-3-methylphenyl ace-
tate (710 mg, 41%).
4.1.2. 2-Chloro-5-{[(2E)-3,7-dimethylocta-2,6-dien-1-yl]oxy}-4-
formyl-3-methylphenyl acetate (5)
Rf 0.46 (10% ethyl acetate/90% 40e60 petrol ether) 1H NMR
(500 MHz, Chloroform-d) d 10.56 (s, 1H), 6.71 (s, 1H), 5.51e5.40 (m,
1H), 5.13e5.05 (m, 1H), 4.60 (d, J ¼ 6.6 Hz, 2H), 2.67 (s, 3H), 2.38 (s,
3H), 2.22e1.97 (m, 4H), 1.73 (s, 3H), 1.69 (s, 3H), 1.62 (s, 3H). LCMS
(ESI) retention time 6.64 min, m/z 365.77/367.26.
R.A. West et al. / European Journal of Medicinal Chemistry xxx (2017) 1e14 7
Please cite this article in press as: R.A. West, et al., African trypanosomiasis: Synthesis& SAR enabling novel drug discovery of ubiquinol mimics
for trypanosome alternative oxidase, European Journal of Medicinal Chemistry (2017), https://doi.org/10.1016/j.ejmech.2017.09.067
4.1.3. 4-Chloro-5-{[(2E)-3,7-dimethylocta-2,6-dien-1-yl]oxy}-2-
formyl-3-methylphenyl acetate (5)
Rf 0.28 (10% ethyl acetate/90% 40e60 petrol ether) 1H NMR
(500 MHz, Chloroform-d) d 10.26 (s, 1H), 6.58 (s, 1H), 5.57e5.41 (m,
1H), 5.09 (t, J¼ 6.1 Hz, 1H), 4.67 (d, J¼ 6.5 Hz, 2H), 2.72 (s, 3H), 2.38
(s, 3H), 2.18e2.07 (m, 4H),1.76 (s, 3H),1.69 (s, 3H),1.62 (s, 3H). LCMS
(ESI) retention time 6.64 min, m/z 365.59/367.66.
4.1.4. 3-Chloro-5-[(2E)-3,7-dimethylocta-2,6-dien-1-yl]-4,6-
dihydroxy-2-methylbenzaldehyde (6)
(colletochlorin B) To a solution of 2-chloro-5-{[(2E)-3,7-
dimethylocta-2,6-dien-1-yl]oxy}-4-formyl-3-methylphenyl ace-
tate (5) (757 mg, 2.1 mmol) in toluene (7.5 mL) was added Fluorosil
(100e200 mesh, 2.3 g). The reaction mixture was heated at reﬂux
for 3 h before being allowed to cool to room temperature and being
ﬁltered. The Fluorosil was washed with ethyl acetate (3 # 15 mL)
and the combined ﬁltrate was concentrated under reduced pres-
sure. Puriﬁcation by ﬂash column chromatography (25 g silica),
eluting with a gradient of petrol ether: ethyl acetate (100: 0) to (95:
5), gave 2-chloro-6-[(2E)-3,7-dimethylocta-2,6-dien-1-yl]-4-
formyl-5-hydroxy-3-methylphenyl acetate as a colourless oil
(212 mg, 28%): Rf 0.67 (5% ethyl acetate/95% 40e60 petrol ether);
1H NMR (500 MHz, Chloroform-d) d 12.53 (s, 1H), 10.31 (s, 1H),
5.21e4.96 (m, 2H), 3.35e3.25 (m, 2H), 2.66 (s, 3H), 2.38 (s, 3H),
2.09e2.01 (m, 2H), 2.01e1.93 (m, 2H), 1.75 (s, 3H), 1.66 (s, 3H), 1.59
(s, 2H).
To a solution of 2-chloro-6-[(2E)-3,7-dimethylocta-2,6-dien-1-
yl]-4-formyl-5-hydroxy-3-methylphenyl acetate (110 mg,
0.3 mmol) in THF (4 mL) and MeOH (1 mL) was added 1 M aqueous
sodium hydroxide (1.5 mL, 1.5 mmol). The reaction mixture was
stirred at room temperature for 3 h during which time the reaction
mixture turned deep purple. The reaction mixture was acidiﬁed to
pH 1 with 1 M aqueous HCl and the reaction colour faded to yellow.
This mixture was extracted with ethyl acetate (3 # 10 mL) and the
combined organic extracts were dried over magnesium sulfate,
ﬁltered and concentrated under reduced pressure. Puriﬁcation by
ﬂash column chromatography (10 g silica), eluting with a gradient
of petrol ether: ethyl acetate (100: 0) to (95: 5), gave the title
compound as an off-white solid (93 mg, 97%): Rf 0.48 (5% ethyl
acetate/95% 40e60 petrol ether); 1H NMR (500 MHz, Chloroform-
d) d 12.70 (s, 1H), 10.16 (s, 1H), 6.42 (s, 1H), 5.29e5.17 (m, 1H),
5.09e5.05 (m, 1H), 3.42 (d, J ¼ 7.1 Hz, 2H), 2.61 (s, 3H), 2.13e2.03
(m, 2H), 2.03e1.97 (m, 2H), 1.80 (s, 3H), 1.66 (d, J ¼ 1.4 Hz, 3H), 1.59
(s, 3H).
4.1.5. 1,3-Bis(methoxymethoxy)-5-methylbenzene (8)
60% Sodium hydride in mineral oil (742 mg, 18.5 mmol) was
added in three portions to a stirred solution of orcinol (7) (1.00 g,
8.1 mmol) in DMF (20 mL) at 0 !C. This was stirred for 40 min and
methyl chloromethoxy ether (1.35 mL, 17.7 mmol) added dropwise.
The reaction was stirred for 16 h and then diluted with water
(100 mL) and extracted with diethyl ether (3 # 100 mL). The
combined ether fractions were washed with 1 M sodium hydroxide
solution (50 mL), saturated brine solution (50 mL), dried over so-
dium sulfate, ﬁltered and concentrated under reduced pressure.
Puriﬁcation by ﬂash column chromatography (20 g silica), eluting
with a gradient of 40e60 petrol ether: ethyl acetate (100: 0) to (95:
5), gave the title compound as a clear oil (1.59 g, 93%): 1H NMR
(500 MHz, chloroform-d) d 6.56 (1 H, s), 6.54 (2H, s), 5.15 (4 H, s),
3.49 (6 H, s), 2.31 (3 H, s); HRMS (ESI) calcd 212.1049 for C11H16O4
[MþH]þ, found 212.1047 m/z.
4.1.6. (E)-3-(3,7-Dimethylocta-2,6-dienyl)-2,4-
bis(methoxymethoxy)-6-methylbenzaldehyde (9)
3-Bis(methoxymethoxy)-5-methylbenzene (8) (2.50 g,
11.8 mmol) was dissolved in dry tetrahydrofuran (90 mL) and
cooled to 0 !C. 2.1 M n-butyl lithium (8.41 mL, 17.7 mmol) was
added drop-wise and the reaction was left to stir for 1 h at 0 !C.
Geranyl bromide (4.48 g, 20.6 mmol) was added to the reaction
mixture in a drop-wisemanner. This was stirred for 1 h and allowed
to come to room temperature. The reactionwas cooled to 0 !C again
and 2.1 M n-butyl lithium (8.41 mL, 17.7 mmol) added followed by
another 1 h stirring at 0 !C. Excess dry DMF was added and the
reaction was allowed to come to room temperature over 1 h. The
reaction was diluted with water (300 mL) and extracted with
diethyl ether (3 # 200 mL). The combined organics were dried over
sodium sulfate, ﬁltered and concentrated under reduced pressure.
Puriﬁcation by ﬂash column chromatography (50 g silica), eluting
with a gradient of 40e60 petrol ether: ethyl acetate (100:0) to
(95:5), gave the title compound as a yellow tinted clear oil (1.28 g,
31%): 1H NMR (500MHz, chloroform-d) d 10.38 (1 H, s), 6.74 (1 H, s),
5.24 (2 H, s), 5.17 (1 H, t, J ¼ 6.6 Hz), 5.04 (2 H, s), 5.01 (1 H, t,
J ¼ 6.4 Hz), 3.57 (3 H, s), 3.46 (3 H, s), 3.36 (2 H, d, J ¼ 6.7 Hz), 2.57
(3 H, s), 2.05 (2 H, m), 1.97 (2 H, m), 1.76 (3 H, s), 1.63 (3 H, s), 1.56
(3 H, s); IR (neat, nmax) cm$1 2932, 1682, 1595, 1560, 1440, 1375,
1315, 1284, 1220, 1152, 1039, 1007, 924; HRMS (ESI) calcd 399.2142
for C23H32NaO5 [MþNa]þ, found: 399.2147 m/z.
4.1.7. 5-Methyl-2-octylbenzene-1,3-diol (10)
3-Bis(methoxymethoxy)-5-methylbenzene (8) (2.00 g,
9.4 mmol) was dissolved in dry tetrahydrofuran (60 mL) and cooled
to 0 !C. 2.5 M n-butyl lithium (4.90 mL, 12.3 mmol) was added
dropwise and the reactionwas left to stir for 1 h at 0 !C. Iodooctane
(2.55 mL, 14.1 mmol) was added to the reaction mixture and this
was stirred for 1 h before being allowed to come to room temper-
ature. The reaction was diluted with water (300 mL) and extracted
with diethyl ether (3 # 200 mL). The organic fractions were dried
over sodium sulfate, ﬁltered and concentrated under reduced
pressure. Puriﬁcation by ﬂash column chromatography (25 g silica),
eluting 40e60 petrol ether: ethyl acetate (100: 0) to (95: 5), gave
1,3-bis(methoxymethoxy)-5-methyl-2-octylbenzene as a colour-
less oil (2.54 g, 83%): Rf 0.79 (10% ethyl acetate/90% 40e60 petrol
ether); 1H NMR (500 MHz, chloroform-d) d 6.59 (2 H, s), 5.17 (4 H,
s), 3.49 (6 H, s), 2.64 (2 H, t, J ¼ 8.0 Hz), 2.30 (3 H, s), 1.50 (2 H, m),
1.32 (10 H, m), 0.89 (3 H, t, J ¼ 6.8 Hz); 13C NMR (126 MHz,
chloroform-d) d 155.7, 136.6, 118.4, 108.7, 94.5, 75.4, 56.0, 31.9, 29.8,
29.7, 29.5, 29.3, 23.2, 22.7, 21.8, 14.1; IR (neat, nmax) cm$1 2924,
2854, 1612, 1586, 1463, 1394, 1154, 1122, 1036, 923, 823; HRMS
(ESI): calcd. 347.2198 for C19H32NaO4 [MþNa]þ, found 347.2187m/z.
1,3-Bis(methoxymethoxy)-5-methyl-2-octylbenzene (350 mg,
1.1 mmol) was suspended in ethylene glycol (10 mL) and heated to
160 !C by microwave irradiation for 5 h in sealed vial. The reaction
mixture was diluted with water (40 mL) and extracted with diethyl
ether (3 # 30 ml). The combined extracts were washed with water
(30 mL), dried over magnesium sulfate, ﬁltered and concentrated
under reduced pressure. Puriﬁcation by ﬂash column chromatog-
raphy (10 g silica), eluting 40e60 petrol ether: ethyl acetate (100: 0)
to (70: 30), gave the title compound as an orange/white powder
(220mg, 86%, m.p. 63e66 !C): Rf 0.32 (10% ethyl acetate/90% 40e60
petrol ether); 1H NMR (500 MHz, chloroform-d) d 6.23 (2 H, s), 4.69
(2 H, s), 2.59 (2 H, t, J ¼ 7.9 Hz), 2.22 (3 H, s), 1.60e1.51 (2 H, m),
1.43e1.23 (10 H, m), 0.89 (3 H, t, J ¼ 6.8 Hz); 13C NMR (126 MHz,
chloroform-d) d 154.4, 137.0, 112.4, 108.7, 75.4, 31.9, 29.8, 29.5, 29.3,
23.0, 22.7, 21.0, 14.1. IR (neat, nmax) cm$1 3427, 3280, 2956, 2918,
2850,1635,1584,1522,1467,1328,1268,1160,1112, 829, 534; HRMS
(ESI): calcd. 237.1849 for C15H25O2 [MþH]þ, found 237.1853 m/z.
4.1.8. 3-Chloro-4,6-dihydroxy-2-methyl-5-octylbenzaldehyde (11)
5-Methyl-2-octyl-benzene-1,3-diol (10) (500mg, 2.1 mmol) was
dissolved in dry DMF (4.08 mL, 52.9 mmol) and cooled to 0 !C.
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Phosphorous oxychloride (0.39 mL, 4.2 mmol) was added slowly by
syringe and the reaction was then allowed to come to room tem-
perature. The reaction was followed by thin layer chromatography
(20% ethyl acetate in 40e60 petroleum ether) and upon completion
after 2 h the reaction was cooled to 0 !C and diluted with 1 M
aqueous sodium hydroxide solution (10 mL). This was stirred for
5 min then acidiﬁed with 1 M aqueous hydrogen chloride solution
(30 mL) and transferred to a separating funnel. The mixture was
then extracted with diethyl ether (3 # 20 mL). The combined
organic layers were washed with water (50 mL) and brine (50 mL).
The organics were dried over magnesium sulfate and concentrated
to dryness under reduced pressure. Puriﬁcation by ﬂash column
chromatography (10 g silica), eluting 40e60 petrol ether: ethyl
acetate (100: 0) to (80: 20), gave 2,4-dihydroxy-6-methyl-3-
octylbenzaldehyde as an orange/white powder (559 mg, 95%,
m.p. 101e103 !C): Rf 0.18 (10% ethyl acetate/90% 40e60 petrol
ether); 1H NMR (500MHz, chloroform-d) d 12.63 (1 H, s),10.09 (1 H,
s), 6.20 (1 H, s), 5.52 (1 H, s), 2.60 (2 H, d, J ¼ 7.1 Hz), 2.50 (3 H, s),
1.59e1.47 (2 H, m), 1.42e1.21 (10 H, m), 0.89 (3 H, d, J ¼ 6.9 Hz); 13C
NMR (126 MHz, chloroform-d) d 193.0, 164.2, 161.0, 141.5, 114.0,
113.4, 110.2, 31.9, 29.7, 29.5, 29.3, 28.7, 22.6, 22.0, 17.9, 14.1; IR (neat,
nmax) cm$1 3111, 2916, 2849, 1605, 1509, 1466, 1284, 1250, 1216,
1135, 829, 773, 644, 567; HRMS (ESI): calcd. 265.1804 for C16H25O3
[MþH]þ, found 265.1805 m/z.
2,4-Dihydroxy-6-methyl-3-octylbenzaldehyde (70 mg,
0.3 mmol) was dissolved in dry diethyl ether (5 mL) and sulfuryl
chloride (32 mL, 0.4 mmol) added. The reactionwas stirred for 1 h at
room temperature before being quenched with 1 M aqueous so-
dium hydroxide (5 mL). The mixture was then extracted with
diethyl ether (2 # 15 mL). The combined organic phases were dried
over magnesium sulfate, ﬁltered and concentrated on celite (1 g).
Puriﬁcation by ﬂash column chromatography over silica (10 g)
eluting 40e60 petrol ether: ethyl acetate (100: 0) to (80: 20) gave
the title compound as a white powder (65 mg, 81%, m.p. 65 !C): Rf
0.58 (10% ethyl acetate/90% 40e60 petrol ether); 1H NMR
(500 MHz, chloroform-d) d 12.65 (1 H, s), 10.14 (1 H, s), 6.34 (1 H, s),
2.69 (2 H, d, J ¼ 7.1 Hz), 2.60 (3 H, s), 1.54e1.47 (2 H, m), 1.30e1.23
(10 H, m), 0.88 (3 H, d, J ¼ 6.9 Hz); 13C NMR (126 MHz, chloroform-
d) d 193.1, 162.5,156.2,137.2,115.8, 113.5,113.0, 31.9, 29.6, 29.5, 29.3,
28.4, 22.9, 22.6, 14.4, 14.1; IR (neat, nmax) cm$1 3327, 2924, 2856,
1606, 1452, 1416, 1374, 1233, 1132, 791, 767, 710, 555; HRMS (ESI):
calcd. 299.1414 for C16H24ClO3 [MþH]þ, found 299.1421 m/z.
4.1.9. Tert-butyl-3-(4-methyl-2,6-dioxocyclohexyl)propanoate (12)
5-Methylcyclohexane-1,3-dione (2.00 g, 15.9 mmol) and t-butyl
acrylate (2.55 mL, 17.4 mmol) were dissolved in N,N-dime-
thylformamide (10 mL) and sodium hydride (635 mg, 15.8 mmol)
added slowly. The reaction was stirred for 1 h at room temperature
then heated to 80 !C for 16 h. The reactionwas allowed cool to room
temperature, acidiﬁed to pH 4with acetic acid then neutralised and
diluted with saturated aqueous sodium hydrogen carbonate solu-
tion (30 mL). This was extracted with ethyl acetate (3# 30 mL). The
combined organics were washed with saturated aqueous sodium
hydrogen carbonate (30mL), dried over magnesium sulfate, ﬁltered
and concentrated under reduced pressure onto celite (4 g). Puriﬁ-
cation by ﬂash column chromatography over silica (25 g) eluting
40e60 petrol ether: ethyl acetate (100:0) to (60:40) gave the title
compound as a pale yellow powder (2.94 g, 73%). Product was
unstable, full characterisation after subsequent reaction to tert-
butyl 3-(2-methoxy-4-methyl-6-oxocyclohex-1-en-1-yl)prop-
anoate (14): 1H (500 MHz, chloroform-d) d 2.49e2.36 (6 H, m),
2.18e2.02 (3 H, m), 1.42 (9 H, s), 1.02 (3 H, d, J ¼ 6 Hz); HRMS (ESI)
calcd 277.1410 for C14H22NaO4 [MþNa]þ, found: 277.1415 m/z.
4.1.10. 5-Methyl-2-octylcyclohexane-1,3-diol (13)
5-Methylcyclohexane-1,3-dione (10.3 g, 81.9 mmol), octanal
(8.54 mL, 54.6 mmol) and L-proline (1.26 g, 10.9 mmol) were dis-
solved in ethanol (150 mL) and stirred for 1 h. Sodium cyanobor-
ohydride (3.43 g, 54.6 mmol) and molecular sieves (350 mg per
mmol of aldehyde) were added and the reaction heated to 80 !C for
2 h. The reaction was poured onto ice (100 g) and the white solid
suspension that formed was vacuum ﬁltered. The solids were dis-
solved in ethyl acetate (40 mL) and washed with water (2# 40 mL).
The organics were dried over magnesium sulfate, ﬁltered and
concentrated under reduced pressure to give the title compound as
a white powder (11.9 g, 91%) Product was a complex mixture of
isomers and full characterisation was conﬁrmed after successful
subsequent reaction to 3-methoxy-5-methyl-2-octylcyclohex-2-
enone (15): Rf 0.12 (20% ethyl acetate/80% 40e60 petrol ether);
HRMS (ESI) calcd 277.1410 for C15H27O2 [MþH]þ: found: 239.2005
m/z.
4.1.11. Tert-butyl-3-(2-methoxy-4-methyl-6-oxocyclohex-1-en-1-
yl)propanoate (14)
Tert-butyl 3-(2-hydroxy-4-methyl-6-oxo-cyclohexen-1-yl)
propanoate (12) (16.00 g, 62.9 mmol) and dimethyl sulfate (7.14mL,
75.5 mmol) were dissolved in tetrahydrofuran (200 mL) and so-
dium hydride (3.02 g, 75.5 mmol) added slowly. The reaction was
stirred at room temperature for 3 h then the reaction was
concentrated under reduced pressure and re-diluted with ethyl
acetate (25 mL) and water (25 mL). This mixture was neutralised
using excess sodium phosphate monobasic. The ethyl acetate was
separated and the aqueous layer extracted with more ethyl acetate
(2 # 30 mL). The combined organics were dried over magnesium
sulfate, ﬁltered and concentrated under reduced pressure onto
celite (2 g). Puriﬁcation by ﬂash column chromatography over silica
(100 g) eluting 40e60 petrol ether: ethyl acetate (100:0) to (80:20)
gave the title compound as a clear colourless oil (15.20 g, 90%). 1H
(600 MHz, choroform-d) d 3.78 (3 H, s), 2.69e2.58 (1 H, m),
2.55e2.43 (2 H, m), 2.43e2.34 (1 H, m), 2.24e2.17 (2 H, m),
2.17e2.09 (2 H, m), 2.05e1.93 (1 H, m), 1.40 (9 H, s), 1.07 (3 H, d, J
6.1).13C NMR (126 MHz, chloroform-d) d 197.6, 172.9, 171.5, 117.7,
79.6, 55.1, 44.7, 34.3, 33.0, 28.4, 28.1, 21.1, 17.8; IR (neat, nmax) cm$1
2973, 1723, 1611, 1367, 1233, 1148, 1084, 846; HRMS (ESI): calcd.
291.1572 for C15H24NaO4 [MþNa]þ, found 291.1572 m/z.
4.1.12. 3-Methoxy-5-methyl-2-octylcyclohex-2-enone (15)
5-methyl-2-octyl-cyclohexane-1,3-dione (13) (567 mg,
2.4 mmol) was dissolved in dry methyl alcohol (5 mL) with 3 Å
molecular sieves (0.5 g) and 4-methylbenzenesulfonic acid (20 mg,
0.1 mmol) was added. The reaction was stirred for 24 h and then
was concentrated onto celite (2 g). Puriﬁcation by ﬂash column
chromatography over silica (10 g) eluting 40e60 petrol ether: ethyl
acetate (100:0) to (90:10) gave the title compound as a yellow oil
(257 mg, 43%): Rf 0.26 (20% ethyl acetate/80% 40e60 petrol ether);
1H (500 MHz, chloroform-d) d 3.80 (3 H, s), 2.71e2.61 (1 H, m), 2.44
(1 H, dd, J ¼ 15.7, 3.2 Hz), 2.28e2.11 (4 H, m), 2.07e1.98 (1 H, m),
1.26 (12 H, s), 1.10 (3 H, d, J ¼ 6.0 Hz), 0.88 (3 H, t, J ¼ 6.9 Hz); 13C
NMR (126 MHz, chloroform-d) d 198.0, 170.8, 119.6, 54.9, 44.8, 33.0,
31.8, 29.6, 29.4, 29.2, 28.6, 28.4, 22.6, 21.9, 21.1, 13.9. IR (neat, nmax)
cm$1 2924, 1709, 1377, 1230, 1128, 1061, 1033, 722; HRMS (ESI):
calcd. 253.2168 for C16H29O2 [MþH]þ, found 253.2163 m/z.
4.1.13. Tert-butyl-3-(5-(hydroxymethylene)-2-methoxy-4-methyl-
6-oxocyclohex-1-en-1-yl)propanoate (16)
Diisopropylamine (4.62 mL, 32.9 mmol) was dissolved in dry
tetrahydrofuran (550 mL) and cooled to $78 !C and 2.5 M n-
butyllithium (12.16 mL, 30.4 mmol) added. The reaction was
warmed to room temperature then cooled to $78 !C and tert-butyl
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3-(2-methoxy-4-methyl-6-oxo-cyclohexen-1-yl)propanoate (14)
(6.8 g, 25.3 mmol) added. The reactionwas stirred for 1 h at $78 !C
then methyl formate (2.34 mL, 38.0 mmol) was added and it was
allowed to warm to room temperature overnight. The reaction was
concentrated under reduced pressure, diluted water (50 mL) and
neutralised by careful addition of 1 M aqueous hydrogen chloride
solution. The organics were dried over magnesium sulfate, ﬁltered
and concentrated under reduced pressure onto celite (5 g). Puriﬁ-
cation by ﬂash column chromatography over silica (100 g) eluting
40e60 petrol ether: ethyl acetate (100:0) to (70:30) gave the title
compound as a yellow oil (4.41 g, 58.6%): Rf 0.22 (20% ethyl acetate/
80% 40e60 petrol ether); 1H NMR (500 MHz, chloroform-d)
d 7.21e7.07 (1 H, m), 3.79 (3 H, s), 2.76e2.69 (1 H, m), 2.67e2.60
(1 H, m), 2.60e2.56 (2 H, m), 2.35e2.25 (3 H, m), 1.41 (9 H, s), 1.16
(3 H, d, J¼ 6.8 Hz); 13C NMR (126 MHz, chloroform-d) d 191.7, 172.7,
170.0, 160.3, 116.5, 111.2, 79.7, 55.2, 34.3, 32.0, 28.3, 28.1, 20.3, 17.5.
IR (neat, nmax) cm$1 2972, 1721, 1607, 1366, 1241, 1146, 1080, 998,
847; HRMS (ESI): calcd. 319.1521 for C16H24NaO5 [MþNa]þ, found
319.1521 m/z.
4.1.14. 6-(Hydroxymethylene)-3-methoxy-5-methyl-2-
octylcyclohex-2-enone (17)
Diisopropylamine (2.67 mL, 19.0 mmol) was dissolved in dry
tetrahydrofuran (150 mL) and cooled to $78 !C and n-butyllithium
(6.18 mL, 15.5 mmol) added. The mixture was allowed to warm to
room temperature and stirred for 30min. This was cooled to$78 !C
and a solution of 3-methoxy-5-methyl-2-octyl-cyclohex-2-en-1-
one (15) (3.00 g, 11.9 mmol) in dry tetrahydrofuran (5 mL) was
added via syringe. This was stirred for 1 h and dry methyl formate
(1.47 mL, 23.77 mmol) was added, the reaction was allowed to
warm to room temperature overnight slowly in the dry ice acetone
bath. The reaction mixture was concentrated under reduced pres-
sure and diluted with ethyl acetate (30 mL) and water (30 mL). This
was neutralised with 1 M aqueous hydrogen chloride, the ethyl
acetate separated and washed with water (30 mL). The organics
were dried over magnesium sulfate, ﬁltered and concentrated un-
der reduced pressure onto celite (2 g). Puriﬁcation by ﬂash column
chromatography over silica (25 g) eluting 40e60 petrol ether: ethyl
acetate (100:0) to (90:10) gave the title compound as a clear yellow
oil (2.25 g, 68%): Rf 0.46 (20% ethyl acetate/80% 40e60 petrol ether)
1H (500 MHz, chloroform-d) d 7.19 (1 H, d, J ¼ 1.2 Hz), 3.79 (3 H, s),
2.75 (1 H, q, J ¼ 6.7 Hz), 2.65 (1 H, dd, J ¼ 16.6, 6.1 Hz), 2.37e2.27
(3 H, m), 1.34 (2 H, m), 1.27 (10 H, m), 1.18 (3 H, d, J ¼ 6.8 Hz), 0.88
(3 H, t, J¼ 6.8 Hz); 13C NMR (126 MHz, chloroform-d) d 191.9, 169.3,
160.5, 111.3, 55.0, 31.9, 31.8, 29.6, 29.4, 29.2, 28.6, 28.3, 22.6, 21.6,
20.4, 14.0. IR (neat, nmax) cm$1 2923, 1608, 1378, 1238, 1159, 1130,
1006, 953; HRMS (ESI): calcd. 281.2117 for C17H29O3 [MþH]þ,
found 281.2113 m/z.
4.1.15. Tert-butyl-3-(3-formyl-2-hydroxy-6-methoxy-4-
methylphenyl)propanoate (18)
(Z)-tButyl 3-(5-(hydroxymethylene)-2-methoxy-4-methyl-6-
oxocyclohex-1-en-1-yl)propanoate (16) (1.00 g, 3.4 mmol) and
2,3-dichloro-5,6-dicyano-1,4-benzoquinone (0.92 g, 4.1 mmol)
were dissolved in toluene (100 mL) and stirred for 16 h at room
temperature. The reactionwas diluted with diethyl ether (200 mL),
the organics were washed with water (6 # 100 mL), dried over
magnesium sulfate, ﬁltered and concentrated under reduced
pressure onto celite (2 g). Puriﬁcation by ﬂash column chroma-
tography over silica (25 g) eluting 40e60 petrol ether: ethyl acetate
(100:0) to (70:30) gave the title compound as awhite solid (835mg,
84%, m.p. 58e59 !C): Rf 0.36 (20% ethyl acetate/80% 40e60 petrol
ether); 1H (500 MHz, chloroform-d) d 12.41 (1 H, s), 10.13 (1 H, s),
6.28 (1 H, s), 3.89 (3 H, s), 2.95e2.86 (2 H, m), 2.57 (3 H, s),
2.45e2.38 (2 H, m), 1.44 (9 H, s). 13C NMR (126 MHz, chloroform-d)
d 193.1, 172.7, 164.1, 162.9, 142.3, 114.1, 113.6, 105.2, 79.9, 55.7, 34.2,
28.1, 18.4, 17.8. IR (neat, nmax) cm$1 2967, 1722, 1637, 1366, 1248,
1125, 1004, 816, 644; HRMS (ESI): calcd. 317.1365 for C16H22NaO5
[MþNa]þ, found 317.1363 m/z.
4.1.16. 2-Hydroxy-4-methoxy-6-methyl-3-octylbenzaldehyde (19)
6-(Hydroxymethylene)-3-methoxy-5-methyl-2-octylcyclohex-
2-enone (17) (77 mg, 0.3 mmol) and 2,3-dichloro-5,6-dicyano-1,4-
benzoquinone (73mg, 4.1 mmol) were dissolved in toluene (20mL)
and stirred for 16 h at room temperature. The reaction was diluted
with diethyl ether (50 mL), the organics were washed with water
(6 # 50 mL), dried over magnesium sulfate, ﬁltered and concen-
trated under reduced pressure onto celite (2 g). Puriﬁcation by ﬂash
column chromatography over silica (25 g) eluting 40e60 petrol
ether: ethyl acetate (100:0) to (70:30) gave the title compound as a
white solid (835 mg, 84%, m.p. 58e59 !C): Rf 0.24 (20% ethyl ace-
tate/80% 40e60 petrol ether); 1H (500 MHz, chloroform-d) d 12.41
(1 H, s), 10.13 (1H, s), 6.28 (1H, s), 3.89 (3H, s), 2.95e2.86 (2H, m),
2.57 (3H, s), 2.45e2.38 (2H, m), 1.44 (9H, s). 13C NMR (126 MHz,
chloroform-d) d 193.1, 172.7, 164.1, 162.9, 142.3, 114.1, 113.6, 105.2,
79.9, 55.7, 34.2, 28.13, 18.4, 17.8. HRMS (ESI): calcd. 279.1955 for
C17H27O3 [MþH]þ, found 279.1948 m/z.
4.1.17. 2-Chloro-6-[(2E)-3,7-dimethylocta-2,6-dien-1-yl]-4-formyl-
5-hydroxy-3-methylphenyl acetate (20)
To a solution of 2-chloro-5-{[(2E)-3,7-dimethylocta-2,6-dien-1-
yl]oxy}-4-formyl-3-methylphenyl acetate (5) (757 mg, 2.07 mmol)
in toluene (7.5 mL) was added Fluorosil (100e200 mesh, 2.3 g). The
reaction mixture was heated at reﬂux for 3 h before being allowed
to cool to room temperature and being ﬁltered. The Fluorosil was
washed with ethyl acetate (3 # 15 mL) and the combined ﬁltrate
was concentrated under reduced pressure. Puriﬁcation by ﬂash
column chromatography (25 g silica), eluting with a gradient of
petrol ether: ethyl acetate (100: 0) to (95: 5), gave the title com-
pound as a colourless oil (212 mg, 28%): Rf 0.67 (5% ethyl acetate/
95% 40e60 petrol ether) 1H NMR (500 MHz, Chloroform-d) d 12.53
(s, 1H), 10.31 (s, 1H), 5.21e4.96 (m, 2H), 3.35e3.25 (m, 2H), 2.66 (s,
3H), 2.38 (s, 3H), 2.09e2.01 (m, 2H), 2.01e1.93 (m, 2H), 1.75 (s, 3H),
1.66 (s, 3H), 1.59 (s, 2H). LCMS (ESI) retention time 6.83 min, m/z
365.43/367.21.
4.1.18. 5-Chloro-3-[(2E)-3,7-dimethylocta-2,6-dien-1-yl]-2,4-
dihydroxybenzaldehyde (21)
To a solution of 6-chloro-2-[(2E)-3,7-dimethylocta-2,6-dien-1-
yl]-4-formyl-3-hydroxyphenyl acetate (22) (70.0 mg, 0.200 mmol)
in tetrahydrofuran (4 mL) and methanol (1 mL) was added 1 M
aqueous sodium hydroxide (1.0 mL, 1.00 mmol). The reaction
mixture was stirred at room temperature for 6 h before being
quenched with 1M aqueous hydrochloric acid (5 mL) and extracted
with ethyl acetate (3 # 10 mL). The combined organic fractions
dried over magnesium sulfate, ﬁltered and concentrated under
reduced pressure. Puriﬁcation by ﬂash column chromatography
(10 g silica), eluting with a gradient of petrol ether: ethyl acetate
(100: 0) to (90: 10), gave the title compound as an off-white solid
(55 mg, 89%): Rf 0.40 (5% ethyl acetate/95% 40e60 petrol ether) 1H
NMR (500 MHz, Chloroform-d) d 11.53 (s, 1H), 9.67 (s, 1H), 7.39 (s,
1H), 6.38 (s, 1H), 5.29e5.19 (m, 1H), 5.10e5.02 (m, 1H), 3.44 (d,
J ¼ 7.2 Hz, 2H), 2.13e2.04 (m, 2H), 2.04e1.97 (m, 2H), 1.81 (d,
J ¼ 1.5 Hz, 3H), 1.66 (d, J ¼ 1.7 Hz, 3H), 1.58 (s, 3H).
4.1.19. 6-Chloro-2-[(2E)-3,7-dimethylocta-2,6-dien-1-yl]-4-formyl-
3-hydroxyphenyl acetate (22)
To a solution of 2-chloro-5-{[(2E)-3,7-dimethylocta-2,6-dien-1-
yl]oxy}-4-formylphenyl acetate (synthesised using the same
method to make 5) (430 mg, 1.22 mmol) in toluene (6.5 mL) was
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added Fluorosil (100e200 mesh, 2.2 g). The reaction mixture was
heated at reﬂux for 3 h before being allowed to cool to room
temperature and being ﬁltered. The Fluorosil was washed with
ethyl acetate (3 # 15 mL) and the combined ﬁltrate was concen-
trated under reduced pressure. Puriﬁcation 3 times by ﬂash column
chromatography (10 g silica), eluting with a gradient of petrol
ether: ethyl acetate (100: 0) to (95: 5), gave the title compound as a
pale yellow oil (78 mg, 18%): Rf 0.59 (5% ethyl acetate/95% 40e60
petrol ether) 1H NMR (500 MHz, Chloroform-d) d 11.41 (s, 1H), 9.82
(s, 1H), 7.51 (s, 1H), 5.13e5.08 (m, 1H), 5.08e5.04 (m, 1H), 3.34 (d,
J ¼ 7.0 Hz, 2H), 2.38 (s, 3H), 2.13e2.01 (m, 2H), 2.01e1.91 (m, 2H),
1.76 (s, 3H), 1.66 (s, 3H), 1.59 (s, 3H). LCMS (ESI) retention time
6.64 min, m/z 351.59/353.19.
4.1.20. 3-[(2E)-3,7-Dimethylocta-2,6-dien-1-yl]-2,4-dihydroxy-6-
methylbenzaldehyde (23)
To a solution of 2-[(2E)-3,7-dimethylocta-2,6-dien-1-yl]-4-
formyl-3-hydroxy-5-methylphenyl acetate (24) (6.0 mg,
0.018 mmol) in tetrahydrofuran (0.5 mL) and methanol (0.12 mL)
was added 4 M aqueous sodium hydroxide (9 mL, 1.00 mmol). The
reaction mixture was stirred at room temperature for 3 h before
being acidiﬁed to pH 2 with 1 M aqueous hydrochloric acid and
extracted with ethyl acetate (3 # 3 mL). The combined organic
fractions dried over magnesium sulfate, ﬁltered and concentrated
under reduced pressure. Puriﬁcation by ﬂash column chromatog-
raphy (1 g silica), eluting with a gradient of petrol ether: ethyl ac-
etate (100: 0) to (90: 10), gave the title compound as a white solid
(2.7 mg, 51%): Rf 0.15 (10% ethyl acetate/90% 40e60 petrol ether) 1H
NMR (500 MHz, Chloroform-d) d 12.78 (s, 1H), 10.09 (s, 1H), 6.22 (s,
1H), 6.15 (s, 1H), 5.31e5.22 (m, 1H), 5.12e5.00 (m, 1H), 3.42 (d,
J ¼ 7.2 Hz, 2H), 2.51 (s, 3H), 2.19e2.01 (m, 4H), 1.82 (d, J ¼ 1.5 Hz,
3H), 1.69 (d, J ¼ 1.6 Hz, 3H), 1.60 (s, 3H). LCMS (ESI) retention time
5.73 min, m/z 289.67.
4.1.21. 2-[(2E)-3,7-Dimethylocta-2,6-dien-1-yl]-4-formyl-3-
hydroxy-5-methylphenyl acetate (24)
To a solution of 3-{[(2E)-3,7-dimethylocta-2,6-dien-1-yl]oxy}-
4-formyl-5-methylphenyl acetate (synthesised using the same
method to make 5) (300 mg, 0.908 mmol) in toluene (9.0 mL) was
added Fluorosil (100e200 mesh, 3.0 g). The reaction mixture was
heated at reﬂux for 3 h before being allowed to cool to room
temperature and being ﬁltered. The Fluorosil was washed with
ethyl acetate (3 # 10 mL) and the combined ﬁltrate was concen-
trated under reduced pressure. Puriﬁcation by ﬂash column chro-
matography (10 g silica), eluting with a gradient of petrol ether:
ethyl acetate (100: 0) to (80: 20) then by prep HPLC, gave the title
compound as a pale yellow oil (12 mg, 4%): Rf 0.28 (10% ethyl ac-
etate/90% 40e60 petrol ether) 1H NMR (500 MHz, Chloroform-d)
d 12.45 (s, 1H), 10.25 (s, 1H), 6.47 (s, 1H), 5.17e5.09 (m, 1H),
5.08e5.01 (m, 1H), 3.28 (d, J ¼ 7.0 Hz, 2H), 2.57 (s, 3H), 2.31 (s, 3H),
2.10e2.00 (m, 2H), 2.01e1.95 (m, 2H), 1.75 (s, 3H), 1.65 (d, J¼ 1.6 Hz,
3H), 1.58 (s, 3H). LCMS (ESI) retention time 6.44 min, m/z 331.72.
4.1.22. 3-[(2E)-3,7-Dimethylocta-2,6-dien-1-yl]-2,4-
dihydroxybenzaldehyde (25)
To a solution of 2-[(2E)-3,7-dimethylocta-2,6-dien-1-yl]-4-
formyl-3-hydroxyphenyl acetate (26) (130 mg, 0.411 mmol) in
tetrahydrofuran (4.0 mL) and methanol (1.0 mL) was added 4 M
aqueous sodium hydroxide (308 mL, 1.23 mmol). The reaction
mixture was stirred at room temperature for 3 h before being
diluted with deionised water (10 mL), acidiﬁed to pH 1 with 1 M
aqueous hydrochloric acid and extracted with ethyl acetate
(3# 10 mL). The combined organic fractions dried over magnesium
sulfate, ﬁltered and concentrated under reduced pressure. Puriﬁ-
cation by ﬂash column chromatography (10 g silica), eluting with a
gradient of petrol ether: ethyl acetate (100: 0) to (80: 20), gave the
title compound as a cream coloured solid (83mg, 73%): Rf 0.36 (20%
ethyl acetate/80% 40e60 petrol ether) 1H NMR (500 MHz, Chloro-
form-d) d 11.79 (s, 1H), 9.70 (s, 1H), 7.32 (d, J ¼ 8.7 Hz, 1H), 6.49 (d,
J ¼ 8.5 Hz, 1H), 6.21 (s, 1H), 5.34e5.21 (m, 1H), 5.11e4.98 (m, 1H),
3.47 (d, J ¼ 7.2 Hz, 2H), 2.18e2.02 (m, 4H), 1.83 (s, 3H), 1.68 (d,
J ¼ 1.7 Hz, 3H), 1.60 (s, 3H). LCMS (ESI) retention time 5.57 min,m/z
275.64.
4.1.23. 2-[(2E)-3,7-Dimethylocta-2,6-dien-1-yl]-4-formyl-3-
hydroxyphenyl acetate (26)
To a solution of 3-{[(2E)-3,7-dimethylocta-2,6-dien-1-yl]oxy}-
4-formylphenyl acetate (synthesised using the same method to
make 5) (520 mg, 1.64 mmol) in toluene (7.5 mL) was added Flu-
orosil (100e200 mesh, 2.6 g). The reaction mixture was heated at
reﬂux for 3 h before being allowed to cool to room temperature and
being ﬁltered. The Fluorosil was washed with ethyl acetate
(3 # 20 mL) and the combined ﬁltrate was concentrated under
reduced pressure. Puriﬁcation 2 times by ﬂash column chroma-
tography (10 g silica), eluting with a gradient of petrol ether: ethyl
acetate (100: 0) to (90: 10), gave the title compound as a pale
yellow oil (133 mg, 26%): Rf 0.50 (10% ethyl acetate/90% 40e60
petrol ether) 1H NMR (500 MHz, Chloroform-d) d 11.54 (s, 1H), 9.85
(s, 1H), 7.44 (d, J¼ 8.5 Hz, 1H), 6.76 (d, J ¼ 8.4 Hz, 1H), 5.17e5.10 (m,
1H), 5.09e5.02 (m, 1H), 3.33 (d, J ¼ 7.0 Hz, 2H), 2.33 (s, 3H),
2.10e2.02 (m, 2H), 2.02e1.94 (m, 2H),1.77 (s, 3H), 1.65 (d, J¼ 1.8 Hz,
3H), 1.58 (s, 3H).
4.1.24. 5-Chloro-3-[(2E)-3,7-dimethylocta-2,6-dien-1-yl]-2-
hydroxybenzaldehyde (27)
To a solution of 5-chloro-2-{[(2E)-3,7-dimethylocta-2,6-dien-1-
yl]oxy}benzaldehyde (synthesised using the same method to make
5) (300 mg, 1.02 mmol) in toluene (5.0 mL) was added Fluorosil
(100e200 mesh, 3.0 g). The reaction mixture was heated at reﬂux
for 3 h before being allowed to cool to room temperature and being
ﬁltered. The Fluorosil was washed with ethyl acetate (3 # 10 mL)
and the combined ﬁltrate was concentrated under reduced pres-
sure. Puriﬁcation 2 times by ﬂash column chromatography (10 g
silica), eluting with a gradient of petrol ether: ethyl acetate (100: 0)
to (99: 1), gave the title compound as a pale yellow oil (45 mg,15%):
Rf 0.12 (100% 40e60 petrol ether) 1H NMR (500 MHz, Chloroform-
d) d 11.22 (s, 1H), 9.84 (d, J¼ 0.8 Hz, 1H), 7.39 (d, J¼ 2.6 Hz,1H), 7.35
(d, J ¼ 2.6 Hz, 1H), 5.37e5.23 (m, 1H), 5.17e5.05 (m, 1H), 3.37 (d,
J ¼ 7.4 Hz, 2H), 2.21e2.02 (m, 4H), 1.76e1.65 (m, 6H), 1.62 (s, 3H).
4.1.25. 3-[(2E)-3,7-Dimethylocta-2,6-dien-1-yl]-2,4,6-
trihydroxybenzaldehyde (28)
To a solution of 2,4,6-trihydroxybenzaldehyde (500 mg,
3.24 mmol) and geranyl bromide (536 mL, 2.70 mmol) in acetone
(30 mL) was added potassium carbonate (224 mg, 1.62 mmol). The
reaction mixture was heated at reﬂux for 5 h before being allowed
to cool to room temperature and being concentrated under reduced
pressure. Puriﬁcation by ﬂash column chromatography (10 g silica),
eluting with a gradient of petrol ether: ethyl acetate (100: 0) to (60:
40), gave the title compound as a yellow solid (102mg,13%): Rf 0.36
(40% ethyl acetate/60% 40e60 petrol ether) 1H NMR (500 MHz,
Chloroform-d) d 12.25 (s, 1H), 10.04 (s, 1H), 7.65 (d, 1H), 7.22 (s, 1H),
5.90 (s, 1H), 5.29e5.23 (m, 1H), 5.05 (t, J ¼ 6.7 Hz, 1H), 3.33 (d,
J ¼ 7.3 Hz, 2H), 2.21e1.97 (m, 4H), 1.80 (s, 3H), 1.67 (s, 3H), 1.59 (s,
3H).
4.1.26. 3-Chloro-5-[(2E)-3,7-dimethylocta-2,6-dien-1-yl]-4,6-
dihydroxy-2-methylbenzonitrile (29)
To a solution of 5-chloro-7-[(2E)-3,7-dimethylocta-2,6-dien-1-
yl]-4-methyl-1,2-benzoxazol-6-ol (synthesised using the same
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method to make 31) (45 mg, 0.141 mmol) in ethanol (4.5 mL) at
room temperature was added 1 M aqueous sodium hydroxide
(1.4 mL, 1.4 mmol). The reaction mixture was stirred at room
temperature for 1 h before being acidiﬁed to pH 1with 1M aqueous
hydrochloric acid. Ethyl acetate (10 mL) was added and the phases
were separated. The aqueous phase was extracted with ethyl ace-
tate (2 # 10 mL) and the combined organic fractions were dried
over magnesium sulfate, ﬁltered and concentrated under reduced
pressure. Puriﬁcation by ﬂash column chromatography (5 g silica),
eluting with a gradient of petrol ether: ethyl acetate (100: 0) to (90:
10), gave the title compound as a colourless oil (17mg, 38%): Rf 0.40
(10% ethyl acetate/90% 40e60 petrol ether) 1H NMR (500 MHz,
Chloroform-d) d 6.24 (s, 1H), 6.17 (s, 1H), 5.28e5.19 (m, 1H),
5.09e5.02 (m, 1H), 3.46 (d, J ¼ 7.2 Hz, 2H), 2.52 (s, 3H), 2.21e2.02
(m, 4H), 1.86e1.78 (m, 3H), 1.70 (d, J¼ 1.3 Hz, 3H), 1.61 (d, J¼ 1.6 Hz,
3H). LCMS (ESI) retention time 5.43 min, m/z 320.15/322.07.
4.1.27. 2-Chloro-6-[(2E)-3,7-dimethylocta-2,6-dien-1-yl]-5-
hydroxy-3,4-dimethylphenyl acetate (30)
To a solution of 2-chloro-6-[(2E)-3,7-dimethylocta-2,6-dien-1-
yl]-4-formyl-5-hydroxy-3-methylphenyl acetate (20) (100 mg,
0.274 mmol) in dichloromethane (5 mL) was added triethylamine
(76 mL, 0.548 mmol) and acetyl chloride (39 mL, 0.548 mmol) at
room temperature. The reaction mixture was stirred at room
temperature for 3 h before being concentrated under reduced
pressure. Puriﬁcation by ﬂash column chromatography (10 g silica),
eluting with a gradient of petrol ether: ethyl acetate (100: 0) to (80:
20), 3-(acetyloxy)-6-chloro-2-[(2E)-3,7-dimethylocta-2,6-dien-1-
yl]-4-formyl-5-methylphenyl acetate as a pale yellow oil (30 mg,
27%): Rf 0.40 (10% ethyl acetate/90% 40e60 petrol ether) 1H NMR
(500 MHz, Chloroform-d) d 10.27 (s, 1H), 5.12e5.01 (m, 1H),
5.01e4.91 (m, 1H), 3.21 (d, J ¼ 6.6 Hz, 2H), 2.68 (s, 3H), 2.37 (s, 3H),
2.36 (s, 3H), 2.09e2.01 (m, 2H), 2.01e1.94 (m, 2H), 1.73 (d,
J ¼ 1.5 Hz, 3H), 1.67 (d, J ¼ 1.7 Hz, 3H), 1.59 (d, J ¼ 1.4 Hz, 3H). LCMS
(ESI) retention time 6.44 min, m/z no ionisation.
To a solution of 3-(acetyloxy)-6-chloro-2-[(2E)-3,7-
dimethylocta-2,6-dien-1-yl]-4-formyl-5-methylphenyl acetate
(30mg, 0.073mmol) in tetrahydrofuran (1.0mL) was added sodium
borohydride (11 mg, 0.295 mmol). The reaction mixturewas stirred
at room temperature for 3 h before being diluted with deionised
water (1 mL), quenched with 1 M aqueous hydrochloric acid (3 mL)
and extractedwith ethyl acetate (3# 10mL). The combined organic
extracts were dried over magnesium sulfate, ﬁltered and concen-
trated under reduced pressure. Puriﬁcation by ﬂash column chro-
matography (10 g silica), eluting with a gradient of petrol ether:
ethyl acetate (100: 0) to (90: 10), gave the title compound as an off-
white solid (15 mg, 58%): Rf 0.57 (10% ethyl acetate/90% 40e60
petrol ether) 1H NMR (500 MHz, Chloroform-d) d 5.43 (s, 1H),
5.22e5.12 (m, 1H), 5.09e4.97 (m, 1H), 3.28 (d, J ¼ 7.6 Hz, 2H), 2.36
(s, 3H), 2.33 (s, 3H), 2.18 (s, 3H), 2.15e2.04 (m, 4H), 1.81 (s, 3H), 1.69
(d, J ¼ 1.4 Hz, 3H), 1.61 (s, 3H). LCMS (ESI) retention time 6.43 min,
m/z no ionisation.
4.1.28. 5-Chloro-3-[(2E)-3,7-dimethylocta-2,6-dien-1-yl]-2,4-
dihydroxybenzonitrile (31)
To a solution of triphenylphosphine (42 mg, 0.162 mmol) in
dichloromethane (2 mL) was added 2,3-dichloro-5,6-dicyano-p-
benzoquinone (37 mg, 0.162 mmol). The dark reaction mixture was
stirred at room temperature for 1min during which time the colour
faded. 4-Chloro-2-2E)-3,7-dimethylocta-2,6-dien-1-yl]-6-
[(hydroxyimino)methyl]benzene-1,3-diol (32) (35 mg, 0.108 mmol)
in dichloromethane (0.5 mL) was added to the reactionmixture in 1
portion and this was stirred for 1 min before being concentrated
under reduced pressure. Puriﬁcation by ﬂash column chromatog-
raphy (10 g silica), eluting with a gradient of petrol ether: ethyl
acetate (100: 0) to (90: 10), gave 5-chloro-7-[(2E)-3,7-
dimethylocta-2,6-dien-1-yl]-1,2-benzoxazol-6-ol as a white solid
(24 mg, 72%).
To a solution of 5-chloro-7-[(2E)-3,7-dimethylocta-2,6-dien-1-
yl]-1,2-benzoxazol-6-ol in ethanol (2.1 mL) at room temperature
was added 1 M aqueous sodium hydroxide (0.69 mL, 0.69 mmol).
The reaction mixture was stirred at room temperature for 1 h
before being acidiﬁed to pH 1 with 1 M aqueous hydrochloric acid.
Ethyl acetate (10 mL) was added and the phases were separated.
The aqueous phase was extracted with ethyl acetate (2 # 10 mL)
and the combined organic fractions were dried over magnesium
sulfate, ﬁltered and concentrated under reduced pressure. Puriﬁ-
cation by ﬂash column chromatography (5 g silica), eluting with a
gradient of petrol ether: ethyl acetate (100: 0) to (90: 10), gave the
title compound as a light green oil (12 mg, 57%): Rf 0.09 (5% ethyl
acetate/95% 40e60 petrol ether) 1H NMR (500 MHz, Chloroform-d)
d 7.38 (s, 1H), 6.31 (s, 1H), 6.11 (s, 1H), 5.33e5.17 (m, 1H), 5.11e4.97
(m, 1H), 3.49 (d, J ¼ 7.4 Hz, 3H), 2.20e2.01 (m, 4H), 1.82 (s, 3H), 1.70
(s, 3H), 1.61 (s, 3H). LCMS (ESI) retention time 4.98 min,m/z 306.09.
4.1.29. 4-Chloro-2-[(2E)-3,7-dimethylocta-2,6-dien-1-yl]-6-
[(hydroxyimino)methyl]benzene-1,3-diol (32)
To a solution of 3-[(2E)-3,7-dimethylocta-2,6-dien-1-yl]-2,4-
dihydroxy-6-methylbenzaldehyde (23) (44 mg, 0.142 mmol) in
ethanol/deionised water/tetrahydrofuran (3:2:2, 0.5 mL) was
added sodium acetate (17 mg, 0.214 mmol) and hydroxylamine
hydrochloride (11 mg, 0.157 mmol). The reaction mixture was
stirred for 16 h before being concentrated under reduced pressure.
Puriﬁcation by ﬂash column chromatography (5 g silica), eluting
with a gradient of petrol ether: ethyl acetate (100: 0) to (90: 10),
gave the title compound as a white solid (37 mg, 80%): Rf 0.30 (5%
ethyl acetate/95% 40e60 petrol ether) 1H NMR (500 MHz, Chloro-
form-d) d 9.31 (s, 1H), 8.10 (s, 1H), 7.08 (s, 1H), 7.02 (s, 1H), 5.88 (s,
1H), 5.35e5.18 (m, 1H), 5.14e5.00 (m, 1H), 3.46 (d, J ¼ 7.2 Hz, 2H),
2.12e2.04 (m, 2H), 2.04e1.96 (m, 2H),1.81 (d, J¼ 1.5 Hz, 3H),1.66 (s,
3H), 1.59 (s, 3H). LCMS (ESI) retention time 5.40 min, m/z 324.09/
326.11.
4.1.30. 3-Chloro-5-[(2E)-3,7-dimethylocta-2,6-dien-1-yl]-4,6-
dimethoxy-2-methylbenzaldehyde (33)
To a solution of 3-chloro-5-[(2E)-3,7-dimethylocta-2,6-dien-1-
yl]-4,6-dihydroxy-2-methylbenzaldehyde (6) (30 mg,
0.0929 mmol) and potassium carbonate (128 mg, 0.929 mmol) in
acetone (2 ml) was added methyl iodide (57 mL, 0.929 mmol). The
reaction mixture was stirred at room temperature for 16 h before
being concentrated under reduced pressure. The residue was dis-
solved in ethyl acetate (5 mL) and deionised water (5 mL). The
phases were separated and the aqueous phase was extracted with
ethyl acetate (2 # 5 mL). The combined organic extracts were dried
over magnesium sulfate, ﬁltered and concentrated under reduced
pressure. Puriﬁcation by ﬂash column chromatography (5 g silica),
eluting with a gradient of petrol ether: ethyl acetate (100: 0) to (95:
5), gave the title compound as a yellow oil (16 mg, 49%): Rf 0.71 (5%
ethyl acetate/95% 40e60 petrol ether) 1H NMR (500 MHz, Chloro-
form-d) d 10.43 (s, 1H), 5.24e5.12 (m, 1H), 5.12e5.00 (m, 1H), 3.88
(s, 3H), 3.83 (s, 3H), 3.42 (d, J ¼ 7.0 Hz, 2H), 2.65 (s, 3H), 2.12e2.04
(m, 2H), 2.04e1.96 (m, 2H), 1.80 (s, 3H), 1.64 (s, 3H), 1.60e1.55 (m,
3H).
4.1.31. 3-Chloro-4-{[(2E)-3,7-dimethylocta-2,6-dien-1-yl]oxy}-6-
hydroxy-2-methylbenzaldehyde (34)
To a solution of 4-chloro-5-{[(2E)-3,7-dimethylocta-2,6-dien-1-
yl]oxy}-2-formyl-3-methylphenyl acetate (50 mg, 0.137 mmol) in
tetrahydrofuran (2 mL) and methanol (0.5 ml) was added 4 M
aqueous sodium hydroxide (68 mL, 0.274 mmol). The reaction
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mixture was stirred at room temperature for 2 h before being
diluted with deionised water (2 mL) and acidiﬁed to pH 2 with 1 M
aqueous hydrochloric acid. The reaction mixture was extracted
with ethyl acetate (3 # 3 mL). The combined organic extracts were
dried over magnesium sulfate, ﬁltered and concentrated under
reduced pressure. Puriﬁcation by ﬂash column chromatography
(10 g silica), eluting with a gradient of petrol ether: ethyl acetate
(100: 0) to (95: 5), gave the title compound as a white solid (31 mg,
70%): Rf 0.16 (5% ethyl acetate/95% 40e60 petrol ether) 1H NMR
(500 MHz, Chloroform-d) d 12.59 (s, 1H), 10.16 (s, 1H), 6.36 (s, 1H),
5.53e5.43 (m, 1H), 5.14e5.03 (m, 1H), 4.67 (d, J ¼ 6.5 Hz, 2H), 2.63
(s, 3H), 2.22e2.05 (m, 4H), 1.76 (d, J¼ 1.4 Hz, 3H), 1.68 (d, J¼ 1.6 Hz,
3H), 1.61 (d, J¼ 1.5 Hz, 3H). LCMS (ESI) retention time 6.88 min,m/z
323.72/325.95.
4.1.32. 3-Chloro-6-{[(2E)-3,7-dimethylocta-2,6-dien-1-yl]oxy}-4-
hydroxy-2-methylbenzaldehyde (35)
To a solution of 2-chloro-5-{[(2E)-3,7-dimethylocta-2,6-dien-1-
yl]oxy}-4-formyl-3-methylphenyl acetate (5) (50 mg, 0.137 mmol)
in tetrahydrofuran (2 mL) and methanol (0.5 ml) was added 4 M
aqueous sodium hydroxide (68 mL, 0.274 mmol). The reaction
mixture was stirred at room temperature for 2 h before being
diluted with deionised water (2 mL) and acidiﬁed to pH 2 with 1 M
aqueous hydrochloric acid. The reaction mixture was extracted
with ethyl acetate (3 # 3 mL). The combined organic extracts were
dried over magnesium sulfate, ﬁltered and concentrated under
reduced pressure. Puriﬁcation by ﬂash column chromatography
(10 g silica), eluting with a gradient of petrol ether: ethyl acetate
(100: 0) to (90: 10), gave the title compound as awhite solid (39mg,
88%): Rf 0.23 (10% ethyl acetate/90% 40e60 petrol ether) 1H NMR
(500 MHz, Chloroform-d) d 10.50 (s, 1H), 6.56 (s, 1H), 6.14 (s, 1H),
5.51e5.43 (m, 1H), 5.14e5.04 (m, 1H), 4.61 (d, J ¼ 6.5 Hz, 2H), 2.69
(s, 3H), 2.21e2.04 (m, 3H), 1.75 (d, J¼ 1.5 Hz, 3H), 1.69 (d, J¼ 1.8 Hz,
3H), 1.62 (s, 3H). LCMS (ESI) retention time 5.88 min, m/z 323.22/
325.21.
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ABSTRACT: New tools are required to ensure the adequate
control of the neglected tropical disease human African
trypanosomiasis. Annual reports of infection have recently
fallen to fewer than 5000 cases per year; however, current
therapies are hard to administer and have safety concerns and,
hence, are far from ideal. Trypanosome alternative oxidase is
an exciting target for controlling the infection; it is unique to
the parasite, and inhibition of this enzyme with the natural
product ascofuranone has shown to clear in vivo infections. We
report the synthesis and associated structure activity relation-
ships of inhibitors based upon this natural product with
correlation to T. b. brucei growth inhibition in an attempt to
generate molecules that possess improved physicochemical properties and potential for use as new treatments for human African
trypanosomiasis.
KEYWORDS: medicinal chemistry, drug design, multiparameter optimization, human African trypanosomiasis
Human African trypanosomiasis (HAT), otherwise knownas African sleeping sickness, is a neglected tropical
disease caused by human infection by the protozoan parasites
T. b. gambiense or T. b. rhodesiense, transmitted by tsetse ﬂies in
sub-Saharan Africa.1 Without treatment, HAT is invariably
fatal;2 the drugs that are currently approved for treatment of
both the hemolymphatic (stage 1) and encenphalitic (stage 2)
phases of the disease either have toxic side eﬀects or require
complex administration procedures.3 Resistant strains of the
parasites have been observed in the clinic, and there is a
requirement for new treatment options to guarantee the
successful control of the disease.4,5 In 2009, it was estimated
that occurrences of the disease had fallen below 20 000
incidences a year and that 65 million people are at risk of
transmission.1
The trypanosome, ﬁrst discovered by Sir David Bruce in
1895,6 undergoes diverse lifecycle adaptations conferring
viability in both the tsetse ﬂy vector and mammalian host.7,8
A predominant feature of Trypanosoma brucei is that it is
capable of successfully evading host immune responses,
predominantly due to its capacity to diversify the surface
antigens that it presents to its host;9 this ability has been a
major factor for preventing the development of an eﬃcacious
vaccine against the pathogen.10 T. b. gambiense is responsible
for >95% of cases of HAT and is a zoonotic disease, residing in
a variety of domestic animals and livestock.11 Trypanosome
infection in cattle and other livestock also has a large burden on
the health and associated economic output of animals; the cost
of delivering trypanocidal agents to control “Nagana” or African
animal trypanosomiasis (AAT) is estimated to be 140 million
USD per year.12
Current treatments for HAT are far from ideal. Stage 1 of the
disease is treated with suramin for T. b. rhodesiense or
pentamidine for T. b. gambiense; both compounds display
undesired toxic side eﬀects in the clinic.13 Resistance against
pentamidine has also been observed and linked to mutations in
the P2 amino purine and other trypanosome uptake trans-
porters.5 Both suramin and pentamidine are unable to permeate
into the central nervous system (CNS) to suﬃcient levels and,
thus, are ineﬀective against stage 2 infections.14 The organo-
arsenide melarsoprol and the more recent combination therapy
of nifurtimox and eﬂornithine (NECT) are currently used to
treat infections of T. b. gambiense and T. b. rhodesiense,
respectively. Both treatments have their limitations. Melarso-
prol shows signiﬁcant toxic eﬀects in those treated, causing
encephalopathy in 5−10% of people treated with the drug.15
Incidences of resistance to melarsoprol are becoming more
commonplace, again linked to mutations in the P2 amino
purine uptake transporters; associated failure rates in the clinic
have been reported to be between 20% and 30% in the early
2000s.5 NECT requires the administration of eﬂornithine via
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slow intravenous infusion of 200 mg/kg every 12 h for 7 days as
it is only trypanostatic, thus requiring trypanocidal action by the
coadministered nifurtimox and innate host clearance mecha-
nisms.16
With the limitations of the currently approved medicines for
treating HAT and the increasing reports of resistance to these
therapies, it is vital to discover new and improved treatments
against the pathogen. An ideal target for drug discovery for
HAT is the trypanosome alternative oxidase (TAO).17 TAO is
the sole terminal oxidase enzyme in the aerobic respiratory
pathway for the long slender blood stage form of Trypanosoma
brucei subspecies. The enzyme utilizes oxygen and ubiquinol as
substrates for the eﬃcient generation of cellular ATP as the
parasite does not express regular cytochrome respiratory
complexes.18 TAO is a di-iron (nonheme) oxidoreductase
that is located in the inner-mitochondrial membrane of the
trypanosome.19 As TAO is not found in mammalian systems,
there is a unique opportunity to attain compounds with
enhanced selectivity and circumvent on-target toxicity.19 It has
recently been reported that the pentamidine and melarsoprol
drug resistant parasites have an increased sensitivity to
inhibition of TAO, as these parasites have a reduced capacity
to eﬄux cellular glycerol that is produced as the result of
anaerobic respiration.20 The crystal structure of TAO has been
reported, allowing a structure based design approach to new
molecules.21 Nanomolar inhibition of TAO has been reported
with the natural product ascofuranone (AF (1)) and its
analogues in validated biochemical assays,22 demonstrating
correlation in ex vivo growth inhibition23 and eﬃcacy in in vivo
clearance models.24
Our previous work identiﬁed robust synthetic routes to close
analogues of AF (1) and structure activity relationships of the
synthesized molecules, highlighting the requirement of both the
chloro and methyl substituents on the aromatic ring for high
potency (Figure 1).23 With these routes in place, we set out to
further explore structurally similar analogues with the aim to
reduce lipophilicity and improve the drug like properties of
these molecules. Our aim of reducing lipophilicity was to
speciﬁcally improve aqueous solubility, decrease metabolism,
and improve the potential to achieve eﬃcacious CNS
concentrations, as new compounds for HAT must be eﬀective
against both stages of the disease.
There are many hurdles preventing permeability of organic
drug molecules to the brain. The blood−brain barrier provides
signiﬁcant protection to xenobiotics; tight junctions around
capillaries prevent permeation, and the expression of ABC-
transporters actively transport solubilized organic molecules out
and away from the barrier and the brain.25 Compounds that
traverse readily into the CNS tend to have high passive
permeability, have low eﬄux from ABC-transporters like P-
glyco-protein (P-gp), and have low metabolic turnover in
human liver microsomes, providing the basis for the generation
of a predictive scoring tool for CNS penetration.26
A major contribution to the poor multiparameter optimiza-
tion (MPO)26 predicted a CNS-penetration score for AF (1),
and colletochlorin B (CCB (2)) is attributed to its high
lipophilicity. Clearly, the major contributor to the high
lipophilicity of CCB (2) is from the geranyl “lipophilic tail”
(Figure 2). Compounds with a cLogP above 5 are commonly
observed to be P-gp substrates and tend to have a high
metabolic liability. We herein report the synthesis and SAR
investigation of analogues focused on reducing the lipophilicity
of the tail region of structural analogues of AF (1) and CCB
(2), with an aim to improve physicochemical properties and
increase the predicted CNS penetration MPO score.
■ RESULTS AND DISCUSSION
The biochemical assessment of the bicyclic 1,2-isoxazole
intermediate prepared to access the aldehyde replacement
with the nitrile analogue of CCB (2) had shown unexpectedly
high potency for inhibiting TAO. Previous reports had
postulated that a hydrogen bond donor was needed at this
position for potent inhibition of TAO.22 To conﬁrm this result,
a synthetic route to the monophenolic compound (11) was
devised (Scheme 1), to rule out the activity arising from an in
situ formation of nitrile compound via a Kemp elimination
(Figure 3).27
Selective bromination of the phenolic aldehyde was achieved
by treatment with trimethylbenzylammonium tribromide at 0
°C; nonselective and over bromination was observed using N-
bromosuccinimide.28 The aldehyde (6) could be successfully
converted to the nitrile (7) by oxime formation with
hydroxylamine hydrochloride and subsequent in situ dehy-
dration. Protection of the phenol (8) to the anisole (9) with
dimethylsulfate was required to facilitate a high yielding Suzuki-
Miyaura cross-coupling using tri-n-octylborane as the coupling
partner that was formed in situ by reacting 1-octene with a
solution of 1 M borane in THF.29 Final deprotection of the
anisol (10) to the free phenol using trimethylsilyl chloride and
sodium iodide provided the monophenol analogue (11) for
biochemical and ex vivo assessment (Table 1).30
Interestingly, the monophenol analogue (11) retained high
potency against TAO that corresponded to the most potent
Figure 1. Summary of previous work23
Figure 2. Per atom contribution to lipophilicity of ascofuranone (AF)
(1) and colletochlorin B (CCB) (2).
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inhibition of T. b. brucei growth for a compound not containing
the benzaldehyde functionality present in AF and CCB. The
removal of one of the ﬂanking substituents ortho to the
brominated coupling position facilitated its reactivity and thus
exploration of this tail. This synthetic route was adopted for
further diversiﬁcation of this tail region. The des-methyl
starting material was accessible from commercially available
sources and was used to initially investigate tail modiﬁcations.
The introduction of polarity into the lipophilic tail was
devised to reduce cLogP and improve upon the predicted CNS
penetration MPO score (>4 required for high predicted CNS
exposure). The introduction of amide functionality in alternate
positions in the chain were planned to mimic the n-octyl
(C8H17) or geranyl chain. The inclusion of the amide
functionality had the largest predicted improvement to both
cLogP and MPO score (Row C, Table 2). 1-Alkene esters were
converted to trialkylboranes using the methodology previously
employed to access the n-octyl analogues (Scheme 2). These
were then coupled with the brominated intermediate (14). The
esters were converted to the desired amides by either in situ
hydrolysis under the demethylation conditions, with subse-
quent HATU amide coupling with the required alkylamine, or a
direct aminolysis of the ester by using 1,5,7-triazabicyclo[4.4.0]-
dec-5-ene (TBD) and the desired alkylamine with subsequent
anisole deprotection with TMSCl/NaI to provide the amide
chain compounds for biological assessment (Table 3).31
The acrylic ester could not be successfully coupled under
these conditions; we postulate that the required trialkylborane
may not form as the alkene is too electron deﬁcient. The
desired ester was synthesized by a Heck-Mizoroki cross-
coupling and subsequent reduction of the double bond, before
chlorination and amide formation with TBD (Scheme 3).
A selection of ether chain analogues was also planned and
synthesized (D, Table 2); these were expected to be more
chemically similar to that of the aliphatic chain with a smaller
amount of polarity introduced in comparison to the amide.
These compounds were less chemically tractable; in our hands,
the anisole deprotection to the phenol proved challenging. The
deprotection conditions that we explored led to the cleavage of
the desired ether functionality present in the chain to the
terminal alcohol. To mitigate this synthetic hurdle, alternative
protecting groups were investigated. Bulkier silyl protecting
groups hindered the cross-coupling and failed to provide the
desired ether tail analogues. Reaction with the phenolic ester
(27) provided some cross-coupled product; the stability of this
protecting group perhaps, unsurprisingly, proved to be labile
under the reaction coupling conditions. The deacetylated
products (29 to 31) were observed and isolated from the
reactions; however, signiﬁcant proportions of the starting
material ester (28) saponiﬁed before cross-coupling providing a
major byproduct of the deacetylated phenol (14) thus resulting
in lower isolated yields (Scheme 4).
Assessment of these less lipophilic analogues showed a large
decrease in potency compared to the n-octyl analogues,
highlighting that even minor increases in polarity in this part
of the lipophilic tail were not tolerated. The most promising
analogues included polarity at the terminal of the chain (22 and
23); however, disappointingly, these compounds resulted in no
measurable inhibition of T. b. brucei growth (Table 3).
This data suggested that a lipophilic tail was required for the
potent inhibition of TAO. To further probe this observation,
analogues were prepared to assess the length of tail needed for
potent inhibition of TAO and whether total lipophilicity could
be decreased by reduction of the carbon chain length (E, Table
2). Previous reports had shown large decreases in potency
against TAO at carbon chain length below 3. The C1−7
analogues (39 to 45) were prepared in a similar fashion to that
of the n-octyl analogue (11); C1−4 analogues were, however,
prepared directly using the alkyl boronic acid or trimeric alkyl
boroxines as the volatile alkene hydrocarbons were not
accessible (Scheme 5).
Interestingly, the reduced carbon chain length analogues
showed good potency against TAO (Table 4), until a notable
decrease in enzymatic inhibition was observed at compounds
with C3 or below, corroborating previous reports.22 What was
more evident was the decrease observed in eﬃcacy against
T. b. brucei growth inhibition as chain length and cLogP
decreased. Compounds showed a distinct drop oﬀ in potency
against T. b. brucei for each carbon reduction. To interrogate
this data, further correlations of cLogP and biochemical and
cellular potency were carried out (Figure 4).
Biochemical potency for these compounds track to a
lipophilic ligand eﬃciency of 3. Cellular potency, however,
correlates to a lipophilic ligand eﬃciency of 1, relating to a 100-
fold decrease in potency from the biochemical activity to the
cellular assay. The 2 log decrease in cellular potency observed
here could be due a combination of reasons that we are
currently investigating; it is of interest that CCB (2) shows a
smaller decrease in potency from the biochemical to cellular
assay. The permeability of the compounds through the cell and
mitochondrial membranes of the trypanosome may be reduced
as the lipophilicity decreases. The compounds could be
substrates for eﬄux transport, that may reduce the intracellular
concentration. The TAO inhibition kinetics of the compounds
may be altered with the reduction in carbon chain length that
Scheme 1. Monophenol Analogue Synthesisa
aReaction conditions: (a) trimethylphenylammonium tribromide,
CH2Cl2/MeOH rt, 3 h, 77%, (b) NH2OH·HCl, EtOH, reﬂux, 16 h,
90%, (c) NCS, Et3N, MeCN, 0 °C to rt, 16 h, 70%, (d) dimethyl
sulfate, acetone, rt, 16 h, 98%, (e) (i) BH3·THF, 1-octene, 0 °C, 20
min, (ii) toluene, H2O, K3PO4, RuPhos, Pd(OAc)2, 50 °C, 16 h, 90%,
and (f) TMS-Cl, NaI, MeCN, 80 °C, 16 h, 65%.
Figure 3. Isoxazole Kemp elimination.
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could result in faster dissociation, resulting in reduced eﬃcacy
on target. The compounds may not locate to the desired cell
compartment as lipophilicity may be required for the inhibitors
to be retained in the inner mitochondrial membrane where the
enzyme is located. Colletochlorin B could be acting on an
unknown complementary antiparasitic target. On-going studies
to better understand these data will aid future analogue design
and synthesis to identify more drug like inhibitors of TAO.
We also noticed positive correlation between cLogP and
both biochemical and cellular activity (Figure 4). Examples of
potency correlating to high lipophilicity have previously been
observed with other membrane proteins and enzymes requiring
lipophilic substrates.33,34
■ CONCLUSIONS
HAT continues to provide a challenge for the development of
new therapies; cases continue to be reported with resistance
more frequently observed. Discoveries of new brain penetrant
T. b. gambiense and T. b. rhodesiense trypanocides are vital for
ensuring the adequate control of HAT in the future. Our work
in this area has been to identify potent inhibitors of TAO that
possess improved physicochemical properties compared to that
of the natural products from which they are derived. Our
exploration in this area has previously shown the requirement
for the methyl and chloro substituents on the aromatic ring for
high potency inhibition of TAO. Our eﬀorts reported here for
modulating the lipophilicity of this molecule by the
introduction of polar functionality in the tail region of this
chemotype has proved challenging. Polar functionality in this
region of the molecule was shown to not be tolerated with large
decreases in potency against TAO observed. The reduction in
the carbon chain length of the tail resulted in identifying
analogues that retained high inhibitory activity of TAO;
however, ex vivo eﬃcacy against T. b. brucei growth was
diminished. We will continue to try to understand this
disconnect and use this generated data for future compound
design toward more drug like inhibitors of TAO.
■ MATERIALS AND METHODS
Experimental Details. ChemAxon Calculator Plugins were
used for structure property prediction and calculation (cLogP),
Marvin 15.5.4, 2015, ChemAxon (http://www.chemaxon.com).
All commercial reagents were purchased from Sigma-Aldrich,
Alfa Aesar, Apollo Scientiﬁc, Fluorochem, or Tokyo Chemical
Industry and of the highest available purity. Unless otherwise
stated, chemicals were used as supplied without further
Table 1. Biological Assay Assessment of Isoxazole and Monophenol Analogues
aNegative log concentration and standard deviation of compounds required for 50% inhibition of trypanosome alternative oxidase. bNegative log
concentration and standard deviation of compounds required for 50% growth inhibition of T. b. brucei Lister427. cNegative log concentration and
standard deviation of compounds required for 50% cytotoxicity of HepG2 cell line (n ≥ 2 in all assays).
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puriﬁcation. Anhydrous solvents were purchased from Acros
(AcroSeal) or Sigma-Aldrich (SureSeal) and were stored under
nitrogen. 40−60 petrol ether refers to the fraction with a
boiling point between 40 and 60 °C. Anhydrous solvents and
reagents were used as purchased. Thin layer chromatography
(TLC) was carried out using glass plates precoated with Merck
silica gel 60 F254. Melting points were determined using an
OptiMelt apparatus and are uncorrected. Proton nuclear
magnetic resonance spectra were recorded at 500 MHz on a
Varian VNMRS 500 MHz spectrometer (at 30 °C), using
residual isotopic solvent (CHCl3, δ = 7.27 ppm, DMSO δ =
2.50 ppm, MeOH δ = 3.31 ppm) as an internal reference.
Chemical shifts are quoted in parts per million (ppm).
Coupling constants (J) are recorded in Hertz (Hz). Carbon
nuclear magnetic resonance spectra were recorded at 125 MHz
on a Varian 500 MHz spectrometer and are proton decoupled,
using residual isotopic solvent (CHCl3, δ = 77.00 ppm, DMSO
δ = 39.52 ppm, MeOH δ = 49.00 ppm) as an internal reference.
Proton and carbon spectra assignments are supported by DEPT
editing. High resolution mass spectrometry (HRMS) data
(ESI) was recorded on Bruker Daltonics, Apex III, ESI source:
Apollo ESI with methanol as spray solvent. Only molecular
ions, fractions from molecular ions, and other major peaks are
reported as mass/charge (m/z) ratios. LCMS data was
recorded on a Waters 2695 HPLC using a Waters 2487 UV
detector and a Thermo LCQ ESI-MS. Samples were eluted
through a Phenomenex Lunar 3 μm C18 50 mm × 4.6 mm
column, using water and acetonitrile acidiﬁed by 0.1% formic
acid at 1 mL/min and detected at 254 nm. The gradient
employed was a 7 min method 30−90% MeCN over a 5 min
gradient, held at 90% MeCN for 1 min, and then re-
equilibrated to 30% MeCN over 1 min. All experiments were
carried out under an inert atmosphere of N2 unless otherwise
stated.
TAO Absorbance Assay. 1-Ubiquinol turnover was
measured by recording the increase in absorbance at 278 nm
(Greiner 96-well UV star ﬂat bottom plates with BMG
PHERAstar FS photo spectrometer) to monitor the increase
of 1-ubiquinone concentration kinetically over 6 min with
puriﬁed rTAO (3 nM). A ﬁnal concentration of 15 μM 1-
ubiquinol was used under the following conditions: 50 mM
Tris-HCl; 0.05% (w/v) C10E8; pH 7.4; 25 °C. The sigmoidal
curve of the inhibition was observed by 10-point 3-fold serial
dilution of test compounds to generate IC50 values.
Growth Inhibition Assays. Bloodstream form Trypanoso-
ma brucei brucei (T. b. brucei or T. b. b.) Lister 427 parasites
were continuously passaged in HMI-9 medium formulated
from IMDM medium (Invitrogen), 10% heat-inactivated fetal
bovine serum, 10% Serum Plus medium supplement (SAFC
Biosciences), 1 mM hypoxanthine (Sigma-Aldrich), 50 μM
bathocuproine disulfonic acid (Sigma-Aldrich), 1.5 mM
cysteine (Sigma-Aldrich), 1 mM pyruvic acid (Sigma-Aldrich),
39 μg/mL thymidine (Sigma-Aldrich), and 14 μL/L β-
mercapthoethanol (Sigma-Aldrich); all concentrations of
added components refer to that in complete HMI-9 medium.
The parasites were cultured in 10 mL of HMI-9 medium in
T75 CELL-STAR tissue culture ﬂasks at 37 °C/5% CO2.
To determine growth inhibitory potency of compounds
against T. b. brucei bloodstream form parasites, 200 nL of 10-
point, 3-fold serially diluted compounds in DMSO were
transferred to the wells of white, solid bottom 384-well plates
(Greiner Bio-One) by either Echo 555 acoustic liquid handling
system or Mosquito. Then, 104 of T. b. brucei parasites in 40 μL
of HMI-9 medium were added to each well, and the plates were
incubated for 48 h at 37 °C in 5% CO2 incubators. Parasite
numbers in individual plate wells were determined through
quantiﬁcation of intracellular ATP amount. The CellTiter-Glo
luminescent cell viability reagent (Promega) was added to plate
wells, and ATP-dependent luminescence signal was measured
on a Tecan M1000 plate Reader after 30 min of incubation.
Suramin an antitrypanosomal drug was used as positive control,
and DMSO was used as negative control. pIC50 values were
calculated using Graph Pad Prism software by plotting the
luminescence values in sigmoidal dose response curves.
Table 2. cLogP and Predicted MPO Scores for Planned
Analoguesa
acLogP calculated from ChemAxon Marvin Sketch; calculated MPO as
described by Wager et al.26
Scheme 2. Amide Tail Linker Synthesisa
aReaction conditions: (a) NBS, MeCN, rt, 16 h, 85%, (b) dimethyl
sulfate, acetone, reﬂux, 3 h, 90%, (c) (i) BH3·THF, 1-alkene ester, 0
°C, 20 min, (ii) toluene, H2O, K3PO4, RuPhos, Pd(OAc)2, 16 h, 50
°C, 90%, (d) TMSCl, NaI, MeCN, 80 °C, 16 h, 35−85%, (e) HATU,
Et3N, R
1′R2′NH, MeCN, rt, 3 h, 60−90%, and (f) TBD, R1′R2′NH,
MeCN, rt, 1−16 h 70−85%.
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Suramin was used as a positive control in screening (pIC50 6.7
± 0.1).
Hep-G2 Cytotoxicity Assay. Human hepatocellular
carcinoma (HepG2) cells were obtained from ATCC and
grown in RPMI media. Twenty-ﬁve μL of 1.6 × 104 cells/mL
were dispensed into sterile 384 well Griener clear plates and
incubated at 37 °C in a 5% CO2 incubator for 24 h. Once the
cells adhered, 125 nL of 10-point, 3-fold serially diluted
compounds in DMSO was transferred onto the cells. After
incubating for an additional 96 h at 37 °C in 5% CO2 incubator,
cells were added with CCK-8 reagent to each well. Plates were
further incubated for 3 h followed by absorbance reading at 450
nM using Envision reader. Absorbance values were used for
determination of cytotoxic concentration (pCC50) required to
inhibit 50% growth. Purmycin was used as positive control in
screening (pCC50 6.3 ± 0.1).
Synthesis. 5-Chloro-7-[(2E)-3,7-dimethylocta-2,6-dien-1-
yl]-1,2-benzoxazol-6-ol (3). To a solution of triphenylphos-
phine (42 mg, 0.16 mmol) in dichloromethane (2 mL) was
added 2,3-dichloro-5,6-dicyano-p-benzoquinone (37 mg, 0.16
mmol). The dark reaction mixture was stirred at room
temperature for 1 min during which time the color faded. 4-
Chloro-2 - [(2E) -3 ,7 -d imethy loc ta -2 ,6 -d ien-1 -y l ] -6 -
[(hydroxyimino)m ethyl]benzene-1,3-diol (35 mg, 0.10 mmol)
Table 3. Biological Assessment of Polar Tail Analogues
aNegative log concentration and standard deviation of compounds required for 50% inhibition of trypanosome alternative oxidase. bNegative log
concentration and standard deviation of compounds required for 50% growth inhibition of T. b. brucei Lister427 (n ≥ 2 in all assays performed).
Scheme 3. Heck Cross-Coupled Amide Tail Linker
Synthesisa
aReaction conditions: (a) ethyl acrylate, SingaCycle, K2CO3, NMP,
100 °C, 16 h, 30%, (b) triethylsilane, Pd/C, EtOH, rt, 16 h, 78%, (c)
SO2Cl2, Et2O, rt, 96 h, 57%, and (d) TBD, n-butylamine, MeCN, 16h,
39%.
Scheme 4. Ether Tail Linker Synthesisa
aReaction conditions: (a) Ac2O, pyridine, DCM, rt, 16 h, 74% and (b)
(i) BH3·THF, 1-alkene ether, 0 °C, 20 min, (ii) toluene, H2O, K3PO4,
RuPhos, Pd(OAc)2, 16 h, 50 °C, 7−24%.
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in dichloromethane (0.5 mL) was added to the reaction
mixture in 1 portion, and this was stirred for 1 min before being
concentrated under reduced pressure. Puriﬁcation by ﬂash
column chromatography (10 g silica), eluting with a gradient of
petrol ether/ethyl acetate (100:0) to (90:10), gave the title
compound as a white solid (24 mg, 72%). 1H NMR (500 MHz,
Chloroform-d) δ 8.60 (s, 1H), 6.10 (s, 1H), 5.42−5.32 (m,
1H), 5.10−5.01 (m, 1H), 3.66 (d, J = 7.3 Hz, 2H), 2.58 (s,
3H), 2.11−2.05 (m, 2H), 2.05−1.98 (m, 2H), 1.84 (d, J = 1.2
Hz, 3H), 1.64 (d, J = 1.4 Hz, 3H), 1.57 (d, J = 1.2 Hz, 3H).
2-Methyl-4-hydroxy-5-bromo-benzaldehyde (6). To a
solution of 2-methyl-4-hydroxy-benzaldehyde (10 g, 73.45
mmol) in CH2Cl2 (100 mL) and methanol (50 mL) was added
a solution of phenyltrimethylammonium tribromide (30.07 g,
77.12 mmol) in CH2Cl2/methanol (1:1, 100 mL) at −5 °C.
The reaction was warmed to ambient temperature and stirred
for 16 h. The reaction was concentrated under reduced
pressure, and the residue was added to 1 M HCl (aq) (200 mL)
to precipitate a white solid; the solid was collected by ﬁltration
and dried under reduced pressure to give the title compound as
a cream precipitate (14.67 g, 94%): mp 160−165 °C,
(methanol/water). IR (neat, vmax) cm
−1, 3063, 1384, 1310,
1136. 1H NMR (500 MHz, DMSO-d6) δ 11.35 (1H, br s), 9.95
(1H, s), 7.91 (1H, s), 6.83 (1H, s), 2.49 (3H, s). 13C NMR
(126 MHz, DMSO-d6) δ 190.8 (CH), 159.2 (C), 142.3 (C),
137.1 (CH), 128.0 (C), 119.1 (CH), 107.4 (C), 19.1 (CH3).
HRMS (ESI−) m/z [M − H]− calculated for C8H6BrO2
212.9557, found 212.9550.
5-Bromo-4-hydroxy-2-methyl-benzonitrile (7). A solution
of 2-methyl-4-hydroxy-5-bromo-benzaldehyde (20.00 g, 93.0
mmol) in acetonitrile (300 mL) was added to hydroxylamine
hydrochloride (6.92 g, 99.5 mmol). The reaction mixture was
heated to reﬂux and stirred for 16 h. The reaction mixture was
cooled to 50 °C, and further hydroxylamine hydrochloride (1.5
g, 21.5 mmol) was added. The reaction mixture was heated to
reﬂux for a further 3 h. This was collected by ﬁltration and dried
under vacuum to give 13.08 g of an oﬀ-white solid. Analysis
showed a good purity product. The ﬁltrate was concentrated
under vacuum. The residue was triturated in MeCN/water
(1:2) and sonicated; the solid was collected by ﬁltration and
dried under vacuum, to provide a further 6.67 g (19.75, quant.).
mp 194−199 °C (MeCN/water). IR (neat, νmax) cm−1 3203,
2232 (CN), 1595, 1402, 1386, 1260, 1221. 1H NMR (500
MHz, DMSO-d6) δ 11.38 (1H, br s), 7.90 (1H, s), 6.92 (1H, s),
Scheme 5. Carbon Chain Length Analogue Synthesisa
aReaction conditions: (a) (i) BH3·THF, 1-alkene, 0 °C, 20 min, (ii)
toluene, H2O, K3PO4, RuPhos, Pd(OAc)2, 16 h, 50 °C, 65−90%, or 1-
boronic acid/boroxine, K3PO4, RuPhos, Pd(OAc)2, 16 h, 80 °C and
(b) TMSCl, NaI, MeCN, 80 °C, 16 h, 35−85%.
Table 4. Biological Assessment of Carbon Chain Length
Analogues
# R3 cLogP TAO pIC50
a T. b. b. pEC50
b
11 n-C8H17 6.3 8.9 ± 0.3 7.6 ± 0.1
45 n-C7H15 5.8 8.5 ± 0.1 6.6 ± 0.2
44 n-C6H13 5.4 8.2 ± 0.1 6.1 ± 0.1
43 n-C5H11 4.9 7.8 ± 0.1 6.0 ± 0.1
42 n-C4H9 4.5 7.7 ± 0.1 5.3 ± 0.1
41 n-C3H7 4.1 7.1 ± 0.1 4.7 ± 0.1
39 n-CH3 3.2 6.2 ± 0.1 4.7 ± 0.1
aNegative log concentration and standard deviation of compounds
required for 50% inhibition of trypanosome alternative oxidase.
bNegative log concentration and standard deviation of compounds
required for 50% growth inhibition of T. b. brucei Lister427 (n ≥ 2 for
all assays performed).
Figure 4. Correlations of cLogP vs TAO inhibition pIC50 (left) and cLogP vs T. b. b. pIC50 growth inhibition (right). LipE is lipophilic ligand
eﬃciency (pIC50 − cLogP).32
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2.49 (3H, s). 13C NMR (126 MHz, DMSO-d6) δ 158.6 (C),
143.4 (C), 137.1 (CH), 117.9 (CH), 117.7 (C), 107.3 (C),
103.8 (C), 19.1 (CH3). HRMS (ESI
−) m/z [M − H]−
calculated for C8H5BrNO 209.9560, found 209.9554.
5-Bromo-3-chloro-4-hydroxy-2-methyl-benzonitrile (8).
Triethylamine (0.83 mL, 5.97 mmol) was added to a solution
of 5-bromo-2-methyl-4-hydroxybenzonitrile (1.15 g, 5.42
mmol) in acetonitrile (50 mL). 1-Chloropyrorolidine-2,5-
dione (1.52 g, 11.38 mmol) was added portionwise to the
stirring solution. To the reaction mixture was added water (50
mL), precipitating a pale-yellow solid that was collected by
ﬁltration to provide the title compound (1.11 g, 83%). mp
166−169 °C, IR (neat, vmax), cm−1 3239, 2236 (CN), 1581,
1468, 1384, 1294, 1224, 1147. 1H NMR (500 MHz, CDCl3) δ
7.70 (s, 1H), 6.39 (s, 1H), 2.58 (s, 3H). 13C NMR (126 MHz,
CDCl3) δ 152.5 (C), 140.9 (C), 134.4 (CH), 122.1 (CH),
116.4 (C), 107.5 (CH), 106.9 (C), 19.0 (CH3). HRMS (ESI
−)
m/z [M − H]− calcd for C8H4BrClNO 243.9170, found
243.9165.
5-Bromo-3-chloro-4-methoxy-2-methyl-benzonitrile (9).
Dimethyl sulfate (0.85 mL, 8.95 mmol) was added to a
suspension of 5-bromo-3-chloro-4-hydroxy-benzonitrile (2.10
g, 8.52 mmol) and potassium carbonate (1.41 g, 10.22 mmol)
in acetone (80 mL). The reaction mixture was heated to reﬂux
for 3 h; the reaction was cooled to RT, and water (160 mL) was
added to precipitate a white solid that was collected by vacuum
ﬁltration to give the title compound (2.07 g, 93%). mp 119−
120 °C, IR (neat, vmax), cm−1 2229 (CN), 1457, 1372, 1275,
1048. 1H NMR (500 MHz, CDCl3) δ 7.74 (s, 1H), 3.94 (s,
3H), 2.58 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 157.4 (C),
141.7 (C), 134.9 (CH), 131.3 (C), 116.3 (C), 116.0 (C), 111.0
(C), 61.0 (CH3), 19.2 (CH3). LRMS EI
+ 261 m/z.
3-Bromo-5-chloro-4-hydroxybenzonitrile (13). N-Bromo-
succinimide (0.30 g, 1.71 mmol) was added to a solution of 3-
chloro-4-hydroxybenzonitrile (0.25g, 1.63 mmol) in acetonitrile
(5 mL). To the reaction mixture was added water (15 mL),
precipitating a white solid; this was collected by ﬁltration and
dried under reduced pressure to provide the title compound as
a white solid (0.36 g, 84%). mp 166−169 °C. IR (neat, vmax),
cm−1 3411, 2229, 1471, 1327, 1294, 1245, 1204, 1156. 1H
NMR (500 MHz, CDCl3) δ 7.75 (s, 1H), 7.64 (s, 1H) 6.37 (s,
1H). 13C NMR (126 MHz, CDCl3) δ 152.8 (C), 135.0 (C),
132.6 (CH), 121.7 (C), 116.3 (C), 110.9 (C), 106.1 (C).
HRMS (ESI−) m/z [M − H]− calcd for C7H2BrClNO
229.9014, found 231.8984.
3-Bromo-5-chloro-4-methoxybenzonitrile (14). Dimethyl
sulfate (0.15 mL, 1.61 mmol) was added to a suspension of
potassium carbonate (0.22 g, 1.61 mmol) and 3-bromo-5-
chloro-4-hydroxy-benzonitrile (0.30 g, 1.29 mmol) in acetone
(10 mL). The reaction mixture was heated to reﬂux for 30 min
and cooled to RT; water was added. The resulting precipitate
was collected by ﬁltration and dried under reduced pressure to
provide the title compound as a white solid (0.29 g, 90%). mp
115−116 °C, IR (neat, vmax), cm−1 2236 (CN), 1539, 1470,
1419, 1272. 1H NMR (500 MHz, CDCl3) δ 7.78 (s, 1H), 7.66
(s, 1H), 3.97 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 157.6
(C), 135.4 (CH), 133.2 (CH), 130.4 (C), 119.5 (C), 116.0
(C), 109.9 (C), 61.0 (CH3). HRMS (ESI
−) m/z [M − H]−
calcd for C8H5BrClNO 243.9170, found 243.9165.
(2-Bromo-6-chloro-4-cyano-phenyl) Acetate (28). 3-
Bromo-5-chloro-4-hydroxy-benzonitrile (500 mg, 2.15 mmol)
was dissolved in dichloromethane (10 mL), before pyridine
(0.26 mL, 3.23 mmol) and acetic anhydride (0.24 mL, 2.58
mmol) were added. The reaction mixture was stirred at room
temperature for 12 h. The reaction mixture was taken up in
water (10 mL), and the organic components were washed with
water (2 × 10 mL). The chlorinated layer was separated,
washed with brine (1 × 10 mL), dried over MgSO4, ﬁltered and
concentrated in vacuo, to give the title compound as a granular
white solid (462 mg, 74%). mp 116−119 °C, IR (neat, vmax,
cm−1) 3088, 2238, 1774. 1H NMR (500 MHz, CDCl3) δ 7.83
(s, 1H), 7.72 (s, 1H), 2.44 (s, 3H). 13C (126 MHz, CDCl3) δ
166.3 (C), 149.3 (C), 135.0 (CH), 132.7 (CH), 130.3 (C),
119.3 (C), 115.7 (C), 112.2 (C), 20.3 (CH3). LRMS EI
+ 275
m/z.
General Protocol for Alkene Cross-Couplings. 1-Alkene
(2.54 mmol) was dropwise added to an ice cooled solution of 1
M borane in THF (0.91 mmol). This solution was warmed to
room temperature and stirred for 15 min. The solution was
quenched with the addition of water (0.25 mL) and diluted
with toluene (2.5 mL). Potassium phosphate tribasic (0.43 g,
2.03 mmol), aromatic bromide (1.01 mmol), palladium(II)
acetate (0.01 g, 0.025 mmol), and 2-dicyclohexylphosphino-2′-
6′-diisopropoxybiphenyl (0.02 g, 0.05 mmol) were added. The
reaction mixture was sealed and heated to 100 °C for 16 h. The
reaction mixture was partitioned between water (10 mL) and
EtOAc (20 mL). The organic layer was separated, dried over
MgSO4, ﬁltered, and concentrated under vacuum. The residue
was puriﬁed by ﬂash silica chromatography, eluting with
petroleum ether to 10−50% EtOAc followed by puriﬁcation
by preparative HPLC 50% MeCN in water to 100% MeCN to
provide the title compounds (11−90%).
3-Chloro-4-methoxy-2-methyl-5-octyl-benzonitrile (10).
IR (neat, vmax) cm
−1 2913, 2849, 2226 (CN), 1468, 1291,
1074. 1H NMR (500 MHz, CDCl3) δ 7.36 (s, 1H), 3.87 (s,
3H), 2.62 (t, J = 7.9 Hz, 2H), 2.57 (s, 3H), 1.61−1.55 (m, 2H),
1.36−1.27 (m, 10H), 0.89 (t, J = 6.8 Hz, 3H).13C NMR (126
MHz, CDCl3) δ 158.2 (C), 139.4 (C), 136.3 (C), 132.0 (CH),
129.7 (C), 117.7 (C), 109.4 (C), 60.9 (CH3), 31.8 (CH2), 30.2
(CH2), 29.7 (CH2), 29.4 (CH2), 29.3 (CH2), 29.1 (CH2), 22.6
(CH2), 18.8 (CH3), 14.0 (CH3). LRMS EI
+ 293 m/z.
5-Chloro-4-methoxy-5-octylbenzonitrile (46 Intermedi-
ate). IR (neat, vmax) cm
−1 2925, 2854, 2232 (CN), 1470,
1426, 1275. 1H NMR (500 MHz, CDCl3) δ 7.53 (s, 1H), 7.40
(s, 1H), 3.90 (s, 3H), 2.66 (t, J = 7.9 Hz, 2H), 1.60 (m, 2H),
1.40−1.26 (m, 10H), 0.90 (t, J = 6.8 Hz, 3H). 13C NMR (126
MHz, CDCl3) δ 158.2 (C), 139.7 (C), 132.4 (CH), 131.7
(CH), 128.9 (C), 117.7 (C), 108.5 (C), 61.1 (CH3), 31.8
(CH2), 30.2 (CH2), 30.0 (CH2), 29.4 (CH2), 29.3 (CH2), 29.1
(CH2), 22.6 (CH2), 14.0 (CH3). HRMS (ESI
−) m/z [M − H]−
calcd for C15H19ClNO 264.1161, found 264.1153.
Methyl 4-(3-chloro-5-cyano-2-methoxy-phenyl)butanoate
(15). IR (neat, vmax), cm−1 2952, 2231 (CN), 1732, 1427, 1276,
993, 877. 1H NMR (500 MHz, CDCl3) δ 7.55 (d, J = 2.1 Hz,
1H), 7.40 (d, J = 2.1 Hz, 1H), 3.90 (s, 3H), 3.68 (s, 3H), 2.70
(t, J = 7.7 Hz, 2H), 2.36 (t, J = 7.3 Hz, 2H), 1.92 (m, 2H). 13C
NMR (126 MHz, CDCl3) δ 158.2 (C), 139.7 (C), 132.4
(CH), 131.7 (CH), 128.9 (C), 117.7 (C), 108.5 (C), 61.1
(CH3), 31.8 (CH2), 30.2 (CH2), 30.0 (CH2), 29.4 (CH2), 29.3
(CH2), 29.1 (CH2), 22.6 (CH2), 14.0 (CH3). LRMS EI
+ 267
m/z.
Methyl 5-(3-chloro-5-cyano-2-methoxy-phenyl)-
pentanoate (16). IR (neat, vmax), cm−1 2951, 2233 (CN),
1733, 1472, 1275. 1H NMR (500 MHz, CDCl3) δ 7.53 (s, 1H),
7.38 (s, 1H), 3.89 (s, 3H), 3.67 (s, 3H), 2.67 (m, 2H), 2.35 (m,
2H), 1.65 (m, 4H). 13C NMR (126 MHz, CDCl3) δ 173.8 (C),
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158.2 (C), 139.9 (C), 132.4 (C), 132.0 (C), 128.9 (C), 117.6
(C), 108.5 (C), 61.1 (CH3), 51.6 (CH3), 33.7 (CH2), 29.7
(CH2), 29.5 (CH2), 24.6 (CH2). LRMS EI
+ 281 m/z.
Methyl 6-(3-chloro-5-cyano-2-methoxy-phenyl)hexanoate
(17). IR (neat, vmax), cm−1 2948, 2232 (CN), 1733, 1472, 1275.
1H NMR (500 MHz, CDCl3) δ 7.53 (s, 1H), 7.38 (s, 1H), 3.89
(s, 3H), 3.67 (s, 3H), 2.65 (m, 2H), 2.32 (m, 2H), 1.70−1.57
(m, 4H), 1.39 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 174.0
(C), 158.2 (C), 139.2 (C), 132.4 (CH), 131.9 (CH), 128.9
(C), 117.7 (C), 108.5 (C), 61.1 (CH3), 51.5 (CH3), 33.8
(CH2), 29.82 (CH2), 29.80 (CH2), 28.8 (CH2), 24.6 (CH2).
LRMS EI+ 295 m/z.
Methyl 7-(3-chloro-5-cyano-2-methoxy-phenyl)-
heptanoate (18). IR (neat, vmax), cm−1 2933, 2232 (CN),
1734, 1472, 1276. 1H NMR (500 MHz, CDCl3) δ 7.52 (s, 1H),
7.38 (s, 1H), 3.88 (s, 3H), 3.66 (s, 3H), 2.64 (m, 2H), 2.31 (m,
2H), 1.66−1.55 (m, 4H), 1.36 (m, 4H). 13C NMR (126 MHz,
CDCl3) δ 174.3 (C), 158.4 (C), 139.6 (C), 132.6 (CH), 132.0
(CH), 129.1 (C), 117.9 (C), 108.6 (C), 61.3 (CH3), 51.7
(CH3), 34.1 (CH2), 30.14 (CH2), 30.08 (CH2), 29.2 (CH2),
29.0 (CH2), 24.9 (CH2). HRMS (ESI
+) m/z [M + Na]+ calcd
for C16H20ClNNaO3 332.1024, found 332.1019.
3-(3-Butoxypropyl)-5-chloro-4-hydroxy-benzonitrile (29).
IR (neat, vmax, cm
−1) 2923, 2236. 1H NMR (500 MHz,
CDCl3) 7.51 (s, 1H), 7.31 (s, 1H), 3.50 (t, J = 6.6 Hz, 2H),
3.43 (t, J = 5.9 Hz, 2H), 2.76 (t, J = 6.9 Hz, 2H), 1.90 (p, J =
6.4 Hz, 2H), 1.62(p, J = 7.1 Hz, 2H), 1.40 (h, J = 7.5 Hz, 2H),
0.95 (t, J = 7.5 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 154.9
(C), 133.0 (CH), 131.5 (CH), 130.4 (C), 121.8 (C), 118.2
(C), 104.0 (C), 71.1 (CH2), 68.5 (CH2), 31.5 (CH2), 29.0
(CH2), 26.4 (CH2), 19.3 (CH2), 13.9 (CH3); HRMS (ESI
−)
m/z [M − H]− calcd for C14H17ClNO2 266.0953, found
266.0953.
3-Chloro-5-(5-ethoxypentyl)-4-hydroxy-benzonitrile (30).
1H (500 MHz, CDCl3) δ 7.49 (s, 1H), 7.33 (s, 1H), 3.47 (q,
J = 7.1 Hz, 2H), 3.41 (t, J = 6.3 Hz, 2H), 2.66 (t, J = 7.8 Hz,
2H), 1.62 (p, J = 8 Hz, 4H), 1.40 (p, J = 7.8 Hz, 2H), 1.20 (t, J
= 7.0 Hz, 3H). 13C (126 MHz, CDCl3) δ 153.6 (C), 132.6
(CH), 130.4, (CH), 120.5 (C), 118.1 (C), 104.1 (C), 88.2 (C),
70.5 (CH2), 66.2 (CH2), 30.2 (CH2), 29.4 (CH2), 28.7 (CH2),
26.0 (CH2), 15.1 (CH3). HRMS (ESI
−) m/z [M − H]− calcd
for C14H17ClNO2 266.0953, found 266.0942.
3-Chloro-4-hydroxy-5-(6-methoxyhexyl)benzonitrile (31).
IR (neat, νmax, cm
−1) 2932, 2860, 2233 (CN), 1174, 1116.
1H NMR (500 MHz, CDCl3) δ 7.49 (s, 1H), 7.33 (s, 1H), 3.55
(s, 3H) 3.36 (t, J = 6.6 Hz, 2H), 2.65 (t, J = 7.8 Hz, 2H), 1.57
(p, J = 7.4 Hz, 4H), 1.37 (m, 4H). 13C (126 MHz, CDCl3) δ
153.3 (C), 132.7 (CH), 130.3, (CH), 120.4 (C), 110.0 (C),
100.2 (C), 88.3 (C), 72.8 (C), 58.6 (C), 30.1 (CH2), 29.5
(CH2), 29.1 (CH2), 28.9 (CH2), 25.9 (CH3). HRMS (ESI
−)
m/z [M − H]−, calcd for C14H17ClNO2 266.0953, found
266.0941.
3-Chloro-4-methoxy-2-methyl-5-pentyl-benzonitrile (36).
1H NMR (500 MHz, CDCl3) δ 7.35 (s, 1H), 3.85 (s, 3H),
2.60 (t, J = 7.8 Hz, 2H), 2.55 (s, 3H), 1.57 (t, J = 7.5 Hz, 2H),
1.41−1.18 (m, 4H), 0.89 (t, J = 6.7 Hz, 3H). 13C NMR (126
MHz, CDCl3) δ 158.1 (C), 139.4 (C), 136.3 (C), 132.0 (CH),
129.6 (C), 117.8 (C), 109.3 (C), 60.9 (CH3), 31.5 (CH2), 29.9
(CH2), 29.7 (CH2), 22.4 (CH2), 18.8 (CH3), 13.9 (CH3).
3-Chloro-5-hexyl-4-methoxy-2-methyl-benzonitrile (37).
1H NMR (500 MHz, CDCl3) δ 7.35 (s, 1H), 3.85 (s, 3H),
2.60 (t, J = 7.6 Hz, 2H), 2.54 (s, 3H), 1.61−1.48 (m, 2H),
1.41−1.17 (m, 6H), 0.87 (t, J = 6.8 Hz, 3H). 13C NMR (126
MHz, CDCl3) δ 158.1 (C), 139.3 (C), 136.3 (C), 132.0 (CH),
129.6 (C), 117.7 (C), 109.3 (C), 60.9 (CH3), 31.6 (CH2), 30.1
(CH2), 29.7 (CH2), 29.1 (CH2) 22.5 (CH2), 18.8 (CH3), 14.0
(CH3).
3-Chloro-5-heptyl-4-methoxy-2-methyl-benzonitrile (38).
1H NMR (500 MHz, CDCl3) δ 7.35 (s, 1H), 3.85 (s, 3H),
2.60 (t, J = 7.9 Hz, 2H), 2.54 (s, 3H), 1.61−1.50 (m, 2H),
1.38−1.11 (m, 8H), 0.87 (t, J = 6.7 Hz, 3H). 13C NMR (126
MHz, CDCl3) δ 158.1 (C), 139.3 (C), 136.3 (C), 132.0 (CH),
129.6 (C), 117.7 (C), 109.3 (C), 60.9 (CH3), 31.7 (CH2), 30.8
(CH2), 29.7 (CH2), 29.3 (CH2) 29.0 (CH2), 22.6 (CH2), 18.8
(CH3), 14.1 (CH3).
General Protocol for Alkylboronic Acid Suzuki-
Miyaura Cross-Coupl ing. Dicyc lohexy l -[2-(2 ,6-
diisopropoxyphenyl)phenyl]phosphane (9 mg, 0.02 mmol)
and palladium(II) acetate (2 mg, 0.01 mmol) were added to a
degassed suspension of 5-bromo-3-chloro-4-methoxy-2-methyl-
benzonitrile (100 mg, 0.38 mmol), boronic acid or trialkylbor-
oxine (0.58 mmol), and tripotassium phosphate (244 mg, 1.15
mmol) in toluene (2 mL). The reaction mixture was sealed,
degassed, put under a nitrogen atmosphere, and heated to 100
°C for 16−72 h. The reaction mixture was ﬁltered through a
pad of Celite; the ﬁltrate was partitioned between ethyl acetate
and water, and the organics were separated, washed with brine,
dried over MgSO4, ﬁltered, and concentrated under vacuum.
The residue was puriﬁed by ﬂash chromatography eluting with
petroleum ether to 10−25% ethyl acetate in petroleum ether.
Material was further puriﬁed by reverse phase ﬂash
chromatography, eluting with water to MeOH if required to
provide the cross-coupled analogues described (36−67%).
3-Chloro-4-methoxy-2,5-dimethyl-benzonitrile (32). 1H
NMR (500 MHz, CDCl3) δ 7.35 (s, 1H), 3.84 (s, 3H), 2.55
(s, 3H), 2.29 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 158.3
(C), 139.5 (C), 132.9 (CH), 131.5 (C), 129.6 (C), 117.6 (C),
109.2 (C), 60.2 (CH3), 18.8 (CH3), 16.0 (CH3).
3-Chloro-5-ethyl-4-methoxy-2-methyl-benzonitrile (33).
1H NMR (500 MHz, CDCl3) δ 7.37 (s, 1H), 3.86 (s, 3H),
2.75−2.60 (m, 2H), 2.56 (s, 3H), 1.22 (t, J = 7.5 Hz, 3H). 13C
NMR (126 MHz, CDCl3) δ 158.0 (C), 139.4 (C), 137.5 (C),
131.4 (CH), 129.6 (C), 117.8 (C), 109.5 (C), 60.9 (CH3), 22.3
(CH2), 18.8 (CH3), 14.4 (CH3).
3-Chloro-4-methoxy-2-methyl-5-propyl-benzonitrile (34).
1H NMR (500 MHz, CDCl3) δ 7.35 (s, 1H), 3.86 (s, 3H),
2.60 (t, J = 6.7 Hz, 2H), 2.55 (s, 3H), 1.66−1.56 (m, 2H), 0.96
(t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 158.2 (C),
139.4 (C), 136.0 (C), 132.1 (CH), 129.7 (C), 117.8 (C), 109.3
(C), 60.9 (CH3), 31.7 (CH2), 23.3 (CH2), 18.9 (CH3), 13.9
(CH3).
5-Butyl-3-chloro-4-methoxy-2-methyl-benzonitrile (35).
1H NMR (500 MHz, CDCl3) δ 7.35 (s, 1H), 3.86 (s, 3H),
2.62 (t, J = 7.7 Hz, 2H), 2.55 (s, 3H), 1.59−1.51 (m, 2H),
1.41−1.31 (m, 2H), 0.93 (t, 3H). 13C NMR (126 MHz,
CDCl3) δ 158.1 (C), 139.4 (C), 136.3 (C), 132.1 (CH), 129.7
(C), 117.8 (C), 109.3 (C), 60.9 (CH3), 32.3 (CH2), 31.7
(CH2), 22.5 (CH2), 18.8 (CH3), 13.8 (CH3).
General Protocol for Demethylation with Trimethyl-
silyl Iodide. Chloro(trimethyl)silane (0.26 mL, 2.0 mmol) was
added to a suspension of sodium iodide (0.31 g, 2.0 mmol) and
anisole (0.51 mmol) in acetonitrile (2 mL). The reaction
mixture was heated to reﬂux for 4−96 h. The cooled reaction
mixture was partitioned between 0.1 M sodium thiosulfate (10
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mL) and ethyl acetate (2 × 20 mL). The organic layers were
separated, combined dried over MgSO4, ﬁltered, and
concentrated under vacuum. The residue was puriﬁed by
ﬂash silica chromatography, eluting with petroleum ether to
30% ethyl acetate to provide the phenolic compounds (28−
80%).
3-Chloro-4-hydroxy-2-methyl-5-octyl-benzonitrile (11). IR
(neat, vmax) cm
−1 3360, 2928, 2850, 2222 (CN), 1601, 1473,
1461, 1163. 1H NMR (500 MHz, CDCl3) δ 7.31 (s, 1H), 6.08
(s, 1H), 2.64 (t, J = 7.7 Hz, 2H), 2.56 (s, 3H), 1.59 (m, 2H),
1.45−1.20 (m, 10H) 0.91 (t, J = 7.2 Hz, 3H). 13C NMR (126
MHz, CDCl3) δ 153.0 (C), 138.2 (C), 132.2 (CH), 128.9 (C),
121.0 (C), 118.0 (C), 110.0 (C), 31.8 (CH2), 29.9 (CH2), 29.3
(CH2), 29.3 (CH2), 29.2 (CH2), 29.1 (CH2), 22.6 (CH2), 18.7
(CH2), 14.0 (CH3). HRMS (ESI
−) m/z [M − H]− calculated
for C16H21ClNO 278.1317, found 278.1303.
4-(3-Chloro-5-cyano-2-hydroxy-phenyl)butanoic Acid
(19a). IR (neat, vmax) cm−1 3345, 2569, 2228 (CN), 1691,
1474, 1253. 1H NMR (500 MHz, CDCl3) δ 12.06 (br s, 1H),
10.43 (br s, 1H), 7.81 (d, J = 2.0 Hz, 1H), 7.51 (d, J = 2.0 Hz,
1H), 2.61 (t, J = 7.5 Hz, 2H), 2.19 (t, J = 7.5 Hz, 2H), 1.73
(quintet, J = 7.5 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ
174.6 (C), 155.6 (C), 133.1 (CH), 132.4 (C), 131.9 (CH),
121.6 (C), 118.7 (C), 102.8 (C), 33.6 (CH2), 29.5 (CH2), 24.5
(CH2). HRMS (ESI
−) m/z [M − H]− calcd for C11H9ClNO3
238.0276, found 238.0266.
5-(3-Chloro-5-cyano-2-hydroxy-phenyl)pentanoic Acid
(20a). IR (neat, vmax), cm−1 3093, 2867, 2243 (CN), 1723,
1471, 1105. 1H NMR (500 MHz, CDCl3) δ 11.98 (br s, 1H),
10.40 (br s, 1H), 7.78 (d, J = 2.0 Hz, 1H), 7.53 (d, J = 2.0 Hz,
1H), 2.59 (t, J = 7.2 Hz, 2H), 2.20 (m, 2H), 1.49 (m, 4H). 13C
NMR (126 MHz, CDCl3) δ 174.8 (C), 155.6 (C), 133.8 (C),
133.0 (C), 131.8 (C), 121.5 (C), 118.8 (C), 102.7 (C), 33.9
(CH2), 29.8 (CH2), 28.7 (CH2), 24.5 (CH2). HRMS (ESI
−)
m/z [M − H]− calcd for C12H11ClNO3 252.0433, found
252.0423.
6-(3-Chloro-5-cyano-2-hydroxy-phenyl)-N-methyl-hexa-
namide (21b). IR (neat, vmax), cm−1 3395, 2941, 2226 (CN),
1638, 1559, 1291, 1271. 1H NMR (500 MHz, DMSO-d6) δ
10.37 (br s, 1H), 7.76 (s, 1H), 7.67 (br s, 1H), 7.51 (s, 1H),
2.56 (t, J = 7.14 Hz, 2H), 2.52 (m, 3H), 2.01 (t, J = 7.2 Hz,
2H), 1.47 (m, 4H), 1.22 (m, 2H). 13C NMR (126 MHz,
DMSO-d6) δ 172.9 (C), 155.6 (C), 133.2 (C), 133.0 (CH),
131.7 (CH), 121.5 (C), 118.8 (C), 102.6 (C5), 35.6 (CH2),
29.9 (CH2, 29.0 (CH2), 28.8 (CH2), 25.8 (CH3), 25.5 (CH2).
HRMS-ESI m/z [M + H]+ calcd for C14H17ClN2NaO2
303.0871, found 303.0865.
7-(3-Chloro-5-cyano-2-hydroxy-phenyl)-N-methyl-hepta-
namide (22b). 1H NMR (500 MHz, CDCl3) δ 7.57 (d, J = 2.0
Hz, 1H), 7.40 (d, J = 2.0 Hz, 1H), 2.69 (s, 3H), 2.66 (t, J = 7.4
Hz, 2H), 2.16 (t, J = 7.6 Hz, 2H), 1.70−1.50 (m, 4H), 1.44−
1.22 (m, 4H). 13C NMR (126 MHz, CDCl3) δ 172.4 (C),
155.2 (C), 132.9 (C), 132.1 (CH), 130.8 (CH), 121.0 (C),
117.8 (C), 102.8 (C). LRMS (ESI+) [M + H]+ 295.1 m/z.
7-(3-Chloro-5-cyano-2-hydroxy-phenyl)-N,N-dimethyl-
heptanamide (23b). 1H NMR (500 MHz, CDCl3) δ 7.48 (s,
1H) 7.31 (s, 1H), 6.93 (br s, 1H), 3.00 (s, 3H), 2.96 (s, 3H),
2.69−2.59 (m, 2H), 2.34−2.24 (m, 2H), 1.67−1.52 (m, 4H),
1.42−1.29 (m, 4H). 13C NMR (126 MHz, CDCl3) δ 173.2
(C), 153.7 (C), 132.6 (CH), 132.0 (C), 130.5 (CH), 120.8
(C), 118.2 (C), 104.1 (C), 37.3 (CH3), 35.5 (CH3), 33.1
(CH2), 29.9 (CH2), 28.83 (CH2), 28.80 (CH2), 28.75 (CH2),
24.6 (CH2). LRMS (ESI
+) [M + H]+ 309.1 m/z.
3-Chloro-4-hydroxy-2,5-dimethyl-benzonitrile (39). 1H
NMR (500 MHz, CDCl3) δ 7.29 (s, 1H), 6.21 (br s, 1H),
2.53 (s, 3H), 2.25 (s, 3H). 13C NMR (126 MHz, CDCl3) δ
153.4 (C), 138.3 (C), 132.8 (CH), 124.2 (C), 120.8 (C), 118.0
(C), 104.9 (C), 18.7 (CH3), 15.9 (CH3). LRMS (ESI
−) [M −
H]− 179.9 m/z.
3-Chloro-5-ethyl-4-hydroxy-2-methyl-benzonitrile (40). 1H
NMR (500 MHz, CDCl3) δ 7.32 (s, 1H), 6.14 (s, 1H), 2.66 (q,
J = 7.6 Hz, 2H), 2.54 (s, 3H), 1.21 (t, J = 7.6 Hz, 3H). 13C
NMR (126 MHz, CDCl3) δ 153.0 (C), 138.3 (C), 131.4 (CH),
130.1 (C), 121.0 (C), 118.1 (C), 105.2 (C), 23.1 (CH2), 18.8
(CH3), 13.4 (CH3). LRMS (ESI
−) [M − H]− 194.0 m/z.
3-Chloro-4-hydroxy-2-methyl-5-propyl-benzonitrile (41).
1H NMR (500 MHz, CDCl3) δ 7.29 (s, 1H), 6.21 (br s,
1H), 2.60 (t, J = 7.7 Hz, 2H), 2.53 (s, 3H), 1.62−1.56 (m, 2H),
0.94 (t, J = 7.3 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 153.2
(C), 138.3 (C), 132.2 (CH), 128.7 (C), 121.1 (C), 118.1 (C),
105.0 (C), 31.9 (CH2), 22.2 (CH2), 18.8 (CH3), 13.7 (CH3).
LRMS (ESI−) [M − H]− 207.9 m/z.
5-Butyl-3-chloro-4-hydroxy-2-methyl-benzonitrile (42). 1H
NMR (500 MHz, CDCl3) δ 7.29 (s, 1H), 6.22 (br s, 1H), 2.61
(t, J = 7.8 Hz, 2H), 2.53 (s, 3H), 1.60−1.50 (m, 2H), 1.40−
1.29 (m, 2H), 0.92 (t, J = 7.3 Hz, 3H). 13C NMR (126 MHz,
CDCl3) δ 153.2 (C), 138.2 (C), 132.1 (CH), 128.9 (C), 121.1
(C), 118.1 (C), 105.0 (C), 31.2 (CH2), 29.6 (CH2), 22.3
(CH2), 18.7 (CH3), 13.8 (CH3). LRMS (ESI
−) [M − H]−
221.9 m/z.
3-Chloro-4-hydroxy-2-methyl-5-pentyl-benzonitrile (43).
1H NMR (500 MHz, CDCl3) δ 7.30 (s, 1H), 6.10 (br s,
1H), 2.62 (t, J = 7.8 Hz, 2H), 2.54 (s, 3H), 1.65−1.52 (m, 2H),
1.37−1.27 (m, 4H), 0.89 (t, J = 6.8 Hz, 3H). 13C NMR (126
MHz, CDCl3) δ 153.1 (C), 138.2 (C), 132.2 (CH), 128.9 (C),
121.0 (C), 118.1 (C), 105.1 (C), 31.4 (CH2), 29.9 (CH2), 28.8
(CH2), 22.4 (CH2), 18.8 (CH3), 14.0 (CH3). LRMS (ESI
−)
[M − H]− 235.9 m/z.
3-Chloro-5-hexyl-4-hydroxy-2-methyl-benzonitrile (44).
1H NMR (500 MHz, CDCl3) δ 7.29 (s, 1H), 6.18 (br s,
1H), 2.61 (t, J = 7.8 Hz, 2H), 2.53 (s, 3H), 1.61−1.50 (m, 2H),
1.38−1.23 (m, 6H), 0.92−0.84 (m, 3H). 13C NMR (126 MHz,
CDCl3) δ 153.1 (C), 138.2 (C), 132.2 (CH), 128.9 (C), 121.0
(C), 118.1 (C), 105.0 (C), 31.6 (CH2), 30.0 (CH2), 29.0
(CH2), 28.9 (CH2), 22.6 (CH2), 18.8 (CH3), 14.1 (CH3).
LRMS (ESI−) [M − H]− 249.9 m/z.
3-Chloro-5-heptyl-4-hydroxy-2-methyl-benzonitrile (45).
1H NMR (500 MHz, CDCl3) δ 7.30 (s, 1H), 6.11 (br s,
1H), 2.61 (t, J = 7.5, 2H), 2.54 (s, 3H), 1.61−1.53 (m, 2H),
1.35−1.22 (m, 8H), 0.88 (t, J = 6.2 Hz, 3H). 13C NMR (126
MHz, CDCl3) δ 153.1 (C), 138.2 (C), 132.2 (CH), 128.9 (C),
121.0 (C), 118.1 (C), 105.1 (C), 31.7 (CH2), 30.0 (CH2), 29.2
(CH2), 29.09 (CH2), 29.06 (CH2), 22.6 (CH2), 18.8 (CH3),
14.1 (CH3). LRMS (ESI
−) [M − H]− 264.0 m/z.
5-Chloro-4-hydrox-5-octylbenzonitrile (46). mp 60.1−61.8
°C. IR (neat, vmax) cm−1 3362, 2927, 2849, 2230 (CN), 1595,
1471, 1316, 1241, 1168. 1H NMR (500 MHz, CDCl3) δ 7.49
(s, 1H), 7.34 (s, 1H), 6.07 (s, 1H), 2.66 (m, 2H), 1.59 (m, 2H),
1.49−1.17 (m, 10H), 0.88 (m, 3H). 13C NMR (126 MHz,
CDCl3) δ 153.4 (C), 132.9 (C), 132.2 (CH), 130.4 (CH),
120.5 (C), 118.2 (CH), 104.6 (C), 32.0 (CH2), 30.3 (CH2),
29.5 (CH2), 29.5 (CH2), 29.4 (CH2), 29.2 (CH2), 22.8 (CH2),
14.3 (CH3). HRMS (ESI
−) m/z [M − H]− calcd for
C15H19ClNO 264.1161, found 264.1151.
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General Protocol for HATU Amide Coupling. Triethyl-
amine (0.07 mL, 0.49 mmol) was added to a solution of
carboxylic acid (0.2 mmol), HATU (0.08 g, 0.22 mmol), and
amine (0.3 mmol) in acetonitrile (0.5 mL). The reaction was
stirred at RT for 16 h. The reaction mixture was partitioned
between ethyl acetate (5 mL) and water (5 mL). The organic
layer was separated, washed with brine, dried over MgSO4,
ﬁltered, and concentrated under reduced pressure. The residue
was puriﬁed by ﬂash silica chromatography eluting with
petroleum ether to ethyl acetate in petroleum ether and then
further puriﬁed by reverse phase chromatography eluting with
water to MeOH if necessary to provide the amides described
(29−67%).
4-(3-Chloro-5-cyano-2-hydroxy-phenyl)-N-propyl-butana-
mide (19b). 1H NMR (500 MHz, CDCl3) δ 10.73 (br s, 1H),
7.95 (br t, 1H), 7.73 (s, 1H), 7.45 (s, 1H), 2.97, (m, 2H), 2.56
(t, J = 7.4 Hz, 2H), 2.04 (t, J = 7.4 Hz, 2H), 1.71 (m, 2H), 1.37
(m, 2H), 0.81 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz,
CDCl3) δ 172.0 (C), 155.4 (C), 132.8 (CH), 131.9 (C), 131.4
(CH), 121.2 (C), 118.3 (C), 102.12 (C), 40.3 (CH2), 34.3
(CH2), 29.1 (CH2), 25.0 (CH2), 22.3 (CH2), 11.4 (CH3).
LRMS (ESI−) [M − H]− 281.0 m/z.
5-(3-Chloro-5-cyano-2-hydroxy-phenyl)-N-ethyl-pentana-
mide (20b). IR (neat, vmax) cm−1 3353, 2945, 2231 (CN), 1649,
1560, 1462, 1174. 1H NMR (500 MHz, DMSO-d6) δ 10.16 (br
1H), 7.76−7.72 (br m, 2H), 7.49 (s, 1H), 3.02 (m, 2H), 2.58
(t, J = 6.3 Hz, 2H), 2.02 (t, J = 6.3 Hz, 2H), 1.45 (m, 4H), 0.96
(t, J = 7.2 Hz, 3H). 13C NMR (126 MHz, DMSO-d6) δ 172.1
(C), 156.0 (C), 133.0 (C), 132.9 (C), 131.7 (C), 121.6 (C),
118.9 (C), 102.1 (C), 35.7 (CH2), 33.6 (CH2), 29.9 (CH2),
28.9 (CH2), 25.4 (CH2), 15.2 (CH3). HRMS (ESI
+) m/z [M +
Na]+ calcd for C14H17ClN2NaO2 303.0871, found 303.0865.
Ethyl(2E)-3-5-cyano-2-hydroxy-4-methylphenyl)prop-2-
enoate (24). Potassium carbonate (0.98 g, 7.07 mmol) was
added to a solution of 5-bromo-4-hydroxy-2-methyl-benzoni-
trile (0.50 g, 2.36 mmol) and ethyl acrylate (0.77 mL, 7.07 mL)
in 1-methyl-2-pyrrolidinone (10 mL). [1,3-Bis(2,4,6-trimethyl-
pheny l ) - 2 , 3 - d i h yd ro - 1H - im i d a zo l - 2 - y l i d ene ] ( {2 -
[(dimethylamino)methyl]phenyl})palladiumylium chloride
(SingaCycle) was added to the suspension, and the reaction
was sealed under nitrogen and heated at 100 °C for 48 h. The
reaction mixture was cooled to RT and diluted with ethyl
acetate (50 mL) and ﬁltered through a Celite pad. The ﬁltrate
was washed with 1 M HCl (aq) (25 mL), 0.5 M LiCl (aq) (25
mL), and brine (25 mL), dried over MgSO4, ﬁltered, and
concentrated under vacuum. The residue was puriﬁed by ﬂash
silica chromatography eluting with petroleum ether to 15%
ethyl acetate in petroleum ether to provide the title compound
as a white solid (0.16 g, 29%). mp 142.6−149.8 °C. IR (neat,
vmax), cm
−1 2923, 2221, 1600, 1274. 1H NMR (500 MHz,
DMSO-d6) δ 11.30 (br s, 1H) 8.07 (s, 1H), 7.73 (d, J = 16 Hz,
1H), 6.90 (s, 1H), 6.70 (d, J = 16 Hz, 1H), 4.17 (d, J = 7.2 Hz,
2H), 2.38 (s, 3H), 1.24 (t, J = 7.2 Hz, 3H). 13C NMR (126
MHz, DMSO-d6) δ 160.9 (C), 160.6 (C), 145.4 (C), 138.2
(CH), 134.4 (CH), 120.3 (C), 119.4 (CH), 118.5 (C), 118.1
(CH), 103.19 (CN), 60.4 (CH2), 20.5 (CH3), 14.6 (CH3).
HRMS (ESI−) m/z [M − H]− calcd for C13H12NO3 230.0823,
found 230.0814.
Ethyl 3-(5-Cyano-2-hydroxy-4-methyl-phenyl)propanoate
(25). Triethylsilane (0.50 g, 4.32 mmol) was added to a
solution ethyl (E)-3-(5-cyano-2-hydroxy-4-methyl-phenyl)-
prop-2-enoate (0.10 g, 0.43 mmol) and 10% palladium on
carbon (4 mg, 0.04 mmol) in ethanol (5 mL). The reaction
mixture was stirred at RT for 16 h. Further triethylsilane (0.50
g, 4.32 mmol) was added, and the reaction mixture was stirred
for a further 16 h. The nitrogen purged reaction mixture was
ﬁltered through a pad of Celite; the ﬁltrate was partitioned
between 1 M HCl (aq) (10 mL) and ethyl acetate (2 × 20
mL). The combined organics were separated, dried over
MgSO4, ﬁltered, and concentrated under vacuum. The residue
was puriﬁed by ﬂash silica chromatography, eluting with
petroleum ether to 50% ethyl acetate in petroleum ether to
provide the title compound as a white solid (0.08 g, 77%). IR
(neat, vmax) cm
−1 3496, 2927, 2225 (CN), 1716, 1199, 1250. 1H
NMR (500 MHz, CDCl3) δ 8.25 (s, 1H), 7.32 (s, 1H), 6.80 (s,
1H), 4.16 (q, J = 7.3 Hz, 2H), 2.84 (m, 2H), 2.70 (m, 2H), 2.44
(s, 3H), 1.25 (t, J = 7.3 Hz). 13C NMR (126 MHz, CDCl3) δ
175.9 (C), 158.4 (C), 142.5 (C), 135.1 (CH), 125.8 (C), 119.0
(CH), 118.6 (C), 104.3 (C), 61.8 (CH2), 35.0 (CH2), 24.0
(CH2), 20.1 (CH3), 14.0 (CH3). HRMS (ESI
+) m/z [M + H]+
calcd for C13H15NNaO3 256.0944, found 256.0941.
Ethyl 3-(3-Chloro-5-cyano-2-hydroxy-4-methyl-phenyl)-
propanoate (26). Sulfuryl chloride (0.02 mL, 0.26 mmol)
was added to a solution of ethyl 3-(5-cyano-2-hydroxy-4-
methyl-phenyl)propanoate (0.05 g, 0.21 mmol) in diethyl ether
(1 mL). The reaction mixture was stirred at RT for 96 h.
Further sulfuryl chloride (0.02 mL, 0.26 mmol) was added, and
the reaction mixture was stirred for a further 16 h. The reaction
mixture was partitioned between 1 M HCl (aq) (10 mL) and
ethyl acetate (2 × 20 mL). The combined organics were
separated, dried over MgSO4, ﬁltered, and concentrated under
vacuum. The residue was puriﬁed by ﬂash silica chromatog-
raphy, eluting with petroleum ether to 25% ethyl acetate in
petroleum ether to provide the title compound as a white solid
(0.043 g, 75%). IR (neat, vmax) cm
−1 3340, 2997, 2228 (CN),
1712, 1210, 1177. 1H NMR (500 MHz, CDCl3) δ 7.33 (s, 1H),
7.03 (s, 1H), 4.14 (q, J = 7.1 Hz, 2H), 2.94 (t, J = 7.1 Hz, 2H),
2.65 (t, J = 7.1 Hz, 2H), 2.55 (s, 3H), 1.24 (t, J = 7.1 Hz, 3H).
13C NMR (126 MHz, CDCl3) δ 173.6 (C), 153.6 (C), 139.4
(C), 132.6 (CH), 126.7 (C), 117.9 (C), 105.3 (C), 61.1 (CH2),
33.7 (CH2), 25.3 (CH2), 18.9 (CH3), 14.2 (CH3). HRMS
(ESI−) m/z [M − H]− calcd for C13H13NO3 266.0589, found
266.0576.
General Protocol for 1,5,7-Triazabicyclo[4.4.0]dec-5-
ene Amide Formation. Amine (0.33 mmol) was added to a
solution of 1,5,7-triazabicyclo[4.4.0]dec-5-ene (0.04 g, 0.26
mmol) and ester (0.13 mmol) in acetonitrile (0.5 mL). The
reaction was stirred at RT for 5−40 h. The reaction mixture
was partitioned between ethyl acetate (25 mL) and water (25
mL). The organic layer was separated, washed with brine, dried
over MgSO4, ﬁltered, and concentrated under reduced pressure.
The residue was puriﬁed by ﬂash silica chromatography eluting
with petroleum ether to 30−50% ethyl acetate in petroleum
ether to provide the amides described (27−80%).
6-(3-Chloro-5-cyano-2-methoxy-phenyl)-N-methyl-hexa-
namide (21a). IR (neat, vmax) cm−1 3300, 2938, 2230 (CN),
1639, 1557, 1281. 1H NMR (500 MHz, CDCl3) δ 7.52 (d, J =
2.0 Hz, 1H), 7.37 (d, J = 2.0 Hz, 1H), 5.44 (br s, 1H), 3.88 (s,
3H), 2.80 (d, J = 5.0 Hz, 3H), 2.65 (t, J = 7.6 Hz, 2H), 2.17 (t, J
= 7.6 Hz, 2H), 1.68 (m, 2H), 1.59 (m, 2H), 1.37 (m, 2H). 13C
NMR (126 MHz, CDCl3) δ 173.5 (C), 158.4 (C), 139.4 (C),
132.6 (CH), 132.0 (CH), 129.1 (C), 117.8 (C), 108.6 (C),
61.3 (CH3), 36.6 (CH2), 30.1 (CH2), 30.0 (CH2), 29.1 (CH2),
26.4 (CH2), 25.5 (CH3). HRMS (ESI
+) m/z [M + Na]+ calcd
for C15H19ClN2NaO2 317.1027, found 317.1019.
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7-(3-Chloro-5-cyano-2-methoxy-phenyl)-N-methyl-hepta-
namide (22a). 1H NMR (500 MHz, CDCl3) δ 7.52 (d, J = 2.0
Hz, 1H), 7.37 (d, J = 2.0 Hz, 1H), 5.41 (br s, 1H), 3.88 (s, 3H),
2.80 (d, J = 5.0 Hz, 3H), 2.64 (t, J = 7.9 Hz, 2H), 2.16 (t, J =
7.6 Hz, 2H), 1.69−1.52 (m, 4H), 1.42−1.28 (m, 4H). 13C
NMR (126 MHz, CDCl3) δ 173.5 (C), 158.2 (C), 139.4 (C),
132.4 (C), 131.8 (C), 128.9 (C), 117.7 (C), 108.4 (C), 61.1
(CH3), 36.6 (CH2), 30.0 (CH2), 29.9 (CH2), 29.1 (CH2), 29.0
(CH2), 26.3 (CH3), 25.5 (CH2). LRMS (ESI
+) [M + H]+ 309.1
m/z.
7-(3-Chloro-5-cyano-2-methoxy-phenyl)-N,N-dimethyl-
heptanamide (23a). 1H NMR (500 MHz, CDCl3) δ 7.52 (s,
1), 7.37 (s, 1H), 3.88 (s, 3H), 2.99 (s, 3H), 2.94 (s, 3H), 2.64
(m, 2H), 2.30 (m, 2H), 1.70−1.53 (m, 4H), 1.43−1.32 (m,
4H). 13C NMR (126 MHz, CDCl3) δ 173.0 (C), 158.2 (C),
139.5 (C), 132.4 (C), 131.8 (C), 128.9 (C), 117.7 (C), 108.4
(C), 61.1 (CH3), 37.3 (CH3), 35.4 (CH3), 33.2 (CH2), 30.1
(CH2), 29.9 (CH2), 29.2 (CH2), 29.2 (CH2), 25.0 (CH2).
LRMS (ESI+) [M + H]+ 323.1 m/z.
N-Butyl-3-(3-chloro-5-cyano-2-hydroxy-4-methyl-phenyl)-
propenamide (27). IR (neat, vmax) cm−1 3369, 2928, 2220
(CN), 1632, 1562, 1157. 1H NMR (500 MHz, CDCl3) δ 10.35
(br s, 1H), 7.24 (s, 1H), 5.55 (br s, 1H), 3.26 (m, 2H), 2.91 (m,
2H), 2.59 (m, 2H), 2.54 (s, 3H), 1.45 (m, 2H), 1.28 (m, 2H),
0.90 (t, J = 7.5 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 173.6
(C), 155.6 (C), 140.0 (C), 132.6 (CH), 127.4 (C), 123.9 (C),
118.3 (C), 104.0 (C), 39.9 (CH2), 36.3 (CH2), 31.4 (CH2),
25.0 (CH2), 19.9 (CH2), 18.9 (CH3), 13.6 (CH3). HRMS
(ESI+) m/z [M + Na]+ calcd for C15H19ClN2NaO2 317.1027,
found 317.1019.
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